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ABSTRACT 
Breast cancer is the most common cause of malignancy affecting women 
worldwide. The complexity of breast cancer is reflected in the different 
classification of molecular subtypes. Included in these subtypes is triple-
negative breast cancer (TNBC), or basal-like breast cancer. Occurring in 
approximately 15-20% of all breast cancer cases, TNBC is characterised by 
the lack of expression of oestrogen receptor (ER) and progesterone (PR), 
and the low expression of the human epidermal growth factor receptor 
(HER2). This phenotype precludes the use of therapies such as tamoxifen 
and trastuzumab that target these receptors. Due to the lack of specific 
treatment options, TNBC has a poorer patient prognosis and is associated 
with increased metastasis and recurrence.	
 
The Wnt/β-catenin signalling pathway is an evolutionarily conserved pathway 
that regulates many aspects of cell fate and is a hallmark of many cancers. 
The canonical Wnt signalling pathway involves binding of Wnt ligands to 
Frizzled receptors and LRP5/6 co-receptors to initiate destabilisation of the β-
catenin destruction complex. This results in nuclear translocation of β-catenin 
where it binds to TCF/LEF transcription factors which regulate the 
transcription of Wnt target genes. TNBC features increased Wnt signalling 
activity compared to other subtypes of breast cancer. Similar to the increased 
Wnt signalling observed in TNBC, the RNA helicase DDX20 (Gemin3, 
DP103) has also been identified to be critical in the progression and 
aggressive nature of the disease. Importantly, DDX20 has been found to be 
overexpressed in the same subset of basal-like breast cancers that also 
display the most active Wnt signalling, suggesting a potential role for DDX20 
in modulating Wnt signalling. 	
 
This thesis focusses on the role of DDX20 in regulating Wnt/β-catenin 
signalling and its impact on cell fate in TNBC.	
 
A novel mechanism of DDX20 regulation of Wnt/β-catenin signalling was 
identified, as well as a previously unknown role for Wnt/β-catenin signalling in 
	 21	
the regulation of cellular redox and mitochondrial function. The loss of 
DDX20 in TNBC results in increased ROS production and oxidative stress 
through differential regulation of two major redox regulators, catalase and 
MnSOD. The loss of DDX20 also causes mitochondrial dysfunction and 
impaired cellular respiration, via downregulation of mitochondrial complex III 
in a Wnt3a/β-catenin/TCF4-dependent signalling cascade.	
 
The role of DDX20 in cancer stem cells (CSCs) isolated from the MDA-MB-
231and BT549 cell lines was elucidated. Consistent with the parental cell 
lines, DDX20 was shown to be an essential regulator of Wnt/β-catenin 
signalling. The results indicated that DDX20 is overexpressed in CSCs when 
compared to the parental cell lines and the loss of DDX20 results in cell 
death and loss of spheroid formation. Stemness and drug resistance 
associated with CSCs were abolished when DDX20 is silenced. DDX20 
drives a positive feedback loop wherein it promotes its increased 
transcriptional regulation by TCF4 to drive the aggressiveness displayed in 
TNBC through Wnt/β-catenin signalling.	
 
Overall, this study has demonstrated a novel regulatory mechanism of 
DDX20-dependent Wnt/β-catenin signalling in TNBC through cellular redox. 
This study implicates that canonical Wnt signalling has a novel role in 
maintaining cellular redox and mitochondrial homeostasis. The implications 
for Wnt regulation of mitochondrial function and reactive oxygen species may 
be applicable to other cancer cell types. This non-canonical function of 
DDX20 may represent a valuable therapeutic target and biomarker in TNBC. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 INTRODUCTION  
Breast cancer represents one of the most significant disease burdens of any 
cancer worldwide. Today, women have a one in eight chance of developing 
breast cancer over their lifetime, a risk that is significantly increased if they 
have inherited harmful mutations in BRCA1 or BRCA2.1 However, breast 
cancer is a complex, heterogeneous disease characterized by a great 
multitude of aberrations at the genomic and molecular level, which can 
manifest in dysregulated signalling pathways.  
Triple-negative breast cancer (TNBC), an aggressive subtype of 
breast cancer with a poor prognosis,2 is characterized by tumours that do not 
express oestrogen receptors (ERs) or progesterone receptors (PRs), nor 
display an overexpression of human epidermal growth factor receptor 2 
(HER2).3 Therapies targeted against HER2-positive breast cancers, such as 
trastuzumab (Herceptin)4, and those targeted against ER-positive breast 
cancers, such as tamoxifen,5 have no therapeutic benefit to individuals with 
the TNBC subtype. Surgical intervention and chemotherapy have been the 
major treatment avenues for TNBC; however, recently developed small 
molecules and immunotherapeutics6 are showing promise.7 A hallmark of 
many cancers is aberrant regulation of the Wnt signalling pathway and 
oxidative stress, and breast cancer is no exception.8  
1.2 TNBC SUBTYPES 
Breast cancer is a diverse and complex disease, broadly characterized by 
four molecularly distinct subtypes including luminal A, luminal B, HER2-
overexpressed, and TNBC.9 The luminal A subtype is characterized as 
ER/PR positive and HER2 negative, expressing Bcl-2, cytokeratin 8/18, and 
low Ki67.10 Luminal B subtypes are more aggressive ER+ breast tumours, 
characterized as HER2- with high Ki67, or HER2+, PR-, and ER+,11 with cyclin 
B1 overexpression.12 The HER2 subtype is characterized by amplification of 
the ERBB2/HER2 gene.13  
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TNBC, including basal-like and claudin-low subtypes, accounts for 10-20% of 
breast cancers and is characterized by a lack of PR, ER, and HER2 
overexpression.14 TNBC patients present with higher incidence of distant 
disease recurrence within 3 years of diagnosis, with a high frequency of 
visceral metastases.15 The prognosis for patients diagnosed with TNBC is 
poor, with patients who respond poorly to adjuvant treatment exhibiting 
worse outcomes.3   
 
TNBC has been categorized into a number of distinct molecular subtypes; 
however, there remains much intertumoural mutational and transcriptional 
heterogeneity within these subtypes. The molecular heterogeneity of TNBC 
confounds the clinical approach to TNBC treatment.16 TNBCs are 
characterized by high clonal frequencies of single gene mutations in key 
tumorigenesis driver genes, including p53, PIK3CA, and PTEN, indicating 
that clonal evolution of these mutated genes is an early event in TNBC 
development.16 However, mutation frequencies within these genes are not 
uniform amongst TNBC cases.16,17  
 
Lehmann et al.18 determined the gene expression signatures in 587 TNBC 
cases from 21 breast cancer datasets, and identified six molecularly distinct 
TNBC subtypes. These include basal-like 1 (BL1), basal-like 2 (BL2), 
immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), 
and luminal androgen receptor (LAR). These subtypes, various gene 
ontology pathways, and associated Wnt genes are described in Table 1. 
Recent RNA profiling performed by Burstein et al.19 showed overlap of LAR 
and MES subtypes based on Lehmann’s gene expression profiling, but was 
unable to reproduce all observations.19 The findings of both these studies 
indicate the presence of at least four molecularly distinct and stable TNBC 
subtypes, defined as luminal androgen receptor (LAR), mesenchymal (MES), 
basal-like immune-suppressed (BLIS), and basal-like immune-activated 
(BLIA).19 Furthermore, these studies suggest molecular targets for the 
development of therapeutics specific to the treatment of TNBC.  
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1.2.1 LAR subtype 
The LAR subtype accounts for approximately 10% of TNBCs, whereby 
tumour cells exhibit positive staining of androgen receptors (ARs) and are 
driven by AR signalling.14,18 There is some discordance within the literature in 
regards to the prognostic utility of AR status, with studies indicating no 
significant effect on survival rates associated with AR expression20, although 
AR+ TNBC individuals have been shown to have a positive clinical response 
to the nonsteroidal antiandrogen, bilcautamide.21,22 In a study designed to 
test the benefit of tamoxifen on ER- and TNBC patients, it was found that 
expression of AR+ versus AR- individuals predicted a decreased recurrence 
rate and treatment benefit with AR+ patients;23 this is a result of tamoxifen 
exhibiting agonist activity on AR expressing cells.24  
 
1.2.2 MES subtype 
The MES subtype, encompassing Lehmann’s mesenchymal (M) and 
mesenchymal stem-like (MSL) and claudin-low subtypes, is characterized by 
the overexpression of genes associated with cellular motility, proliferation, 
and growth signalling pathways.18,19 MES subtypes have high expression of 
platelet derived growth factor, insulin-like growth factor 1, and c-kit.19 MES 
tumours express mesenchymal stem cell markers, including the breast stem 
cell marker ALDH1A1, and are enriched in genes associated with epithelial-
mesenchymal transition (EMT) and other stem-like properties.18,25 Within 
Lehmann’s M and MSL subtype, there are a number of enriched genes 
associated with EMT that are also modulated by Wnt signalling, including 
metalloproteinase-2 (MMP2), Twist-related protein 1 (TWIST), Zinc finger 
protein SNAI2 (SNAI2), and Transcription factor 7-like 2 (TCF4).26 A gene set 
involved in Wnt/β-catenin signalling in the M and MSL subtypes, including β-
catenin (CTNNB1), Dickkopf-related protein 2 (DKK2), Dickkopf-related 
protein 3 (DKK3), Secreted-frizzled related protein 4 (SFRP4), TCF7L2, and 
Frizzled-4 (FZD4), was also found to be enriched.18 MES tumours are 
associated with a poorer distant metastasis-free survival at five years 
compared to other subtypes, likely associated with increased expression of 
cellular motility genes leading to increased metastasis.18 
	 27	
 
1.2.3 BLIS subtype 
BLIS is characterized as an immune-suppressed TNBC subtype with 
downregulated immune signalling pathways and reduced expression of 
immune function genes.19,27 BLIS tumours exhibit enhanced expression of 
mitotic and cell cycle pathway genes, with overexpression of proliferative 
genes, including CENPF, BUB1, and PRC1,27 Sry-related HMG box (SOX) 
transcription factors, and the immune-regulatory molecule V-domain-
containing T-cell activation inhibitor (VTCN1).19 Survival analysis shows that 
patients with the BLIS subtype TNBC experience lower rates of recurrence-
free survival compared to other TNBC subtypes.27 
 
1.2.4 BLIA subtype 
The BLIA subtype is characterized by upregulation of immune activating 
pathways, with overexpression of signal transducer and activator of 
transcription (STAT) transcription factors and cytotoxic T-lymphocyte-
associated protein 4.19 BLIA tumours have increased levels of lymphocytic 
infiltration and are thus associated with improved disease-free survival rates 
and patient outcomes compared to other TNBC subtypes, although still 
associated with a relatively high risk of recurrence (~20%).19,28  
 
1.3 WNT SIGNALLING  
1.3.1 Wnt signalling pathways 
1.3.1.1 WNT/β-catenin pathway (Canonical pathway) 
There are currently two models of canonical Wnt/β-catenin signalling. In the 
classical model, the destruction complex remains intact in the absence of 
Wnt stimulation (Figure 1A). Casein kinase 1 (CK1) primes β-catenin for 
destruction by phosphorylating Ser45, which then allows activated Glycogen 
synthase kinase 3 (GSK3) to phosphorylate β-catenin at Ser33, Ser37, and 
Thr41.29 The phosphorylated residues of β-catenin interact with the β-
propeller domain of the E3 ubiquitin ligase β-TrCP, which then ubiquitinates 
β-catenin, thus targeting it for proteosomal degradation.30 Wnt/β-catenin 
signalling is initiated by Wnt ligands binding to a Frizzled receptor (FZD), as 
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well as the co-receptors low density lipoproteins 5/6 (LRP5/6). This results in 
activation of FZD, permitting binding of Dishevelled (Dvl)31 and 
phosphorylation of one or more cytoplasmic motifs of LRP5/6. A single 
phosphorylated motif is sufficient to activate Wnt signalling.32 Phosphorylated 
LRP5/6 can then interact with Axin. This interaction destabilizes the β-catenin 
destruction complex, which requires Axin as a scaffold and contains Dvl, the 
serine-threonine kinases casein kinase 1α/β (CK1), glycogen synthase 
kinase 3α/β (GSK3), and adenomatous polyposis coli (APC).33 Destabilizing 
the destruction complex prevents phosphorylation of β-catenin, which then 
accumulates in the cytosol before translocating to the nucleus. Once there, it 
binds to Transcription factor/lymphoid enhancer-binding factor (TCF/LEF) 
transcription factors and displaces transcriptional repressor Groucho to 
initiate the transcription of Wnt target genes (Figure 1B).34 
In the new model,35-37 the destruction complex is stabilized by Axin in both 
the presence and absence (Figure 1C) of Wnt activation, and β-catenin is 
degraded through phosphorylation-mediated recognition by β-TrCP in the 
intact complex. This allows newly synthesized β-catenin to accumulate in the 
cytosol before nuclear translocation (Figure 1D). This was demonstrated 
through co-immunoprecipitation, whereby β-catenin phosphorylated at 
Ser33/Ser37/Thr41 was shown to interact with the destruction complex upon 
Wnt activation, which also disrupted the interaction of β-TrCP with the Axin1-
β-catenin complex.36 It has also been proposed that GSK3 inhibition, and 
thus β-catenin translocation after Wnt activation, is mediated through the 
sequestration of GSK3 inside multivesicular endosomes.38 This further 
demonstrates the complexity of Wnt signalling. 
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Figure 1.1. Classical and new Wnt/β-catenin canonical and non-canonical pathways. A. 
Overview of the ‘classical’ model of Wnt/β-catenin signalling in OFF state with no ligand 
bound to FZD receptor B. Overview of the ‘classical’ model of Wnt/β-catenin signalling 
pathway in the ON state where Wnt ligand is bound to FZD receptor. C. Overview of the 
‘new’ model of Wnt/β-catenin signalling in ON state with Wnt ligand bound to FZD receptor. 
D. Overview of ‘new’ model of Wnt/β-catenin signalling in OFF state with no ligand bound to 
FZD receptor. E. Overview of Wnt planar cell polarity pathway (PCP) in ON state. Wnt binds 
multiple receptors including FZD and co-receptors ROR and Ryk. This activates Rho and 
Rac, which activate ROCK and JNK respectively, leading to actin polymerization and 
regulation of cytoskeletal arrangements.  F. Overview of Wnt/Ca2+ pathway in the ON state. 
Wnt is able to bind FZD, Ryk to initiate signal transduction which is effected through Dvl and 
G-proteins (α, β, γ). Gene transcription is induced through proteins PKC, CaMKII, and Cn 
(Calcineurin) activating transcription factors. 
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1.3.1.2 Planar cell polarity (PCP) pathway 
The PCP pathway (Figure 1E) is a non-canonical, b-catenin independent 
pathway that regulates cellular organisation and polarity, partly through 
cytoskeletal organisation.39 Wnt ligands, such as Wnt5a, bind to FZD 
receptors and co-receptors, including ROR, 40 Ryk,41 and PTK.42 Dvl 
interacts with Rac143 and Dishevelled-associated activator of morphogenesis 
1 (DAAM1). Rac1 activates c-Jun N-terminal kinase (JNK), leading to actin 
polymerization,43 while DAAM1 activates Rho, which in turn activates Rho-
associated kinase (ROCK) to regulate cellular cytoskeletal arrangements.44 
 
1.3.1.3 WNT/Ca2+ pathway  
The Wnt/Ca2+ pathway (Figure 1F) is activated through Wnt binding to FZD, 
which interacts with G proteins and Dvl.45 These interactions can activate 
cGMP-specific phosphodiesterase or phospholipase C, resulting in a release 
of intracellular calcium. This results in the activation of downstream signalling 
proteins, Protein kinase C (PKC), calcineurin, and Calcium/calmodulin-
dependent protein kinase II (CaMKII).46 CaMKII activates nuclear factor of 
activated T-cells (NFAT), which can regulate cell adhesion and migration.47 
Wnt5a induces activation of CaMKII-dependent Wnt/Ca2+ signalling. CaMKII 
phosphorylates transforming growth factor b-activated kinase (TAK1), which 
activates Nemo-like kinase (NLK).48 This cascade antagonizes canonical 
Wnt/b-catenin signalling by NLK phosphorylation of TCF4 and prevents the 
b-catenin-TCF4 complex from binding to DNA.49  
 
1.3.2 WNT SIGNALLING COMPONENTS 
1.3.2.1 WNT ligands 
To date, 19 members of the Wnt family have been identified in mammals, all 
ranging between 350-400 amino acids in length and characterized by a 
conserved fold containing a conserved motif of 24 cysteine residues (Figure 
2A).50 Wnt ligands are modified by lipidation, specifically, the addition of a 
palmitoleyl group to a conserved serine by the membrane bound O-
acyltransferase Porcupine (PORCN).51 Wnt lipidation is crucial for secretion 
from the endoplasmic reticulum 52 and essential for Wnt function. Wnt 
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lipidation was initially suggested to occur at Cys77 of Wnt3a (cysteine 3 of 
the Wnt fold);53 however, lipidation at this cysteine has been conclusively 
disproven by crystallographic,54 mutational, 52 and imaging studies.51 
 
1.3.2.2 Frizzled (FZD) receptors 
FZD receptors are a group of ten membrane proteins featuring an 
extracellular cysteine-rich domain (CRD) and a seven-transmembrane (7TM) 
domain.55 Along with the Smoothened receptor (Smo), the FZDs comprise 
the family of Class F G protein-coupled receptors (GPCRs). The crystal 
structure of XWnt8 in complex with the mouse FZD8 CRD54 revealed an 
unusual interaction involving the direct binding of the Wnt lipid to a binding 
site on one side of the CRD (the “thumb” region), as well as the binding of 
the region from cysteines 19-22 of XWnt8 to the other side of the CRD (the 
“index finger” region) (Figure 2A).56 Although no complete structures are 
available for any FZD, several structures of Smo are known,57-59 most 
recently including both the CRD and 7TM regions (Figure 2B),60 which are 
suggestive of the likely structure of FZD.  
 
1.3.2.3 Disheveled (DVL) 
Three Dvl homologues are known (Dvl1/2/3), sharing high overall sequence 
similarity.61 Dvl consists of three structurally-defined domains: the DIX, PDZ, 
and DEP domains. These three domains are separated by large insertions of 
unknown structure (Figure 2C); however, some functional significance has 
been ascribed to conserved sequences within the unstructured regions.62 
Dvl polymerizes via the head-to-tail interaction of its DIX domain (Figure 2D). 
The DIX domain also mediates interaction with Axin.63 Mutations (V67A, 
K68A, Y27D) in the polymerization interface of the DIX domain strongly 
suppress Wnt signalling.64 The PDZ domain of Dvl (Figure 2E) interacts with 
a conserved motif in the FZD C-terminal (KTxxxW).45 The PDZ-FZD 
interaction is relatively weak, and is likely supplanted by interactions of the 
DEP domain with FZD. Greater insight in the role of the DEP domain in Wnt 
signalling was recently revealed, with this domain shown to bind as a 
monomer to FZD, then undergo subsequent domain swapping to assemble 
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Wnt signalosomes. Furthermore, upon Wnt stimulation, DEP domain 
swapping initiates DIX-dependent Dvl and Axin polymerization, leading to the 
inhibition of GSK3 and Wnt signal transduction. Mutants (E499G, D460K, 
G436P, K438M, D449I, and D452I) in the DEP domain strongly diminish Wnt 
signalling upon Wnt stimulation (Figure 2F)65,66. Dvl has also been shown to 
promote ubiquitination-mediated FZD degradation by RNF43.67 This finding 
suggests a dual agonist/antagonist role for Dvl in Wnt signalling. 
 
1.3.2.4 Low density lipoprotein receptor 5/6 (LRP5/6) 
The extracellular domain of LRPs consists of 4 b-propeller repeats 
interspersed with epidermal growth factor (EGF) repeats, followed by three 
LRP type A repeats (Figure 2G).31 The majority of Wnts bind to the first b-
propeller/EGF repeat (P1E1-P2E2), although Wnt3 and 3a preferentially bind 
to the second repeat (P3E3-P3E4).68  Wnt3 and Wnt3a binding to LRPs is 
competitively inhibited by Dickkopf (Dkk) binding to LRP (Figure 2H).69-71 The 
intracellular action of LRP5/6 is less clearly understood, although it is known 
that Wnt activation initiates phosphorylation of the intracellular PPPSPxP 
motifs of LRP5/6 by GSK3 and CK1, allowing the recruitment of Axin.72 
Importantly, it has also been shown that without the FZD-Dvl interaction, Wnt 
is unable to induce phosphorylation of LRP6, reinforcing the complex 
interplay of proteins involved in Wnt signalling.45,72  
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Figure 1.2. Molecular structures of key Wnt signalling proteins and interactions. A. X-ray 
crystal structure of the Xenopus Wnt8 complex with the mouse FZD8 cysteine-rich domain 
(PDB 4F0A). Key structural regions of the Wnt fold are highlighted, as are the major Wnt-
interacting regions of the CRD. B. X-ray crystal structure the Smoothened receptor (PDB 
5L7D), a Class F G protein-coupled receptor, related to FZD. Key structural regions of Smo 
are highlighted, as well as helix 8, which is of relevance for Dishevelled binding by FZD. C. 
Schematic representation of the location of the DIX, PDZ, and DEP domains within Dvl. D. 
X-ray crystal structure of the DIX homodimer (PDB 4WIP). E. X-ray crystal structure of the 
PDZ domain bound to a peptide (red) (PDB 3CBX). The peptide-binding site is shown in 
yellow. F. X-ray crystal structure of a DEP homodimer (PDB 5LNP), highlighting residues 
known to affect Wnt signalling (shown in red). G. Model of the LRP6 ectodomain generated 
by molecular dynamics flexible fitting of the crystal structures of the P1E1-P2E2 domains 
(PDB 3S94) and P3E3-P4E4 domains (PDB 4A0P), and a homology model of the LDL-R 
type A domains (generated in Prime, based on the crystal structure of the LDL receptor 
ectodomain (PDB 1N7D)) to the electron microscopy structure (EMDatabank accession 
1964). Gaps in the crystal structures and between the various components modelled using 
Prime. H. X-ray crystal structure complex of the cysteine-rich domain 2 of Dickkopf with 
Kremen and the LRP6 P3E4-P4E4 domains (PDB 5FWW) Figures from Pohl et al, 2017.7 
 
1.3.2.5 ROR-Family receptor tyrosine kinases (RTKs) 
The ROR-family of receptor tyrosine kinases (RTKs) consists of two 
evolutionarily conserved members, ROR1 and ROR2.73 The ROR 
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ectodomains feature a FZD-type CRD most closely related to that of the 
skeletal muscle receptor tyrosine-protein kinase (MuSK)74. ROR2 is involved 
in Wnt5a-mediated signalling; Wnt5a binding to ROR2 initiates ROR2 
homodimerization, stimulating autophosphorylation at Tyr646. 75 It has been 
demonstrated that Wnt5a and Wnt3a both bind to ROR2; however, only 
Wnt5a is able to initiate the activation of the ROR2 signalling cascade.76 
Recently, high expression of ROR1 has been demonstrated in TNBC cell 
lines, where it interacts with CK1e to promote tumour survival and growth 
after stimulation with Wnt5a to activate phosphoinositide 3-kinase 
(PI3K)/AKT signalling.77  
 
1.3.3 WNT ANTAGONISM AND SECRETED FRIZZLED-RELATED 
PROTEINS 
There are two classes of antagonists that inhibit canonical and/or non-
canonical Wnt signalling. The first class are secreted factors that can bind to 
either the Wnt ligands or FZD receptors. Included in this class are the 
secreted frizzled-related proteins (SFRPs), Wnt inhibitory factors (WIFs), 
Cerberus, and soluble Adenomatosis polyposis coli down-regulated 1 
(APCDD1) 78. The second class of Wnt antagonists can bind to LRP5/6 co-
receptors, such as Dkk, Wise/SOST, and Insulin-like growth factor binding 
protein 4 (IGFBP4).78 A subclass of Wnt signalling negative regulators 
includes the membrane bound proteins RNF43/ZNRF3 and Tiki. 
RNF43/ZNF3 are E3 ubiquitin ligases that downregulate FZD receptors 
through ubiquitin-mediated endocytosis in a Dvl-dependent manner.67,79 
Furthermore, RNF43/ZNRF3 have been demonstrated to be direct targets of 
TCF4 transcription, suggesting an evolutionarily conserved mechanism to 
regulate turnover of FZD receptors and thereby mediate Wnt signalling.80 
Tiki, a recently discovered Wnt signalling antagonist, proteolytically cleaves 
Wnt ligands, resulting in reduced receptor binding.81 
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Figure 1.3. Model of Wnt signalling antagonism. Wnt signalling antagonism can occur 
through proteolytic cleavage of Wnt ligands mediated by TIKI1, RNF43 dependent ubiquitin-
mediated Frizzled receptor endocytosis and degradation, and Wnt ligand antagonism 
through SFRPs inhibiting Wnt binding to Fzd, and Dkk inhibiting Wnt binding to LRPs. This 
can result in a decrease in signal transduction in both canonical and non-canonical Wnt 
signalling.  
 
1.3.3.1 Secreted Frizzled Related Proteins (SFRPs) 
Secreted frizzled-related proteins (SFRP1–5) are a family of secreted 
glycoproteins that classically act as antagonists of Wnt ligands.82 Structurally, 
SFRPs consist of two ordered domains, an N-terminal cysteine-rich domain 
(CRD) and a C-terminal netrin-like domain (NLD); the structure of a Xenopus 
analogue, Sizzled, was recently revealed (Figure 4). Wnt antagonism has 
been reported to be mediated through the CRD78, although SFRP1 has been 
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demonstrated to bind to the Wnt Drosophila orthologue Wingless (Wg) in a 
CRD-independent manner83. SFRPs have also been demonstrated to bind to 
numerous proteins involved in other signalling pathways, including integrins 
84,85 and epidermal growth factor (EGF).86  
 
Figure 1.4. Structure of Xenopus Sizzled. Ribbon model of Xenopus Sizzled including the 
cysteine-rich domain (blue) and netrin-like domain (pink) with inter-domain linker (residues 
143-154). (PDB 5XGP) 
 
1.3.3.2 Secreted Frizzled-Related Protein 4 (SFRP4) 
The SFRP4 gene is located on the short arm of chromosome 7 (7p14.1) and 
codes for a 346 amino acid protein with a molecular weight of 39.9kDa.78 
SFRP4 (formerly DDC-4) was originally discovered through differential 
display in the mammary gland and corpus luteum undergoing apoptosis and 
has been implicated in various diseases, including cancer and diabetes.87,88 
Hypermethylation of the promoter region of the SFRP4 gene in cancerous 
tissue has been linked to its downregulation and the subsequent progression 
of carcinogenesis, presumably through increased Wnt signalling.89 The 
exogenous addition of SFRP4 to cancer cells with demonstrated SFRP4 
gene downregulation has shown its pro-apoptotic and anti-angiogenic role.90 
Recently, in studies of glioblastoma multiforme (GBM), ovarian, head and 
neck, prostate, and breast cancer stem cells, the addition of SFRP4 has 
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been shown to induce mitochondrial outer membrane permeability (MOMP)-
mediated apoptosis.91-93 Furthermore, the addition of SFRP4 in the same 
cells has a demonstrated additive effect on their response to first-line 
chemotherapeutics.91 The role of SFRP4 in inducing apoptosis and 
antagonising the canonical and non-canonical Wnt signalling pathways has 
led to its interest as a potential therapeutic option and a lead molecule for 
pharmaceutical development.    
1.3.4 WNT DYSREGULATION IN TNBC AND TNBC STEM CELLS 
Aberrant Wnt signalling is a characteristic of TNBC, with both canonical and 
non-canonical pathways implicated in TNBC tumorigenesis94,95 and 
metastasis.96 Enrichment of Wnt/β-catenin signalling is evident in TNBC and 
is associated with poor clinical outcomes within this subtype.97,98 TNBC 
patients displaying dysregulated Wnt/β-catenin signalling are more likely to 
develop lung and brain secondary metastases.96 Studies have shown that 
nuclear accumulation of β-catenin promotes cell migration, colony formation, 
stem-like features, and chemoresistance of TNBC cells in vitro, and TNBC 
tumorigenesis in mouse cancer models; thus suggesting that canonical Wnt 
signalling is a major driving force of TNBC tumorigenesis.94 Although the 
Wnt/β-catenin pathway is associated with the clinicopathological features of 
TNBC, this is not due to CTNBB1 mutations.98 Studies have also implicated 
dysregulation of non-canonical Wnt signalling pathways in the highly 
metastatic behaviour of TNBC cells and cancer stem cells, specifically 
through aberrant JNK activation.99  
 Cancer stem cells (CSCs), or cancer stem-like cells, are a small 
subset of cells within the heterogeneous tumour bulk that are thought to be 
responsible for tumour initiation.100 These cells also have intrinsic 
mechanisms for chemoresistance, such as upregulation of drug transporters, 
including the breast cancer resistance protein (also known as ABCG2).101 By 
evading the standard chemotherapeutic treatments, it is thought the CSCs 
are also responsible for the relapse experienced in many cancers, especially 
TNBCs.102 Studies have also shown that these cells are a main contributor to 
metastasis, and are able to initiate solid tumour formation when 
xenotransplanted at low cell densities.103 TNBC stem cells are isolated from 
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tumours as CD44+ (homing cell adhesion molecule), CD24- (heat stable 
antigen), CD49f+ cells.104 CSCs also differ metabolically to other cancer cells. 
They are more reliant on mitochondrial respiration, which is supported by 
their higher mitochondrial reactive oxygen species, enhanced oxygen 
consumption, and higher mitochondrial mass, allowing for features such as 
resistance to DNA damage.105  
Wnt signalling is essential for normal breast stem cell function and 
mammary gland development during embryogenesis, postnatal development, 
and pregnancy,106 with adult mammary glands containing Wnt-responsive 
stem cell populations.107 Studies have shown that aberrant Wnt signalling in 
breast cancer stem cells (BCSCs) is a key event in breast tumorigenesis.108 
Wnt/β-catenin signalling has been linked to TNBC tumorigenesis by 
regulating key tumour-associated characteristics, including migration, 
stemness, proliferation, and chemoresistance in TNBC cells and CSCs.94 A 
recent study has also demonstrated that Wnt/β-catenin signalling activity is 
higher in breast CSCs than the bulk tumour population, based on β-catenin, 
TCF4, and LEF1 expression in Aldefluor positive cells versus Aldefluor 
negative cells.109 Treatment with Wnt3a increased the number of ALDH+ 
breast CSCs, and knockdown of Wnt1 reduced the tumour forming efficiency 
of breast CSCs in vitro.109 
Studies have shown that Wnt-derived breast tumours are 
maintained by clones capable of re-activating Wnt overexpression post Wnt 
inhibition, indicating that aberrant Wnt activation is a key driver of breast 
cancer recurrence and progression.110 A recent review highlighted the 
potential importance of Wnt/β-catenin signalling, along with other 
developmental signalling pathways, including Cripto-1 and Notch/CSL, in the 
regulation of TNBC stem cells and therapy resistance in TNBC.111  
The TNBC subtypes also display characteristics associated with 
increased Wnt signalling. The LAR subtype of TNBC displays genomic 
amplification of CCND1, a gene regulated by the Wnt/β-catenin pathway. 19 
This BLIS subtype contains increased SOX transcription factor expression, 
which share a closely related consensus binding sequence to TCF/LEF 
transcription factors 112 and are known modulators of Wnt/β-catenin 
signalling. 113 Furthermore, the BLIA subtype demonstrates amplification of 
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CDK1, which was recently found to phosphorylate the Wnt regulator TAZ. 
19,114. A table summarising the genes found with Wnt association in the 
Lehmann subtypes can be found in Table 1. 
 
Table 1.1. Molecular subtypes of TNBC and their association with Wnt 
signalling 
TNBC Lehmann et 
al Subtype 
Gene Ontology 
Pathways (GOP) 
Genes found in GOPs 
with Wnt association 
Luminal Androgen 
Receptor (LAR) 
Steroid pathway FKBP5115 
 Androgen metabolism SPDEF116 
 Fatty acid synthesis FASN117 
Mesenchymal 
(M)/Mesenchymal 
stem-like (MSL) 
EMT 
 
MMP226, SNAI226, 
TCF426, TWIST126, 
ZEB1118 
 Wnt/β-catenin signalling CTNNB118, DKK2/318, 
TCF418, TCF7L218, 
CCND218, FZD418, 
CAV118, CAV218 
Basal 1 (BL1)/ Basal 
2 (BL2) 
DNA Damage CHEK1119, FANCA120, 
FANCG120, MSH2121, 
RAD21122 
 Proliferation/Cell Cycle AURKB123, PLK1124, 
CENPA124, BUB1124, 
CCNA2125, PRC1126, 
MYC127, NRAS128 
Immunomodulatory 
(IM) 
JAK/STAT Cytokine 
Pathway 
CCR2129, CCR5130 
 
 IL7 Pathway IL7131 
Table 1. Summary of the six molecular subtypes of TNBC characterized by Lehmann et al18. 
Various gene ontology pathways were found to be enriched in the LAR, MSL, BL1, BL2, and 
IM subtypes. Analysis of the genes enriched in these pathways identified genes associated 
with Wnt signalling.  
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1.3.4.1 FZDs in TNBC 
1.3.4.1.1 FZD6 
FZD6 exhibits increased gene copy number variations and overexpression in 
breast cancers. This is more frequent in TNBC than ER+ tumours. A study by 
Corda et al. 132 determined that FZD6 was involved in the regulation of cell 
motility, invasion, and 3-D growth, although it did not regulate proliferation in 
TNBC. This was confirmed by a significant reduction in distant metastases 
detected in various organs in vivo after the injection of MDA-MB-231 TNBC 
cells depleted of FZD6. shRNA directed at FZD6 in vitro was found to reduce 
cell invasion through a reduction in active Rho and the subsequent reduction 
in fibronectin fibres. This indicated that FZD6 regulates cell motility and 
invasion through non-canonical Wnt signalling. This study also suggests that 
FZD6 overexpression in TNBC has a high prognostic value in determining 
the risk of metastasis.132 
 
1.3.4.1.2 FZD7 
Microarray analysis determined that FZD7 expression is upregulated in 
TNBC tissue and cell lines, and promotes tumorigenesis via canonical Wnt 
signalling pathways.133 shRNA-mediated silencing of FZD7 reduced 
invasiveness and colony formation in TNBC cell lines.133 A recent study 
found that ΔNp63, an isoform of Transformation-related protein 63 (p63), 
enhanced FZD7 expression and increased Wnt signalling in TNBC tumour 
tissue and cell lines.134  
Aberrant FZD7 expression is implicated in TNBC stem cell-
mediated tumorigenesis. A study recently found that knockdown of ΔNp63 in 
TNBC cell lines decreased FZD7 expression and tumoursphere formation, 
indicating that ΔNp63/FZD7 upregulation induced TNBC stem cells and 
promoted tumour formation in TNBC.134 The findings of this study highlight 
the potential clinical importance of ΔNp63/FZD7-Wnt signalling in TNBC 
stem cells as a key driver of tumorigenesis and progression of TNBC.134,135  
 
1.3.4.1.3 FZD8 
Gene expression studies have recently linked FZD8-driven Wnt signalling to 
chemoresistance in TNBC cell lines and TNBC stem cells. Treatment with 
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cisplatin and tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL) in TNBC cell lines resulted in increased FZD8 expression in residual 
tumours of xenograft models.136 Furthermore, FZD8 silencing led to 
increased Wnt pathway-driven TNBC cell apoptosis in vitro and in vivo.136 
The study showed that treatment with TRAIL/cisplatin increased expression 
of LEF-1 and TCF-7 in residual TNBC stem cells, thus implicating 
upregulation of Wnt signalling components in the development of 
chemoresistance.136 An inverse correlation between FZD8 and miR-100 was 
shown, where decreased miR-100 expression was linked to increased FZD8 
expression and Wnt signalling, resulting in increased loco-regional breast 
cancer metastasis.136,137 The role of microRNAs in Wnt signalling and TNBC 
is discussed in further detail below. c-Myc overexpression has been linked to 
FZD8 overexpression in TNBC cell lines, associating c-Myc driven 
transcription to chemoresistance and TNBC cancer stem cell survival.138  
 
1.3.4.2 LRP5/6 in TNBC  
LRP5/6 are essential for normal mammary development by regulating breast 
stem cell activity and are linked to basal-derived breast tumorigenesis.139-141 
Studies in transgenic mice indicated that LRP5 knockdown led to resistance 
to Wnt1-induced tumour formation.140  
Gene expression analyses found that LRP6 is overexpressed in 
human TNBC.133,141 In vivo studies have shown that LRP6 silencing inhibited 
tumour growth in TNBC cell line-derived xenograft models.142 LRP6 and Wnt 
target gene SOX9 have been shown to influence regulation of one another in 
TNBC cell lines. LRP6 overexpression lead to SOX9 upregulation, while 
knockdown of SOX9 reduced LRP6 transcription, and decreased cell 
invasion and proliferation.143 
LRP6 overexpression led to the upregulation of Wnt signalling and 
was associated with increased stemness in TNBC cells.144 CD138 
(Syndecan-1) is an EMT marker associated with both development and 
breast tumorigenesis,145 and has been shown to modulate TNBC stem cell 
properties by targeting Wnt signalling.144 Ibrahim et al.144 showed that CD138 
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modulates Wnt signalling in TNBC stem cells through LRP6, whereby CD138 
silencing resulted in downregulated LRP6 expression and Wnt signalling.144  
 
1.3.4.3 RORs in TNBC 
Primary breast cancer cDNA microarray dataset analysis has shown that 
ROR1 is expressed in breast cancer cells and absent in normal breast cells, 
with high ROR1 expression associated with poorer survival.146 Furthermore, 
the study showed that ROR1 silencing in TNBC cell lines increased 
apoptosis and reduced cell growth. High ROR1 expression in breast cancer 
cells is associated with high expression of EMT gene profiles and high 
incidences of disease recurrence and progression.147 ROR1 knockdown in 
TNBC cell lines resulted in reduced EMT-associated protein expression, 
reduced cell migration and invasion in vitro, and inhibited metastasis in 
xenograft models.147 ROR2 expression is present in both TNBC and non-
TNBC, with ROR2+ TNBC patients exhibiting poorer survival outcomes 
compared to other subtypes.148 The study found that ROR2 knockdown in 
TNBC cell lines inhibited Wnt signalling and reduced TCF/LEF 
transcription.148 These findings indicate the potential prognostic and 
therapeutic significance of high ROR1/2 expression in TNBC. 
 
1.3.5 CURRENT AND EMERGING THERAPIES FOR TNBC AND TNBC 
STEM CELLS 
Systemic cytotoxic chemotherapy is clinically indicated in early TNBC and is 
associated with a greater treatment benefit and reduced reoccurrence rate 
than hormone receptor positive tumours.149 Numerous early phase clinical 
trials are currently underway, investigating various targeted molecules and 
combination therapies for the treatment of TNBC. In this section, we review 
current and emerging small molecule therapeutics for the treatment of TNBC 
(Figure 1.5); immunotherapeutics are reviewed elsewhere.6 
 
1.3.5.1 Chemotherapy 
Anthracycline/taxane-based regimens are currently the standard of care in 
the treatment of adjuvant and neoadjuvant TNBC. However, a recent in vitro 
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study has shown that treatment with docetaxel or doxorubicin had transient 
and negligible impact on cell growth in two TNBC cell lines respectively, 
which may be due to the molecular subtype of the cell lines. Furthermore, the 
study found that docetaxel and doxorubicin treatment resulted in deregulation 
of genes associated with stemness in TNBC cells.150 Molecular analysis 
found that doxorubicin treatment deregulated stem cell signalling pathways 
associated with cell growth, renewal, and differentiation, with altered gene 
expression demonstrated in components of the Wnt signalling pathway, 
including FZD2, FZD4, FZD5, FZD6, FZD7, FZD9, Axin1, Wnt11, Wnt10a, 
and Wnt5a. As such, the study concluded that docetaxel and doxorubicin 
induce stemness in differentiated TNBC cells, which likely accounts for 
acquired chemoresistance seen in refractory TNBC tumours.150 
 
1.3.5.2 Platinum Agents 
Platinum-based chemotherapeutics are a class of DNA-damaging agents, 
including cisplatin, carboplatin, and oxaliplatin; these have established 
efficacy in breast cancer treatment.151 In vitro studies have indicated that 
combining TRAIL and cisplatin significantly increased BCSC death compared 
to other standard of care treatments in TNBC cell lines.152 The study showed 
that treatment with TRAIL and cisplatin inhibited Wnt1-mediated signalling 
and expression of cyclin D1, as well as the phosphorylation of β-catenin. 
Combination treatment with cisplatin and TRAIL also enhanced apoptosis, 
and inhibited proliferation and tumoursphere formation.152 
 
1.3.5.3 Wnt signalling inhibitors 
Treatment with the small molecule β-catenin/TCF inhibitor CWP232228, 
inhibited β-catenin-mediated transcription, leading to inhibition of stem cell 
proliferation and reduction in tumour bulk in TNBC cell lines and TNBC 
patient-derived xenograft models respectively.153 PRI-724, a CREB-binding 
protein inhibitor, and LGK-974, a Porcupine inhibitor, are two small 
molecules currently undergoing clinical development. Both molecules are 
currently under investigation for single agent use in ongoing phase I clinical 
trials in TNBC patients,154 with interim results yet to be released. Recent in 
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vitro studies have shown that LGK-974 in combination with the 
PI3K/AKT/mTOR inhibitor BKM120, worked synergistically to decrease cell 
viability and enhance anti-tumour efficacy in TNBC cell lines.155 
 
1.3.5.4 PARP inhibitors 
Poly (ADP-ribose) polymerase (PARP) is an enzyme involved in DNA repair 
mechanisms necessary for maintaining BRCA-mutated cell viability.156,157 
Included in the PARP enzyme family are tankyrase-1 (TNKS1) and 
tankyrase-2 (TNKS2). TNKS1 and TNKS2 are regulators of Wnt signalling 
through their interaction with Axin.158,159 Many TNBCs share phenotypic 
characteristics with BRCA-mutated cancers, thus providing support for the 
use of PARP inhibitors (PARPi).160 The small molecule TNKS1/2 inhibitor 
XAV939 showed effectiveness in the destabilization of Axin and reduction of 
Wnt activity, although data suggest a combination approach may be more 
beneficial.159 Clinical trials evaluating the oral PARP inhibitor (PARPi) 
olaparib in BRCA1/2 positive metastatic breast cancer are currently 
underway, with interim results showing efficacy.161 Veliparib is another 
PARPi currently being evaluated in combination with paclitaxel and 
carboplatin for metastatic TNBC.162 Data from Phase I clinical trials of 
veliparib show acceptable safety, tolerance, and good anti-neoplastic 
activity.162  
 
1.3.5.5 HDAC inhibitors 
Histone deacetylase inhibitors (HDACis) are emerging as promising anti-
TNBC agents due to their multifunctional capacity to regulate gene 
expression, cell growth, and survival, as well as their ability to restore cellular 
aberrations due to epigenetic effects.163 Entinostat is an HDACi recently 
shown to have anti-CSC effects in TNBC stem cells. An in vivo study found 
that entinostat treatment reduced TNBC stem cell populations, tumoursphere 
formation, and miR-181a expression in TNBC cell lines.164 Furthermore, the 
study found that entinostat treatment in TNBC patient-derived xenografts 
reduced tumour growth and inhibited the development of lung metastases.164 
Further in vivo studies have shown that triple therapy, combining entinostat, 
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all-trans retinoic acid, and doxorubicin, induced apoptosis of TNBC stem 
cells in culture and induced differentiation of TNBC CSCs both in vitro and in 
vivo.165 Panobinostat (LBH589) decreased cell survival and cell cycle 
progression at the G2/M stage in TNBC cell lines and in vivo. It also 
increased acetylation of the histones H3 (Lys3) and H4 (Lys8).163 Treatment 
with panobinostat upregulated cadherin-1 (CDH1) and reversed the 
mesenchymal phenotype; CDH1 has been identified as a Wnt signalling 
component in invasive breast carcinoma.166 An in vivo study found that 
salinomycin, a compound that selectively inhibits CSCs,167 in combination 
with panobinostat, significantly inhibited the growth of TNBC stem cells in 
TNBC patient-derived xenografts. The study found salinomycin and 
panobinostat worked synergistically to inhibit cell cycle progression, enhance 
apoptosis, and regulate EMT in TNBC stem cells.167  
 
 
 
 
 
 
 
 
 
Figure 1.5. Overview 
of Wnt signalling 
regulators 
contributing to TNBC 
progression and their 
targeted therapies. 
Canonical and non-
canonical Wnt 
pathways are 
activated through 
Fzd, LRP, and ROR 
receptors. Blue 
arrows indicate 
suppression or 
inhibition of Wnt 
regulators and 
pathways (with a net 
result of 
downregulation of 
Wnt target gene 
transcription, 
indicated by yellow 
cross), red arrows 
indicate activation of 
Wnt regulators and 
pathways.
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1.4 DEAD-BOX RNA HELICASE FAMILY 
1.4.1 Structure of DEAD-Box family proteins 
DEAD-Box helicases (DDXs) are characterised by an evolutionarily 
conserved motif of D-E-A-D (Asp-Glu-Ala-Asp) in the Walker B (II) motif of 
the helicase core. There are currently 44 DEAD-box proteins identified within 
the H.sapiens genome, with many of these being assigned yeast 
orthologues.168 The N-terminus of DEAD-box proteins contains the helicase 
core, made up of two separate domains; domains 1 and 2, which resemble 
the recombinase A (RecA) protein found in bacteria. Domain 1 contains the 
Q, I, Ia, Ib, Ic, II and III motifs. Domain 2 contains the IV, Iva, V, Va, and VI 
motifs. Domains 1 and 2 are separated by an amino acid linker, allowing 
flexibility for ATP binding and ATP hydrolysis.169 Within Domain 1 and 2, 
motifs Q, I, II, and VI have been shown to mediate ATP binding, while the Ia, 
Ib, Ic, IV, Iva, and V are mediators of interactions with RNA (Figure 6). The 
DEAD-box proteins belong to a larger family of helicase proteins known as 
the superfamily 2, or SF2. The SF2 superfamily contains proteins that feature 
the Walker B motif, although the D-E-A-D is conserved as D-E-x-D/H (Asp-
Glu-x-Asp/His).170 While the primary role of DEAD-box helicases is 
unwinding, eIF4aIII can act as an RNA clamp during RNA splicing171 through 
its interaction with serine/arginine-rich splicing factor 2 (SRSF2).172  
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Figure 1.6 (previous page). Structure of DEAD-Box helicases. A. Ribbon model of 
DDX19B in view of ATP-binding domain. Light pink = c-terminal domain of helicase core, 
light blue = n-terminal helicase core. ATP analogue ANP-PNP is depicted as ball and stick 
model. Colours of segments correspond to domains within ATP or RNA binding domain. Red 
(Q), Orange (I), Blue (Ia), Teal (Ib), Yellow (II), Olive (III), Sky blue (IV), Green (V), Pink (VI). 
B. Ribbon model of DDX19B rotated 90 degrees to show RNA binding site. C. Schematic 
representation of ribbon models, with domain colours corresponding to the model. Models 
developed from crystal structure of DDX19B (PDB 3G0H).173 
 
 
1.4.2 Functional roles of DEAD-Box helicase proteins 
DEAD-box helicases have functional roles in many aspects of RNA 
metabolism, including transcriptional regulation, ribosome biogenesis, and 
non-sense mediated decay. It has been found that many DDX proteins are 
preferentially expressed in specific tissue and cell types, and have key 
functional roles in the homeostatic or carcinogenic behaviours of these cells. 
DDX protein involvement in RNA metabolism is summarised in Table 2, while 
their associations with cancer are listed in Table 3. 
 
1.4.2.1 DEAD-Box helicases in RNA splicing 
The role of DDX proteins in pre-mRNA splicing has been widely studied in a 
multitude of organisms, including Saccharomyces cerevisiae (yeast), Homo 
sapiens (human), and Drosophila melanogaster (fruit fly). The yeast DDX 
protein, Prp5p, has been demonstrated to activate the U2 small 
ribonucleoprotein (snRNP), a protein that specifically binds to the 
polypyrimidine tract adenine nucleotide, which initiates lariat formation.174  
It was identified that seven different genes all encoding for yeast 
DDX proteins, when mutated, all regulated different steps of spliceosome 
assembly and pre-mRNA splicing. For example, Brr2 regulated ATP-
dependent dissociation of U4/6 snRNPs, while Prp16 initiated the second 
transesterification step.175 The role of DEAD-box proteins in the regulation of 
pre-mRNA splicing and spliceosome assembly is frequently comprehensively 
reviewed. 168-170,176 
 
1.4.2.2 DEAD-Box helicases in stem cells 
DDX proteins are highly involved in the regulation of embryonic (ESC), 
neural stem cells (NS), and haematopoietic stem cells (HSCs). In a 
comprehensive transcriptional profiling analysis of ESCs, NS, and HSCs, 
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DDX1 and DDX4 were found to be enriched in all three cell types.177 DDX4 
(or Vasa) is a cytoplasmic protein expressed in primordial germ cells in both 
males and females. It was found to bind to uracil-rich (U) motifs in the 3’ UTR 
of mRNAs to inhibit miRNA activity and regulate germline stem cell fate.178 
Controversially, it was reported that oogonial stem cells were able to be 
FACS-isolated using DDX4 as a marker; it has subsequently been shown 
that these cells are neither DDX4-positive or germ cells.179,180 
In HSCs, DDX46 was implicated in the regulation of erythropoiesis 
and lymphopoiesis in zebrafish caudal haematopoietic tissue.181 The same 
phenotypic haematopoietic changes were observed in zebrafish with the 
homozygous DDX18 mutation, although the embryos exhibited increased cell 
death in a p53-dependent manner. The same study revealed that non-
synonymous variants of DDX18 are found in human acute myeloid 
leukaemia. 182 
Recently, Li et al.183 determined DDX5 to be a key regulator of 
pluripotency in induced pluripotent stem cells. DDX5 negatively regulated 
somatic reprogramming through downregulation of development-specific 
genes by directly targeting the non-canonical polycomb complex 1 (PRC1) 
subunit RYBP. DDX5 simultaneously increased the transcription of 
pluripotency-associated genes, such as Kdm2b, through RYBP-mediated 
recruitment of OCT4 to their respective promoter regions. 
 
1.4.2.3 DEAD-Box helicases in organelle-specific RNA metabolism 
The mitochondrial genome contains 37 genes, 13 of which are components 
of the electron transport chain (ETC) and are fundamental for oxidative 
phosphorylation (OXPHOS); the others are rRNAs and tRNAs.184 Within the 
mitochondrial matrix exists the RNA granule-contained mitoribosomal 
proteins, assembly factors, and RNA metabolism factors, which translate 
mitochondrial mRNA into nascent polypeptides. It was reported that DDX28 
is a key RNA metabolism factor located within the RNA granule.185 DDX28 
was localised to the mitochondria where depletion of DDX28 resulted in 
decreased OXPHOS assembly and respiration through downregulation of 
Complex I, III, IV, and V. DDX28 interacted with 16s RNA and mt-LSU 
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proteins to regulate mitoribosome biogenesis. Furthermore, it was found that 
this was dependent on its helicase C-terminal domain.185  
 
Table 1.2. Cellular functions of DEAD-Box family members and cellular 
localisations in RNA metabolism. 
FUNCTION DDX FAMILY 
MEMBER 
CELLULAR 
LOCALISATION 
Ribosome biogenesis DDX3X, DDX3Y, DDX5, 
DDX10,DDX18, DDX21, 
DDX24, DDX27, 
DDX31, DDX47, 
DDX48, DDX49, 
DDX50, DDX51, 
DDX52, DDX54, 
DDX55, DDX56 
Nucleus 
Transcription DDX5, DDX17, DDX20, 
DDX21 
Nucleus 
Pre-mRNA splicing DDX3X, DDX3Y, 
DDX23, UAP56, 
DDX42, DDX46 
Nucleus 
RNA export DDX3X, DDX3Y, 
DDX19, DDX25, 
DDX39, UAP56 
Nuclear pore complex 
snRNP biogenesis DDX20 Cytoplasm 
Nonsense mediated 
decay 
DDX48 Cytoplasm 
miRNA processing 
(RISC assembly) 
DDX5, DDX20 Cytoplasm 
Translation DDX2A, DDX2B, 
DDX3X, DDX3Y, DDX4, 
DDX19 
Ribosome 
RNA storage DDX3X, DDX3Y, DDX6 Cytoplasm 
RNA decay	 DDX5, DDX6 Cytoplasm 
Organelle-specific 
RNA metabolism 
DDX28 Mitochondrion 
 
1.4.3 DEAD-Box proteins in cancers 
DDXs are frequently mutated and overexpressed in many cancers. Many of 
the mutations have yet to be determined as possessing oncogenic or loss-of-
function properties, and may be silent mutations.186 
In hormone receptor-positive breast cancer, DDX5 and DDX17 
have been implicated in the activation of oestrogen receptor a (ERa) in a co-
dependent manner. They were determined to be critical in the transcription of 
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ERa target genes and oestrogen-dependent growth. 187 Furthermore, it was 
demonstrated that DDX5/DDX17 regulated alternative splicing of GSK3b, 
controlling the stability of the ER and AR in breast and prostate cancers 
respectively.188 
DDX proteins have been implicated in the progression and 
development of colorectal cancer. DDX3 was shown to drive Wnt-dependent 
tumorigenesis through CK1e and Dvl2, which ultimately lead to inhibition of b-
catenin degradation by PP2A.189 Mechanistically, it was earlier shown that 
DDX3 binds to CK1e, directly activating it to phosphorylate Dvl to promote 
Wnt signalling.190 In colorectal cancer, it was also reported that DDX5 directly 
promoted cell survival by through inhibition of FOXO3a and subsequent 
activation of Akt.191   
A role for DDX proteins in CSCs has also been demonstrated. 
Prominin-1 (CD133) is a common cell surface marker for the sorting of 
cancer stem cells from gliomas and ovarian carcinomas. In ovarian 
CD133positive stem cells, it was found that expression of DDX4 was 
positively correlated with the expression of CD133 and co-localised in 
immunofluorescence evaluation. This was not observed in CD133 negative 
cells.192 
 
1.4.3.1 DDXs in Wnt and TNBC 
1.4.3.1.1 DDX3 
DDX3 is known to play an oncogenic role in breast cancer, where non-
tumorigenic MCF10A cell lines overexpressing DDX3 showed increased 
EMT, motility, and invasiveness.193 The same study demonstrated that DDX3 
expression was positively correlated with a more aggressive phenotype, and 
was highly expressed in TNBC cell lines. DDX3 overexpression resulted in E-
cadherin downregulation and subsequent nuclear β-catenin translocation.193 
Similarly, DDX3 inhibition by NZ51, a ring-expanded nucleoside analogue 
that is predicted to bind to the ATP-binding site of DDX3, led to decreased 
proliferation, motility, and invasiveness in TNBC cell lines and reduced 
tumour load and metastatic burden in preclinical in vivo models.194  
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1.4.3.1.2 DDX5 (p68) 
DDX5 acts as a co-activator of Wnt/β-catenin signalling through regulation of 
TCF4 expression. In turn, β-catenin/TCF4 regulates DDX5 expression, 
forming a positive feedback loop associated with increased EMT marker 
expression in TNBC cells.195 DDX5 is thought to regulate p53-mediated 
repair of DNA damage, and DDX5 overexpression contributes to 
tumorigenesis and progression in breast cancers.196 DDX5 is highly 
expressed in basal-like breast cancers compared to luminal-like, and 
correlates with high epidermal growth factor receptor (EGFR) and Ki67 
expression in TNBC tissue.197 Furthermore, the study found that DDX5 
regulates the expression of miR-21 and miR-182 in basal breast cancers, 
and is associated with malignant disease.  
 
Table 1.3. Associations of DEAD-Box family members in cancers.186 
TUMOUR 
TYPE 
CANCER DEAD-BOX PROTEIN 
SOLID Prostate DDX5, DHX9 
 Hepatocellular carcinoma DDX3, DDX20, DDX27 
 Testicular DHX9 
 Colorectal DDX3, DDX6, DDX5, 
DDX17, DHX32 
 Breast DDX2, DDX3, DDX5, 
DDX17, DDX10, 
DDX18, DDX20, 
DDX21, DDX24, 
DDX43, DHX9 
 Lung DDX2, DDX3, DDX5, 
DHX9 
BLOOD Chronic myeloid leukaemia DDX10, DDX43 
 Chronic lymphocytic leukaemia DDX10, DDX3X 
 Acute lymphoblastic leukaemia DDX3, DDX5, DDX53 
 Acute myeloid leukaemia DDX6, DDX10, DDX43 
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1.4.4 DEAD-Box Helicase DDX20 (Gemin3, DP103) 
DDX20 (Gemin3, DP103) is an evolutionarily conserved protein that can be 
found in the genome of multicellular, eukaryotic, phagotrophic 
bacterivores.198 While there is significant sequence variation in DDX20 
between species, the nine conserved motifs remain present. Structurally, 
DDX20 has the characteristic conserved N-terminal helicase core, and an 
approximately 368 amino acid long, potentially highly phosphorylated (and 
presumably, structurally disordered) C-terminal region that is thought to 
modulate its RNA helicase activity and co-factor interactions.199(Figure 7) 
The C-terminal of DDX20 has been shown to interact with a variety of 
proteins in both Human and Drosophila, and in doing so, regulating a variety 
of cellular functions. These include RNP assembly,200 RNA silencing,201 and 
transcriptional regulation201 in both homeostatic and carcinogenic conditions. 
 
 
Figure 1.7. Sequence comparison of DDXs to DDX20. A. The evolutionary history was 
inferred by using the Maximum Likelihood method based on the Poisson correction model202. 
The bootstrap consensus tree inferred from 50 replicates53 is taken to represent the 
evolutionary history of the taxa analyzed53. Branches corresponding to partitions reproduced 
in less than 50% bootstrap replicates are collapsed. The percentage of replicate trees in 
which the associated taxa clustered together in the bootstrap test(50 replicates) are shown 
next to the branches53. Initial tree(s) for the heuristic search were obtained automatically by 
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated 
using a JTT model, and then selecting the topology with superior log likelihood value. The 
analysis involved 32 amino acid sequences. All positions containing gaps and missing data 
were eliminated. There were a total of 211 positions in the final dataset. Evolutionary 
analyses were conducted in MEGA X B. Schematic of DDX20 in comparison to other DDXs. 
The N-terminal (light blue) and C-terminal (light orange) are separated by an amino acid 
linker (black line) – extended in DDX20. The elongated C-terminal contains the primary 
regions known for DDX20 protein-protein interaction. 
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1.4.4.1 DDX20 regulation of snRNP biogenesis 
DDX20 is a member of the large, multiprotein survival motor neuron (SMN) 
complex. Gemins 2, 3 (DDX20), 4, 5, 6, 7, and 8, named for their subcellular 
localisation in Gemini of Cajal bodies (gems), primarily function in 
maintaining the SMN complex to assemble snRNPs. snRNPs are 
indispensable for spliceosome assembly and pre-mRNA splicing.203 Within 
this complex, DDX20 (Gemin3) has been shown to interact with Gemin 4, 
5204 and SMN1.205 DDX20 has been shown to localise to subcellular 
organelles rich in snRNPs, named U bodies.206 Knockdown of DDX20 gene 
expression in these systems has been demonstrated to disrupt snRNP 
assembly and other processes of RNA metabolism, including proofreading of 
snRNAs.207,208 These roles in snRNP biogenesis and ultimately spliceosome 
assembly have implicit consequences for development. Homozygous 
deletion of Gemin3 (Mouse) and mel-46 (C. elegans) is embryonically 
lethal.209,210 The role of DDX20 in RNA splicing mechanisms may be of 
interest in a disease such as cancer, in which aberrant RNA splicing is 
frequently found.211 
 
1.4.4.2 DDX20 regulation of gene expression 
DDX20 has also been shown to influence gene expression, both through 
gene silencing pathways212 and as a cofactor for transcriptional activation 
and repression.213 RNA interference (RNAi) is the process of gene silencing 
where double-stranded RNA (dsRNA) is cleaved by Dicer into small 
interfering RNAs (siRNAs). These siRNAs are then introduced into the RNA 
induced silencing complex (RISC), which then base pairs with mRNA 
containing the antisense sequence to the siRNA, initiating cleavage of the 
mRNA and reducing gene expression.214 Argonaute (Ago) proteins are an 
essential component of the RISC complex and are required for translation 
inhibition. There has been a demonstrated physical interaction between Ago2 
and DDX20, which regulates miRNA metabolism.201 In hepatocellular 
carcinoma, miRNA-140 is associated with DDX20 expression and directly 
targets DNA methyltransferase 1 (Dmnt1) mRNA expression215. Interestingly, 
in this tissue context, DDX20 acts as a tumour suppressor, which is contrary 
to findings in other cancerous tissues.216 
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DDX20 can influence gene expression through directly interacting with and 
subsequently modulating the activity of transcription factors such as 
Steroidogenic factor 1 (SF-1) and Forkhead box protein L2 (FOXL2).217 
DDX20 interacts with the PRD domain of SF-1 to act as a transcriptional 
repressor for genes essential in early development, including  early growth 
response protein 2 (Egr2).218 It was later found that DDX20 could only 
interact after a small ubiquitin-like modifier (SUMO) was added to SF-1 by 
protein inhibitor of activator STAT (PIASg); this mechanism is independent of 
the ATPase/RNA helicase activity of DDX20.219 In granulosa cells, DDX20 
has been shown to directly interact with FOXL2 in the region necessary for 
SF-1 interaction.220 The co-expression of DDX20 and FOXL2 increases 
apoptosis, potentially through a redox-dependent mechanism, as SOD2 has 
been shown to be a direct target of FOXL2 transcription.217,221 
  
1.4.4.3 DDX20 in carcinogenesis    
DDX20 is frequently mutated or exhibits copy number variations in a variety 
of cancers. Analysis of large data cohorts from the TCGA PanCancer Atlas 
demonstrates that DDX20 is mutated in uterine, colorectal, lung, head & 
neck, cervical, stomach, breast, pancreas, and liver cancers (Figure 1.8). 
While the role of DDX20 in these cancers has not yet been identified, it is 
already known that the tumour suppressor or oncogene activity of DDX20 is 
tissue-specific.199  
The role of DDX20 in regulating carcinogenesis is not yet fully 
understood, although in lymphomas and TNBC, mechanistic data suggest 
that DDX20 is a key regulator of cell fate. In B cell lymphoma cell lines, 
DDX20 was shown to physically interact with Epstein-Barr virus encoded 
nuclear antigen 3C (EBNA3C), which mediates its subsequent interaction 
with p53. In EBNA3C+ cells, this interaction negatively regulated p53-
mediated apoptosis. Short hairpin RNA (shRNA) knockdown of DDX20 
increased gene expression of p53, Bax, and p21, and significantly increased 
cell death.222 
Recently, it was discovered through a comprehensive 
bioinformatics and laboratory based study that DDX20 was overexpressed in 
the basal or TNBC subtype of breast cancer.216 The protein expression of 
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DDX20 also positively correlated with the metastatic potential of isogenic cell 
lines and correlated with an increased breast metastatic gene signature.216 
Mechanistically, DDX20 interacted with TGF-b-activated kinase 1 (TAK1), 
which lead to increased NF-kB activity through increased phosphorylation of 
NF-kB-activating IkB kinase 2 (IKK2). Furthermore, depletion of DDX20 
resulted in decreased NF-kB-mediated matrix metalloproteinase-9 (MMP9) 
expression and increased invasion, both in vitro and in vivo.216  
Figure 1.8. Alteration frequency of DDX20 across TCGA cancer types. Data 
accessed through cBioPortal.  
 
1.5 REACTIVE OXYGEN SPECIES AND THEIR ROLE IN CELL 
SIGNALLING 
Reactive oxygen species (ROS) collectively refers to oxygen-derived (O2) 
free radical and non-radical species.223 Radical ROS species include the 
superoxide anion (O2-), hydroxyl radical (HO•), peroxyl radical (ROO•), and 
alkoxyl radical (RO•).224 Non-radical ROS species include hydrogen peroxide 
(H2O2) and peroxynitrite (ONOO-)225,226. A tight balance between intracellular 
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ROS and ROS regulating systems is critical for maintaining cellular 
homeostasis.227 Therefore, excessive generation of ROS or deficient anti-
oxidant capacity alters the cellular redox state, with profound effects on cell 
growth, proliferation, and survival. Homeostatic levels of ROS are maintained 
by both enzymatic and non-enzymatic antioxidants. A depletion or 
overexpression of these antioxidants can alter cell fate. For example, 
overexpression of antioxidant enzyme superoxide dismutase 2 (SOD2) can 
protect cells from TNF-induced apoptosis.228 This protected the cell from 
H2O2 cell death and promoted cell survival. On the other hand, SOD1 has 
been shown to be a potential therapeutic target in some cancers.229 These 
contrasting roles for similar antioxidant enzymes demonstrates that the tight 
balance of ROS levels can determine whether cells will survive or undergo 
apoptosis. The dogmatic view that any increase in intracellular ROS is linked 
to cell injury and death has been challenged by substantial experimental 
evidence attributing a secondary messenger function to a mild increase in 
ROS or a ‘pro-oxidant’ milieu. Alterations in the cellular redox metabolism is 
linked to ageing 230 as well as a host of pathological states, such as 
cancer,231 Alzheimer’s disease,232 Parkinson’s disease,233 diabetes,234 
atherosclerosis,235 non-alcoholic fatty liver disease (NAFLD),236 and 
asthma.237 
 
1.5.1 Intracellular sources of  ROS 
The mitochondrion serves as an important source of intracellular ROS 
[elegantly reviewed in 238], mainly generating O2- from Complex I (NADH 
dehydrogenase)239 and Complex III (cytochrome c reductase)240, when 
electrons derived from NADH or flavin adenine dinucleotide2 leak out onto 
and reduce molecular oxygen.241 The mitochondrial O2- levels are regulated 
by the action of manganese superoxide dismutase (MnSOD) in the inner 
matrix that generates H2O2 in the process.242  H2O2 in turn can be scavenged 
by catalase, glutathione peroxidases, and peroxiredoxins.243 A second 
important site of O2- generation, best exemplified in phagocytic cells, is the 
NADPH oxidase (NOX) family of enzymes. NOX enzymes are made up of six 
subunits: a Rho guanosine trisphosphatase (GTPase) and five phagocytic 
oxidase subunits (gp91, p22phox, p40phox, p47phox and p67phox)(Figure 
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9).244 Additional sources of ROS include O2- from xanthine oxidases,245 
cyclooxygenases or prostaglandin-endoperoxide synthase (PTGS),246 the 
cytochrome P450 enzyme family,247 and non-heme lipoxygenases.248 
 
Figure 1.9. Sources of ROS. Intracellular sources of ROS are primarily through superoxide 
generation from the electron transport chain (ETC). Superoxide (O2-) generated from the 
ETC can undergo dismutation to H2O2 by SOD2 in the inner mitochondrial membrane. O2- is 
also produced by the NADPH oxidase complex in the plasma membrane. Misfolding of 
proteins can undergo redox reactions and generate H2O2 in the endoplasmic reticulum. 
While nitric oxide (NO) can react with O2- to form peroxynitrite (ONOO-). Long chain fatty 
acids (LCFA) can produce H2O2 following b-oxidation, which is scavenged in the peroxisome 
by catalase.  
 
1.5.2 Reactive oxygen species as signalling molecules 
It is now widely accepted that ROS function as important signalling 
molecules, implicated in nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB), mitogen activated protein kinase (MAPK), Keap1-
Nrf2-ARE, PI3K-Akt, Notch and Wnt signalling pathways.249,250 The various 
functional consequences of an altered redox milieu have been associated 
with a critical balance between the two major ROS molecules, O2- and 
H2O2.251-253 Whereas, an overwhelming increase in either of these species 
results in cell injury and death; a tilt in the ratio in favour of O2- confers a 
survival advantage while a significant shift towards H2O2 creates a 
permissive environment for death execution.254,255  For example, H2O2 is 
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known to suppress Wnt/β-catenin signalling, an important survival and 
growth pathway, through a variety of mechanisms, including targeting the 
interaction between nucleoredoxin and dishevelled (Dvl)256 and via oxidative 
modification of the zinc-coordinating cysteines of tankyrase, resulting in its 
inactivation.257 ROS-mediated Wnt signalling regulation of Bcl-2 involving 
GSK3β/β-catenin has been reported upon chronic exposure to Cr(VI) 
compounds.258 Furthermore DEAD-Box family members have been 
implicated in the regulation of mitochondrial stress responses and the 
detoxification of ROS, namely H2O2.259  
 
1.5.3 Reactive oxygen species mediation of cell fate 
Upon apoptotic stimulation, either death receptor- or drug-induced, a 
cascade of caspase activation results in the induction of mitochondrial outer 
membrane permeabilization (MOMP). In the case of death receptor 
signalling, direct executioner caspase activation is induced in certain cell 
types where the death initiating signalling complex (DISC) is efficiently 
formed (Type 1 or extrinsic pathway); however, in other cell types, the 
initiator caspase activation is relatively weak to autonomously engage the 
executioner caspase(s), and therefore the signal is routed through the 
mitochondria for efficient death execution (Type 2 or intrinsic signalling). The 
latter is also the preferred mode of execution triggered upon exposure of 
cells to DNA damaging agents, g-irradiation, as well as other forms of 
chemotherapy. Importantly, the recruitment of the mitochondria is a function 
of the pro-apoptotic members of the Bcl-2 family that, upon apoptotic 
stimulation, translocate to the mitochondria, forming oligomeric complexes260 
that compromise the permeability of the outer membrane261, thereby 
facilitating the egress of death amplification factors such as cytochrome c262, 
Smac/DIABLO,263 and apoptosis inducing factor (AIF).264  The anti-apoptotic 
members of the Bcl-2 family, in particular Bcl-2 and Bcl-xL, prevent MOMP 
by competing with and inhibiting the oligomerization of the pro-apoptotic 
members, such as Bax and Bak.265-267  As such, the apoptosis inhibitory 
function of Bcl-2 is strongly associated with the Type 2 death signalling 
pathway (Figure 10).   
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Figure 1.10.  Schematic of type 1 and type 2 death receptor pathways. Type 1 (bold black 
line) FAS (CD95) death signalling pathway signals independent of the intrinsic pathway. 
Following FAS ligand binding, signals are transduced through FADD mediated caspase-8 
activation and caspase-3/7 activation for cells to undergo apoptosis. Type 2 (bold grey line) 
death signalling through FAS is directed through caspase-8 mediated Bid activation. Bcl-2 is 
the primary inhibitor of anti-apoptosis in type 2 signalling. Bad/Bax can direct apoptosis by 
the release of cytochrome c, and the activation of Apaf-1 and caspase-9. Dotted lines 
indicate no pathway involvement. 
	
 
1.5.4 Reactive oxygen species in triple-negative breast cancer 
The role of ROS in the progression of breast cancer is not yet fully 
understood. Changes to the intracellular and extracellular redox environment 
favouring a pro-oxidant state have been shown to be a crucial factor in the 
initiation of cancer growth and metastasis.268 The generation of electrons by 
oxidative phosphorylation can result in the production of O2-, primarily by 
complex I and complex III.241 In TNBC stem cells, it has been demonstrated 
that increased oxidative phosphorylation and increased ROS, regulated 
through MYC transcriptional regulation of mtDNA genes and MCL-1 
regulation of OXPHOS, was a key feature of drug-resistant TNBC cells.269 
Conversely, in MDA-MB-231 cells, the overexpression of a rotenone-
insensitive yeast NADH Dehydrogenase gene, Ndi1, subsequently increased 
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complex I activity and resulted in a shift of the NAD+/NADH redox balance 
and acted to suppress metastasis and tumour growth.270 
The role of several antioxidant scavenging enzymes in tumour 
progression and metastasis is currently far from clear, with numerous 
conflicting results reported. Catalase has been reported to be overexpressed 
in TNBC and to be associated with lower tumour occurrence and increased 
overall survival rates in one South Korean cohort.271 SOD2 is overexpressed 
in TNBC and was demonstrated to promote a strong EMT phenotype driven 
by H2O2, while knockdown of SOD2 promoted a mesenchymal-to-epithelial-
like (MET) phenotype, primarily driven by O2-.272 Furthermore, SOD2 was 
also demonstrated to restrict transformation from a CD44low/CD24high 
epithelial phenotype to a CD44high/CD24low mesenchymal-like type in head 
and neck cancers.273 In MDA-MB-436 cells, oxidative stress from increased 
H2O2 was able to promote expression of N-cadherin and induce 
phosphorylation of EGFR; this could be ameliorated in the presence of N-
acetylcysteine (NAC). NAC was also able to reduce the migratory capacity of 
the same cells.274 The knockdown or downregulation of other antioxidant 
enzyme systems has also been demonstrated to influence TNBC cell fate. 
Thioredoxin reductase inhibition was associated with an increase in ROS, 
increase in radio-sensitivity, as well as increased DNA damage in TNBC cell 
lines.275  
This shows a clear role for ROS and ROS scavenging enzymes 
systems in the initiation, progression, and metastasis of TNBC. The exact 
role of the various ROS species in cell fate is not yet entirely known. It is 
clear that a tight balance exists, whereby high levels of various ROS species 
can promote tumour progression or cause cell death. This is tissue-specific 
and relies on feedback mechanisms from the other ROS generating and 
regulatory systems when there is dysfunction or an unbalance in one.276-278 
 
1.5.5 WNT/b-Catenin signalling in the regulation of mitochondrial ROS 
and mitochondrial function 
The role of Wnt/b-catenin signalling in regulating mitochondrial function and 
ultimately mitochondrial ROS (mitoROS) has yet to be fully elucidated. 
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Conflicting evidence as to whether activation of Wnt/b-catenin signalling 
positively or negatively regulates mitochondrial function has been presented. 
This may be dependent on the cell type and mutational status of these cells. 
In a model of haematopoetic stem cells (HPSC) derived from 
mouse bone marrow, it was demonstrated that the activation of canonical 
Wnt signalling induced apoptosis mediated through a loss in mitochondrial 
function. Mice with a floxed exon3 of b-catenin (CTNNB1(ex3)fl/-), leaving it 
constitutively active, had a higher level of HSP cell death, significant 
downregulation of Bcl-2 and a loss of mitochondrial membrane potential. This 
was able to be restored with the ectopic expression of Bcl-2.279 This study, 
although implicating Wnt/b-catenin signalling in mitochondrial function and 
depolarisation, did not demonstrate any substantial mechanistic data.  
Conversely, inhibition of canonical Wnt signalling in colorectal 
cancer  through the depletion of LGR5 resulted in decreased mitochondrial 
membrane potential and increased apoptosis.280 Similar findings in a model 
of lung cancer were found, when the addition of a soluble form of the LRP6 
E1-E2 domains (sLRP6E1E2) was introduced to lung cancer cells. When 
overexpressed, sLRP6E1E2 acted as a decoy receptor, leading to 
antagonism of Wnt/b-catenin signalling and, ultimately, to cell death. This 
mitochondrial-mediated cell death was evident by the transition from 
mitochondrial-embedded cytochrome c to its localisation in the cytoplasm. 
The signalling mechanisms in this study were demonstrated to be due to a 
loss of PI3K-Akt signalling.281 
A study by Chen et al.282 in Rat-1 fibroblast cells expressing Wnt1 
demonstrated that Wnt1 activation of TCF4/b-catenin-mediated transcription 
inhibited cytochrome c release and supressed apoptosis. The 
overexpression of a dominant-negative TCF4 (dnTCF4; missing the b-
catenin binding domain) blocked Wnt1-mediated survival. While luciferase 
assays were used to demonstrate that this suppressed canonical Wnt 
signalling transcriptional activity, there were no specific genes implicated in 
the induction of mitochondrial-mediated apoptosis.  
In a study that provided strong mechanistic data for a role in mitochondrial 
ROS generation, function, and biogenesis by canonical Wnt signalling, Yoon 
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et al.283 developed an siRNA screen implicating Wnt/b-catenin signalling in 
mitochondrial dynamics. The addition of Wnt3a increased mitochondrial 
DNA, volume, and O2- production. Furthermore, Wnt3a increased the 
expression of numerous genes involved in oxidative phosphorylation. To 
implicate canonical Wnt signalling further, a dnTCF4 was overexpressed in 
the presence of Wnt3a and could supress the increase in mtDNA. Chromatin 
immunoprecipitation (ChIP) of TCF4 was then performed on the insulin 
receptor substrate-1 (IRS-1) promoter and of IRS-1 on the MYC promoter, to 
demonstrate that the changes in mitochondrial function were directed 
through a Wnt3a-IRS-1-MYC transcriptional axis.  
Finally, in melanoma cell lines, the addition of Wnt3a was able to 
regulate mitochondrial bioenergetics and mitochondrial morphology. 
Interestingly, this was dependent on the presence of a phosphatase and 
tensin homologue (PTEN) allelic deletion. In PTENWT cells, the addition of 
Wnt3a was shown to negatively regulate mitochondrial function and cause a 
remodelling of cellular mitochondrial networks. Furthermore, in PTENMut cell 
lines, Wnt3a increased overall mitochondrial bioenergetics, which were 
decreased in the PTENWT melanoma cells.284 
These studies illustrate a clear role for canonical Wnt signalling in 
mitochondrial function, although this is tissue specific and as yet no direct 
evidence for TCF4 transcription of genes involved in mitochondrial regulation 
has been provided. 
The multitude of studies which have yet to identify a conclusive 
role for TCF4 and DDX20-mediated Wnt/b-catenin signalling in the regulation 
of mitochondrial function and cellular redox demonstrates the importance for 
studies which may elucidate these mechanisms. In doing so, a better 
understanding of the role of mitochondrial metabolism and ROS is the 
determination of cell fate decisions in TNBC may be identified. 
 
1.6 THESIS AIMS AND SCOPE 
This thesis will contain a “Materials and Methods” as Chapter 2, followed by 
three experimental chapters, each with its own Introduction, Results, and 
Conclusions. The thesis will be concluded with a chapter consisting of an 
overall discussion, conclusions, and future directions. 
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Experimental Chapter 1 (Chapter 3) is titled “DDX20 regulates TNBC 
intracellular redox in a Wnt/b-catenin dependent manner”. Overall, I 
addressed several key experimental questions. The aim was to determine 
the role of DDX20 in regulating intracellular redox conditions through 
modulation of Wnt/b-catenin signalling. Therefore, I addressed several 
hypotheses including; 
• DDX20 depletion results in oxidative stress-induced cell death in triple 
negative breast cancer.  
• DDX20, through mediation of canonical Wnt signalling, regulates the 
intracellular redox status of TNBC cells through transcriptional control. 
 
Overall, this was an important study to fill gaps in the knowledge of DDX20 
regulation of Wnt and Wnt-mediated regulation of ROS. There is no direct 
evidence for canonical Wnt signalling through TCF/LEF transcription factors 
in the regulation of ROS scavengers. Currently, there is no published 
evidence of DDX20 mediating canonical Wnt signalling. The present 
evidence of ROS regulating Wnt/b-catenin signalling is currently through 
upstream activation or inhibition of important Wnt signalling molecules 
including Dvl and Axin stabiIisation.256,257 There is currently no evidence for 
transcriptional regulation of ROS scavengers. Previous studies have 
demonstrated that b-catenin-mediated transcription of ROS is through FOXO 
transcription factors, which are widely known to regulate the gene expression 
of ROS scavenger enzymes, such as Catalase.285,286 In this study it is shown 
that depletion of DDX20 causes increased oxidative stress through TCF4-
mediated transcription of Catalase. 
 
Experimental Chapter 2 (Chapter 4) is titled “DDX20 regulates TNBC 
mitochondrial homeostasis in a Wnt/b-catenin manner”. In this chapter, the 
aim was to determine whether diminished DDX20 would negatively regulate 
mitochondrial bioenergetics and function. Furthermore, I wanted to determine 
whether this was mediated in a Wnt dependent manner. Therefore, our 
hypotheses were; 
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• DDX20 depletion results in mitochondrial dysregulation in triple 
negative breast cancer.  
• Mitochondrial dynamics and bioenergetics are regulated through 
TCF4-mediated transcription of mitochondrial redox regulators 
dependent on DDX20. 
There are currently no experimental data that demonstrate that DDX20 can 
regulate mitochondrial function. Furthermore, there is no direct evidence that 
canonical Wnt transcriptional regulation can regulate genes involved in 
mitochondrial respiration or mitochondrial ROS scavenging. In this study it 
was found that DDX20, through TCF4-transcription, can differentially regulate 
mitochondrial electron transport component, UQCRC2, and ROS scavenger, 
SOD2, to cause mitochondrial dysfunction, which inevitably impacts 
mitochondrial dynamics. 
 
The final experimental chapter (Chapter 5) is titled “DDX20 is an essential 
regulator of Wnt/b-catenin signalling in triple-negative breast cancer stem 
cells”. The aims were to determine if, in enriched CSCs from TNBC cell lines, 
DDX20 played a functional role in regulating Wnt signalling. It is known that 
CSCs exhibit features such as a quiescent cell cycle, multi-drug resistance, 
and properties characteristic of stem cells. Therefore, the hypotheses were; 
• DDX20 in an essential regulator of Wnt/b-catenin signalling in triple-
negative breast cancer stem cells 
• Depletion of DDX20 will diminish the characteristic CSC features of 
drug resistance, altered cell cycle, and increased stem cell 
transcription factors. 
• Antagonism of the Wnt signalling pathway will downregulate DDX20 
expression. 
 
In this chapter, it was explored whether depletion of DDX20 will result in the 
same functional cellular changes regardless of PTEN mutational status of the 
cell. This was an important question as unpublished data demonstrate that 
DDX20 directly associates with GSK3b, which is known to interact with PTEN 
and be a downstream target of PI3K-Akt signalling.  
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It was found that depletion of DDX20 resulted in diminished Wnt signalling,  
chemosensitisation to doxorubicin, altered cell cycle progression, and 
downregulation of transcription factors that classically regulate stem cell 
pluripotency. Interestingly, there were some effects from DDX20 knockdown 
that were differentially observed between cell lines, suggesting that future 
studies on DDX20 will needed to be considered within an entire cell 
signalling context. 
 
Overall this study has found a novel protein, DDX20, that regulates Wnt/b-
catenin signalling in triple-negative breast cancer, and a new regulator of 
cellular redox and mitochondrial function. Furthermore, a new role for Wnt 
signalling in the regulation of mitochondrial function and redox homeostasis 
was determined, which, through an in vivo drosophila model, suggests may 
be partially evolutionarily conserved. 
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CHAPTER 2: MATERIALS AND METHODS 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1. CELL CULTURE 
Monolayer culture - MDA-MB-231 and MDA-MB-436 TNBC cell lines were 
purchased from ATCC and cultured in Dulbecco’s Modified Eagle 
Medium/High glucose with L-glutamine and sodium pyruvate (SH3002201 - 
Hyclone, GE Healthcare), 10% foetal bovine serum (FBS) (SFBS-AU, 
Bovogen, Australia), and 1X penicillin-streptomycin (15070063 – Thermo 
Fisher Scientific). BT549 cells were a kind gift from Peter Leedman (Harry 
Perkins Institute of Medical Research) and MCF-7 cells were purchased from 
ATCC; both cell lines were maintained in RPMI-1640 (SH30096.01, Hyclone, 
GE Healthcare), 10% FBS (SFBS-AU, Bovogen, Australia), and 1X penicillin-
streptomycin (15070063 – Thermo Fisher Scientific). MCF10A cells were a 
kind gift from Peter Hartman (University of Western Australia) and were 
cultured in DMEM/F12 (Gibco, GE Healthcare), 20ng/mL epidermal growth 
factor (EGF, Prospec), 0.5mg/ml hydrocortisone (H0888 – Sigma Alrdrich, 
Missouri, USA), 10µg/mL insulin (I-1882 – Sigma Alrdrich, Missouri, USA), 
10% FBS (SFBS-AU, Bovogen, Australia), and 1X penicillin-streptomycin 
(15070063 – Thermo Fisher Scientific). Cells were maintained at 37°C and 
5% CO2. 
 
3-D Spheroid Culture - Monolayer cells were dissociated from the flask using 
TrypLE™Express (12604013 - ThermoFisher Scientific). Cancer stem cells 
(CSCs) were then isolated by plating them at a density of 1x104 cells/cm2 on 
low attachment plates (Corning) in a medium consisting of a 1:1 ratio of basal 
medium DMEM (MDA-MB-231) or DMEM/F12 (BT549) with DMEM High 
Glucose (Hyclone) and supplemented with 20ng/mL epidermal growth factor 
(EGF, CYT-217, Prospec, Israel), 20ng/mL basic fibroblast growth factor 
(bFGF, CYT-218, Prospec, Israel), B-27 (Life Technologies), and 1X 
Penicillin-Streptomycin (CSC medium). Cells were cultured for at 37°C and 
5% CO2 until the presence of mammospheres were visible (5-7 days). The 
breast cancer stem-like cells were then assessed for the surface markers, 
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CD44high/CD24-/low, by flow cytometry using an LSRFortessa flow cytometer 
(BD Biosciences).91  
 
2.2. REAGENTS, CHEMICALS, AND RECOMBINANT PROTEINS 
Recombinant human Wnt3a (5036-WN-010), human Dickkoff1 (Dkk1) (5439-
DK-010), and human secreted frizzled related protein 4 (SFRP4) (1827-SF-
025) were all acquired from R&D Systems. Wnt3a, Dkk1 and SFRP4 were all 
used at concentrations of 200ng/mL, 100ng/mL and 250pg/mL respectively. 
 
The purified recombinant cysteine-rich domain (CRD) and netrin-like domain 
(NLD) were a kind gift from Prof. E. Y. Jones (STRUBI, University of Oxford).   
 
b-catenin/TCF inhibitor III (iCRT3) was made by Calbiochem (#219332) and 
purchased from Merck Millipore. It was dissolved to a stock concentration of 
12.1625µM in dimethyl sulphoxide (DMSO) (D8414 - Sigma Aldrich). 
Doxorubicin hydrochloride (D1515 – Sigma Aldrich) was dissolved in MilliQ 
H2O. Staurosporine (S5921 – Sigma Aldrich) was dissolved in DMSO. 
 
Hydrogen peroxide (30% v/w) was purchased from Merck Millipore 
(#107209). Stock solutions were made to 100µM, protected from light, and 
frozen at -20°C. Riboflavin (R1706 - Sigma Aldrich) was prepared as a 30mM 
stock solution in MIlliQ H2O, protected from light, and stored at 4°C. 
Glutathione stock (5mM) was purchased from Promega (#V6611) and 
catalase (1000U/µL) was purchased from Abcam (ab83464). 
 
Oligomycin A (75351-5MG), carbonyl cyanide 4-
trifluoromethoxyphenylhydrazone (FCCP) (C2920), rotenone (R8855), and 
antimycin A (A8674-50MG) were all purchased from Sigma Aldrich, and 
prepared as 100X stock solutions in DMSO. Ac-DEVD-AFC (#14459) was 
purchased from Cayman Chemical and resuspended in DMSO. MitoSox Red 
(M36008, chloromethyl-2,7- dichlorodihydrofluorescein diacetate acetyl ester 
(CM-H2DCFDA) (C6827), and dihydroethidium (DHE) (D11347) were 
purchased from Thermo Fisher Scientific and used at concentrations of 5μM, 
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5μM, and 10μM respectively. Mitotracker™ DeepRed (M22426) and 
Mitotracker™ Green (M7514) were purchased from ThermoFisher Scientific. 
All ROS probes and Mitotracker reagents were prepared in DMEM High 
Glucose basal medium. 
 
 
2.3. siRNA AND PLASMID DNA TRANSFECTIONS 
A combination of three unique siRNA duplex oligonucleotides (27mer) 
targeting DDX20 and universal scrambled control (SR323381 - Origene 
Technologies, Rockville, MD) were each transfected at 20nM using 
RNAiMAX transfection reagent (13778030 - Thermo Fisher Scientific) in 
complete medium minus antibiotic. The culture medium was changed to 
complete medium with antibiotic six hours post-transfection and protein 
knockdown was assessed 72 hours later. DNA plasmids, pCMV-HA-vector, 
pCMV-DDX20-HA (purchased from Sinobiologicals, Beijing, China), 
pcDNA3.1-dnTCF4, and pcDNA3.1-vector (a kind gift by Prof. David Virshup, 
Duke-NUS) were transfected with Lipofectamine 2000 (11668027 – Thermo 
Fisher Scientific) in OPTI-MEM reduced serum medium (31985062 – Thermo 
Fisher Scientific). The culture medium was changed 4 hours post-
transfection and over-expression was validated 48 hours post-transfection. 
Prior to transfection, all siRNAs and plasmid DNA was prepared in OPTI-
MEM medium. 
	
2.4. TCF/LEF REPORTER ASSAY 
The Cignal™ TCF/LEF reporter assay was purchased from Qiagen (#CCS-
018L) and performed following the manufacturer’s instructions for the 
luciferase-based system. Briefly, after optimisation with a constitutively-
expressing green fluorescence protein-containing (GFP) plasmid, cells were 
seeded at 3,500 cells/well before transfection with the TCF/LEF-responsive 
Firefly luciferase construct and constitutively-expressing Renilla luciferase 
construct in Lipofectamine®2000 in OPTI-MEM medium. The medium was 
changed 4 hours after transfection and incubated for an additional 48 hours. 
Luciferase Firefly and Renilla were detected using Dual-Glo® Luciferase 
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Assay system (E2920 – Promega, Australia) following the manufacturer’s 
instructions. 
 
2.5. MEASURE OF MITOCHONDRIAL MEMBRANE POTENTIAL 
Mitochondrial behaviour was measured using the JC-1 mitochondrial 
membrane potential assay kit (701560 - Cayman Chemical, MI, USA). Cells 
were cultured in ultra low-adherent 24 well plates, at a density of 15,000 
cells/cm2. After 24 hours of treatment with 1µM doxorubicin, 50μl of JC-1 
staining solution was added to the medium and incubated for 15 mins at 
37°C and 5% CO2. Cells were then analysed using an LSRFortessa flow 
cytometer (BD Biosciences). Emissions at approximately 529nm and 590nm 
for the green monomers and red dimers respectively were monitored using 
two separate instrument channels. FloJo (version 10) software was then 
used for post experimental data processing. 
 
2.6. CASPASE 3/7 ACTIVITY ASSAY 
Equal amounts of protein lysate (20µg) were loaded into a black 96-well 
plate. The Ac-DEVD-AFC substrate was diluted to a final concentration of 
1:20 in protease assay buffer (20mM PIPES, 100mM NaCl, 10mM DTT, 
1mM EDTA, 0.1% (w/v) CHAPS, 10% sucrose, pH 7.2). Following the 
addition of the substrate to lysates, cells were incubated for two hours at 
37°C in the dark. Excitation of 400nm and measurement of emission at 
505nm was performed using a Perkin Elmar Enspire plate reader.  
 
2.7. CELL CYCLE ANALYSIS 
MDA-MB-231 cells were transfected with scrambled siRNA or siRNA against 
DDX20, then fixed in 70% ethanol (459844 – Sigma Aldrich) overnight at 
4°C, washed twice in PBS (P5493 – Sigma Aldrich), and stained for ten 
minutes at room temperature with propidium iodide (PI)/RNase staining 
solution (4087 - Cell Signaling Technologies). Samples were analysed using 
a BD FACS CantoII cell sorter and FloJo v10 software. 
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2.8. FLOW CYTOMETRY FOR CANCER STEM CELL 
CHARACTERISATION 
MDA-MB-231- and BT549-enriched cancer stem cells were grown in culture 
for seven days. Cells were collected, washed twice with PBS, and stained 
with CD44 conjugated to allophycocyanin (CD44-APC) at 0.25µg in 100µl of 
medium and CD24 conjugated to phycoerythrin/Cy7 (CD24-PE/Cy7) at 
0.25µg in 100µl of medium. Cells were incubated for 30 minutes in the dark 
before being analysed using a BD FACS CantoII flow cytometer and FloJo 
v10 software. 
 
2.9. FLOW CYTOMETRY FOR ROS PROBES 
Cells were stained with MitoSox Red, CM-H2DCFDA, and DHE for 15 
minutes in DMEM medium at 37°C in 5% CO2, followed by two washes with 
PBS. Cells were then collected in PBS and detected by flow cytometry (BD 
LSRFortessa™). Emission/excitation for probes were 510/580nm for MitoSox 
Red, 492/530nm for CM-H2DCFDA, and 518/605nm for DHE. 
 
2.10. FLOW CYTOMETRY FOR MITOTRACKER PROBES 
Mitotracker stains were used at 10nM for flow cytometry. Cells were stained 
in 12 well plates with Mitotracker™ dyes in serum-free DMEM high glucose 
medium for 15 minutes in the dark at 37°C in 5% CO2. Plates were then 
washed twice in PBS, before being scraped into 400μl of PBS and detected 
by flow cytometry (BD LSRFortessa™). Emission/excitation for probes were 
644nm/665nm for Mitotracker™ DeepRed and 490nm/516nm for 
Mitotracker™Green. 
 
2.11. IMMUNOFLUORESCENCE FOR MITOTRACKER PROBES 
Cells were stained in 96 and 12 well plates with Mitotracker™ dyes in serum-
free DMEM high glucose medium for 15 minutes in the dark at 37°C in 5% 
CO2. Plates were then washed twice in PBS, and phenol red-free RPMI-
medium (SH3060501 – Hyclone, GE Healthcare) with 5% FBS was added. 
Images were photographed using a Nikon A1 confocal microscope and data 
were visualised on NIS Elements Viewer software (V4.11.0).Co-localisation 
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analysis was performed on Fiji Software plugin JACoP (Just Another 
Colocalization Plugin).287 
 
2.12. WESTERN BLOTTING 
Whole cell lysates were collected using radioimmunoprecipitation assay 
(RIPA) buffer (150mM NaCl, 1.0% IGEPAL-630, 0.5% sodium deoxycholate, 
0.1% SDS, 50mM Tris, pH 8.0) (R0278-500ML, Sigma Aldrich) with protease 
and phosphatase inhibitor (5872S - Cell Signaling Technologies). Protein 
was separated using 10-12% SDS-PAGE gels and transferred onto 0.45µm 
nitrocellulose membranes (10600002 – Amersham Protran, GE Healthcare). 
Membranes were blocked in 5% skim milk powder in Tris-buffered saline 
(1706435 – Bio-Rad, CA, USA) with 0.1% Tween®20 (P9416 – Sigma 
Aldrich) (TBST) for 1 hour at room temperature. Primary antibodies were 
incubated overnight at 4°C. Following three washes in TBST, secondary 
antibodies were incubated at room temperature for 1 hour. Proteins were 
visualised by electrogenerated chemiluminescence (ECL) detection (RPN-
2106 - Amersham, GE Healthcare) using ChemiDoc (Bio-Rad). Primary and 
secondary antibody details are in Table 2.1. 
 
Table 2.1. Primary and secondary antibody details 
ANTIBODY COMPANY CATALOGUE 
NUMBER 
DILUTION 
DDX20 BD Biosciences 612152 1:1000 
b-CATENIN Cell Signaling 
Technologies 
D10A8 1:1000 
ACTIVE b-
CATENIN 
Cell Signaling 
Technologies 
8814S 1:1000 
GSK3b Cell Signaling 
Technologies 
27C10 1:1000 
PSER9GSK3b Cell Signaling 
Technologies 
9336S 1:1000 
DVL3 Cell Signaling 
Technologies 
3218S 1:1000 
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DVL2 Cell Signaling 
Technologies 
30D2 1:1000 
CYCLIN D1 Abcam ab134174 1:10,000 
C-MYC Cell Signaling 
Technologies 
D84C12 1:1000 
TCF4 Cell Signaling 
Technologies 
2569S 1:1000 
PARP Cell Signaling 
Technologies 
9542S 1:1000 
BCL-XL Cell Signaling 
Technologies 
54H6 1:1000 
SFRP4 Abcam ab154167 1:1000 
SOD2 Cell Signaling 
Technologies 
D3X8F 1:1000 
SOD1 Cell Signaling 
Technologies 
71G8 1:1000 
CATALASE Cell Signaling 
Technologies 
D4P7B 1:1000 
b-TUBULIN Cell Signaling 
Technologies 
D2N5G 1:1000 
b-ACTIN Cell Signaling 
Technologies 
13E5 1:1000 
a-RABBIT IgG, 
HRP 
Cell Signaling 
Technologies 
7074S 1:10,000 
a-MOUSE IgG, 
HRP 
Cell Signaling 
Technologies 
7076S 1:10,000 
 
2.13. GENE EXPRESSION ANALYSIS 
Total intracellular RNA was extracted using ISOLATE II RNA Mini Kit (BIO-
52072 - Bioline, London, UK) following the manufacturer’s protocol. The ratio 
between absorbance at 260nm and 280nm was assessed using Nanodrop 
spectrophotometers (Thermo Scientific). RNAs with a 260/280 ratio greater 
than 1.8 were used for downstream experiments. RNA was subjected to 
reverse transcription using High-capacity cDNA Reverse Transcription Kit 
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(4368813 - Applied Biosystems, California, USA). Samples were subject to 
thermal cycling. The thermal cycler protocol was as follows: (25°C for 10 
mins, 37°C for 120 mins, 85°C for 5 mins, and 4°C for ¥). KAPA SYBR FAST 
qPCR Universal Kit (#KK460) was used following the manufacturer’s 
instructions. The thermal cycler protocol was as follows: (95°C for 3mins, 
(97°C for 1min, Tm°C for 1mins) x 40 cycles). Housekeeping genes, 18S and 
GAPDH were validated against each other to ensure experimental 
treatments did not alter 18S or GAPDH mRNA levels. The DDCT method was 
used to calculate fold change (2-ΔΔCt). Primer sequences for genes of interest 
are as follows in Table 2.2:  
 
Table 2.2. Human primer sequences, melting temperature, and size of 
amplicon for QPCR (quantitative PCR) 
GENE NAME PRIMER (5ʹ - 3ʹ) Tm 
(°C) 
SIZE 
(BP) 
DDX20 Fwd GCACAGCAGAGCACAACATT 59 171 
DDX20 Rev GCATCAATCCCACGAGAAGT 58 171 
TCF7L2 Fwd GGGAGCCTCCAGAGTAGACA 60 286 
TCF7L2 Rev ATCCTAGCGGATGGGGGATT 60 286 
LEF1 Fwd TTCTTGGCAGAAGGTGGCAT 60 198 
LEF1 Rev AGGCAGCTGTCATTCTTGGA 59 198 
AXIN2 Fwd TAACCCCTCAGAGCGATGGA 60 80 
AXIN2 Rev CCTCCTCTCTTTTACAGCAGGG 60 80 
FZD7 Fwd CGACGCTCTTTACCGTTCTC 59 247 
FZD7 Rev GCCATGCCGAAGAAGTAGAG 58 247 
SOX2 Fwd CCATCCACACTCACGCAAAA 59 139 
SOX2 Rev TATACAAGGTCCATTCCCCCG 59 139 
POU5F1 Fwd TCCCATGCATTCAAACTGAGG 59 103 
POU5F1 Rev CCAAAAACCCTGGCACAAACT 60 103 
NANOG Fwd TGGACACTGGCTGAATCCTTC 60 142 
NANOG Rev CGTTGATTAGGCTCCAACCAT 59 142 
KLF4 Fwd CTGCGGCAAAACCTACACAA 59 182 
KLF4 Rev GGTCGCATTTTTGGCACTG 59 182 
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SOD2 Fwd TGCTCCCCGCGCTTTCTTA 62 124 
SOD2 Rev AACATGCTGCTAGTGCTGGT 60 124 
CAT Fwd ACTGTTGCTGGAGAATCGGGT 62 228 
CAT Rev AGGACGTAGGCTCCAGAAGT 60 228 
UQCRC2 Fwd GGGAAAGTGTTAGCGGGGAA 60 80 
UQCRC2 Rev ACGGTCACTGCCGGATTAAA 60 80 
ATP5F1A Fwd TCGGCCATTTTGTCCCAGTC 61 145 
ATP5F1A Rev AGCATTTCTGGAGACCAGTCC 60 145 
GAPDH Fwd CAGAACATCATCCCTGCCTCTACT 62 258 
GAPDH Rev GTCGCTGTTGAAGTCAGAGGAGAC 62 258 
18S Fwd GCAATTATTCCCCATGAACG 60 68 
18S Rev GGGACTTAATCAACGCAAGC 60 68 
 
2.14. ROS-Glo™H2O2 ASSAY 
A luciferase-based H2O2 assay was obtained from Promega Corporation 
(#G8820) and used following the manufacturer’s instructions. Briefly, 72 
hours after control siRNA and siRNA targeting DDX20 were transfected, the 
H2O2 substrate was added to the complete medium and incubated at 37°C 
for 30 minutes. Following this, the ROS-Glo detection solution was added 
and incubated at room temperature for 20 minutes before luminescence was 
read on a Perkin Elmar Enspire plate reader.  
 
2.15. GSH/GSSG-Glo™ ASSAY 
A luciferase based GSH/GSSG-Glo™ assay was obtained from Promega 
Corporation (V6611) and used following the manufacturer’s instructions. 
Briefly, 72 hours after control siRNA and siRNA targeting DDX20 were 
transfected, a reagent for total glutathione content and cell lysis, or oxidised 
glutathione content and cell lysis, was added to the cells. The plate was 
shaken for five minutes before the luciferin generation reagent was added 
and incubated for 30 minutes. The luciferase detection reagent was then 
added and allowed to equilibrate at room temperature for 15 minutes before 
detection of luminescence on the Perkin Elmar Enspire plate reader. 
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2.16. IMMUNOFLUORESCENCE 
Immunofluorescent staining was performed by fixation in 100% methanol for 
20 minutes at -20°C. Samples were washed three times with cold PBS, and 
blocked for 1 hour at room temperature in PBS with 5% BSA. They were then 
incubated overnight at 4°C with the following primary antibodies: 1:100 
DDX20/Gemin3 (sc-57007 Santa Cruz Biotechnology, USA), 1:400 active 
(non-phosphos33/s37/t41) b-catenin (8814S - Cell Signaling, USA), 1:200 
cytochrome C (sc-13561 - Santa Cruz Biotechnology, USA), 1:400 CD44 
(3570S - Cell Signaling, USA), 1:100 Bcl-2 (sc-509, Santa Cruz 
Biotechnology), 1:50 8-deoxyguanosine (OHdG) (ab10802 – Abcam), 1:400 
catalase (sc-271803 - Santa Cruz Biotechnology), 1:400 c-MYC (5605S - 
Cell Signaling, USA), and 1:400 GSK3b (27C10 - Cell Signaling, USA). Anti-
rabbit Alexafluor488 (ab150077), anti-mouse Alexafluor488 (ab150113), anti-
rabbit Alexafluor555 (ab150074), anti-mouse Alexafluor555 (ab150106), and 
anti-rabbit Alexafluor647 (ab150079) were all purchased from Abcam and 
were incubated for 1 hour at room temperature at a dilution of 1:500. 
ProlongGold with DAPI (P36935 – Molecular Probes, Life Technologies, 
USA) was then added for counterstaining and preservation. Images were 
photographed using a Nikon A1 confocal microscope and data were 
visualised on NIS Elements Viewer software (V4.11.0). 
 
2.17. CELL SORTING FOR ROSBRIGHT AND ROSDIM POPULATIONS 
Cells were grown in 15cm plates until 90% confluent. Cells were then 
washed twice in PBS before being scraped into 5mL of PBS. The cells were 
then centrifuged at 350g for five minutes and resuspended in 2ml of basal 
DMEM medium containing a 1:1000 dilution of CM-H2DCFDA for 15 minutes 
at 37°C. Cells to run as the unstained control were incubated for 15 minutes 
at 37°C in basal DMEM medium without CM-H2DCFDA. Cells were then 
stained with 5µL 7-aminoactinomycin D (7-AAD) (420404 - Biolegend) before 
being run on a BD FACSJazz™ cell sorter and collected in PBS contained 
10% FBS. Cells were then immediately centrifuged at 350g for five minutes 
before being washed once in PBS and then lysed in 1X RIPA buffer for 
downstream protein expression analysis. 
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2.18. CELL VIABILITY ASSAYS 
Cell viability was assessed by seeding 2,500 cells/well and allowing the cells 
to attach overnight. The following day, siRNA transfections were performed 
following the previously described protocol (“siRNA and plasmid DNA 
transfections”), with a medium change performed 4-6 hours post-transfection. 
After the indicated treatments, cells were measured for viability using the Cell 
Counting Kit-8 (96992 CCK8 – Sigma Aldrich), WST-8, and colorimetric 
probe following the manufacturer’s protocol. Briefly, 10µL was added to 
100µL complete medium and incubated in the dark for 4 hours. Absorbance 
was then measured at 450nm using a Perkin Elmar Enspire plate reader. 
 
2.19. MAMMOSPHERE FORMING ASSAYS 
CSCs were isolated as previously described (“3-D spheroid culture) and 
seeded at 1,000 cells/well in low-adherent 24-well plates. The following day, 
siRNA transfection before the cells were left to incubate at 37°C in 5% CO2 
for seven days. After the culture period, mammospheres greater than 40µm 
were counted at 20X magnification from four random fields. Mammosphere-
forming efficiency (MFE) was calculated with the following equation:  
 𝑀𝐹𝐸	 % = 	100×𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑚𝑎𝑚𝑚𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠	𝑝𝑒𝑟	𝑤𝑒𝑙𝑙𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑒𝑙𝑙𝑠	𝑠𝑒𝑒𝑑𝑒𝑑	𝑝𝑒𝑟	𝑤𝑒𝑙𝑙  
 
2.20. CHROMATIN IMMUNOPRECIPTATION 
Bioinformatics analysis to determine TCF4-binding sites on DNA was 
conducted using using the USCD ENCODE ChiP-seq matrix 
(https://www.encodeproject.org/chip-seq/). If ChIP-seq peaks were found, 
primers were designed using Primer-Blast (NCBI) around the consenus 
TCF4 binding motif (T-C/G-A-A-A-G/A). Cells were cultured in 15cm dishes. 
After their respective treatments, they were crosslinked with 1% 
formaldehyde at room temperature for ten minutes, and quenched for five 
minutes with 125mM glycine. Cells were washed with ice-cold PBS and lysed 
in ChIP cell lysis buffer (20mM TrisHCl, pH 8.0, 85mM KCl, 0.5% IGEPAL-
630) containing protease inhibitor cocktail, and then kept on ice for ten 
minutes. Cells were centrifuged at 5,000rpm for five minutes at 4°C. Nuclei 
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were resuspended in nuclear lysis buffer (50mM TrisHCl, pH 8.0, 10mM 
EDTA, 1% SDS with protease inhibitors) and kept on ice for 30 minutes. 
Sheared chromatin of 500-1000 base pairs in length was generated by 
sonication for 15 cycles (ten seconds on, ten seconds off) at 4°C. Samples 
were then centrifuged at 13,000rpm for 20 minutes at 4°C. Samples were 
precleared with Protein A Dynabeads (10001D – Invitrogen, Thermo Fisher 
Scientific) for 1 hour at 4°C, before 1:50 dilution of TCF4 antibody (2569S - 
Cell Signaling Technologies) and 2μg of normal rabbit IgG (NI01 – Merck 
Millipore) with Protein A Dynabeads were added overnight on rotation at 4°C. 
Beads were washed twice with low salt wash (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 20mM TrisHCl, pH 8.0, 150mM NaCl), twice with high salt wash 
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM TrisHCl, pH 8.0, 500mM 
NaCl), once with LiCl wash (250mM LiCl, 1% Igepal-630, 1% sodium 
deoxycholate, 1mM EDTA, 20mM TrisHCl, pH 8.0), and twice with TE buffer 
(10MM Tris-Cl, 1mM EDTA, pH 8.0). All washes were performed for five 
minutes at 4°C. Elution was performed with 120μl of elution buffer for 15 
minutes at room temperature, twice, and reverse crosslinked with added 
RNase A (EN0531 - Thermo Fisher Scientific) overnight at 65°C, followed by 
heating with Proteinase K (71049 – Merck Millipore) for 45°C for 1 hour. DNA 
was purified using GeneJET PCR purification Kit (K0701 - Thermo Fisher 
Scientific), and eluted into 30μl of buffer. PCR and Q-PCR were performed 
as described previously. Primer sequences are described in Table 2.3. 
 
Table 2.3. Human primer sequences, melting temperature, and size of 
amplicon for ChIP-QPCR (quantitative PCR)  
GENE NAME PRIMER (5’ - 3’) Tm 
(°C) 
SIZE 
(BP) 
CAT –Fwdbinding CAGTATTTCAAGAAGGGCACCA 59 245 
CAT –Revbinding TTTTACATTCGCCGAAGCAGG 60 245 
CAT –Fwdnon-binding CGCTTTCTAAACGGACCTTC 57 231 
CAT –Revnon-binding TGATTGGCTGAGCCTGAAGT 59 231 
SOD2 –Fwdbinding TAGTGAGGAAGGTGGGAACT 57 187 
SOD2 –Revbinding CCTAAGAACAGTTCTTGGACA 55 187 
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SOD2 –Fwdnon-binding AACCAAAACTCAGGGGCAGG 60 162 
SOD2 –Revnon-binding CCTGTCTGCCGTACTTGAGT 59 162 
UQCRC2 Fwdbinding AACTACGCCGGGCTTCGATA 61 74 
UQCRC2 Revbinding CGTTGGAGGCTTCAGGAGAT 59 74 
ATP5F1A Fwdbinding ACGGACAGCATCTTTGCAGT 60 181 
ATP5F1A Revbinding AAAAATGCAGAGTGGCGG 57 181 
NDUFB8 Fwdbinding CTTTGCAGCCACTGGACT 58 161 
NDUFB8 Revbinding GTTGAACCCTTCGGCTTTTC 58 161 
 
Fold enrichment was calculated relative to IgG control using the 2-ΔΔCT 
method.  
 
2.21. MITOCHONDRIAL MASS QUANTIFICATION 
Cells were seeded in a 6-well plate. Following transfection with either control 
siRNA or siDDX20 for 72 hours cells cells was collected and washed once 
with PBS before the cell pellet was re-suspended in 300µl lysis buffer (10mM 
Tris-HCl, 400mM NaCl, 2mM EDTA, 1% SDS, 0.5% Proteinase K, pH 8.0). 
Samples were then cooled on ice before 100µl 6M NaCl was added and 
vortexed for 30secs. Sample was then centrifuged at maximum speed for 2 
minutes before supernatant was transferred to a new tube and centrifuged 
again for 2 minutes at maximum speed. DNA was precipitated by adding 
350µl isopropanol on ice and inverting before centrifugation at maximum 
speed for 2 minutes. The supernatant was discarded before 1mL of cold 70% 
ethanol was added, vortex and centrifuged again at maximum speed, twice. 
The ethanol is discarded before the DNA pellet is air-dried and resuspended 
in 100µl MIlliQ H2O. The DNA is rehydrates at 65°C for 1 hour. DNA is 
quantified on NanoDrop before Q-PCR is performed using primers in Table 
2.3. 
 
Table 2.4. Human primer sequences for mitochondrial and nuclear DNA  
GENE NAME PRIMER (5ʹ - 3ʹ) TM 
(°C) 
SIZE 
(BP) 
nucDNA Fwd AACTACGCCGGGCTTCGATA 55 74 
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nucDNA Rev CGTTGGAGGCTTCAGGAGAT 55 74 
mtDNA Fwd TTCCTAATGCTTACCGAACG 55 98 
mtDNA Rev TCAGCGAAGGGTTGTAGTA 55 98 
 
2.22. SEAHORSE XF96 EXTRACELLULAR FLUX ASSAY 
Seahorse XF96 flux analyser (Agilent) was used to perform mitochondrial 
stress tests according to the manufacturer’s instructions. Cells were seeded 
at 2,500 cells/well and allowed to attach overnight. The following day, siRNA 
targeting DDX20 or control siRNA was transfected for 72 hours. For plasmid 
DNA of pCDNA-dnTCF4 and pCMV-DDX20 and empty vector controls, cells 
were seeded at 3,500 cells/well and allowed to attach overnight before 
transfection, which was assessed 48 hours later. Prior to performing 
Seahorse analysis, cell culture medium was removed and changed to serum-
free DMEM with phenol red (pH 7.4) containing 1mM sodium pyruvate 
(P2256-25G – Sigma Aldrich), 2mM glucose (G7021-1KG – Sigma Aldrich), 
and 2mM sodium bicarbonate (S5761-1KG – Sigma Aldrich), and incubated 
for at least 60 mins at 37°C in 5% CO2. The injection strategy was oligomycin 
(2 µM), carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 0.3 
µM), and finally, rotenone/antimycin A in combination (1 µM). Normalisation 
of data was determined using BCA assay. Basal respiration, proton leak, 
spare respiratory capacity, and maximal respiration were all determined 
following normalisation and performed using Wave software (version 2.3.0). 
 
2.23. BIOINFORMATICS ANALYSIS OF COHORT DATASETS 
Data Analysis and Collection - Breast carcinoma datasets were obtained 
from the TCGA and METABRIC studies via cBioPortal 288 in November 2017; 
specifically, the Breast Invasive Carcinoma (TCGA, Provisional)289 Breast 
Cancer (METABRIC)290 data sets. Examination of various Wnt, redox, and 
mitochondrial regulatory genes for correlations, survival, and enrichment of 
gene families was facilitated via Perl scripts developed in-house. 
 
Survival Analysis - Survival analysis was performed for selected patient 
groups meeting specific criteria. Patients were categorized as “high” or “low” 
expressers of genes, using an absolute mRNA expression z-score cut-off of 
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0.75; such groups required a minimum of 10 patients before further analysis 
was performed. The log-rank test was used to assess whether differences in 
survival were statistically significant; comparisons yielding p-values less than 
0.05 were selected as statistically significant. Patient groups with single gene 
high/low phenotypes were assessed, as well as groups with two gene 
high/low phenotypes. 
 
Gene set enrichment analysis – Gene set enrichment analysis (GSEA) was 
performed using the GSEA software.291,292 TNBC subtypes were selected on 
the criteria of being ER-/PR-/HER2- by immunohistochemistry (IHC). The list 
of patients corresponding to each patient group for comparison were 
manually provided to GSEA to create phenotypes for analysis. GO gene sets 
293 were used in the analysis. Gene sets affording p-values less than 0.05 
and q-values (false discovery rates) of less than 0.25 were selected as being 
significantly altered between the patient groups. 
 
2.24. DROSOPHILA STOCKS, GENE EXPRESSION, AND 
MITOCHONDRIAL MASS 
Drosophila fly stocks – The loss of function Gem3B and the overexpressing 
UAS-Flag-Gemin3 fly stocks were gifted from Prof. A Gregory Matera, 
University of North Carolina, Chapel Hill. Two ubiquitous drivers were used in 
combination for overexpression of UAS-Gemin3, armadillo-GAL4, and 
daughterless-GAL4.294 The double GAL4 driver line and Oregon R flies were 
used as wild-type controls. 
 
Drosophila RNA extraction and qPCR – Total RNA was extracted from 50μl 
Drosophila embryos selected for fertilisation and development stage for each 
genotype using a Qiagen RNA extraction kit following the manufacturer’s 
protocol. RNA preparations were incubated with RNAse-free DNase1 (NEB) 
at 37°C for ten minutes to remove any potential DNA contamination. After the 
treatment, DNase1 was inactivated by incubating the RNA samples at 75°C 
before quantification using Nanodrop 2000. 1μg RNA was used as template 
for the first strand cDNA synthesis. cDNA was synthesised using 
oligonucleotide dT, random primers, and reverse transcriptase from 
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QuantiTect Reverse Transcription Kit (Qiagen - #205314). Primer sequences 
to amplify the target gene regions were designed using NCBI primer design 
tool for all target genes and reference gene (RpL32). Real time PCR was 
carried out using a PikoReal 96 real time PCR system (Thermo Scientific) 
following the manufacturer’s instructions. Expression levels were determined 
in a 10μl reaction volume in triplicate using QuantiFast SYBR Green. qPCR 
was conducted at 95°C for seven mins, followed by 40 cycles of 95°C for  
five seconds and 60°C for one minute. The specificity of the reaction was 
verified by melt curve analysis. Raw data has been analysed by the 2-ΔΔCT 
method.295 Results were generated from three technical repeats and three 
biological repeats for each mRNA. The average relative expression ± 
standard deviation (SD) was determined and two-way ANOVA was carried 
out to determine statistical significance. Primer sequences are given in Table 
2.5.  
 
Table 2.5. Drosophila primer sequences, melting temperature, and size 
of amplicon for QPCR (quantitative PCR) 
 
GENE NAME PRIMER (5ʹ - 3ʹ) Tm (°C) SIZE (BP) 
Sod1 Fwd GGACCGCACTTCAATCCGTA 60 127 
Sod1 Rev TGGAGTCGGTGATGTTGACC 60 127 
Sod2 Fwd TTTCGCAAACTGCAAGCCTG 60 99 
Sod2 Rev TGATCTCCCGGCAGATGATAG 59 99 
Sod3 Fwd GTGCTCACTATAACCCCGATAAG 58 112 
Sod3 Rev GTAACGTCGATAATGCCCGTG 60 112 
Cat Fwd GATGCGGCTTCCAATCAGTTG 60 139 
Cat Rev GCAGCAGGATAGGTCCTCG 60 139 
Trx2 Fwd GACGATAAAGTTTCTGCGATCCT 59 98 
Trx2 Rev GGTCGTAATCATAGCGTGGTCT 60 98 
Prx3 Fwd ATGTCTTTCGTAGCACGCTCA 60 83 
Prx3 Rev GCGGCAATCTGTTTCTGCTG 60 83 
Dhd Fwd TGGATCTGCGCGACAAGAAAG 61 116 
Dhd Rev GAAGGTCTGGGCGGTGATTG 61 116 
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Rpl32 GCCCAAGGGTATCGACAACA 60 85 
Rpl32 GCGCTTGTTCGATCCGTAAC 60 85 
 
Drosophila mtDNA copy number quantification - Developmental stage-
synchronized Drosophila embryos were collected from three different crosses 
(wildtype, Gemin3B KO, and Gem3B OE). Experiments were performed 
using 10ng of DNA in a 20μL reaction mix to determine the mtDNA copy 
number. Real-time PCR (qRT-PCR) method with SYBR Green was used. 
Data were analyzed using the 2-ΔΔCT method.296 Primer sequences are given 
in Table 2.6. 
 
Table 2.6. Drosophila primer sequences for mitochondrial and nuclear DNA  
GENE NAME PRIMER (5ʹ - 3ʹ) TM 
(°C) 
SIZE 
(BP) 
nucDNA Fwd CGAGGGATACCTGTGAGCAGCTT 65 152 
nucDNA Rev GTCACTTCTTGTGCTGCCATCGT 65 152 
mtDNA Fwd GCTCCTGATATAGCATTCCCACGA 61 151 
mtDNA Rev CATGAGCAATTCCAGCGGATAAA 61 151 
 
2.25. STATISTICAL ANALYSIS 
Statistical analysis was performed using one-way analysis of variance 
(ANOVA) for groups with one variable or two-way ANOVA for groups with 
two variables. For single comparisons an unpaired Student’s t-test was 
performed, where p < 0.05 was considered significant. For multiple t-test 
comparisons, a Bonferroni post hoc test was utilised with an a of 0.05. All 
calculations were performed using Prism GraphPad v6.0e.  
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IN A WNT/b-CATENIN DEPENDENT MANNER 
	
3.1. INTRODUCTION 
DDX20 is an ATP-dependent RNA helicase that has been implicated as a 
regulator of apoptosis in cancer cells through a variety of mechanisms, 
including Wnt and reactive oxygen species (ROS). This chapter focuses on 
elucidating the mechanisms of DDX20-dependent regulation of canonical 
Wnt signalling and intracellular ROS in TNBC. For this study, two TNBC cell 
lines were utilised, MDA-MB-231 and MDA-MB-436. These were chosen due 
to their high DDX20 expression, highly invasive phenotype297 and lack of 
PI3K pathway mutations;298 PI3K regulation of the Akt-FOXO pathway is 
important in ROS detoxification, especially the transcriptional regulation of 
catalase.299 Previous reports have implicated b-catenin regulation of both 
FOXO and TCF/LEF transcription factors, which is dependent on intracellular 
redox conditions.286,300 These cell lines allow the study of Wnt-mediated 
transcriptional regulation of ROS scavengers without variations in FOXO and 
TCF/LEF transcriptional activity. The results demonstrate that depletion of 
DDX20 results in an increase in intracellular ROS, predominately in the form 
of H2O2; high intracellular H2O2 can adversely affect canonical Wnt signalling. 
They also demonstrate that high intracellular ROS levels are partially due to 
a decrease in catalase expression, which is transcriptionally regulated by 
TCF4 transcription factors through Wnt/b-catenin signalling dependent on 
DDX20 (Figure 3.1).   
 
	 86	
 
Figure 3.1. Schematic of Wnt-mediated ROS regulation in TNBC. DDX20high cells 
stimulated by Wnt3a demonstrate lower levels of ROS and proper conductance of Wnt 
signalling. This is mediated through increased expression of catalase-mediated by TCF4. 
DDX20low cells have higher levels of ROS and impaired Wnt signalling. There is a loss of 
catalase expression and an increase in intracellular ROS. 
 
3.2. RESULTS  
 
3.2.1. DDX20 is associated with oxidative stress regulation and catalase 
is associated with Wnt signalling in TNBC 
Data from the METABRIC TNBC (n=270) were used to perform 
gene-set enrichment analysis (GSEA).291,292 GSEA on individuals with a 
DDX20high (n=73) phenotype compared to a DDX20low (n=73) phenotype 
revealed an enrichment of genes associated with regulation of oxidative 
stress-induced cell death (GO:1903201) in the DDX20high phenotype. This 
gene set included regulators of ROS such as thioredoxin (TXN) and NRF2 
(NFE2L2) (Fig 3.2A).  
A bioinformatics approach was used to determine if there was an 
association of redox regulators with Wnt signalling. Using data accessed 
from cBioPortal,288,301 it was determined that catalase was commonly 
amplified in three large cohort data sets: METABRIC,290 TCGA,289 and the 
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newly created TCGA PanCancer Atlas.302 Furthermore, DDX20 and AXIN2 
exhibited amplification among the patient data sets (Fig 3.8B). Analysis of the 
different molecular subtypes revealed that catalase is significantly 
overexpressed in the claudin-low TNBC subtype, compared to both luminal B 
and HER2+ breast tumours (Fig 3.8C). To determine if there was an 
association with canonical Wnt signalling, gene expression correlation 
studies between mRNA expression of catalase (CAT) and b-catenin 
(CTNNB1) were performed. Data from 1898 patients from the METABRIC 
cohort revealed a strong positive correlation between CAT and CTNNB1 
gene expression. When the subtypes were analysed individually, both TNBC 
subtypes - Basal and claudin-low - also demonstrated a strong positive 
correlation (Fig 3.8D,E,F). When survival analysis was performed on the 
METABRIC basal subtype cohort of individuals exhibiting either a 
DDX20hi/CAThi individuals versus DDX20low/CATlow phenotype or a 
CTNNB1hi/CAThi individuals versus CTNNB1low/CATlow phenotype, no 
significant differences in survival were observed. Median survival rates 
increased in individuals with a low DDX20 and CAT expression (7.58 to 9.9 
years) and low CTNNB1 and CAT expression (5.42 to 8.75 years) when 
compared to individuals exhibiting high gene combinations of the respective 
gene combinations (Fig S3.1).  
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Figure 3.2. Gene set enrichment analysis of DDX20 and bioinformatics analysis on 
DDX20 and catalase A) GSEA enrichment plot of GO gene set Regulation of Oxidative 
Stress induced Cell Death in DDX20high vs DDX20low patient phenotypes. Nominal p-value, 
FDR (False discovery rate), enrichment score (ES), normalised ES were calculated using 
GSEA software from Broad Institute. B) Oncoprint of mutations, amplifications, and deletions 
accessed from cBioPortal for CAT, DDX20, and AXIN2. C) Catalase mRNA expression 
based on PAM50 molecular subtypes of breast cancer. D) Spearman’s correlation (r or Rho) 
of CAT and CTNNB1 in TCGA cohorts for all breast cancer subtypes and PAM50 E) claudin-
low and F) basal subtypes. Data are represented as mean±SEM of at least 3 biological 
replicates. Statistical analysis was performed using unpaired students t-test, *p<0.05, 
**p<0.01, ***p<0.001. 
 
3.2.2. DDX20 and Wnt signalling regulate intracellular redox conditions 
To validate whether DDX20 regulated intracellular redox conditions in vitro, 
we first utilised two ROS probes, DHE, to measure superoxide production, 
and CM-H2DCFDA, to measure oxidative stress induced by multiple ROS 
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species, by flow cytometry. Knockdown of DDX20 was assessed 72 hours 
after transfection and resulted in a significant increase in ROS, as indicated 
by a significant increase in the mean fluorescence intensity (MFI) of CM-
H2DCFDA in both cell lines. This was only partially rescued by the addition of 
exogenous catalase in both cases (Fig 3.3A & 3.3B). 
To test the effect of Wnt activation on intracellular redox 
conditions, a GSK3b inhibitor, lithium chloride (LiCl) (20mM), was added to 
the medium for three and six hours. There was a significant decrease in the 
MFI of CM-H2DCFDA at the six hour time point in both MDA-MB-436 and 
MDA-MB-231 cell lines (Fig 3.3C & 3.3D). Conversely, there was a 
significant increase in intracellular superoxide levels, as indicated by a 
significant increase in the MFI of DHE at the six hour time point in both cell 
lines (Fig 3.3E & 3.3F).  
 
 
Figure 3.3. Evaluation of intracellular redox after modulation of DDX20 and Wnt 
signalling. A. Bar graph and representative histogram of CM-H2DCFDA of MDA-MB-436 
and B. MDA-MB-231 cell lines 72 hours post-transfection with ctDDX20, siDDX20 and 
siDDX20 with the addition of catalase (1000U/mL) for 1 hour. Grey = negative control, Blue = 
ctDDX20, Red = siDDX20 and Black = siDDX20+catalase. C. Bar graph and representative 
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histogram of CM-H2DCFDA of MDA-MB-436 and D. MDA-MB-231 cell lines with LiCl for 
three and six hours. Grey = negative control, Blue = PBS control, Red = 3hr and Black = 6hr. 
E. Bar graph and representative histogram of DHE of MDA-MB-436 and F. MDA-MB-231 
with LiCl for three and six hours.. Grey = negative control, Blue = PBS control, Red = 3hr 
and Black = 6hr. All data are represented as mean±SEM of at least three biological 
replicates. Statistical analysis was performed using unpaired students t-test, *p<0.05, 
**p<0.01, ***p<0.001.  
 
To determine the primary species of ROS that is upregulated on depletion of 
DDX20, a H2O2-specific luciferase assay was utilised. Upon depletion of 
DDX20, a >3-fold and >2.5-fold increase in H2O2 production in MDA-MB-436 
and MDA-MB-231 cell lines respectively was observed (Fig 3.4A & 3.4B). 
The increase in overall oxidative stress mediated by H2O2 was confirmed by 
measuring the ratio of reduced glutathione (GSH) to oxidised glutathione 
(GSSG). In both cell lines, a significant reduction in the ratio between 
GSH/GSSG was observed in cells with diminished DDX20 (Fig 3.4C & 3.4D). 
 
 
Figure 3.4. Hydrogen peroxide induced oxidative stress in TNBC cells. A&B) ROS-Glo 
H2O2 assay of MDA-MB-231 and MDA-MB-436 cells after transfection with siDDX20. H2O2 
production is measured as relative luciferase units (RLUs). C&D) GSH/GSSG-Glo assay of 
MDA-MB-231 and MDA-MB-436 cells after transfection with siDDX20. Data are relative to 
cells transfected with control siRNA.  All data are represented as mean±SEM of three 
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biological replicates. Statistical analysis was performed using unpaired students t-test, 
*p<0.05, **p<0.01, ***p<0.001.  
 
3.2.3. TCF4 transcription mediated by DDX20 is responsible for Wnt 
signalling-mediated oxidative stress 
To further validate that Wnt signalling can cause changes to intracellular 
redox conditions, immunofluorescence was used to co-stain for CM-
H2DCFDA and Mitotracker Deep Red. To confirm that the Wnt-mediated 
regulation of intracellular redox was due to DDX20 activating TCF4 
transcription, a dnTCF4, which has a deleted N-terminal β-catenin-binding 
domain (D1-67), and DDX20 (pCMV-DDX20) were overexpressed. The ratio 
of Mitotracker Deep Red fluorescence intensity to CM-H2DCFDA staining 
was measured to determine if the resultant increase in ROS was associated 
with changes to the mitochondrial membrane potential (Djm).  
In both cell lines, cells transfected with either control siRNA or 
empty vectors exhibited a Mitotracker Deep Red to CM-H2DCFDA ratio that 
was close to or greater than one, indicating Mitotracker fluorescence was 
greater than CM-H2DCFDA fluorescence. In cells with a loss of DDX20 ROS 
fluorescence exceeded that of the Mitotracker Deep Red fluorescence. This 
was mirrored in cells transfected with dnTCF4. Furthermore, cells that 
overexpressed DDX20 and the dnTCF4 exhibited significantly increased 
ROS intensity relative to Mitotracker Deep Red intensity (Fig 3.5 A-L).  
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Figure 3.5. Wnt signalling mediation of intracellular redox and mitochondrial 
membrane potential. Immunofluorescence images of cells co-stained with CM-H2DCFDA 
(Green) and Mitotracker Deep Red (Red). MDA-MB-231 cells were transfected with A) 
control siRNA B) empty vector C) siRNA targeting DDX20 D) dominant-negative TCF4 
(dnTCF4) and E) dnTCF4 and pCMV-DDX20. F) Quantification of Mitotracker Deep Red to 
CM-H2DCFDA ratio. MDA-MB-436 cells were transfected with G) control siRNA H) empty 
vector I) siRNA targeting DDx20 J) dominant-negative TCF4 (dnTCF4) and K) dnTCF4 and 
pCMV-DDX20. L) Quantification of Mitotracker Deep Red to CM-H2DCFDA ratio. All data are 
represented as mean±SEM of three biological replicates. Statistical analysis was performed 
using students t-test, determined using the Sidak-Bonferroni method, a=0.005. *p<0.05, 
**p<0.01, ***p<0.001. Scale bar = 100µm. 
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3.2.4. Intracellular redox conditions modulate Wnt/b-catenin signalling 
in TNBC 
To test what effect the overall cellular ROS levels would have on Wnt/b-
catenin signalling in TNBC cells, fluorescent-activated cell sorting (FACS) 
was performed on both MDA-MB-231 and MDA-MB-436 cells using the CM-
H2DCFDA general ROS probe. We sorted cells based on a ROSdim and 
ROSbright phenotype that were also 7-AAD negative (as cells positive for 7-
AAD are dead and exhibit higher levels of ROS) (Fig 3.6A). Following cell 
sorting, we performed Western blot analysis for the Wnt proteins active b-
catenin (unphosphorylated S33/S37/T41) and Dvl3, as well as DDX20. The 
ROSbright population in MDA-MB-231 cells demonstrated a significant 
decrease in the levels of both Dvl3 and active b-catenin proteins compared to 
the ROSdim population. DDX20 protein levels were decreased, although not 
significantly. In the MDA-MD-436 cells, the same trends were observed in 
ROSbright cells (Fig 3.6B & 3.6C). 
Both cell lines were then subject to general Wnt signalling 
stimulation with LiCl (20mM) coupled with increasing doses of exogenous 
H2O2. We performed Western blotting and probed for proteins involved in 
canonical Wnt signalling. A dose-dependent decrease in the expression of 
both Dvl3 and active b-catenin proteins was observed, with the most effective 
doses being 100 and 150µM of H2O2 (Fig 3.6D). To further validate this, we 
used the same concentrations of H2O2 and performed a luciferase based 
TCF/LEF reporter assay to test for Wnt signalling activity. In both cell lines, 
doses of 150µM of H2O2 led to significant decreases in the levels of TCF/LEF 
transcriptional activity (Fig 3.6E). A H2O2 dose reponse was carried out on 
both cell lines, which revealed that MDA-MB-436 cells were more sensitive to 
lower doses of H2O2 than MDA-MB-231 cells (Fig S3.2). 
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Figure 3.6. Effect of oxidative stress on Wnt/b-catenin signalling. A) Flow cytometry 
contour plots of gating strategy and sort populations for MDA-MB-231 and MDA-MB-436 
ROSbright and ROSdim populations. Cell sorting populations are represented by red and blue 
gates for ROSdim and ROSbright populations respectively. X-axis is log scale CM-H2DCFDA 
fluorescence and Y-axis is log scale 7-AAD fluorescence. B) Western blots of MDA-MB-231 
and MDA-MB-436 ROSdim and ROSbright cell populations for DDX20, Dvl3, and active-b-
catenin. C) Quantification of Western blots for MDA-MB-231 and MDA-MB-436 ROSdim and 
ROSbright cell populations for DDX20, Dvl3, and active-b-catenin. D) Western blot of MDA-
MB-231 and MDA-MB-436 cells after stimulation with 20mM LiCl for 1 hour and increasing 
doses of H2O2 for 4 hours. Blots represent the results of one experiment, repeated three 
times with the same trend. E. TCF/LEF reporter assay of MDA-MB-436 and MDA-MB-231 
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cells after stimulation with 20mM LiCl for 1 hour and increasing doses of H2O2 for 8 hours. 
Data are represented as mean±SEM of at least three biological replicates. Statistical 
analysis was performed using unpaired students t-test, *p<0.05, **p<0.01, ***p<0.001.  
 
 
3.2.5. Antioxidants partially rescue DDX20-mediated cell death 
To validate whether the previously observed cell death upon loss of DDX20 
(Cai & Pohl et al, unpublished) was due to oxidative stress, we performed 
cell viability rescue experiments with two antioxidants, glutathione and 
riboflavin (vitB2). The loss of DDX20 resulted in significant cell death in both 
cell lines. The addition of glutathione at regular 24-hour timepoints was able 
to completely restore the cell viability lost by DDX20 depletion (Fig 3.7A & 
3.7B). To further test whether the oxidative stress-mediated cell death was 
due to lipid peroxidation, riboflavin was added every 24 hours to one group of 
cells transfected with both control siRNA and siDDX20. In both cell lines, a 
partial restoration of cell viability 96 hours post-transfection was observed 
(Fig 3.7C & 3.7D). 
 
Figure 3.7. Effect of antioxidants on DDX20 depleted cells. A & B) MDA-MB-436 and 
MDA-MB-231 cells treated with 500nM glutathione every 24 hours for 96 hours in one group 
of cells transfected with control of siRNA targeting DDX20. C & D) MDA-MB-436 and MDA-
MB-231 cells treated with 600nM riboflavin every 24 hours for 96 hours in one group of cells 
transfected with control of siRNA targeting DDX20. Data are represented as mean±SEM of 
at least 3 biological replicates. Statistical analysis was performed using unpaired students t-
test, *p<0.05, **p<0.01, ***p<0.001.  
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3.2.6. Catalase expression is mediated through a Wnt-DDX20-TCF4 axis 
To validate the in silico finding that catalase was associated with DDX20 and 
canonical Wnt signalling, DDX20 was knocked down and Western blotting for 
catalase expression performed. In both cell lines, catalase expression was 
significantly reduced (Fig 3.8A & 3.8B). Furthermore, when a dnTCF4 
plasmid was overexpressed, a significant reduction in catalase expression 
was observed. This was unable to be rescued with the ectopic 
overexpression of DDX20 (Fig 3.8C & 3.8D). 
 
 
Figure 3.8. Catalase expression regulation by DDX20 and Wnt signalling. A) Western 
blots of Catalase expression in MDA-MB-231 and MDA-MB-436 cells transfected with 
control siRNA or siRNA targeting DDX20. B) Quantification of catalase expression from 
Western blots. C) Western blots of catalase in MDA-MB-436 and MDA-MB-231 cells 
transfected with empty vector, dnTCF4 or pCMV-DDX20 in combination with dnTCF4. D) 
Quantification of Western blots for catalase protein expression in MDA-MB-436 and MDA-
MB-231 cells. Data are represented as mean±SEM of at least three biological replicates. 
Statistical analysis was performed using unpaired students t-test, *p<0.05, **p<0.01, 
***p<0.001.  
 
 
3.2.7. Catalase is transcriptionally regulated by TCF4 mediated by 
Wnt3a and DDX20 
Using the ENCODE ChIP-seq portal (http://genome.ucsc.edu/encode), it was 
found that there were TCF4 (TCF7L2) ChIP-seq peaks situated distal to the 
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core promoter region in the DNA of catalase (Fig 3.9A). To validate whether 
this occurred MDA-MB-231 and MDA-MB-436 cells, chromatin 
immunoprecipitation (ChIP) was performed using primers designed around 
the TCF4 binding site, and a binding site proximal to the core promoter to 
which TCF4 was not predicted to bind. After immunoprecipitation of TCF4, it 
was found that TCF4 was bound to catalase DNA at the predicted binding 
site (Fig 3.9C). Furthermore, we witnessed an increase in the recruitment of 
TCF4 to the catalase gene in cells stimulated with Wnt3a for two hours (Fig 
3.9D). Conversely, in cells depleted of DDX20, there was a decrease in the 
recruitment of TCF4 to the catalase gene, albeit in the presence of Wnt 
stimulation (Fig 3.9E). These changes in TCF4 recruitment were mirrored by 
changes in gene expression. We witness significant decreased catalase 
gene expression following knockdown of DDX20 (Fig 3.9F) and increased 
expression of catalase following Wnt3a stimulation (Fig 3.9G). 
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Figure 3.9. Transcription regulation of Catalase by TCF4. A) ChIP-seq tracks and peaks 
from MCF-7, HCT-116, and HeLa cells from ENCODE ChIP-seq data viewer centred around 
catalase gene TSS. Coloured bases indicate TCF4 binding sequence on CAT DNA. B) 
Schematic of primer design and binding sites of TCF4 on Catalase DNA. CAT1 is TCF4 
binding site, CAT2 is non-TCF4 binding site. C) Semi-quantitative PCR of TCF4 ChIP in cells 
stimulated with Wnt3a (200ng/mL) for two hours and cells stimulated with Wnt3a and 
silenced DDX20. D) ChIP-qPCR of fold recruitment relative to IgG control after Wnt3a 
simulation. E) ChIP-qPCR of fold recruitment relative to IgG control after transfection with 
siDDX20 and Wnt3a stimulation. ChIP-qPCR for siDDX20 treated cells is a representative 
result of three biological repeats with a similar trend. ChIP-qPCR for Wnt3a represents a 
representative result of two biological repeats with a similar trend. F) Q-PCR of catalase 
expression following knockdown of DDX20. G) Q-PCR of catalase expression following 
stimulation with 200ng/mL for 4 hours. Q-PCR data are represented as mean±SEM of at 
least three biological replicates. Statistical analysis was performed using unpaired students 
t-test, *p<0.05, **p<0.01, ***p<0.001.  
 
 
3.2.8. DDX20 regulates intracellular redox in vivo  
A Gemin3 (DDX20) knockout and Gemin3 over-expressing Drosophila model 
was generated (Tolwinski Lab, Yale-NUS College, Singapore). Gemin3 
knockout is embryonically lethal, therefore, the assessment of ROS 
scavenger gene expression was performed on embryos. A GAL4/UAS 
system was utilised to develop the Gemin3-overexpressing model driven by 
an ubiquitously-expressed double driver of Armadillo and Daughterless 
(Gemin3arm/da), the Drosophila orthologues for b-catenin and TCF4 
respectively (Fig 3.10A).  
When gene expression in the Gemin3 KO and Gemin3arm/da was 
performed, the results clearly demonstrated that Gemin3 regulates the gene 
expression of a variety of ROS scavengers. In the Gemin3 knockout, 
expression of Sod1, Sod3, and dhd (Drosophila orthologue of thioredoxin-1) 
were all significantly increased, while all were significantly decreased when 
Gemin3 was overexpressed (Fig 3.10B). Catalase expression was 
decreased in the Gemin3 knockout, although the overexpression of Gemin3 
had a similar effect.  
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Figure 3.10. In vivo validation of DDX20 regulation of ROS. A) Schematic of generation 
of Gemin3 overexpressing Drosophila fly embryos. B) Q-PCR of Drosophila mRNA 
expression for Sod1, Sod3, Cat, and dhd in control (GAL4arm/da), Gemin3 knockout 
(Gemin3KO) and Gemin3 overexpressing (Geminarm/da) flies. Data are represented as 
mean±SEM of at least three biological replicates. Statistical analysis was performed using 
unpaired students t-test, *p<0.05, **p<0.01, ***p<0.001.  
 
 
3.3 DISCUSSION 
This is the first study to implicate DDX20 in the regulation of cellular redox. 
Furthermore, this is also the first time that canonical Wnt signalling – directly 
through TCF4-mediated gene transcription – has been directly associated 
with the regulation of genes involved in ROS detoxification, namely catalase. 
We have provided evidence to demonstrate that DDX20 is essential for 
canonical Wnt signalling and the loss of DDX20 can cause an increase in 
oxidative stress, mediated through decreased catalase expression, resulting 
in cell death.  
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Using a combination of ROS probes, it was demonstrated that a 
loss of DDX20 resulted in increased oxidative stress, primarily through 
increased H2O2 production; conversely, the activation of the Wnt pathway 
decreased overall oxidative stress while increasing superoxide (O2-) 
production. While GSK3b inhibition with LiCl is known to activate other 
targets, it is widely known for increasing active b-catenin and promoting its 
nuclear translocation.303,304  Superoxide is a known activator of oncogenic 
signalling. A recent study by Ogrunc et al.305 demonstrated that superoxide 
generated from Rac1 and NADPH4 initiates hyperproliferation of cancer 
cells. Conversely, lower concentrations of H2O2 have been shown to be pro-
proliferative in mammalian cells.306 Furthermore, favouring O2- over H2O2 has 
been clearly shown to promote oncogenic signalling.251 This is consistent with 
results in this study, wherein the activation of Wnt signalling coincides with 
intracellular redox conditions favouring a pro-oxidant environment. 
H2O2 and oxidative stress have been shown to both positively and 
negatively regulate Wnt/b-catenin signalling. Previous studies suggest that 
apoptotic doses (>200µM) activate Wnt signalling initially (<60 minutes),256 
although longer term treatment results in the suppression of b-catenin-
mediated signalling.307 Exogenous treatment with H2O2 was found to 
suppress Wnt signalling at the level of Dvl, which affects downstream active 
b-catenin expression. This is consistent with a study by Shin et al.307, which 
demonstrated that overexpression of Dvl-1 rescued H2O2-mediated 
suppression of Wnt signalling. By using cell sorting to separate cells based 
on their overall levels of oxidative stress, it was determined that even in 
clonal cell populations, there are differences in the variations in ROS levels. 
These levels were shown to impact Wnt signal transduction through 
regulation of protein expression of Dvl3 and active b-catenin. A significant 
decrease in DDX20 was not observed, which suggests that DDX20 is either 
upstream or parallel to Dvl in Wnt signalling transduction and may not be 
affected by H2O2 suppression of Dvl3.  
High levels of basal ROS have been shown to be pivotal in 
carcinogenesis, specifically by activating oncogenic signalling pathways.308 
When levels of ROS become too high, this can initiate cell death through a 
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variety of mechanisms, including DNA damage,309 caspase activation,310 and 
iron-dependent cell death, or ferroptosis.311 The loss of DDX20 increases 
intracellular ROS to a point that results in cell fate decisions favouring cell 
death. This was completely rescued after the cells were treated with 
glutathione. Glutathione is able to reduce oxidative stress through its redox 
cycle312 and has been demonstrated to be required for cancer initiation.313 
Riboflavin was evaluated for its ability to rescue DDX20-mediated cell death, 
which would provide evidence that DDX20 loss results in high levels of lipid 
peroxidation and is suggestive of death by ferroptosis.314,315 Cell death was 
incompletely rescued after the loss of DDX20, suggesting that although 
increased lipid peroxidation may be partially responsible, it is not the major 
contributor to the observed cell death. 
Catalase is an ROS scavenging enzyme responsible for catalysing 
the breakdown of H2O2 to oxygen and water. This study suggests that the 
downregulation of catalase mediated by the loss of DDX20 may be partially 
responsible for the increased H2O2-induced oxidative stress and cell death 
demonstrated. The exogenous addition of catalase did not completely 
abrogate the increase in ROS levels after DDX20 depletion, although 
catalase will not directly endocytose into the cell within a short period of time 
and therefore will not scavenge intracellular H2O2. Furthermore, this study 
provides direct evidence that Wnt/b-catenin signalling through TCF4 
transcription regulates catalase expression. Higher levels of catalase through 
Wnt activation keep H2O2 levels low, and confer a pro-oxidant environment 
permissive for oncogenic signalling. Low levels of catalase following the loss 
of DDX20 create high levels of H2O2 and oxidative stress-induced cell death. 
A previous report has demonstrated that the loss of b-catenin in 
haematopoietic stem cells resulted in increased oxidative stress, which was 
concurrent with decreased catalase expression, although there was no 
mechanistic data provided.316 All previous reports of b-catenin-mediated 
transcription of catalase were through the association of b-catenin with FoxO 
transcription factors,285,300 which have a primary role in the regulation of 
ROS-scavenging enzymes.317 This occurs during oxidative stress, where b-
catenin is diverted from TCF transcription factors to FoxO transcription 
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factors.318 A possible explanation why catalase expression is not kept at 
homeostatic levels by b-catenin diverting to FoxO transcription factors under 
oxidative stress in this study, is that the loss of DDX20 also results in the loss 
of transcriptionally active b-catenin (Cai & Pohl, unpublished, also see 
Chapter 5). This results in the loss of available b-catenin, which would 
otherwise be diverted to FoxO, and instead could lead to the suppression of 
FoxO-mediated transcription of catalase, resulting in high intracellular 
concentrations of H2O2. 
DDX20 has been confirmed in this study to influence the 
transcription of redox regulator genes in vivo using a Drosophila embryo 
model in which Gemin3 (DDX20) is knocked out and in a Gemin3-
overexpressing model driven by the orthologues of human b-catenin and 
TCF transcription factors. This is also the first report of Gemin3 influencing 
cellular redox in an in vivo model. Catalase gene expression was reduced in 
Gemin3KO embryos, although Gemin3KO embryos had increased expression 
of Sod1, Sod3, and dhd (thioredoxin 1). Conversely, the overexpression of 
Gemin3 decreased the expression of Sod1, Sod3, and dhd. A genetically 
encoded ROS probe was attempted to be used in the Gemin3KO and 
Gemin3OE models, although the ROS sensor was not able to be expressed at 
high enough levels at the embryonic stage in which embryos were still viable. 
The changes in gene expression of these redox regulators are suggestive of 
changes in overall cellular redox. It has been previously demonstrated that 
differences in the intracellular redox mileu can directly lead to changes in the 
expression of specific gene targets to counter a rise or fall in ROS 
concentrations.319 A recent study by Wang et al,320 has implicated Wnt 
signalling in redox regulation of germ cell differentiation in Drosophila larvae 
through glutathione-S-transferase (GST) expression. Upon knockdown of 
dishevelled (Dsh) in Drosophila larvae, intracellular ROS was increased, 
which also coincided with a decrease in germ cell differentiation. This was 
rescued in dshKD larvae that overexpressed catalase, Sod1, and GST2. This 
study demonstrates that Wnt signalling is a determinant of cell fate in a 
redox-mediated mechanism. 
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Overall, this report has demonstrated that DDX20/Gemin3 is a 
regulator of cellular redox in vitro and in vivo in a Wnt-dependent manner. 
This is the first study to directly implicate TCF4 is the regulation of cellular 
redox through catalase expression. An increase in oxidative stress, 
predominately in the form of increased H2O2, was observed, which resulted 
in cell death. The addition of catalase was unable to completely rescue the 
increased ROS, which suggests that there is another source of ROS within 
these cells that is contributing to the increased oxidative stress. A major 
source of ROS within the cells is from the mitochondria. These findings 
demonstrated that mitochondrial polarisation is dependent on DDX20 and 
Wnt signalling through TCF4. Mitochondrial ROS and redox regulators 
involved in ROS detoxification located within the mitochondria may provide a 
further source contributing to the increased oxidative stress witnessed with 
depletion of DDX20 and suppression of Wnt signalling. 
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3.5 SUPPLEMENTARY MATERIALS CHAPTER 3 
 
 
Fig S3.1. Survival analysis from TNBC METABRIC cohorts. A) Overall survival analysis 
of DDX20hi/CAThi individuals versus DDX20low/CATlow from PAM50 basal subtype of 
METABRIC cohort. B) Overall survival analysis of CTNNB1hi/CAThi individuals versus 
CTNNB1low/CATlow from PAM50 basal subtype of METABRIC cohort. Survival statistics were 
performed using Mantel-Cox (logrank) test and calculated on Prism GraphPad. 
 
 
Fig S3.2. Dose response to H2O2 treatment. CCK8 viability assay of MDA-MB-231 and MDA-
MB-436 cells after increasing doses of H2O2 for 24 hours. Data is representative of two 
biological repeats with four technical replicates.  
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CHAPTER 4: DDX20 REGULATES MITOCHONDRIAL 
FUNCTION IN A WNT/b-CATENIN DEPENDENT MANNER  
	
4.1 INTRODUCTION 
Mitochondrial dynamics and metabolism play a crucial role in the progression 
of cancer.321 TNBC is characterised by having many mitochondrial functional 
and genetic defects that contribute to the mitochondrial heterogeneity among 
TNBC patients.322 This chapter will focus on the role of DDX20 mediation of 
mitochondrial function through Wnt/b-catenin signalling in two TNBC cell 
lines, MDA-MB-231 and MDA-MB-436. In a study investigating mitochondrial 
dysfunction in TNBC, MDA-MB-231 and MDA-MB-436 cells both exhibited a 
similar mitochondrial metabolic profile in terms of oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR).323 The results demonstrate 
that the loss of DDX20 results in differential regulation of Ubiquinol 
cytochrome c Reductase subunit 2 (UQCRC2) – a component of the 
mitochondrial electron transport chain Complex III – and SOD2, a 
membrane-bound mitochondrial ROS scavenger. This leads to increased 
mitochondrial oxidative stress, respiratory dysfunction, loss of membrane 
potential, and changes to mitochondrial DNA (mtDNA) copy numbers. 
Activation of Wnt signalling results in increased expression of UQCRC2 and 
decreased expression of SOD2 (Fig 4.1). This is the first report of TCF4-
mediated regulation of SOD2 and UQCRC2, clearly implicating canonical 
DDX20-medated Wnt signalling in the regulation of mitochondrial ROS 
(mitoROS) and mitochondrial respiration. 
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Figure 4.1. DDX20 mediation of mitochondrial function. A) DDX20high cells demonstrate 
increased canonical Wnt signalling, which increases UQCRC2 expression while decreasing 
SOD2 expression mediated through TCF4. This results in higher OXPHOS and increased 
energy production for tumorigenesis. B) The loss of DDX20 results in increased SOD2 
expression and decreased UQCRC2 expression. This results in decreased mitochondrial 
respiration and increased oxidative stress, ultimately leading to loss of mitochondrial 
membrane potential, mitochondrial dysfunction, and changes in mtDNA copy number. 
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4.2 RESULTS 
 
4.2.1 DDX20HIGH phenotypes are enriched in gene sets relating to 
mitochondrial processes and mitochondrial apoptosis regulation 
To determine whether DDX20 was associated with mitochondrial function 
and regulation, GSEA was performed on the DDX20high and DDX20low 
phenotypes from the METABRIC TNBC cohort. The results indicated 
numerous gene sets enriched in the DDX20high population involved with 
mitochondrial processes, including apoptotic mitochondrial changes 
(GO:0008637), protein localization to mitochondrion (GO:0070585), 
mitochondrial RNA metabolic process (GO:0000959), and regulation of 
release of cytochrome C from mitochondria (GO:0090199) (Fig 4.2A,B,C&D). 
 
 
 
Figure 4.2. Gene set enrichment analysis of DDX20 in TNBC. GSEA enrichment plot of 
GO gene set A) Apoptotic mitochondrial changes; B) Protein localization to mitochondrion; 
C) Mitochondrial RNA metabolic process; and D) Regulation of release of cytochrome C 
from mitochondria in DDX20high vs DDX20low patient phenotypes. Nominal p-value, FDR 
(false discovery rate), enrichment score (ES), and normalised ES were calculated using 
GSEA software from Broad Institute.291  
 
To determine whether there was an association between DDX20, canonical 
Wnt signalling, and mitochondrial gene expression, publicly-available 
datasets from cBioPortal were accessed. To confirm an association between 
DDX20 and UQCRC2, co-expression analysis was performed on DDX20 and 
nine nuclear-encoded complex III subunits. The only positive correlation in 
gene expression between DDX20 and the complex III subunits was with 
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UQCRC2 (Fig 4.3A). When this analysis was performed for multiple cancer 
types, it was demonstrated that the highest frequency of UQCRC2 was in the 
METABRIC and TCGA breast cancer cohorts (Fig 4.3B). It was previously 
demonstrated (Chapter 3) that the loss of DDX20 results in increased H2O2. 
This observation led to the examination of the major producer of H2O2 in the 
mitochondria, SOD2. It was revealed that SOD2 is overexpressed in the 
basal and claudin-low TNBC subtypes (Fig 4.3C) and in TNBC cell lines 
when compared to luminal subtypes (Fig 4.3D). When co-expression 
analysis was performed on SOD2 and the Wnt target gene AXIN2, there was 
a significant negative correlation between the two (Fig 4.3E). Survival 
analysis on individuals with combinatorial patterns of DDX20 and SOD2 
expression failed to reveal any phenotype with a significantly better or poorer 
survival outcome; when median survival was calculated, it was identified that 
individuals with a DDX20hi/SOD2hi, DDX20low/SOD2low, DDX2low/SOD2hi, and 
DDX20hi/SOD2low phenotype had median overall survivals of 7.3, 8.7, 7.1, 
and 5.2 years respectively (Fig S4.1A). 
 
 
 
 
Figure 4.3. Bioinformatics analysis on DDX20, SOD2, and UQCRC2 in breast cancer 
cohorts. A) Spearman’s correlation (r or Rho) of DDX20, UQCRC2 and all mitochondrial 
complex III subunits in TCGA cohorts for all breast cancer. B) Alteration frequency of 
UQCRC2 in various cancer cohorts. C) PAM50 subtypes for SOD2 expression in 
METABRIC breast cancer cohort. D) SOD2 expression in a selection of TNBC and luminal 
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subtype cell lines. Accessed from CCLE data through cBioPortal. E) Spearman’s correlation 
(r or Rho) of SOD2 and AXIN2 in TCGA cohorts for all breast cancer subtypes. Statistical 
analysis was performed using unpaired Student’s t-test, *p<0.05, **p<0.01, ***p<0.001.  
 
 
4.2.2 DDX20 regulates mitochondrial ROS and mitochondrial membrane 
potential 
To confirm the previous observations (Chapter 3) that depletion of DDX20 
results in changes to mitochondrial membrane potential and mitochondrial 
morphology, higher magnification immunofluorescence was used to stain for 
Mitotracker Deep Red. The results revealed that polarised mitochondrial 
membranes in the control cells (ctDDX20) were much more tubular and 
dispersed throughout the cytoplasm, whereas cells diminished of DDX20 
(siDDX20) presented a more fragmented appearance and were situated 
around the perinuclear regions of the cell (Fig 4.3A&B). Next, mitochondrial 
superoxide levels were assessed. These results indicated that the loss of 
DDX20 in both cell lines corresponded to a significant decrease in 
mitochondrial superoxide, as measured by the MitoSox Red probe (Fig 
4.3C&D). Furthermore, 3D immunofluorescence stacking of MDA-MB-231 
cells after DDX20 knockdown demonstrates a clear decrease in the 
distribution and amount of Mitotracker Deep Red in siDDX20 transfected 
cells (Fig S4.2). 
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Figure 4.4 Measurement of mitoROS and membrane potential. A) MDA-MB-231 cells 
transfected with control siRNA (ctDDX20) or siDDX20 stained for Mitotracker Deep Red 
(Red) and DAPI (Blue). B) MDA-MB-436 cells transfected with control siRNA (ctDDX20) or 
siDDX20 stained for Mitotracker Deep Red (Red) and DAPI (Blue). Images were taken at 
60X, scale bar = 75µm. C) Flow cytometric measurement of MitoSox Red in MDA-MB-231 
cells, and D) Flow cytometric measurement of MitoSox Red in MDA-MB-436 cells. Data are 
represented as mean fluorescence intensity (MFI). Statistical analysis was performed using 
unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
 
4.2.3 Mitochondrial membrane potential and mass is regulated by 
DDX20 in a TCF4-dependent manner 
To determine whether the changes in mitochondrial membrane potential 
were associated with a change in mitochondrial mass, co-staining of MDA-
MB-231 and MDA-MB-436 cells was performed using Mitotracker Green and 
Mitotracker Deep Red; Mitotracker Green stains mitochondria irrespective of 
membrane potential, while Mitotracker Deep Red will only stain mitochondrial 
membranes that are not depolarised. To assess the proportion of 
mitochondria with polarised membranes relative to overall mitochondrial 
number, Pearson’s correlation coefficient was calculated to quantify the 
amount of colocalisation of Mitotracker Green with Mitotracker Deep Red. In 
MDA-MB-231 cells, both controls (ctDDX20 and empty vector) demonstrated 
a higher Pearson’s correlation coefficient compared to the siDDX20 
transfected cells. There was a significant decrease in the correlation 
coefficient in cells transfected with the dnTCF4 plasmid (Fig 4.4A-F). When 
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the same analysis was performed on MDA-MB-436 cells, the results 
indicated that transfection with either siDDX20 or dnTCF4 significantly 
reduced the correlation coefficient, which was unable to be rescued after 
overexpressing DDX20 in cells transfected with a dnTCF4. MDA-MB-436 
cells treated with either siDDX20, dnTCF4 or pCMV-DDX20 and dnTCF4 in 
combination all exhibited an increase in Mitotracker Green fluorescence 
relative to the control cells (Fig 4.4G-L). 
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Figure 4.5. Colocalisation of Mitotracker Green and Mitotracker Deep Red. 
Immunofluorescence images of MDA-MB-231 cells stained with Mitotracker Green (Green) 
and Mitotracker Deep Red (Red). Colocalisation analysis was carried out for cells treated 
with: A) ctDDX20; B) empty vector; C) siDDX20; D) dnTCF4; and E) pCMV-
DDX20+dnTCF4. F) Quantification of Pearson’s correlation coefficient for colocalisation of 
Mitotracker Green and Mitotracker Deep Red. Immunofluorescence images of MDA-MB-436 
cells. Colocalisation analysis was carried out for cells treated with: G) ctDDX20; H) empty 
vector; I) siDDX20; J) dnTCF4; and K) pCMV-DDX20+dnTCF4. L) Quantification of 
Pearson’s correlation coefficient of colocalisation of Mitotracker Green and Mitotracker Deep 
Red. Correlation coefficients were calculated using Fiji software plugin JACoP (Just Another 
Colocalization Plugin).287 Data represented as mean±SEM of at least three biological 
replicates. Statistical analysis was performed using unpaired Student’s t-test, *p < 0.05, **p < 
0.01, ***p < 0.001. Scale bar = 50µm. 
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4.2.4 Pharmacological inhibition of TCF4-b-catenin complex determines 
mitochondrial fate 
To assess the single cell populations stained with Mitotracker Deep Red and 
Mitotracker Green, flow cytometry was performed 16 and 24 hours after the 
addition of a small molecule inhibitor of the TCF4-b-catenin complex, iCRT3. 
The results in MDA-MB-436 cells revealed that after the addition of iCRT3 
there was a shift in a cell population, predominately Mitotracker 
Greenhigh/Mitotracker Deep Redhigh to a small subset of cells that now 
exhibited a Mitotracker Greenlow/Mitotracker Deep Redlow profile in a time-
dependent manner (Fig 4.5A&B). Similarly, in the MDA-MB-231 cells, the 
addition of iCRT3 initiated the formation of a subset of cells exhibiting a 
Mitotracker Greenlow/Mitotracker Deep Redlow profile (Fig 4.5C&D) 
 
 
 
 
Figure 4.6. Pharmacological inhibition of b-catenin-mediated TCF4 transcription 
determines mitochondrial fate. A) Representative dot plots of MDA-MB-436 cells co-
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stained with Mitotracker Green and Mitracker Deep Red. B) Quantification of percentage of 
Mitotrackerhigh/low populations after each treatment for MDA-MB-436 cells. C) Representative 
dot plots of MDA-MB-436 cells co-stained with Mitotracker Green and Mitracker Deep Red. 
D) Quantification of percentage of Mitotrackerhigh/low populations after each treatment for 
MDA-MB-436 cells. Gates included represent a Mitotracker Greenhigh/Mitotracker Deep 
Redhigh profile (red) and a Mitotracker Greenlow/Mitotracker Deep Redlow profile (blue). iCRT3 
was given at 50µM for 16 and 24 hours, with controls cells treated with DMSO. Data are 
represented as mean±SEM of at least 3 biological replicates. Statistical analysis was 
performed using unpaired Student’s t-test, *p<0.05, **p<0.01, ***p<0.001. 
  
4.2.5 Mitochondrial morphology is regulated by DDX20 in a Wnt-
dependent manner. 
To better assess the changes in mitochondrial morphology and mitochondrial 
dynamics, Mitotracker Green images were assessed. In the MDA-MB-436 
cells, the control cells exhibited mitochondria that were small and rod-
shaped, with a condensed network appearance (Fig 4.6A&B). After 
knockdown of DDX20, the mitochondria appeared as larger rods with larger 
networks. After ectopic expression of a dnTCF4 and overexpression of 
DDX20, the mitochondrial morphology mirrored that of the cells where 
DDX20 was knocked down (Fig 4.6E). Quantification of the mean network 
size and length revealed an increase in both parameters in the cells 
diminished of DDX20 and the cells transfected with the dnTCF4 and DDX20 
compared to their respective controls (Fig 4.6F&G). The MDA-MB-231 
control cells exhibited a large network size, with a corresponding increase in 
rod size (Fig 4.6H&I). Similarly to the MDA-MB-436 cells, the average 
network length of the mitochondria of the MDA-MB-231 cells increased after 
knockdown of DDX20, the introduction of dnTCF4 or overexpression of both 
DDX20 and dnTCF4 (Fig 4.6M). Conversely, the mean network size 
decreased after the respective treatments (Fig 4.6N). 
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Fig 4.7. Morphological assessment of mitochondria. Mitotracker Green staining and 
corresponding binary images for MDA-MB-436 cells treated with: A) control siRNA; B) empty 
vector; C) siDDX20; D) dnTCF4; and E) pCMV-DDX20+dnTCF4. Quantification of MDA-MB-
436 cells :F) Mean network size (branches), and G) Mean network length. Mitotracker Green 
staining and corresponding binary images for MDA-MB-231 cells treated with: H) control 
siRNA; I) empty vector; J) siDDX20; K) dnTCF4; and L) pCMV-DDX20+dnTCF4. 
Quantification of MDA-MB-231 cells: M) Mean network size (branches) and N) Mean 
network length. Mitochondrial morphological parameters were calculated on MiNA 
(Mitochondrial Network Analysis) plugin for Fiji software. Data are represented as 
mean±SEM of at least three biological replicates. Statistical analysis was performed using 
unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 50µm. 
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To further quantify the changes in mitochondrial mass, flow cytometric 
analysis of Mitotracker Green was performed. Confirming the 
immunofluorescence analysis, MDA-MD-231 cells that were transfected with 
the dnTCF4 or the combination of DDX20 and the dnTCF4 demonstrated a 
decrease in Mitotracker Green fluorescence (Fig 4.7A-D). The results from 
the flow cytometric analysis of the MDA-MB-436 cells were also consistent 
with the immunofluorescent images. Cells transfected with either siDDX20, 
dnTCF4 or a combination of dnTCF4 and DDX20 all exhibited significantly 
higher Mitotracker Green fluorescence than the respective control cells (Fig 
4.7E-H). 
 
 
 
Figure 4.8. Flow cytometric analysis of Mitotracker Green after suppression of Wnt 
signalling. Flow cytometry assessment of Mitotracker Green for MDA-MB-231 cells treated 
with A) empty vector, dnTCF4, pCMV-DDX20(OE)+dnTCF4, and B) ctDDX20 and siDDX20. 
Quantification of Mitotracker Green median fluorescence intensity (MFI) in cells treated with 
C) empty vector, dnTCF4, pCMV-DDX20(OE)+dnTCF4, and D) ctDDX20 and siDDX20. 
Mitotracker Green assessment for MDA-MB-436 cells treated with E) empty vector, dnTCF4, 
pCMV-DDX2O(OE)+dnTCF4, and F) ctDDX20 and siDDX20. Quantification of Mitotracker 
Green median fluorescence intensity (MFI) in cells treated with G) empty vector, dnTCF4, 
pCMV-DDX20(OE)+dnTCF4, and H) ctDDX20 and siDDX20. Data are represented as 
mean±SEM of at least three biological replicates. Statistical analysis was performed using 
unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
4.2.6 DDX20-TCF4 axis is an essential regulator of mitochondrial 
respiration and bioenergetics. 
To determine if the differences in mitochondrial mass quantification 
witnessed between MDA-MB-231 and MDA-MB-436 cells resulted in 
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differential functional outcomes, a mitochondrial stress test to measure 
changes in oxygen consumption rate (OCR) was performed using a 
Seahorse Flux Analyser. It was confirmed the overexpression of DDX20 and 
the combination of dnTCF4 and pCMV-DDX20 both resulted in 
overexpression of DDX20 by Western blotting analysis (Fig 4.8A). MDA-MB-
231 and MDA-MB-436 cell lines both exhibited severe mitochondrial 
respiration dysfunction after treatment with siDDX20 and dnTCF4 with 
DDX20 (Fig 4.8B&C). Analysis of key mitochondrial respiration and 
bioenergetics parameters revealed that knockdown of DDX20 resulted in 
increased proton leak and decreased maximal respiration in both cell lines. 
ATP production was only affected in the MDA-MB-436 cells following the loss 
of DDX20. Strikingly, both cell lines completely lost their spare respiratory 
capacity following knockdown of DDX20 (Fig 4.8D&E). The results following 
the overexpression of the dnTCF4 and DDX20 mirrored those seen after the 
knockdown of DDX20, with the addition that ATP production was decreased 
in MDA-MB-231 cells. Consistent with the knocked down cells, the spare 
respiratory capacity of both cell lines was completely abolished following the 
expression of a dnTCF4 and DDX20 (Fig 4.8D&E).  
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Fig 4.9. Mitochondrial bioenergetics analysis of DDX20 depleted and TCF4 
suppressed cells. A) Western blot of DDX20 following overexpression of empty vector, 
pCMV-DDX20, and pCMV-DDX20 and dnTCF4. Representative Seahorse analysis trace of 
oxygen consumption rate following treatment with ctDDX20, siDDX20, empty vector, and 
dnTCF4 with pCMV-DDX20 in B) MDA-MB-436 and C) MDA-MB-231 cells. D) Quantification 
of mitochondrial respiratory parameters protein leak, maximal respiration, spare respiratory 
capacity, and ATP production measured in MDA-MB-436 cells following transfection with 
ctDDX20, siDDX20, empty vector, and dnTCF4 with pCMV-DDX20. E) Quantification of 
mitochondrial respiratory parameters protein leak, maximal respiration, spare respiratory 
capacity, and ATP production measured in MDA-MB-231 cells following transfection with 
ctDDX20, siDDX20, empty vector, and dnTCF4 with pCMV-DDX20. Data are represented as 
mean±SEM of at least 3 biological replicates for ctDDX20 and siDDX20 treated cells. Data 
are represented as mean±SEM of at least 5 technical repeats of one experiment performed 
three times with the same trend. Statistical analysis was performed using unpaired Student’s 
t-test, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
4.2.7 SOD2 and UQCRC2 are regulated through Wnt-mediated TCF4 
transcription dependent on DDX20. 
The resultant mitochondrial dysfunction and increased H2O2 that was 
previously witnessed suggested dysregulation in mitochondrial ROS 
scavengers and components of the ETC mediated by Wnt signalling. Using 
the ENCODE ChIP-seq database, it was identified that SOD2 and UQCRC2 
have TCF4 binding sites and TCF4 ChIP-seq peaks at their 5ʹ-UTR promoter 
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regions in MCF-7, HCT-116, and HeLa cell lines (Fig S4.3A&C). These 
binding sites are located 744 and 449 base pairs upstream of the 
transcription start sites for SOD2 and UQCRC2 respectively (Fig S4.3B&D). 
To confirm if this was also the case in MDA-MB-231 cells, ChIP-QPCR for 
TCF4 on the predicted binding sites on both SOD2 and UQCRC2 was 
performed. ChIP-QPCR revealed that TCF4 bound to the promoter of both 
genes. The depletion of DDX20 yielded differential results for TCF4 binding; 
after DDX20 knockdown, there was increased recruitment of TCF4 to the 
SOD2 promoter region and decreased recruitment of TCF4 to the UQCRC2 
promoter (Fig 4.9A&B). The loss of DDX20 increased SOD2 mRNA 
expression while decreasing the expression of UQCRC2 (Fig 4.9C,D,G,H). 
Conversely, the addition of Wnt3a increased UQCRC2 expression while 
decreasing the expression of SOD2 (Fig 4.9E,F,I,J). These results were 
corroborated with Western blotting, revealing that pharmacological inhibition 
of the b-catenin-TCF4 complex resulted in an increase in the protein level of 
SOD2 (Fig 4.9K&L). Similarly, overexpression of a dnTCF4 and DDX20 
resulted in an increase in SOD2 expression. 
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Fig 4.10. Transcriptional regulation of SOD2 and UQCRC2 mediated by TCF4. ChIP-
QPCR of TCF4 on the promoters of A) SOD2 and B) UQCRC2 in MDA-MB-231 cells 
transfected with ctDDX20 or siDDX20 with the addition of 200ng/mL Wnt3a for two hours. 
Gene expression of MDA-MB-231 cells after transfection with siDDX20 for C) SOD2 and D) 
UQCRC2. Gene expression of MDA-MB-231 cells after the addition of 200ng/mL Wnt3a for 
4 hours for E) SOD2 and F) UQCRC2. Gene expression of MDA-MB-436 cells after 
transfection with siDDX20 for G) SOD2 and H) UQCRC2. Gene expression of MDA-MB-436 
cells after the addition of 200ng/mL Wnt3a for 4 hours for I) SOD2 and J) UQCRC2. K) 
Western blot of MDA-MB-436 and MDA-MB-231 cells after the addition of increasing doses 
of iCRT3 for 24 hours. L) Quantification of iCRT3 treated of MDA-MB-436 and MDA-MB-231 
cells. M) Western blot of MDA-MB-436 and MDA-MB-231 cells after transfection of empty 
vector control or dnTCF4 with pCMV-DDX20. N) Quantification of transfected MDA-MB-436 
and MDA-MB-231 cells. ChIP-PCR data are representative of one experiment repeated 
three times with similar results. All other data are represented as mean±SEM of at least 3 
biological replicates. Statistical analysis was performed using unpaired Student’s t-test, *p < 
0.05, **p < 0.01, ***p < 0.001. 
 
 
4.2.8 DDX20 regulates mitoROS genes and mtDNA copy number in vitro 
and in vivo 
To test whether these results were replicated in vivo, gene expression from 
Gemin3KO and overexpressing Gemin3arm/da Drosophila embryos were 
analysed. Confirming the in vitro results, Sod2 gene expression was 
significantly increased in Gemin3KO embryos, while being significantly 
decreased in Gemin3arm/da embryos. When the mRNA expression of 
mitochondrial ROS regulators – thioredoxin-2 (Trx2) and peroxiredoxin-3 
(Prx3) – were analysed, a similar result was observed (Fig 4.10A). To 
quantify the changes of mitochondrial mass after DDX20/Gemin3 depletion, 
mtDNA copy number was quantified by QPCR. Contrasting results were 
witnessed between the in vivo model and the TNBC cell lines. Gemin3KO 
embryos had a significant decrease in mtDNA copy numbers, while a 
significant increase was observed in the MDA-MB-436 cells after loss of 
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DDX20 (Fig 4.10B&C). There was no significant change in the amount of 
mtDNA in MDA-MB-231 cells depleted of DDX20 (Fig 4.10D). 
 
 
 
Figure 4.11. In vivo validation of DDX20 regulation of Mitochondrial ROS regulators 
and dynamics. A) Schematic of generation of Gemin3-overexpressing Drosophila fly 
embryos and Q-PCR of Drosophila mRNA expression for Trx2, Prx3, and Sod2 in control 
(GAL4arm/da), Gemin3 knockout (Gemin3KO), and Gemin3 overexpressing (Geminarm/da) flies. 
B) Mitochondrial DNA (mtDNA) copy number assessment by QPCR in GAL4arm/da and 
Gemin3KO flies. C) mtDNA copy number assessment by QPCR of MDA-MB-436 cells after 
transfection with control siRNA or siDDX20. D) mtDNA copy number assessment by QPCR 
of MDA-MB-4231 cells after transfection with control siRNA or siDDX20. Data are 
represented as mean±SEM of at least three biological replicates. Statistical analysis was 
performed using unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
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4.3 DISCUSSION 
This study implicates DDX20 in the regulation of mitochondrial 
redox and function. This regulation occurs in a Wnt-mediated manner that is 
dependent on TCF4 transcription. This is the first report of direct regulation of 
SOD2 and UQCRC2 by canonical Wnt signalling and DDX20. 
Previous reports have demonstrated that increased ROS-
mediated oxidative stress is associated with an increase in mitochondrial 
mass.324,325 This observation was mirrored in MDA-MB-436 cells, which upon 
depletion of DDX20 resulted in an increased mitochondrial mass, measured 
by Mitotracker Green fluorescence through confocal microscopy, flow 
cytometry, and mtDNA copy number. Contrarily, MDA-MB-231 cells had no 
significant alteration in mitochondrial mass when mtDNA was measured, 
although the immunofluorescence images demonstrated that overexpression 
of a dominant-negative TCF4 and DDX20 resulted in an overall reduction in 
Mitotracker Green fluorescence, indicative of a reduction in mitochondrial 
mass. These results could be explained by the mutational differences 
between the cell lines, which lead MDA-MB-231 to be more sensitive to 
mitophagy; MDA-MB-231 harbours an oncogenic Kras mutation (G13D) and 
oncogenic BRAF mutations, while MDA-MB-436 is Kras wild-type.326 It has 
previously been demonstrated that oncogenic Kras is a mediator of 
mitophagy and is associated with increased levels of the autophagy-
associated proteins Beclin-1, Atg5, and LC3-II.327 Furthermore, the decrease 
in mitochondrial mass and increased fragmentation in MDA-MB-231 cells can 
be associated with increased oncogenic RAS and MAPK pathways through 
the regulation of Ser592 phosphorylation of dynamin-1-like protein (DRP1), 
which regulates mitochondrial fission and fragmentation events.328 
Previously, it was demonstrated that mitochondrial fission and fusion events 
were modulated by Wnt5a/Ca2+ signalling, where Wnt5a increased 
intracellular calcium, leading to increased phosphorylation of Drp1 at Ser616 
and decreased phosphorylation of Drp1 at Ser637. The addition of Wnt5a led 
to a dynamic change in mitochondrial fusion and fission events. The 
regulation of TCF4 transcription through canonical Wnt signalling mediated 
by DDX20 demonstrates that canonical Wnt signalling is a regulator of 
mitochondrial fusion and fission.329 
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Despite the differences in mitochondrial dynamics between the 
cell lines upon DDX20 depletion and the suppression of TCF4 transcription, 
overall mitochondrial bioenergetics and respiration were both equally 
affected. Proton leak was increased while maximum respiration and spare 
respiratory capacity were severely depleted. Increased proton leak can be 
induced through uncoupling proteins and adenine nucleotide translocase, 
which can be activated due to increased ROS and byproducts of 
peroxidation. A large increase in proton leak is also generally seen in 
damaged mitochondria.330 Furthermore, increased proton leak can be due to 
dysregulation of both Complex I and Complex III of the ETC.331 The addition 
of FCCP acts as a protonophore, uncoupling the mitochondrial ETC. In both 
cell lines, mitochondria were unable to respond to stress and were unable to 
conduct proper respiration after knocking down DDX20. The same result was 
observed when dnTCF4 and DDX20 were simultaneously overexpressed, 
which indicated that this was due to suppression of Wnt signalling mediated 
by DDX20. A previous study implicated Wnt signalling in mitochondrial 
function, where the addition of Wnt3a increased both the basal and 
maximum respiration of muscle cells, while the overexpression of dnTCF4 
reduced the OCR. Furthermore, it was demonstrated that Wnt3a increased 
the gene expression of ATP synthase subunit 5g1 and Cytochrome c oxidase 
subunit II (Cox2) while increasing mtDNA. This study then implicated MYC-
mediated transcription in the mitochondrial biogenesis observed with Wnt3a 
stimulation.283 
The loss of mitochondrial spare respiratory capacity in MDA-MB-
231 and MDA-MB-436 cells suggests that there is dysregulation in a 
component critical for the regulation of oxidative phosphorylation. Ubiquinol 
cytochrome c Reductase subunit 2 (UQCRC2) is a component of Complex III 
and has been demonstrated to be essential for the assembly and 
stabilisation of the Ubiquinol cytochrome c Reductase supercomplex. 
Structural analysis revealed that a point mutation (A183W) of UQCRC2 
resulted in impaired Complex III assembly.332 DDX20 knockdown resulted in 
decreased UQCRC2 expression, regulated through canonical Wnt signalling, 
which was mediated by TCF4 transcription. The reduction of UQCRC2 would 
destabilise Complex III and impair mitochondrial respiration, leading to 
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increased electron slippage. UQCRC2 has also been demonstrated to be 
upregulated, along with other components of the ETC, in breast cancer. This 
leads to hyperactivation of oxidative metabolism and may partly explain the 
differences in energy requirements between normal and cancer cells.333 
These data clearly demonstrate a DDX20-dependent mechanism of Wnt 
signalling, whereby TCF4 transcription is responsible for expression of 
UQCRC2 and mitochondrial function.  
Mitochondrial superoxide can be released to both sides of the 
inner mitochondrial membrane from Complex III.240 Inhibition or dysfunction 
of Complex III increases mitochondrial superoxide production through the 
increased slippage of electrons.334 The loss of DDX20 and the dysregulation 
of mitochondrial respiration resulted in a decrease in mitochondrial 
superoxide. This decrease in superoxide can be attributed to the increase in 
SOD2 expression that occurred after DDX20 knockdown. SOD2 is a 
mitochondrial membrane-bound protein that primarily acts as an antioxidant 
through the dismutation of superoxide to hydrogen peroxide.335 Increased 
superoxide production and increased SOD2 expression would result in 
increased mitochondrial H2O2, leading to oxidative stress, mitochondrial DNA 
damage,336 and mitochondrial membrane peroxidation.337 Interestingly, lipid 
peroxidation of the mitochondrial membrane has been shown to decrease 
the activity of Complex III.338 H2O2 has also been demonstrated to induce 
depolarisation of mitochondrial membranes.339,340 This suggests that the loss 
of mitochondrial membrane potential following the loss of DDX20 and 
suppression of TCF4 transcription may be the result of increased H2O2 
formed due to increased SOD2 expression. 
SOD2 is overexpressed in TNBC, and has been demonstrated to 
negatively impact survival outcomes in individuals with high SOD2 
expression.341 The overexpression of SOD2 has also been implicated in the 
induction of an EMT phenotype in basal breast cancer. Forced expression of 
SOD2 reduced E-cadherin expression while increasing N-cadherin, vimentin, 
and b-catenin expression.272 These reports are contrary to the findings of this 
study, which demonstrates that SOD2 overexpression may be pivotal in 
inducing oxidative stress-mediated mitochondrial dysfunction through 
increased H2O2. These findings are consistent with a study by Gong et al.342 
	 129	
that demonstrated that Pigment Epithelial-derived Factor (PEDF) 
antagonised Wnt signalling mediated by Wnt3a and induced autophagy in 
pancreatic neoplasms; antagonism by PEDF lead to an increase in SOD2 
expression. This is consistent with the observations of this study, whereby 
antagonising Wnt signalling through the loss of DDX20 or suppression of 
TCF4-mediated transcription leads to an increase in SOD2 expression. Gong 
et al. demonstrated that the addition of PEDF resulted in increased 
recruitment of the p65 subunit of NFkB to the SOD2 promoter, resulting in 
increased transcription; while these data demonstrate that canonical Wnt 
signalling mediated through TCF4 is responsible for the changes in the 
expression of SOD2. Interestingly, this study also demonstrated that the 
overexpression of a dnTCF4 resulted in an increase in SOD2 expression. 
This suggests that b-catenin may act as a repressor when TCF4 is bound to 
SOD2 DNA, or prevent the transcriptional activation of TCF4, which is 
completely at odds with its canonical function. 
The Gemin3 (DDX20)-mediated regulation of Sod2 was confirmed 
in this study in vivo in a Drosophila model. The depletion of Gemin3 triggered 
an elevation in the expression levels of the antioxidant genes Trx2 and Prx3, 
which may be explained as a rescue mechanism following increased ROS 
levels. Furthermore, it has been demonstrated that Prx3 and Prx5 play a 
critical role in thiol homeostasis, survival, and lifespan in Drosophila.343 As 
Gemin3 knockouts are embryonically lethal in Drosophila, it is therefore 
feasible that increased Prx3 in Gemin3KO embryos is a mechanism to attempt 
to prolong lifespan. The in vivo data demonstrated that Gemin3 knockout 
embryos were depleted of mtDNA, a result which is contrary to mtDNA copy 
numbers increasing with oxidative stress.344 The increase in mtDNA is 
thought to be a feedback mechanism to compensate for dysfunctional 
mitochondria or mutated mtDNA.345  While these results were all witnessed 
after short term (24-72 hours) exposure to oxidative stress, it is possible that 
while increasing mtDNA copy number is the initial mechanism, longer term 
treatment and exposures to oxidative stress result in decreased 
mitochondrial number. This may be the effect seen in the later stage 
Gemin3KO embryos. 
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This study has demonstrated that the depletion of DDX20-
mediated Wnt signalling results in an increase in SOD2 expression and a 
decrease in UQCRC2 expression. The result of UQCRC2-mediated changes 
in mitochondrial respiration lead to increased superoxide production. The 
increased superoxide is dismutased by the increased SOD2 expression, 
leading to increased H2O2-induced mitochondrial oxidative stress and loss of 
mitochondrial membrane potential. These results elucidate a novel role for 
canonical Wnt signalling in the regulation of mitochondrial dynamics and 
function through transcription of mitochondrial ROS scavengers and ETC 
components. 
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4.5 SUPPLEMENTARY MATERIALS CHAPTER 4 
 
 
Fig S4.1 Survival analysis of SOD2 and DDX20. A) Kaplan-Meier survival 
analysis of METBRIC PAM50 basal cohort of individuals with DDX20hi/SOD2hi, 
DDX20low/SOD2low, DDX2low/SOD2hi, and DDX20hi/SOD2low phenotype. Statistics were 
performed using Log-rank (Mantel-Cox) test calculated median survival in Prism GraphPad.  
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Fig S4.2. 3D Mitotracker Deep Red staining. MDA-MB-231 cells stained for Mitotracker 
Deep Red (Red) and DAPI (blue) were transfected with either A) control siRNA or B) 
siDDX20. 3D images were taken using a Nikon A1 confocal microscope using Z-stacks. Z-
stack parameters used were; width: 210.91µm, height: 210.91µm: and depth: 9.25µm. Each 
image was taken at a depth of 0.25µm. 
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Fig S4.3. TCF4 binding sites on SOD2 and UQCRC2. A) ChIP-seq tracks and peaks from 
MCF-7, HCT-116, and HeLa cells from ENCODE ChIP-seq data viewer centred around the 
SOD2 gene TSS. Coloured bases indicate the TCF4 binding sequence on SOD2 DNA. B) 
Schematic of primer design and binding sites of TCF4 on SOD2 DNA. C) ChIP-seq tracks 
and peaks from MCF-7, HCT-116, and HeLa cells from ENCODE ChIP-seq data viewer 
centred around the UQCRC2 gene TSS. Coloured bases indicate the TCF4 binding 
sequence on UQCRC2 DNA. B) Schematic of primer design and binding sites of TCF4 on 
UQCRC2 DNA. 
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CHAPTER 5: DDX20 IS AN ESSENTIAL REGULATOR OF 
WNT/b-CATENIN SIGNALLING IN TRIPLE-NEGATIVE BREAST 
CANCER STEM CELLS 
 
5.1 INTRODUCTION 
Wnt/b-catenin signalling is a fundamental driver of TNBC progression and 
has been demonstrated to enhance many of the characteristic traits of 
CSCs.7 CSCs display a quiescent cell cycle, multi-drug resistance, and the 
ability to self-renew and to differentiate into a heterogeneous population.346 
The common cell surface markers for the characterisation of TNBC stem 
cells are CD44high/CD24low/-.347 The basal-like molecular subtype of TNBC 
displays increased Wnt signalling and also a higher proportion of cells 
displaying the phenotypic characteristics and functions of CSCs (Figure 5.1). 
Transcription factors, such as Homeobox protein NANOG (Nanog), sex-
determining region-box 2 (Sox2), and octamer-binding transcription factor 4 
(Oct4) regulate the expression of genes involved in embryonic stem cell 
pluripotency and differentiation, and are overexpressed in CSCs.348,349.  
 
 
Figure 5.1. Association between the molecular subtypes of TNBC, Wnt signalling and 
CSCs. (Adapted from 7,9,18) 
 
This chapter explores the role of DDX20 in the regulation of Wnt/b-catenin in 
TNBC stem cells. DDX20 directly associates with GSK3b, leading to 
increased canonical Wnt signalling (Cai & Pohl et al., unpublished). As Wnt 
signalling is increased in CSCs, it is important to evaluate whether there 
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were any differences in DDX20 expression in TNBC stem cells, and if 
depletion of DDX20 through RNAi would negatively alter the characteristic 
traits exhibited by these cells. Two TNBC cells lines were selected, MDA-
MB-231 and BT549, and compared with the non-tumorigenic MCF-10A and 
oestrogen receptor-positive MCF-7 cell lines. MDA-MB-231 is a poorly 
differentiated invasive TNBC cell line that also exhibits downregulation of 
claudin-3 and claudin-4.298 Originally established from the pleural effusion of 
a 51-year-old Caucasian female,350 this cell line carries BRAFG464V, 
CDKN2A1_471del471, RASG13D, and p53R280K mutations, and is mutationally 
BRCA1 and PTEN wild-type, although it exhibits an allelic loss of BRCA1. 
MDA-MB-231 has been reported to express the highest levels of DDX20 
expression in a large panel of breast cancer cell lines.216 BT549 was derived 
from a 74-year old Caucasian female and is an epithelial-like TNBC cancer 
cell line exhibiting giant multinucleated cells.298 It carries PTENV275fs*1, 
RB1265_607del343, and p53R249S mutations. BT549 has an allelic loss of BRCA1, 
although is mutation status wild-type. This chapter explores whether the 
PTEN mutational status of the cell lines would impact the effect of DDX20 
knockdown. Cell lines with PTEN mutations exhibit constitutively active PI3K-
Akt signalling.351 It has been previously reported that GSK3b can regulate the 
stability of PTEN, and PTEN can regulate GSK3b through activation of 
Akt.352,353 Furthermore Protein phosphatase 2A (PP2A), which is responsible 
for the dephosphorylation of b-catenin, has been shown to interact with 
PTEN.354 Therefore PTEN deficiency and mutations can lead to 
dysregulation and b-catenin and Wnt signalling.355 The use of these cell lines 
allowed us to determine whether DDX20 could regulate GSK3b and Wnt 
signalling independent or dependent of PTEN mutational status.  
	
5.2. RESULTS 
 
5.2.1. Enrichment of cancer stem cells from immortalised cell lines 
The evaluation of the ability of MCF-10A, MCF-7, BT549, MDA-MB-436, and 
MDA-MB-231 cells to form mammospheres in culture was followed using a 
previously published method.91 After seven days in culture, all tumorigenic 
cell lines were able to form mammospheres, while the non-tumorigenic cell 
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line MCF-10A failed to form mammopsheres that exceeded 40µm in size 
(Figure 5.2). 
 
Figure 5.2. Evaluation of CSCs enriched from immortalised cell lines. A variety of cell 
lines were cultured under conditions for the enrichment of CSCs. MCF-10A failed to form 
mammospheres, oestrogen receptor positive and TNBC cell lines formed mammospheres 
after 7 days in 3-D culture. Scale bar = 40µm. 
 
5.2.2. Characterisation of TNBC stem cells 
After seven days in culture, MDA-MB-231 and BT549 cells were 
assessed for CD44 and CD24 expression using flow cytometry. 93.% of 
MDA-MB-231 enriched CSCs exhibited a CD44+/CD24- phenotype, and 
4.23% exhibited a CD44+/CD24+ phenotype. BT549-enriched CSCs had cell 
populations of 80.1% CD44+/CD24- and 11.1% CD44+/CD24+ (Figure 5.3A).  
To assess if these enriched CSCs also displayed overexpression 
of classical stem cell transcription factors, Q-PCR was utilised for mRNA 
expression of KLF4, POU5F1 (Oct4), NANOG, and SOX2, and the canonical 
Wnt target gene AXIN2 as an indicator of Wnt activity. In both cell lines, 
KLF4, POU5F1, NANOG, and SOX2 were overexpressed. NANOG was 6-
fold and 4-fold higher in MDA-MB-231 and BT549 enriched CSCs 
respectively when compared to the parental cells. MDA-MB-231 and BT549 
CSCs both overexpressed AXIN2, indicating higher Wnt activity, although 
this was much more pronounced in the MDA-MB-231 CSCs (Fig 5.3B&C). 
CSCs from TNBC cell lines characteristically overexpress CD44. 
To validate this, Western blotting was performed on cells from the parental 
cell lines and enriched CSCs. It was found that both cell lines significantly (p 
> 0.05) overexpressed CD44 protein in the CSC-enriched population (Fig 
5D). 
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Finally, to determine DDX20 expression in the CSC-enriched 
population, Q-PCR was performed. It was found that only in MDA-MB-231 
cells were DDX20 mRNA levels significantly overexpressed in CSCs 
compared to the parental cell line (Fig 5E&F). 
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Figure 5.3. Characterisation of TNBC stem cells. A) Flow cytometry assessment of MDA-
MB-231 and BT549 enriched CSCs using CD44-APC and CD24-PE/Cy7 antibodies. B & C) 
mRNA expression of AXIN2, KLF4, POU5F1, NANOG, and SOX2 in MDA-MB-231 and 
BT549 CSCs. D. Protein expression of CD44 in CSC and parental cells from MDA-MB-231 
and BT549 cells. E&F) mRNA expression of DDX20 from MDA-MB-231 and BT549 cells. All 
data represented as mean±SEM, of at least three biological replicates. Statistical analysis 
was performed using unpaired students t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
 
5.2.3. DDX20 is an essential regulator of Wnt/b-catenin signalling in 
TNBC stem cells 
To evaluate whether DDX20 was a regulator of Wnt/b-catenin signalling in 
TNBC stem cells, a knockdown strategy using three separately-targeting 
siRNAs against DDX20 was used. 72 hours post-transfection, we examined 
protein expression of total levels of cellular b-catenin, as well as the 
transcriptionally active b-catenin (Ser33/Ser37/Thr41). Successful 
knockdown of the DDX20 protein was concomitant with a significant 
decrease in the levels of active b-catenin in both cell lines, while total b-
catenin remained unchanged (Fig 5.4A,B,C). 
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To further evaluate the role of DDX20 in the regulation of Wnt signalling, cells 
were subjected to a “Wnt ON” environment, whereby we stimulated both cell 
lines with recombinant Wnt3a ligand for three hours with and without 
depletion of DDX20. While stimulation with Wnt3a in MDA-MB-231 and 
BT549 cells with DDX20 led to an increase in the levels of active b-catenin, 
cells without DDX20 were unable to properly conduct Wnt signalling upon 
Wnt3a stimulation (Fig 5.4D). 
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Fig 5.4. DDX20 is an essential regulator of Wnt/b-catenin signalling. A) Western blots of 
siRNA knockdown of DDX20 in BT549 and MDA-MB-231 cells for active b-catenin levels. 
B&C) Quantification of protein levels of total and active b-catenin protein following DDX20 
knockdown 72 hours post-transfection. D) Western blots for active b-catenin in cells 
stimulated with 200ng/ml recombinant Wnt3a for three hours. All data are represented as 
mean±SEM of at least three biological replicates. Statistical analysis was performed using 
unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
 
5.2.4. Depletion of DDX20 results in destabilisation of the b-catenin 
destruction complex 
Destabilisation of the b-catenin destruction complex is responsible for 
increased levels of transcriptionally active b-catenin in cells. To evaluate the 
effect DDX20 has on expression of destruction complex proteins, protein 
expression for Dishevelled 2 (Dvl2), levels of GSK3b phosphorylated at Ser9 
(pSer9GSK3β), as well as total cellular levels of GSK3b, after knockdown of 
DDX20 was assessed (Fig 5.5A). 
While the levels of Dvl2 were significantly decreased in both cell 
lines, there was a differential regulation in the levels of phosphorylation of 
GSK3b. In BT549 cells, knockdown of DDX20 resulted in an increased level 
of GSK3b phosphorylation, while it was decreased in the MDA-MB-231 cells 
(Fig 5.5B&C). 
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Figure 5.5. DDX20 causes destabilisation of the b-catenin destruction complex. A) 
Western blots of Dvl2, pSer9GSK3b, and GSK3b in BT549 and MDA-MB-231 cell lines 
following knockdown of DDX20. B) Quantification of pSer9GSK3b relative to total GSK3b 
protein expression. C) Quantification of Dvl2 protein expression in BT549 and MDA-MB-231 
cell lines. All data are represented as mean±SEM, of at least three biological replicates. 
Statistical analysis was performed using unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p 
< 0.001.  
 
5.2.5. DDX20 co-localises with CD44 and regulates transcription factors 
involved in pluripotency 
It has also been reported that CD44 promotes Wnt signalling 
through its direct association with LRP6.356 Due to these previous findings, 
we decided to determine whether DDX20 and CD44 could associate with one 
another. 
Co-staining for DDX20 and CD44 in MDA-MB-231 CSCs revealed 
extensive co-localisation of CD44 and DDX20 at the membrane in basal 
conditions. Furthermore, when assessing protein levels by 
immunofluorescence, there was a noticeable decrease in CD44 membranous 
expression on DDX20 knockdown (Fig 5.6A). Western blotting demonstrated 
that DDX20 depletion in MDA-MB-231 cells - but not BT549 – resulted in 
markedly reduced protein expression of CD44 (Fig 5.6B). 
To test whether DDX20 could regulate ‘stemness’ characteristics 
of TNBC stem cells, mRNA expression of NANOG, POU5F1, and SOX2 
were determined in both cell lines. All genes displayed a significant reduction 
	 143	
in expression upon depletion of DDX20 (Fig 5.6C). Furthermore, AXIN2 was 
also significantly reduced in both cell lines after siRNA-mediated knockdown 
of DDX20 (Fig 5.6D). 
 
 
 
 
Figure 5.6. DDX20 co-localises with CD44 and regulates mRNA expression of 
transcription factors involved in stemness. A) Immunofluorescence co-staining of DDX20 
(Alexafluor488) and CD44 (Alexafluor555) in cells with and without DDX20. B) Western blots 
showing protein expression of CD44 in MDA-MB-231 and BT549 cell lines. C) mRNA 
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expression of NANOG, POU5F1, and SOX2 in MDA-MB-231 and BT549 cells after 
transfection with siRNA against DDX20. D) mRNA expression of AXIN2 in MDA-MB-231 and 
BT549 cells after transfection with siRNA against DDX20. All data are represented as 
mean±SEM of at least three biological replicates. Statistical analysis was performed using 
unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 50µm. 
 
5.2.6. DDX20 is a regulator of cell cycle progression 
CSCs are quiescent cells, and this property is one of the reasons they are 
able to evade forms of chemotherapy targeting highly proliferative cells.357  
Western blotting was used to assess the protein levels of cyclin 
D1 and c-MYC after DDX20 depletion. Cyclin D1 was significantly decreased 
in both cell lines after DDX20 knockdown. Interestingly, cMYC protein 
expression was unaltered in  BT549 cells but was significantly decreased in 
MDA-MB-231 cells (Fig 5.7A&B). Flow cytometric analysis of cell cycle 
progression in MDA-MB-231 CSCs, demonstrated that knockdown of DDX20 
was able to significantly alter cells in various stages of the cell cycle. In 
DDX20-depleted cells there was a significant increase in cells in the sub G0 
phase, and a decrease in cells in the G0-G1 and G2 phases (Fig 5.7C&D). 
Furthermore, GSEA on DDX20high versus DDX20low phenotypes from 
METABRIC cohort revealed significantly upregulated gene sets involved in 
cell cycle regulation, including cell division (GO:0051301), mitotic cell cycle 
checkpoint (GO:0007093), cell cycle checkpoint (GO:0000075), cell cycle 
phase transition (GO:1901989), and cell cycle G1-S phase transition 
(GO:0044843) (Fig 5.7E). 
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Figure 5.7. DDX20 regulates cell cycle progression. A) Western blots of cyclin D1 and c-
MYC in BT549 and MDA-MB-231 cells after treatment with siRNA targeting DDX20 
(siDDX20) or control siRNA (ctDDX20). B) Quantification of Western blots of cyclin D1 and c-
MYC. C) Quantification of the percentage of cells in cell cycle phase (Sub G0, G0-G1, S, 
and G2) in MDA-MB-231 cells after DDX20 depletion. D) Representative histogram of cell 
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counts after cell cycle analysis of MDA-MB-231 cells after transfection with siDDX20. E) 
Schematic and bar graph of enriched gene sets involved in cell cycle regulation in DDX20high 
vs DDX20low phenotype of the METABRIC TNBC cohort. All data are represented as 
mean±SEM of at least three biological replicates. Statistical analysis was performed using 
unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
	
	
5.2.7. Knockdown of DDX20 induces apoptosis and increases 
sensitivity to doxorubicin 
The ability of MDA-MB-231 and BT549 cells to form 
mammospheres after transfection with siRNA was assessed using a 
mammosphere forming assay. BT549 cells were able to form more spheroids 
than MDA-MB-231 cells, although this ability was significantly diminished in 
both cell lines following siDDX20 knockdown (Fig 5.8A). It was found that 
knockdown of DDX20 only caused a significant decrease in viability in the 
MDA-MB-231 cells, not in the BT549 CSCs (Fig 5.8B). 
As there was no significant difference in viability in the BT549 cell 
line, MDA-MB-231 was used for the subsequent cell death assays. The 
ability of MDA-MB-231 cells to be sensitised to 1µM doxorubicin following 
DDX20 knockdown was assessed using the JC-1 probe, which accumulates 
in live mitochondria. Increased JC-1 monomers are an indicator of a loss of 
mitochondrial membrane potential. Transfection with siDDX20 increased JC-
1 monomers compared to cells transfected with control siRNA. There was an 
additive effect when siDDX20 and doxorubicin were added in combination, 
when compared to doxorubicin alone (Fig 5.8C). 
To further confirm the increase in cell death, Western blotting was 
performed for the anti-apoptotic mitochondrial proteins Bcl-xL and PARP (Fig 
5.8D&E). Depletion of DDX20 results in a significant decrease in levels of 
PARP, as well as the presence of the cleaved PARP protein fragment. A 
caspase-3/7 assay was performed, which indicated increased caspase 
activity in cells transfected with siDDX20 (Fig5.8F). To validate the previous 
findings in the parental cells, we used the H2O2 assay to test whether ROS - 
specifically H2O2 – were increased in the CSCs after knockdown of DDX20. 
Consistent with the previous reports, silencing of DDX20 produced a 
significant increase in H2O2 production (Fig 5.8G). 
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Figure 5.8. Loss of DDX20 induces apoptosis and increases chemosensitisation. A) 
Mammosphere-forming efficiency in BT549 and MDA-MB-231 cells transfected with siRNA 
targeting DDX20. B) Cell viability measured by CCK8 assay in cells transfected with siRNA 
targeting DDX20. C) JC-1 assayed measured by flow cytometry in control cells, cells 
transfected with control siRNA, cells transfected with siRNA targeting DDX20, 1µM 
doxorubicin, or a combination of the two. 1µM staurosporine was used as a positive control. 
Cells were treated with doxorubicin and staurosporine for 24 hours. D) Western blots of 
PARP and Bcl-xL in MDA-MB-231 cells after DDX20 knockdown. E) Quantification of 
Western blots. F) Fluorogenic Caspase-3/7 assay in MDA-MB-231 cells after siDDX20. G) 
ROS-Glo H2O2 assay of MDA-MB-231 cells after transfection with siDDX20. JC-1 data are a 
representative dot plot of three individual experiments with similar results. All other data are 
represented as mean±SEM of at least three biological replicates. Statistical analysis was 
performed using unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
 
5.2.8. Wnt antagonist, SFRP4, downregulates DDX20 through its 
cysteine-rich domain (CRD) 
Previous data suggest that DDX20 is upstream of the b-catenin destruction 
complex (Cai & Pohl et al., unpublished). To test whether antagonism of the 
Wnt pathway could decrease the expression of DDX20, recombinant SFRP4  
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was exogenously added to the cell medium for 48 hours. In MDA-MB-231 
cells there was a significant decrease in DDX20 protein expression, while in 
BT549 cells, there was no significant difference (Fig 5.9A&B). In MCF-10A 
cells, SFRP4 could not significantly decrease DDX20 expression, and 
conversely, Wnt3a could not significantly increase DDX20 expression (Fig 
5.9C&D). 
The CRD of SFRP4 has been previously shown to bind Wnt 
ligands to antagonise Wnt signalling, while the exact mechanisms of action of 
the netrin-like domain (NLD) of SFRP4 have yet to be fully elucidated. To 
determine which domain is responsible for the decrease in DDX20, we added 
purified CRD and NLD protein to both cell lines. The addition of SFRP4DNLD 
(consisting of just the CRD) resulted in a significant decrease in DDX20 
expression in MDA-MB-231 cells. This was not observed in BT549 cells. The 
addition of SFRP4DCRD (consisting of just the NLD) had no significant effect 
on either cell line (Fig 5.9E&D). 
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Figure 5.9. DDX20 is downregulated by the CRD of SFRP4. A) Western blots and 
quantification of SFRP4 (250pg/mL) treated MDA-MB-231 and BT549 cells. B) Western blots 
and quantification of SFRP4 (250pg/mL) and Wnt3a (200ng/mL) treated MCF-10A cells. C) 
Schematic of purified proteins of SFRP4 domains. D&E) Western blots and quantification of 
SFRP4DCRD and SFRP4DNLD (250pg/mL) treated MDA-MB-231 and BT549 cells. All data are 
represented as mean±SEM of at least three biological replicates. Statistical analysis was 
performed using unpaired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.  
 
5.2.9. DDX20 regulates Wnt signalling through a positive feedback loop 
Wnt3a causes increased nuclear localisation of b-catenin, where it binds to 
TCF/LEF transcription factors. This is diminished in the absence of DDX20 
(Fig 5.10A). To determine the effect of Wnt3a stimulation on DDX20 mRNA 
expression, a time course experiment was conducted after the addition of 
Wnt3a (200ng/mL) from two to 16 hours. Significant increases in DDX20 
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expression were found at 4, 8, and 12 hours, with maximum gene expression 
at 12 hours. AXIN2 was used as a positive control and exhibited similar 
results, although maximal gene expression was reached at eight hours 
(Figure 5.10B).  
To determine if DDX20 is a direct target of TCF/LEF transcription, 
an inhibitor of b-catenin/TCF4 transcription, iCRT3, was added to MDA-MB-
231 cells. Cells treated with iCRT3 exhibited a significant dose-dependent 
decrease in DDX20 expression (Fig 5.10C&D). 
To further validate that DDX20 was a target of TCF4 transcription, 
USCD ChIP-seq data across three different cell lines - HeLa, MCF7, and 
HCT-116 – were examined. All three cell lines demonstrated peak signals of 
TCF4 (TCF7L2) on the 5ʹ-UTR region of the DDX20 promoter (Fig 5.10E).  
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Figure 5.10. DDX20 regulates a Wnt/b-catenin positive feedback loop. A) 
Immunofluorescence of active b-catenin (Alexafluor555) and DAPI after Wnt3a (200ng/mL) 
stimulation for three hours with and without DDX20 in MDA-MB-231 cells. B) mRNA 
expression of DDX20 and AXIN2 at indicated time points after the addition of Wnt3a. C) 
Quantification of DDX20 protein expression after treatment with iCRT3 for 24 hours. D) 
Western blot of DDX20 protein expression after treatment with iCRT3 for 24 hours. E) 
ENCODE ChIP-seq data view of TCF4 (TCF7L2) ChIP-seq in HeLa, MCF7, and HCT116 
cells visualised over DDX20 DNA. Statistical analysis was performed using unpaired 
Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 50µm. 
 
	
5.3. DISCUSSION 
This is the first report of DDX20 regulating Wnt signalling in any cell type. 
These data convincingly show that depletion of DDX20 results in a decrease 
in the transcriptionally-active form of b-catenin, albeit with Wnt3a stimulation, 
as well as destabilisation of the destruction complex through Dvl 
downregulation. Other DDX family members have been implicated in the 
regulation of Wnt signalling in TNBC.7 DDX5 has been demonstrated to 
directly interact with b-catenin and promote Wnt signalling,358 while DDX3 
has also been reported to directly interact with CK1e to influence Dvl 
phosphorylation and positively regulate Wnt signalling.189 Interestingly, 
depletion of DDX20 exhibited the same effect on both active b-catenin and 
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Dvl2 expression, although there was a differential regulation in the 
phosphorylation of Ser9 of GSK3b. Inhibition of GSK3b is a known event for 
the activation of Wnt signalling.359 Recent reports suggest that 
phosphorylation of GSK3β Tyr216 may have a greater influence.360 A recent 
study has demonstrated that phosphorylated C-terminal motifs of the Wnt 
receptor LRP6 are responsible for the inhibition of GSK3b by binding to the 
residues surrounding Tyr216 of GSK3β.361 It is possible that loss of DDX20 
can influence the Akt-mediated-phosphorylation of GSK3b without affecting 
Wnt signalling.  
The B56 subunit of PP2A regulates the dephosphorylation of b-
catenin, leading to its ubiquitin-mediated degradation.362 It has been shown 
that PP2A interacts with PTEN, and therefore PTEN deficiency can in fact 
lead to an increase in b-catenin stabilisation and tumour progression through 
increased Wnt signalling.354,363 The increased basal active b-catenin levels in 
BT549 cells compared to MDA-MB-231 was confirmed in this study. 
CD44 is a transmembrane glycoprotein that binds extracellular 
ligands to regulate extracellular matrix adhesion. CD44 has also been 
implicated as an important mediator of intracellular signalling, in which it can 
elicit signal transduction through heterodimerisation with receptor tyrosine 
kinases and other plasma-membrane bound receptors. These separate 
functions explain its role in tumour progress and metastasis.364 
These data demonstrated that CD44 is overexpressed in CSCs 
when compared to parental cell lines. When both cell lines were depleted of 
DDX20, a significant decrease in CD44 expression was observed in the 
MDA-MB-231 cell line. BT549 expresses a constitutively active Akt, which 
has been reported to inhibit hyaluronan synthase (HAS2) repression of CD44 
expression; this was found to be mediated by FOXO1 and worked through a 
positive feedback loop.365 Therefore, CD44 expression may be kept high in 
BT549 cells through Akt signalling, independent of DDX20 expression. We 
used co-staining immunofluorescence to determine whether DDX20 would 
co-localise with CD44. We saw extensive co-localisation of DDX20 and 
CD44 at the membrane of MDA-MB-231 CSCs. It may be possible that 
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DDX20 and CD44 are involved in Wnt signalosome assembly and signal 
transduction with other Wnt signalosome components. 
This study demonstrated that depletion of DDX20 results in a 
reduction in gene expression of transcription factors regulating pluripotency, 
including NANOG, SOX2, and POU5F1, and the Wnt target gene AXIN2. 
This is consistent with the decrease in transcriptionally active b-catenin seen 
with knockdown of DDX20. b-catenin has been demonstrated to upregulate 
Nanog expression through its interaction with Oct3/4.366 Furthermore, it has 
been shown that TCF4 downregulation coincides with decreased expression 
of SOX2367 and POU5F1.368 
The regulation of cell cycle progression by DDX20 in CSCs was 
also examined. We focussed on two master regulators of cell cycle 
progression – c-MYC, which is essential for the entry of quiescent cells into 
the cell cycle,369 and cyclin D1, which progresses the cells from G1 to S 
phase.370 Unexpectedly, while levels of cyclin D1 protein were reduced after 
DDX20 knockdown in both cell lines, c-MYC levels were altered in BT549 
cells. A previous report implicated active GSK3b in the phosphorylation 
(Thr58) and degradation of cMYC.371 BT549 has higher levels of inhibited 
GSK3b after DDX20 depletion, which, in turn, could suggest less c-MYC 
degradation. After flow cytometric cell cycle analysis of MDA-MB-231 cells, 
the majority of cells were in the sub G0 phase, indicative of cells undergoing 
apoptosis.372 
To evaluate the impact of DDX20 depletion on apoptosis, the 
ability of these cells to form mammospheres was examined and their cellular 
viability assessed through CCK8 assay. Both cell lines had significantly 
reduced mammosphere formation after DDX20 depletion, although cell 
viability was only significantly reduced in the MDA-MB-231 cells. It is quite 
possible that BT549 cells are dependent on PI3K/Akt/mTOR signalling, and 
depletion of Wnt signalling itself is not enough to initiate apoptosis. A study in 
BT549 cells demonstrated that dual targeting of both the PI3K/Akt/mTOR 
and MEK/ERK pathways was critical to induce high levels of apoptosis.373  
As CSCs are known to exhibit drug resistance,374 we used a 
measure of mitochondrial membrane potential, the JC-1 assay, to determine 
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the response of MDA-MB-231 cells to combinatorial treatment. We found that 
the knockdown of DDX20 increased the response of the cells to doxorubicin, 
compared to doxorubicin alone. Previous studies have demonstrated the 
effect of antagonising the Wnt pathway on the sensitivity of cells to 
chemotherapeutics.375 The addition of the Wnt antagonist SFRP4 has been 
reported to increase the response of ovarian cancer,376 glioma stem cells,93 
and head and neck CSCs92 to a variety of chemotherapeutics. 
Next, whether antagonising Wnt signalling was able to decrease 
DDX20 protein expression was examined. The addition of SFRP4 to MDA-
MB-231 cells resulted in a significant decrease in the expression of DDX20 at 
48 hours, although this was not seen in the BT549 cells. It was shown that 
basal breast CSCs with high levels of Wnt signalling also expressed higher 
levels of SFRP1.377 SFRP1 and SFRP4 can bind Wnt3a,378,379 therefore, the 
exogenous addition of SFRP4 in the presence of endogenous SFRP1 may 
no longer be able to exert its normal function on Wnt antagonism. DDX20 is 
under expressed in non-tumorigenic MCF-10A cells, and MCF-10A cells 
have been shown to be minimally responsive to both Wnt3a stimulation and 
Dkk1 antagonism.216,377 We tested the addition of Wnt3a and SFRP4 on 
MCF-10A cells but saw no response in regards to changes in DDX20 
expression. 
To confirm that the decrease of DDX20 expression was due to 
canonical Wnt signalling, exogenous CRD and NLD proteins from SFRP4 
were added to the cell medium. A significant decrease in CRD-mediated 
DDX20 expression in MDA-MB-231 cells, although not in BT549 cells, was 
witnessed. This confirmed that the decrease was due to canonical Wnt 
signalling, as the CRD has been widely studied and confirmed to be the 
SFRP domain responsible for binding and antagonising Wnt ligands.380-382 
This is thought to be due to homology between the CRD of SFRPs and Fzd 
receptors, allowing SFRPs to act as soluble decoy receptors for Wnt ligands.  
Finally, as SFRP4 was able to downregulate DDX20 protein 
expression, it was conceivable that DDX20 gene expression was regulated 
by canonical Wnt signalling. A time course experiment was conducted with 
Wnt3a stimulation, which resulted in a maximal peak of DDX20 gene 
expression at 12 hours. This indicated that DDX20 was a downstream target 
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of Wnt signalling. It has been previously reported that DDX5 is a target of b-
catenin-dependent TCF4 transcription in breast cancer.358 To validate if the 
same regulatory mechanism was governing DDX20 expression, 
pharmacological inhibition of the b-catenin/TCF4 complex was utilised. This 
demonstrated that DDX20 expression was downregulated by directly 
targeting TCF4 transcription. To further validate this, previously published 
ChIP-seq data from three different cell lines were examined. In all cell lines, 
the data indicated that TCF4 was bound to the promoter region of the DDX20 
gene. This indicates that DDX20 is regulated by a positive feedback loop 
through a Wnt3a-b-catenin-TCF4 axis, all of which is dependent on DDX20 
being able to facilitate Wnt signalling. This is the first report of Wnt regulation 
by DDX20 in TNBC stem cells. 
Overall, this study provides evidence for the role of DDX20 in the 
regulation of Wnt/b-catenin signalling in TNBC stem cells. Depletion of 
DDX20 led to a reduction in the classical characteristics exhibited by CSCs, 
including overexpression of stem cell transcription factors and drug 
resistance. While many of the results were consistent between cell lines, 
particular cell functions were not diminished in PTEN mutant cells upon 
depletion of DDX20. This may be due to cellular signalling mechanisms that 
are reliant on PI3K/Akt signalling to function. 
These data propose a model for the progression of TNBC, 
whereby increased Wnt signalling, through increased stromal Wnt ligands, 
leads to increased DDX20. DDX20, in turn, increases Wnt signalling, which 
drives tumorigenesis. 
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This thesis has determined that DDX20 is an essential regulator of Wnt/b-
catenin signalling in triple-negative breast cancer. In regulating Wnt 
signalling, it has been found that DDX20 regulates the TCF4-mediated 
expression of key genes involved in ROS scavenging and mitochondrial 
function - catalase, SOD2 and UQCRC2. 
The depletion of DDX20 results in increased H2O2-mediated 
oxidative stress and cell death. Mechanistically, it was found that excessive 
ROS may be generated from two sources: the mitochondria and from 
downregulation of catalase. Mitochondrial ROS was generated from ETC 
dysfunction, where UQCRC2 downregulation may result in the destabilisation 
of mitochondrial Complex III, leading to increased superoxide production. 
The superoxide produced is dismutated by SOD2 within the mitochondrial 
membrane to give increased H2O2, which can lead to loss of mitochondrial 
membrane potential and induce DNA damage.383 Catalase may be partially 
localised to the mitochondria to protect against exogenous and endogenous 
H2O2 production.384 Thus, mitochondrial oxidative stress due to increased 
H2O2 may be exacerbated by the downregulation of catalase. Furthermore, it 
has been demonstrated that peroxisomal catalase inhibition results in 
increased MitoROS and a decrease in the membrane potential of the inner 
mitochondrial membrane.385  
The differential changes in the expression of catalase and SOD2 
following Wnt antagonism were previously demonstrated by Gong et al.342 In 
pancreatic neoplasms, the addition of PEDF antagonised Wnt3a-mediated 
Wnt/b-catenin signalling activation and reduced catalase expression, while 
increasing SOD2 expression. The details of the transcriptional regulation of 
catalase were not determined, although the increase of SOD2 expression 
was due to nuclear translocation of NF-kB. The data presented in this thesis 
clearly demonstrates that the changes in catalase and SOD2 mRNA 
expression can be both directly associated with TCF4 transcription.  
After the enrichment of CSCs from both MDA-MB-231 and BT549 
cell lines, it was determined that DDX20 was overexpressed in TNBC stem 
cells compared to the parental cell lines. There have been many reports 
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implicating the essential role of Wnt/b-catenin signalling in stem cell 
maintenance and fate.386,387 This study implicates DDX20 in the regulation of 
CSC fate through a Wnt-mediated mechanism. The loss of DDX20 resulted 
in an altered cell cycle, increased chemotherapeutic sensitivity and a loss of 
stemness characteristics. Furthermore, following the knockdown of DDX20, 
there was cell death and increased H2O2 production, suggesting that the 
mechanism of cell death is consistent with that of the parental cell lines. 
Tumours have high levels of ROS compared to normal tissue, while low 
levels of ROS in CSCs are required for stem cell maintenance.388 The low 
levels of ROS may be partly a result of increased Wnt signalling activity in 
CSCs.7 This study demonstrated increased expression of ROS scavenging 
enzymes following Wnt stimulation. This may be a mechanism by which ROS 
levels are kept low in stem cell populations.  
Through the use of a Drosophila model, this study has confirmed 
the regulation of cellular redox genes by Gemin3/DDX20 in vivo. Several 
signalling pathways critical in responding to changes in the oxidative stress 
tolerance have been identified in Drosophila 389,390. This is the first report of 
Gemin3 driven by an armadillo and daughterless expression system 
regulating cellular redox in a Drosophila model. The embryonic lethality of the 
Gemin3 knockout flies, together with the evidence of redox changes after the 
loss of Gemin3, suggests that the mechanism of cell death in Drosophila is 
due to oxidative stress and mitochondrial dysfunction. 
	
Future directions include confirming the mechanism of cell death 
following DDX20 depletion in an in vivo mouse model. DDX20 knockout is 
embryonically lethal in mice embryos,199 which precludes the development of 
a DDX20-/- mouse. An appropriate mouse model to gain mechanistic insight 
could be using a Cre-loxP approach, with a DDX20 conditional allele crossed 
with a MMTV-Cre transgene. This would allow for the conditional knockout of 
DDX20 in cells primarily in mammary epithelium.391  
Small molecule inhibitors of DDX proteins are currently under development. 
A small molecule inhibitor of phosphorylated DDX5 is in Phase I clinical trials 
for various solid tumours.392 Previous data (Cai & Pohl, unpublished) has 
demonstrated that DDX20 may also require phosphorylation to interact with 
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GSK3b. Preliminary studies demonstrate that the inhibitor of phospho-DDX5 
may be efficacious in targeting DDX20. Optimising this small molecule to 
directly target DDX20 may prove to be a new therapeutic option in TNBC. 
Furthermore, identification of the kinase responsible for phosphorylation of 
DDX20 may also provide a potential target for drug development. 
The canonical role of DDX20 was reported to be in spliceosome 
assembly, where its primary subcellular localisation has been in subnuclear 
structures known as Cajal bodies.219 The localisation of DDX20 in the 
cytoplasmic-plasma membrane region in TNBC could provide evidence of 
how DDX20 dysregulation may lead to aberrant Wnt signalling. One possible 
explanation is the disruption of the nuclear localisation sequence (NLS) of 
DDX20. The C-terminal of DDX20 contains many residues that have been 
demonstrated to be phosphorylated.199 The C-terminal contains the NLS, 
with a number of residues that may be substrates for phosphorylation. 
Mutagenesis of these residues, followed by the examination of DDX20 
localisation, may provide mechanistic insight into the mislocalisation of 
DDX20 in TNBC.  
This study has presented a novel role for Wnt/b-catenin signalling 
in the regulation of intracellular redox and mitochondrial function. Future 
studies may extend this finding to both human-derived and murine-derived 
organoid models. These have proven invaluable in providing models that 
recapitulate the whole organ system and mimic the tumour 
microenvironment393 and may confirm the role of Wnt/b-catenin-driven ROS 
production in tumour progression. The evaluation of changing ROS levels 
through organoid development in cancer models may provide new insight 
into the role of ROS in carcinogenesis. This has been made easier with 
genetically encoded ROS probes, such as HyPer, that are able to be stably 
transfected into cells for the evaluation of specific ROS species in a live-cell 
system.394  
This report has clearly demonstrated a role for DDX20 and Wnt/b-
catenin signalling in the regulation of mitochondrial function and dynamics. 
An interesting observation was the differences in mitochondrial morphology 
between the MDA-MB-231 and MDA-MB-436 cell lines after the loss of 
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DDX20 and the suppression of TCF4 mediated signalling. Future studies 
may focus of difference between the fission and fusion machinery after these 
respective treatments. Identifying changes in key fission proteins, such as 
Drp1 and Mff, or fusion proteins Opa1, Mfn1 and Mfn2 may provide insight to 
the differences in mitochondrial morphology that were seen in these two cell 
lines.395 
Overall, this study has clearly demonstrated a DDX20-dependent 
mechanism of Wnt signalling, whereby TCF4 transcription is responsible for 
expression of catalase, SOD2 and UQCRC2, which regulates the 
intracellular redox environment and mitochondrial function. While catalase, 
SOD2 and UQCRC2 were identified as targets of canonical Wnt signalling in 
TNBC it would be valuable to explore TCF4-regulated redox genes in a 
variety of cancers, and determine their impact on tumour progression, 
metastasis and overall patient survival.   
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Abstract
Significance: B cell lymphoma-2 (Bcl-2) was discovered over three decades ago and is the prototype anti-
apoptotic member of the Bcl-2 family that comprises proteins with contrasting effects on cell fate. First
identified as a consequence of chromosomal translocation (t 14:18) in human lymphoma, subsequent studies
have revealed mutations and/or gene copy number alterations as well as posttranslational modifications of Bcl-2
in a variety of human cancers. The canonical function of Bcl-2 is linked to its ability to inhibit mitochondrial
membrane permeabilization, thereby regulating apoptosome assembly and activation by blocking the cytosolic
translocation of death amplification factors. Of note, the identification of specific domains within the Bcl-2
family of proteins (Bcl-2 homology domains; BH domains) has not only provided a mechanistic insight into the
various interactions between the member proteins but has also been the impetus behind the design and de-
velopment of small molecule inhibitors and BH3 mimetics for clinical use.
Recent Advances: Aside from its role in maintaining mitochondrial integrity, recent evidence provides testi-
mony to a novel facet in the biology of Bcl-2 that involves an intricate cross talk with cellular redox state. Bcl-2
overexpression modulates mitochondrial redox metabolism to create a ‘‘pro-oxidant’’ milieu, conducive for cell
survival. However, under states of oxidative stress, overexpression of Bcl-2 functions as a redox sink to prevent
excessive buildup of reactive oxygen species, thereby inhibiting execution signals. Emerging evidence indicates
various redox-dependent transcriptional changes and posttranslational modifications with different functional
outcomes.
Critical Issues: Understanding the complex interplay between Bcl-2 and the cellular redox milieu from the
standpoint of cell fate signaling remains vital for a better understanding of pathological states associated with
altered redox metabolism and/or aberrant Bcl-2 expression.
Future Directions: Based on its canonical functions, Bcl-2 has emerged as a potential druggable target. Small
molecule inhibitors of Bcl-2 and/or other family members with similar function, as well as BH3 mimetics, are
showing promise in the clinic. The emerging evidence for the noncanonical activity linked to cellular redox
metabolism provides a novel avenue for the design and development of diagnostic and therapeutic strategies
against cancers refractory to conventional chemotherapy by the overexpression of this prosurvival protein.
Antioxid. Redox Signal. 00, 000–000.
Keywords: B cell lymphoma 2, Bcl2, reactive oxygen species, ROS, oxidative stress, BH domains
1Stem Cell and Cancer Biology Laboratory, Curtin Health and Innovation Research Institute, Curtin University, Bentley,
Western Australia.
2School of Biomedical Sciences and 3Curtin Institute for Computation, Curtin University, Perth, Western Australia.
4Department of Physiology, Yong Loo Lin School of Medicine and 5NUS Graduate School for Integrative Sciences and Engineering,
National University of Singapore, Singapore, Singapore.
6National University Cancer Institute, National University Health System, Singapore, Singapore.
ANTIOXIDANTS & REDOX SIGNALING
Volume 00, Number 00, 2018
ª Mary Ann Liebert, Inc.
DOI: 10.1089/ars.2017.7414
1
D
ow
nl
oa
de
d 
by
 C
ur
tin
 U
ni
ve
rs
ity
 o
f T
ec
hn
ol
og
y 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
12
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Introduction
B cell lymphoma 2: the founding member
of a functionally disparate family
Bcell lymphoma 2 (Bcl-2) is the prototypical Bcl-familyprotein and a major regulator of cell death. Bcl-2 was
discovered following the cloning of leukemic cells bearing
the t(14;18) (q32;q21) chromosome translocation (175). Sub-
sequent chromosome mapping identified BCL2 as a putative
gene involved in the pathogenesis of B cell and follicular
lymphomas (174). McDonnell et al. (115) demonstrated that
this interchromosomal translocation resulted in the over-
expression of Bcl-2 and extended the life span of B cells.
Bcl-2 is primarily localized in the mitochondria (67),
however, its localization has also be extended to the nucleus
and endoplasmic reticulum (ER). Functionally, Bcl-2 is
characterized as an antiapoptotic protein due to its role in
inhibiting proapoptotic proteins; these include the Bcl-2
family members Bak and Bax (28). On apoptotic stimula-
tion, death receptor- or drug-induced, a cascade of caspase
activation results in the induction of mitochondrial outer
membrane permeabilization (MOMP). In the case of death
receptor signaling, direct executioner caspase activation is
induced in certain cell types where the death initiating sig-
naling complex is efficiently formed (Type 1 or extrinsic
pathway); however, in other cell types, the initiator caspase
activation is relatively weak to autonomously engage the
executioner caspase(s), and therefore, the signal is routed
through the mitochondria for efficient death execution (Type
2 or intrinsic signaling). The latter is also the preferred mode
of execution triggered on exposure of cells to DNA damaging
agents, c-irradiation, as well as other forms of chemotherapy.
Importantly, the recruitment of mitochondria is a function of
the proapoptotic members of the Bcl-2 family that, on apo-
ptotic stimulation, translocate to the mitochondria forming
oligomeric complexes (40) that compromise the permeability
of the outer membrane (15), thereby facilitating the egress of
death amplification factors such as cytochrome c (83), Smac/
direct IAP binding protein with low pI (DIABLO) (1), and
apoptosis inducing factor (75). The antiapoptotic members of
the Bcl-2 family, in particular Bcl-2 and Bcl-xL, prevent
MOMP by competing with and inhibiting the oligomerization
of the proapoptotic members, such as Bax and Bak (117, 135,
190). As such, the apoptosis inhibitory function of Bcl-2 is
strongly associated with the Type 2 death signaling pathway
(Fig. 1).
Bcl-2 expression has also been shown to regulate autop-
hagy, a process of self- consumption induced on starvation or
other stress states. Autophagy has emerged as a central player
in the removal of damaged organelles as well as a source of
nutrients for cells under starvation, hence the association with
a prosurvival phenotype. Autophagy has also been linked to
cell death signaling in response to certain noxious stimuli.
Interestingly, being a survival promoting protein, Bcl-2 has
also been shown to have a critical role in regulating autop-
hagy (97). Pattingre et al. demonstrated the antiautophagic
role of Bcl-2, promoting cell survival, which was depen-
dent on its interaction with Beclin1 (139). This interaction
utilized the BH1 and BH2 domains of Bcl-2. Beclin1 ex-
pression is low to absent in many cancer cells, leading to loss
of autophagy and promotion of cell survival. Cancer cells
expressing Beclin1 exhibited higher levels of LC3-induced
autophagy, which was inhibited upon overexpression of Bcl-
2. The expression of Bcl-2 mutants (G145A/W188A) re-
sulted in the loss of Bcl-2:Beclin1 interaction, as well as the
initiation of cellular autophagy. Interestingly, this was only
observed when Bcl-2 was localized to the ER, not the mito-
chondria (139). The interaction was also found to be depen-
dent on JNK1-mediated phosphorylation of Thr69, Ser70,
and Ser87. This starvation-dependent phosphorylation re-
sulted in a dissociation of Beclin1 from Bcl-2 and the in-
duction of autophagy (182) (Fig. 2). The inhibitory effect of
Bcl-2 on apoptosis and autophagy lends credence to the hy-
pothesis that apoptosis and autophagy work in tandem to
regulate processes involved in cellular transformation and its
progression.
FIG. 1. Schematic of type 1 and
type 2 death receptor pathways.
Type 1 (bold black line) FAS
(CD95) death signaling pathway
signals independent of the intrinsic
pathway. Following FAS ligand
binding, signals are transduced
through FADD-mediated caspase-8
activation and caspase-3/7 activa-
tion for cells to go under apoptosis.
Type 2 (bold gray line) death sig-
naling through FAS is directed
through caspase-8-mediated Bid
activation. Bcl-2 is the primary in-
hibitor of antiapoptosis in type 2
signaling. Bad/Bax can direct apo-
ptosis by the release of cytochrome
c, and the activation of Apaf-1 and
caspase-9. Dotted lines indicate no
pathway involvement. Bcl-2, B cell
lymphoma 2. To see this illustration
in color, the reader is referred to the
web version of this article at www
.liebertpub.com/ars
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Expression in cancer and mutational landscape. Genomic
alterations in BCL2 are common in a variety of cancers. Data
sets obtained from The Cancer Genome Atlas (TCGA) ac-
cessed by cBioPortal (24, 53) revealed a high percentage of
copy number alterations across the majority of cancers sur-
veyed. In this regard, gene amplifications and deletions are
the primary alterations (Fig. 3A). Unsurprisingly, amplifi-
cations and mutations occurred with higher frequencies in B
cell lymphomas. The expression of BCL2 mRNA was also
determined by accessing the same data sets across 21 cancer
types. Bcl-2 is not a ubiquitously expressed protein and there
seems to be no correlation between organ systems and Bcl-2
expression in cancers, although hematopoietic and lymphoid
malignancies were consistently high (Fig. 3B). Although
BCL2 expression was low in carcinomas of the bladder and
testicular cancer, it still holds promising predictive power for
outcomes in patients (35, 44). Interestingly, the lowest ex-
pression was found in hepatocellular carcinoma, where nu-
merous studies have implicated its role as delaying the
progression of carcinogenesis by delaying cell cycle pro-
gression (148, 177).
The mutational landscape of BCL2 extends to both he-
matopoietic and nonhematopoietic tumors. To assist the in-
terpretation of the likely impact of these mutations on Bcl-2
function, we have prepared a putative Bcl-2 homodimer
model, based on the crystal structure complex of Bcl-2 with a
Bax BH3 peptide (PDB 2XA0) (86), the solution structure of
Bcl-xL in its p53-bound conformation (PDB 2ME8) (50), and
the crystal structure of the Bcl-xL domain-swapped homo-
dimer (PDB 2B48) (131) (Fig. 3C). Characteristic gain of
copy number and expression in diffuse large B cell lym-
phoma has been associated with R129H missense mutation.
In the putative Bcl-2 homodimer, Arg129 appears to facilitate
BH2 domain swapping; R129H may facilitate this more ef-
ficiently. The G128E mutation was identified in stomach
cancer, although was not associated with a variation in copy
number. This residue is on the Bcl-2 surface and is not in-
volved in interactions; therefore, the influence of the Gly128
mutation on Bcl-2 function is unclear from the structure.
Numerous G47S mutations have been identified in stom-
ach cancer. Gly47 is located in the large unstructured loop
region between the BH4 and BH3 domains and occurs at
the dimer interface in the domain-swapped homodimer;
G47S would likely enhance homodimer stability. Mutations
in melanoma include T96I and A224V. Thr96 is located at
the dimer interface; T96I will likely enhance homodimer
stability. Ala224 is located in the TM region of Bcl-2;
A224V will likely embed in the membrane more efficiently.
A more comprehensive overview of the mutational landscape
is accessible from the TCGA. Further probing of the func-
tional relevance of mutations in BCL2 is required for the
significance in various disease contexts.
FIG. 2. Schematic of Bcl-2 role in apoptosis and autophagy.Bcl-2 localized to the ER directly interacts with Beclin 1 to inhibit
autophagy. Starvation induced JNK1 activation leads to phosphorylation of Thr69, Ser70, and Ser87 of Bcl-2 disrupting the
interaction with Beclin1 to induce autophagy. Interaction between the BH3 domains of Beclin1 and Bcl-2 results in the inhibition
of autophagy. BNIP3 can interrupt the interaction between Bcl-2 and Beclin1 under conditions of hypoxia-induced ROS inducing
autophagy. The autophagy pathway consists of nucleation, autophagosome assembly followed by fusionwith the lysosome to result
in the formation of an autolysosome. Bad/Bax forms heterodimers with Bcl-2 causing its inactivation and the initiation of apoptosis.
BH, Bcl-2 homology domains; BNIP3, Bcl-2/adenovirus E1B 19-kDa protein-interacting protein 3; JNKs, c-Jun N-terminal
kinases. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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FIG. 3. BCL2 gene expression, mutational landscape, and copy number variations in cancer. (A) TCGA data sets
retrieved from cBioPortal indicate copy number andmutation alterations across 21 cancer types. Deletions (red), amplifications
(blue), mutations (green), and multiple alterations (yellow) are shown as their alteration frequency in cancers sorted from high
BCL2mRNA expression to low BCL2mRNA expression. (B) BCL2mRNA expression across 21 cancer types from TCGA data
sets retrieved from cBioPortal. (C) Putative homodimer structure ofBcl-2 bound toBaxBH3 peptide withmutations highlighted.
Color guide: blue - Bcl-2 molecule 1; green - Bcl-2 molecule 2; yellow - Bax BH3 peptides; violet - mutations identified in
TCGA (not visible/highlighted: Gly47 in Bcl-2 molecule 1, Gly128 in either Bcl-2 molecule). TCGA, The Cancer Genome
Atlas. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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Structural knowledge of Bcl-2 and its interactions with
peptides and small molecule inhibitors. The structure of
Bcl-2 family proteins has been extensively characterized by
X-ray crystallography and NMR spectroscopy, and in the
majority of cases, structural details of interactions with other
proteins and prospective inhibitors are known. Bcl-2 family
proteins are characterized by the presence of one or more
BH domains. The BH3 domain is the most highly conserved,
being present in all members of the Bcl-2 antiapoptotic mul-
tidomain, proapoptotic multidomain, and BH3-only domain
members (Fig. 4). The antiapoptoticmembers contain all BH1-
BH4 domains, except MCL-1 (induced myeloid leukemia cell
differentiation protein) and A1, which lack the BH4 motif.
Bcl-2 itself features four BH domains (in sequence order,
BH4, BH3, BH1, and BH2), which facilitate protein/protein
interactionswith proteins from and outside of the Bcl-2 family.
The majority of the family proteins, excluding some of the
BH3-only members (Bad, Bmf, Bid, Puma, and Noxa),
possess a TM domain that is critical for homo- and hetero-
oligomerization at the mitochondrial membrane (135, 191).
The structure of Bcl-2 was first determined by NMR
spectroscopy using a Bcl-2 construct, in which the loop
between the BH4 and BH3 motifs was replaced by the
equivalently located and shorter loop from the related protein
Bcl-xL (146). This construct has been used to provide the
majority of Bcl-2 structures (Table 1). The overall structural
similarity of Bcl-2 to Bcl-xL, the native (119) and peptide-
bound (147, 161) structures of which were already known at
the time, was revealed and provided the first indications as to
the different peptide binding specificities of the two proteins.
The structure of Bcl-2 has since been resolved with a
small range of peptide interactors, including fragments from
naturally occurring proteins as well as designed peptides
(Table 1). In all cases, binding is achieved via an a-helix
(13, 74, 86) or a-helix-like (25) structure interacting with a
groove formed by the BH3, BH1, and BH2 domains (Fig. 5).
Furthermore, peptides are oriented within the groove in the
same way in all structures, with the N-terminal oriented
FIG. 4. Schematic view of Bcl-2 family proteins. To see
this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
Table 1. Experimentally Determined Bcl-2 Structures
PDB IDa Method Resolution (A˚)
Resolved portion
of structureb Bound moleculesc Reference
1G5M NMR N/A 3-34, 92-207 None (146)
1GJH NMR N/A 3-34, 92-207 None (146)
1YSW NMR N/A 3-34, 92-207 2-phenethylbenzothiazole analog
of Compound 1
(134)d
2O21 NMR N/A 3-34, 92-207 2-phenethylbenzothiazole analog
of Compound 1
(18)d
2O22 NMR N/A 3-34, 92-207 Compound 1b (18)d
2O2F NMR N/A 3-34, 92-207 Compound 43a (18)d
2 W3L X-ray 2.10 9-35, 92–203 Phenylpyrazole 2 (149)
2XA0 X-ray 2.70 10–31, 92–206 Bax BH3 peptide (86)
4AQ3 X-ray 2.40 9-31, 92–203 Compound 18 (141)
4IEH X-ray 2.10 9-31, 92–204 Compound 6 (173)
4LVT X-ray 2.05 9-32, 92–204 Navitoclax (ABT-263) (167)d
4LXD X-ray 1.90 6-33, 92–204 Compound 2 (167)d
4MAN X-ray 2.07 8-29, 92–204 Indole analog of compound 2 (167)d
5AGW X-ray 2.69 8-31, 92–204 a/b-1 (25)
5AGX X-ray 2.24 8-32, 92–204 a/b-1-LIN (25)
5FCG X-ray 2.10 6-34, 92–203 Peptide from HBx protein (74)
5JSN X-ray 2.10 7-32, 87–207 aBCL2 peptide (13)d
aAll structures obtained from Bcl-2:Bcl-x(L) chimera except 2XA0, 5FCG, and 5JSN, which were determined from full-length Bcl-2.
bAll structures have been determined from the Bcl-2 construct in which the BH4-BH3 loop of Bcl-2 replaced with shorter loop from Bcl-
xL, except PDB 5JSN. In the NMR structures, the structure resolved is continuous; the replaced loop is largely not resolved in X-ray.
cTo avoid long systematic names, compounds are named according to their designation in their original publication; see the original
publication cited in the corresponding row of the Reference column for specific compound details.
dThis study also reports ligand complexes with Bcl-xL; see the respective publication for further details.
Bcl-2, B cell lymphoma 2; BH, Bcl-2 homology domains; N/A, not applicable.
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toward the BH1 domain and the C-terminal oriented toward
the BH2 domain; peptide binding to Bcl-xL also displays the
same directionality in all cases (7, 49, 93, 94, 132). Peptide
binding to Bcl-2 appears largely mediated by a series of up
to five hydrophobic residues (typically branched-chain amino
acids) on one face of the peptide helix interacting with hy-
drophobic pockets along the Bcl-2 binding groove; this feature
is present in all peptides cocrystallized with Bcl-2, both nat-
urally derived and designed peptides. Three hydrophobic
pockets of Bcl-2 with which peptides interact may be defined:
a large pocket formed largely by BH1-derived residues (herein
referred to as the ‘‘BH1 pocket’’; Leu119, Val133, Leu137,
Ala149, and Phe153), a smaller pocket formed from near the
end of the BH3 domain (herein referred to as the ‘‘near-BH3
pocket’’; Phe104, Tyr108, and Phe112), and a second large
pocket formed from residues from the BH3, BH1, and BH2
domains (herein referred to as the ‘‘BH2-incorporating pock-
et’’; Ala100, Phe104, Trp144, Val148, Phe198, Leu201, and
Tyr202). Peptides engaging all three pockets generally bind,
from N to C terminal, the BH1 pocket with the most N-
terminal hydrophobic residues (1–2 residues), the near-BH3
pocket with the middle hydrophobic residue, and then, the
BH2-incorporating pocket with the final hydrophobic residues
(1–2 residues). The HBx-derived peptide primarily engages
the BH1 pocket, while the aBCL2 peptide uses a single leucine
to engage the BH1 and near-BH3 pockets. In addition, a range
of supporting hydrogen bonds are present in each structure,
however, just two are present in all structures (except the HBx
complex); these are the interactions of an acidic residue
(typically aspartate) between the hydrophobic residues en-
gaging the BH1 and BH2-incorporating pockets with Asn143
and Arg146 of Bcl-2. As the majority of hydrogen bonds in the
peptide complexes with Bcl-2 are solvent exposed, these may
be transient in typical cellular conditions. These hydrogen
bonds are not replicated in any of the small molecules struc-
turally characterized in complex with Bcl-2.
The structure of Bcl-2 has also been extensively character-
ized in complex with prospective small molecule inhibitors
FIG. 5. Overview of the structural basis of Bcl-2 recognition of peptides. (A) Bcl-2 in complex with Bax BH3 peptide
(PDB 2XA0). Bcl-2 shown as a surface, with the BH4 (blue), BH3 (magenta), BH1 (yellow), and BH2 (green) motifs
highlighted. Bax BH3 peptide shown in cartoon view, colored as a blue to red rainbow from the N to the C terminus. (B)
Electrostatic potential surface of Bcl-2 in complex with Bax BH3 peptide (yellow). Hydrophobic residues of the Bax BH3
peptide interacting with Bcl-2 shown as transparent spheres. Electrostatic potential shown as a red-white-blue gradient, from
negative (red) to neutral (white) to positive (blue). (C) The three major binding sites within the Bcl-2 binding groove. (D)
Hydrogen bonding interactions observed in the Bax BH3 complex with Bcl-2. Asn143 and Arg146 of Bcl-2, and Asp68 of Bax
BH3 labeled in italics and underlined to indicate that these residues are involved in hydrogen bonds replicated in the majority
of peptide complexes with Bcl-2. Electrostatic potential calculated using the PDB2PQR/APBS web server; figures generated in
PyMOL. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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(Table 1) (18, 134, 141, 149, 167, 173). Due to the similarities
between the Bcl-2 and Bcl-xL binding pockets, many of these
inhibitors have also been structurally characterized in com-
plex with Bcl-xL; achieving selectivity for Bcl-2 over Bcl-xL
is a major challenge in the design of clinically useful Bcl-2
inhibitors (8). Inhibitors structurally characterized in com-
plex with Bcl-2 typically engage Bcl-2 in a remarkably
similar way to the peptides, featuring long structures capable
of binding to all three of the major pockets of the Bcl-2
binding groove; this also gives the majority of inhibitors
molecular weights well over 500 Da, outside the typical
range for small molecule drugs (103). Most inhibitors fea-
ture a small hydrophobic group, typically a single aromatic
ring, bound to the BH1 pocket, a relatively straight structure
comprising two rings connected in series, followed by a sul-
fonamide, lying between the BH1 and BH2-incorporating
pockets, and a large flexible hydrophobic group interacting
with the BH2-incorporating pocket (Fig. 6); these molecular
features are largely carried over from the prototypical Bcl-2
inhibitor, ABT-737 (discussed in further detail in section IV: A
Brief Overview of Bcl-2 Inhibitors: Past, Present, and Future).
An exception to this is phenylpyrazole 2 (149), which does
not engage the BH2-incorporating pocket; despite this, phe-
nylpyrazole 2 exhibits*10-fold selectivity for Bcl-2 over Bcl-
xL, although its overall potency is eclipsed by ABT-737.
Further modification of phenylpyrazole 2 yielded compound
18 (141), which does extend to the BH2-incorporating pocket
and displays overall greater structural similarity to ABT-737.
Reactive oxygen species and their role in cell signaling
Reactive oxygen species (ROS) collectively refer to
oxygen-derived (O2) free radical and nonradical species (31).
Radical ROS include superoxide anion (O2
.-), hydroxyl
radical (HO), peroxyl radical (ROO), and alkoxyl radical
(RO) (61). Nonradical ROS include hydrogen peroxide
(H2O2) and peroxynitrite (ONOO
-) (153, 172). A tight bal-
ance between intracellular ROS and ROS regulating systems
is critical for maintaining cellular homeostasis (38). There-
fore, excessive generation of ROS or deficient antioxidant
capacity alters cellular redox state with profound effects on
cell growth, proliferation, and survival. Homeostatic levels of
ROS are maintained by both enzymatic and nonenzymatic
antioxidants. A depletion or overexpression of these antiox-
idants can alter cell fate. For example, overexpression of
antioxidant enzyme SOD2 can protect cells from tumor ne-
crosis factor (TNF)-induced apoptosis (110). This protected
the cell from H2O2-induced cell death and promoted cell sur-
vival. On the contrary, SOD1 has been shown to be a potential
therapeutic target in some cancers (56). These contrasting roles
for similar antioxidant enzymes demonstrate that the tight
balance of ROS levels can determinewhether cells will survive
or undergo apoptosis. The dogmatic view that any increase in
intracellular ROS is linked to cell injury and death has been
challenged by substantial experimental evidence attributing a
secondary messenger function to a mild increase in ROS or a
‘‘pro-oxidant’’ milieu. Alterations in the cellular redox me-
tabolism is linked to aging (105) as well as a host of patho-
logical states, such as cancer (102), Alzheimer’s disease (112),
Parkinson’s disease (29), diabetes (71), atherosclerosis (62),
nonalcoholic fatty liver disease (17), and asthma (43).
Intracellular sources of ROS. The mitochondrion serves
as an important source of intracellular ROS [elegantly re-
viewed in (30)], mainly generating O2
.- from Complex I
(NADH dehydrogenase) (60) and Complex III (cytochrome c
reductase) (120), when electrons derived from NADH or
FADH2 leak out on to and reducemolecular oxygen (121). The
mitochondrial O2
.- levels are regulated by the action of man-
ganese superoxide dismutase (MnSOD) in the inner matrix
that generates H2O2 in the process (118). H2O2 in turn can be
scavenged by catalase, glutathione peroxidases, and peroxir-
edoxins (85). A second important site of O2
.- generation, best
exemplified in phagocytic cells, is the NADPH oxidase (NOX)
family of enzymes. NOX enzymes aremade up of six subunits:
a Rho guanosine triphosphatase (GTPase) and five phagocytic
oxidase subunits (gp91, p22phox, p40phox, p47phox, and
p67phox) (91). Additional sources of ROS include O2
.- from
xanthine oxidases (88), cyclooxygenases or prostaglandin-
endoperoxide synthase (PTGS) (55), the cytochrome P450
enzyme family (14), and nonheme lipoxygenases (21).
FIG. 6. Structural determinants of small molecule interactions with Bcl-2. (A) Bcl-2 in complex with navitoclax
(ABT-263) (PDB 4LVT). (B) Overlay of all small molecules structurally characterized in complex with Bcl-2, highlighting
key molecular features present in the majority of ligands. To see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
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ROS as signaling molecules. It is now widely accepted
that ROS function as important signaling molecules, impli-
cated in nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-jB), mitogen-activated protein kinase (MAPK),
Keap1-Nrf2-ARE, PI3K-Akt, Notch, and Wnt signaling
pathways (20, 192). The various functional consequences of an
altered redox milieu have been associated with a critical bal-
ance between the two major ROS molecules, O2
.- and H2O2
(34, 145, 156). Whereas an overwhelming increase in either of
these species results in cell injury and death, a tilt in the ratio in
favor of O2
.- confers a survival advantage, while a significant
shift toward H2O2 creates a permissive environment for death
execution (84, 144). For example, H2O2 is known to suppress
Wnt/b-catenin signaling, an important survival and growth
pathway, through a variety of mechanisms, including targeting
the interaction between nucleoredoxin and disheveled (Dvl)
(52) and via oxidative modification of the zinc-coordinating
cysteines of tankyrase resulting in its inactivation (78). Inter-
estingly, ROS-mediated Wnt signaling regulation of BCL2
involving GSK3b/b-catenin has been reported on chronic ex-
posure to Cr(VI) compounds (166). NF-jB signaling is closely
linked to the transcriptional regulation of Bcl-2(22). Further-
more, Nrf2-ARE signaling can also regulate BCL2 transcrip-
tion through the antioxidant response elements (ARE) located
within the BCL2 promoter under conditions of oxidative stress
(129). Interestingly, there is evidence of considerable cross
talk between Nrf2 and NF-jB (181). For a more detailed ac-
count of the disparate functional outcomes on changes in in-
tracellular ROS, please refer to these two comprehensive
reviews (153, 154).
The cross talk between cellular redox status and Bcl-2
Apart from the role of Bcl-2 as a major regulator of apo-
ptosis and cell fate, there is convincing experimental evi-
dence to indicate a close interplay between cellular redox
status and Bcl-2 expression. Of note, there are reported
observations supporting both a pro-oxidant activity and an
antioxidant activity of Bcl-2 (68, 197). Not only does the
expression of Bcl-2 impact intracellular redox milieu but also
a reciprocal regulation of Bcl-2 expression and/or function
has been associated with intracellular ROS (26). For exam-
ple, Bcl-2 has been shown to modulate intracellular ROS
through increased catalase and glutathione peroxidase/re-
ductase expression (46), as well as increased total levels of
NADPH and reduced glutathione (GSH) (47). On the flip side
of it, there is emerging and significant evidence that Bcl-2
expression impacts mitochondrial ROS metabolism to stim-
ulate O2
.- production, through increased COX activity,
thereby creating a pro-oxidant environment that favors cell
survival (26, 145).
The mRNA expression of BCL2 is also tightly correlated
with the expression of genes involved in ROS detoxification
and production (Fig. 7). Many peroxidase elimination en-
zymes, such as peroxiredoxins, and other redox proteins, such
as thioredoxins, exhibit a strong negative correlation with
BCL2. This relationship may be due to an intrinsic mecha-
nism through which cellular redox levels are in a constant
pro-oxidant state, facilitating cancer cell survival. This pro-
oxidant environment has been established as critical for the
stability and antiapoptotic function of Bcl-2 (107). This hy-
pothesis is also supported by a strong positive correlation
between O2
.- producing enzymes NADPH oxidases, NOX2
and NOX4. Interesting to note is the strong negative corre-
lation between BCL2 and SOD1 across 18 of the 21 cancers
surveyed, while SOD2 only exhibits a negative correlation in
tumors with higher expression of BCL2. SOD3, the extra-
cellular superoxide dismutase, was found to be positively
correlated with Bcl-2 expression. The negative correlation of
BCL2with SOD1 in multiple cancers supports the notion that
Bcl-2 may also function to maintain the pro-oxidant intra-
cellular milieu necessary for cell survival (107). These data
suggest that the expression of BCL2 is strongly correlated
with the expression of many antioxidant enzymes and the
tight interplay between regulating intracellular redox levels
plays an important role in cell fate, especially in the context
FIG. 7. Correlation be-
tween BCL2 and antioxidant
genes. Cancers were sorted
from Bcl-2 high to low mean
mRNA expression as ob-
tained from TCGA data sets.
Correlations (Spearman’s q)
are indicated as red-white-
blue gradient (positive-none-
negative). To see this illus-
tration in color, the reader is
referred to the web version
of this article at www
.liebertpub.com/ars
8 POHL ET AL.
D
ow
nl
oa
de
d 
by
 C
ur
tin
 U
ni
ve
rs
ity
 o
f T
ec
hn
ol
og
y 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
12
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
of carcinogenesis. A list of key publications in terms of Bcl-2
and the regulation of Bcl-2 by ROS have been described in
Table 2.
Bcl-2 serves as a protector against oxidative insult. The
protective role of Bcl-2 on an overt oxidative stress was
originally discovered after Bcl-2-overexpressing cells
demonstrated increased resistance to H2O2 and menadione-
induced cell death (68). Subsequently, contradicting evi-
dence has emerged to suggest that Bcl-2-mediated cellular
protection from H2O2 was both independent (3) and depen-
dent (73) on NF-jB activation. The latter study indicated that
Bcl-2 induces constitutively active NF-jB signaling, result-
ing in the upregulation of c-glutamylcysteine ligase, the first
enzyme in the biosynthetic pathway of GSH (73). Tran-
scriptional regulation of BCL2 by NF-jB is now well char-
acterized (22, 63). Bcl-2 is able to provide protection against
other oxidizing species, including potassium cyanide, tert-
butyl hydroperoxide (165), and c-irradiation (122, 196).
The protective role of Bcl-2 also includes safeguarding
against nitric oxide (NO)-induced apoptosis (116). Bcl-2-
overexpressing murine macrophages exposed to NO donors,
S-nitrosoglutathione (GSNO) and spermine-NO, and activa-
tors of inducible NO, lipopolysaccharide and interferon-c,
demonstrated apoptotic resistance to that of their neo control
cells (116). While it has often been hypothesized that the
mechanism by which Bcl-2 protects against oxidative insult
is an intrinsic antioxidant property (68, 69, 95, 157), current
evidence suggests that the antioxidant activity of Bcl-2 is
merely a secondary effect (36, 54). Bcl-2 may be thought of
as an ‘‘antioxidant-by-proxy’’ when in complex with GSH
(197); this is discussed in detail in the following section
(Mitochondrial-Dependent Regulation of Cellular Redox by
Bcl-2). Cox and Hampton (36) demonstrated that Bcl-2 was
able to protect cells against apoptotic (<200lM), but not
necrotic (>200 lM), doses of H2O2. These cells also showed
no difference in the levels of GAPDH and peroxiredoxin 2
oxidation, while exhibiting evidence of increased micro-
nuclei formation and genomic instability. This suggests that
the antiapoptotic and pro-oncogenic role of Bcl-2 is through
preventing the elimination of cells damaged by oxidation
(36). Besides the apparent antioxidant activity of Bcl-2, re-
cent evidence also suggests that Bcl-2 promotes cell survival
by providing a pro-oxidant environment capable of sup-
porting tumorigenesis (26, 170, 189).
Mitochondrial-dependent regulation of cellular redox by
Bcl-2. Mitochondrial metabolism and its redox environ-
ment are highly dependent on Bcl-2 and GSH (111). In this
respect, Bcl-2 regulates the mitochondrial pool of GSH and
may act as a redox sensor. GSH may be displaced from Bcl-2
via competitive binding of BH3-only proteins (e.g., Bim) and
BH3 mimetics (e.g., ABT-737) and induces mitochondrial
dysfunction, oxidative stress, and cell death (197). Recently,
it was demonstrated that Bcl-2 and 2-oxoglutarate carrier
(OGC), a glutathione transport molecule, directly interact in
the presence of GSH. This suggests that Bcl-2 and OGC
participate in the transport of GSH to increase the glutathione
Table 2. List of Milestone Publications for Bcl-2 and Its Interplay with Reactive Oxygen Species
Key publications in the interplay between Bcl-2 and ROS
Authors Year Journal Publications
Tsujimoto et al. (175) 1984 Science Cloning of the chromosome breakpoint of neoplastic
B cells with the t(14;18) chromosome translocation
Hockenbery et al. (67) 1990 Nature Bcl-2 is an inner mitochondrial membrane protein that
blocks programmed cell death
Hockenbery et al. (68) 1993 Cell Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Oltvai et al. (135) 1993 Cell Bcl-2 heterodimerizes in vivo with a conserved homolog,
Bax, that accelerates programmed cell death
Yin et al. (191) 1994 Nature BH1 and BH2 domains of Bcl-2 are required for inhibition
of apoptosis and heterodimerization with Bax
Muchmore et al. (119) 1996 Nature X-ray and NMR structure of human Bcl-xL, an inhibitor
of programmed cell death
Petros et al. (146) 2001 PNAS Solution structure of the antiapoptotic protein bcl-2
HIldeman et al. (66) 2003 PNAS Control of Bcl-2 expression by reactive oxygen species
Clement et al. (33) 2003 Cell Death and
Differentiation
Decrease in intracellular superoxide sensitizes Bcl-2-
overexpressing tumor cells to receptor and drug-induced
apoptosis independent of the mitochondria
Oltersdorf et al. (134) 2005 Nature An inhibitor of Bcl-2 family proteins induces regression
of solid tumours
Cox and Hampton (36) 2007 Carcinogenesis Bcl-2 over-expression promotes genomic instability by
inhibiting apoptosis of cells exposed to hydrogen peroxide
Chen and Pervaiz (26) 2007 Cell Death and
Differentiation
Bcl-2 induces pro-oxidant state by engaging mitochondrial
respiration in tumor cells
Chen and Pervaiz (27) 2010 Cell Death and
Differentiation
Involvement of cytochrome c oxidase subunits Va and Vb
in the regulation of cancer cell metabolism by Bcl-2
Velaithan et al. (178) 2011 Blood The small GTPase Rac1 is a novel binding partner of Bcl-2
and stabilizes its antiapoptotic activity
Low et al. (107) 2014 Blood Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration
of PP2A-B56delta stabilizes its antiapoptotic activity
GTPase, guanosine triphosphatase; PP2A, protein phosphatase 2, ROS, reactive oxygen species.
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mitochondrial pool, and a mechanism through which the
mitochondria are protected from oxidative stress (184). It has
been shown that Bcl-2 overexpression relocalized GSH to the
nucleus, altering nuclear redox and blocking caspase acti-
vation to promote cell survival (179). Glutathione homeo-
stasis regulated by Bcl-2 has been shown in MCF-7 breast
cancer cells, where Bcl-2 overexpression increases glutathi-
one content, although this was found to be independent of
changes in gene expression related to glutathione synthesis.
The inhibition of glutathione synthesis was able to overcome
Bcl-2-induced cisplatin resistance (160).
The mechanisms by which Bcl-2 regulates mitochondrial
respiration are vital for the understanding and interpretation
of the overall cellular redox environment (106). Bcl-2 ex-
pression has been linked to the activity of cytochrome c ox-
idase (COX), the rate-limiting enzyme in mitochondrial
electron transport chain (ETC), and thus vital in the regula-
tion of mitochondrial respiration (26). Leukemic lympho-
blastic cells (CEM cell line) overexpressing Bcl-2 exhibited
higher levels of mitochondrial O2
.-, oxygen consumption,
and higher COX activity, while the opposite was seen after
the introduction of siRNA directed at BCL2 (26, 27). It
should be pointed out that the effect of Bcl-2 on mitochon-
drial COX activity and oxygen consumption is dependent on
the redox milieu of the mitochondria. In this regard, under
states of normoxia, Bcl-2 upregulates mitochondrial respi-
ration and COX activity through increased import and as-
sembly of COX subunits Va and Vb (27).
Evidence also suggests a possible interaction between Bcl-2
and COX Va, and higher expression of Bcl-2 promoted the
mitochondrial translocation of COX Va. On the contrary, dur-
ing states of overt oxidative stress induced on pharmaco-
logically inhibition of mitochondrial ETC complexes, Bcl-2
overexpression elicited a negative effect on mitochondrial res-
piration and COX activity. The latter is corroborated by a recent
report demonstrating that conditionalBCL2 knockout inmurine
pancreatic b cells exhibited increased superoxide dismutase
(SOD) activity, increased mitochondrial respiration, and ulti-
mately, cell death (2). The regulatory effect of Bcl-2 on mito-
chondrial respiration has also been reported in neuronal cells
(77), in SOD1G93A mouse models of amyotrophic lateral scle-
rosis (138), rat ascites hepatoma (165), and hepatocytes (176).
Bcl-2-dependent increase in mitochondrial O2
.- levels was
also associated with the downstream activation of signal
transducer and activator of transcription 3 (STAT3), which
was mediated through a function of Rac1 (79). Over-
expression of Bcl-2 induced phosphorylation of STAT3 on
Tyr705, which was mediated by increased O2
.-. Furthermore,
constitutively active mutants of STAT3 increased mito-
chondrial O2
.- production (79). This study demonstrates the
numerous signaling pathways that Bcl-2 can influence in
regulating mitochondrial redox metabolism.
Bcl-2 family members have also been shown to mediate
the switch between mitochondrial fusion and fission, which
in turn suggests an influence of the family on mitochondrial
metabolism and bioenergetics (183). Mammalian proteins
Drp-1 and Fis-1 have been shown to be crucial in mito-
chondrial fission, while Mfn1/2 and OPA1 have been shown
to play a role in fusion events. Bcl-2 family members Bax and
Bak are required for mitochondrial fusion, where Bax inter-
acts directly with Mfn2 (80). Bax has also been shown to
colocalize with both Drp1 and Mfn2 during apoptosis and
promotes mitochondrial fragmentation (164). Mammalian
Bcl-2 is yet to be identified in having a role in either profusion
or fission events (159), although it has also been described in
the Caenorhabditis elegans homologue CED-9 (108). The
study by Lu et al. found that CED-9 interacts with DRP-1 to
promote mitochondrial fission. One could then speculate that
Bcl-2 may function as a receptor for DRP-1 in a mammalian
system to promote changes in mitochondrial dynamics and
metabolism, although this is yet to be proven (159).
Taken together, it appears that the regulation of mito-
chondrial ROS extends into a variety of cellular contexts, and
therefore, an alternative therapeutic strategy against refrac-
tory cancers could be to target key players involved in the
regulation of mitochondrial metabolism to favorably modu-
late the cellular redox milieu for death execution (142).
Oxidative stress induced transcriptional regulation ofBCL2.
Early studies assessing the relationship between oxidative
stress and BCL2 expression indicated that acute oxidative
stress induced by bright light in retinal rod receptor cells
and cyclosporin A in human endothelial cells reduced BCL2
expression (104). Later studies in t(14;18) lymphoma cells
revealed that BCL2 expression is tightly linked to NF-jB
activation by the presence of cyclic AMP response element
(CRE) and Sp1 binding sites (63). In prostate cancer cells, the
overexpression of p50/p65 subunits of NF-jB increased ex-
pression of BCL2, and likewise, stimulation with TNF-a re-
sulted in an increase in BCL2 promoter activity (22). In U937
cells, NF-jB has also been implicated in ROS-induced up-
regulation of BCL2 (37). BCL2 transcriptional regulation has
also been linked to Sonic hedgehog signaling through gli-1
and Wnt/b-catenin signaling by Wnt3a stimulation in oste-
oblast progenitor cells (5).
ROS have been shown to regulate BCL2 gene expression
indirectly, through which variations in cellular ROS levels
lead to both an increase or decrease in BCL2 gene expression
depending on the cell context. Hildeman et al. (66) demon-
strated that the addition of antioxidant manganese (III) tet-
rakis (4-benzoic acid)porphyrin (MnTBAP) to T cells in vivo
significantly increased BCL2 gene expression, although did
not regulate other Bcl-2 family members, including Bcl-xL,
Bad, and BimEL. MnTBAP also decreased intracellular ROS
levels and inhibited death execution. ROS production was
shown to be upstream of BCL2 downregulation and to involve
a Bim-independent mechanism. These results were mirrored
by retroviral expression of catalase, which increased BCL2
expression and rescued cells from oxidative stress-induced
cell death (66). Similarly, H2O2 induced downregulation
of Bcl-2 protein and gene expression, while concurrently
upregulating Bax in cardiac myocytes (113). While the ma-
jority of studies have found that BCL2 was downregulated
when exposed to oxidative stress, Kaufmann et al. found
that aged rats had increased BCL2 expression in the hippo-
campus and cerebellum, which was a consequence of oxi-
dative stress (81).
Bcl-2 regulation through oxidative stress was also dem-
onstrated in hippocampal neurons, where the addition of
H2O2 and glucose oxidase resulted in a decrease in BCL2 gene
and protein expression (150). The downregulation of Bcl-2 and
concurrent increase in oxidative stress-induced apoptosis were
able to be rescued through the addition of N-acetylcysteine
(NAC), which subsequently increased Bcl-2 expression (151).
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Transcriptional regulation of BCL2 is partly controlled by
cyclic AMP response element binding protein (CREB) (185).
Oxidative insult through H2O2 or glucose oxidase decreased
CREB activity on the BCL2 promoter, which was reversed in
the presence of NAC and manganese (III) tetrakis (1-methyl-
4-pyridyl) porphyrin (MnTMPyP) (150). In rat liver, the in-
duction of oxidative stress with triiodothyronine (T3) re-
sulted in increased Bcl-2 expression, which was abrogated
with the addition of a-tocopherol (vitamin E) (48). These
studies demonstrate that Bcl-2 not only regulates the cellular
redox milieu but oxidative stress itself can reciprocally reg-
ulate Bcl-2 expression as well.
Posttranslational modifications of Bcl-2 mediated by oxi-
dative stress. The regulation of apoptosis by Bcl-2 has
been shown to be mediated through various kinases, ligands,
and oxidative stress signals due to changes in the expression
and function of antioxidant enzymes. The regulation of Bcl-2
by posttranslational modification induced by oxidative stress
is summarized in Figure 8. Bcl-2 suppression of apoptosis
is partly facilitated through its direct interaction with extra-
cellular signal-related kinase (ERK) 1/2 (109). This interac-
tion can be regulated through oxidative stress, through which
increased H2O2 induces Bcl-2 cysteine oxidation and the
disruption of the ERK1/2-Bcl-2 complex. Mutagenesis in-
dicated that the key residues regulating this interaction were
Cys158 and Cys229. Cys158 is located adjacent to the Bcl-2
BH1 domain and is buried in both the monomeric and puta-
tive dimer forms (Fig. 2C) of the protein, although may be-
come exposed during the conformational change that would
be required to achieve dimer formation; Cys229 is suggested
to be located within the Bcl-2 transmembrane helix. A
C158A and C229A double mutant was resistant to oxidation,
as well as H2O2-induced ubiquitination and subsequent deg-
radation (109). The degradation of Bcl-2 through the
ubiquitin-mediated pathway is also regulated by TNF-a-
induced oxidative stress. H2O2 and TNF-a-induced oxidative
stress resulted in degradation of Bcl-2, which was linked to
the dephosphorylation of Ser87. The resultant dephosphor-
ylation after TNF-a stimulation was demonstrated to be
protein phosphatase 2 (PP2A) and PP2B independent (16).
H2O2 has also been shown to regulate PKC-mediated Bcl-2
phosphorylation through a phospholipase Cc1-dependent
(PLC-c1) mechanism. Plcg1 null cells exhibited reduced
viability and reduced Bcl-2 phosphorylation, following an
insult with low levels of H2O2 (10).
Furthermore, c-Jun N-terminal kinase ( JNK) activa-
tion can induce apoptosis through phosphorylation and in-
activation of Bcl-2 (188). In response to menadione-induced
oxidative stress, JNK phosphorylation and degradation of
Bcl-2 were increased, but could be blocked on addition of
NAC (193). Contrary to this study, Kelkel et al. demonstrated
FIG. 8. Schematic of post-translationalmodifications of Bcl-2 due to oxidative stress.Posttranslationalmodifications of Bcl-2
occur under an insult of oxidative stress. Depletion or inhibition of SOD1 can initiate nitration of T289 on PP2A’s B56d subunit,
preventing binding to the A/C subunits and the generation of the holo-enzyme. This prevents dephosphorylation of Ser70 of Bcl-2,
stabilizing its antiapoptotic ability. Hydrogen peroxide can stabilize Bcl-2 through PKM2-mediated phosphorylation of T69, aswell
as causing its degradation through the ubiquitin-mediated pathway. PLC-c1 mediates hydrogen peroxide resistance allowing
phosphorylation of key residues by PKC and stabilization, while the opposite can also occurwhere hydrogen peroxide can stimulate
dephosphorylation of Bcl-2. During cellular stress and starvation, JNK1 has also been shown to phosphorylate Bcl-2 at T69/S70/
S87. Bcl-2 interacts with GSH and OGC to regulate the mitochondrial pool of GSH. GSH, glutathione; H2O2, hydrogen peroxide;
NO, nitric oxide; ONOO-, peroxinitrite; OGC, 2-oxoglutarate carrier; PLC-c1, phospholipase Cc1-dependent; PPA2, protein
phosphatase 2. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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that JNK activation and phosphorylation of Bcl-2 were in-
dependent, via the addition of the ROS-inducing agent diallyl
tetrasulfide to U937 human histiocytic lymphoma cells (82).
These opposing results suggest that redox-dependent post-
translational modifications of Bcl-2 are highly dependent on
the level of ROS. High levels of H2O2 primarily result in
oxidation of Bcl-2 and degradation, while low levels initiate
phosphorylation and stabilization of Bcl-2.
Functionally, ROS-mediated Bcl-2 phosphorylation has
been linked to cell cycle transitions (39). The expression
of phosphomimetic, gain-of-function Bcl-2 mutants (S70E
and T69E/S70E/S87E) reduced intracellular ROS and in-
hibited G1/S cell cycle progression. The reduced G1/S phase
progression was overridden by the addition of H2O2, through
the downregulation of p27 and increased activation of Cdk2.
Decreased ROS were attributed to increased SOD1 and cata-
lase expression, which resulted in an antioxidant intracellular
milieu on expression of the Bcl-2 phosphomimetics (39).
The relationship between the members of the SOD family
and Bcl-2 has been explored in a number of cellular contexts.
In spinal cord mitochondria, mutant SOD1 (G93A) and wild-
type Bcl-2 have been shown to interact in the mitochondria,
where they promote structural abnormalities and mitochon-
drial dysfunction. The mutant SOD1 causes a conformational
change in Bcl-2, resulting in the exposure of the BH3 do-
main, which promotes mitochondrial toxicity (140). Low
et al. (107) demonstrated that the stability and antiapoptotic
function of Bcl-2 were enhanced in a pro-oxidant environ-
ment. Specifically, reducing SOD1 activity either by phar-
macological means or siRNA directed at SOD1 increased
phosphorylation of Bcl-2 at Ser70 (pSer70). Increased levels
of ONOO-, as a result of increased O2
.-, induced selective
nitration of Tyr289 of the B56d subunit of PP2A. ONOO--
induced nitration of PP2A at Tyr289 prevented the assembly
of the holoenzyme involving the regulatory B subunit and the
core A-C subunits. Importantly, SOD1 expression and Bcl-2
pSer70 were found to be negatively correlated in vivo; high
Bcl-2 p70 could predict a poor patient prognosis. Further-
more, in vitro studies showed an association between high
levels of Bcl-2 pSer70 and chemoresistance. This suggests
the possibility for the use of redox modulators as chemo-
sensitizers in the treatment of lymphomas (107). The study by
Low et al. provided mechanistic insight to observations
published previously by Zhao et al., demonstrating that Bcl-2
pSer70 was required for protection against oxidative stress,
which was abolished through the activation of PP2A (194).
Liang et al. (100) recently demonstrated that under H2O2-
induced oxidative stress, Bcl-2 is stabilized through phos-
phorylation of Thr69 (pThr69) by pyruvate kinase M2
isoform (PKM2), promoting tumorigenesis in glioma cells.
Oxidative stress induces mitochondrial translocation and a
potential conformational change in PKM2, resulting in the
phosphorylation of Bcl-2 at Thr69. This potential confor-
mational change may be facilitated through the ATPase ac-
tivity of HSP90a1 and permits the binding of PKM2 to Bcl-2.
pThr69 prevents ubiquitination by a Cul3-based ubiquitin
E3 ligase, thus preventing its degradation. This HSP90a1-
PKM2-Bcl-2 axis is crucial in stabilizing the antiapoptotic
function of Bcl-2 and driving tumorigenesis (100).
The Bcl-2:Beclin1 interaction has been demonstrated to be
potentially redox dependent. Bcl-2/adenovirus E1B 19-kDa
protein-interacting protein 3 (BNIP3) is a proapoptotic pro-
tein, whose expression is regulated by HIF-1a. It functions as
a redox sensor during times of prolonged hypoxia-induced
oxidative stress. Dimerization of BNIP3 was shown to be
sensitive to H2O2-induced oxidative stress (87). Hypoxia-
induced BNIP3 expression has been demonstrated to disrupt
the interaction between Bcl-2 and Beclin 1 to induce autop-
hagy (12). These studies show that apoptosis and autophagy
are clearly linked to specific Bcl-2 binding partners in various
cellular components. To that end, S-nitrosylation of Bcl-2
negatively regulates autophagy; nitrosylation of Cys158 and
Cys229 stabilizes the interaction between Bcl-2 and Beclin1,
thereby inhibiting Beclin1 activity and as a result decreas-
ing autophagic flux (187). This effect is reversed on addition
of ABT-737, aminoguanidine (NO inhibitor), and a redox-
inactive Bcl-2 double-mutant (C158A/C299A). Interestingly,
these cysteine residues were previously shown to be prone to
H2O2-induced oxidation (109).
Furthermore, S-nitrosylation of Bcl-2 was previously dem-
onstrated to inhibit its ubiquitin-mediated proteasomal degra-
dation. This NO-mediated effect was independent of Ser87
phosphorylation and decreased cellular apoptosis (9). These
studies highlight the importance of NO-driven signaling and
Bcl-2 in the regulation of autophagic and apoptotic signal-
ing. NO has also been demonstrated to increase carbonylation
of Bcl-2 (19), and IL-1b-induced NO production increased
Bcl-2 carbonylation, which preceded its downregulation.
The downregulation of Bcl-2 coincided with an increase in
NO-mediated DNA fragmentation (19). This is contrary to
the previously mentioned studies where NO was associated
with resistance to apoptosis, suggesting that the regula-
tion of cell fate by NO is dependent on the precise post-
translational modification of Bcl-2.
Bcl-2 and peroxide eliminating enzymes. A study by
Gouaze et al. (58) demonstrated that glutathione peroxidase-1
(GPx1) overexpressing cells were resistant to CD95-induced
apoptosis. T47D cells overexpressing GPx1 exhibited lower
levels of ROS and Bcl-2. Similarly, Clement et al. (33)
showed that Bcl-2 overexpression blocked CD95-induced
cell death, which was restored on NOX inhibition or over-
expression of dominant-negative Rac1, decreasing overall
levels of O2
.-. To that end, Rac1 has also been demonstrated
to increase O2
.- and inhibit apoptosis in melanoma and
bladder carcinoma cells (143). Further studies provided evi-
dence for an interaction between Bcl-2 and Rac1 in leukemic
cells that increased intracellular O2
.-, thus creating a pro-
oxidant environment that favors cell survival and/or inhibits
apoptotic execution (178). Synthetic BH3 peptides and BH3
mimetics were able to block the interaction of Rac1 and Bcl-
2, decrease O2
.- production, and sensitize human leukemia
cells to chemotherapeutics. Previously, it was also demon-
strated that Rac1 was needed for the phosphorylation of Bcl-2
by the JNK/stress-activated protein kinase ( JNK/SAPKb)
p54-SAPKb (114).
Peroxiredoxins are functional antioxidant enzymes that
control intracellular peroxide levels. BCL2 mRNA expression
has been shown to exhibit a primarily negative correla-
tion with the five peroxiredoxins (PRDX1, PRDX3, PRDX4,
PRDX5, and PRDX6) in a wide range of primary tumor
samples. In lung cancer either a weak or negative correlation
is observed (Fig. 7). In A549 lung cancer cells with gefitinib
resistance (A549/GR), shRNA knockdown of PRDX2 resulted
12 POHL ET AL.
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in a decrease in Bcl-2 expression and concurrent increase in
peroxide levels in the cell, culminating in cell death (89). The
change in correlation in gefitinib-resistant cells can be hy-
pothesized to be directly due to JNK/ROS activation, both of
which were altered compared to the A549 cells. H2O2 also
protected cardiomyocytes from oxidative stress-induced apo-
ptosis, which was associated with an increase in Bcl-2. H2O2-
induced oxidative stress caused a decrease in the level of both
Prx2 and Bcl-2, showing a strong correlation between intra-
cellular peroxide levels and Bcl-2 expression (195). Bcl-2
expression has also been shown to be associated withmembers
of the thioredoxin family. The use of antisense BCL2 therapy
in neuroblastoma cells demonstrated that decreasing levels of
Bcl-2 were associated with increasing levels of thioredoxin.
This seems to be consistent across a range of tumors (Fig. 7)
and may involve a cellular compensatory mechanism when
cells are undergoing oxidative stress (99).
Redox-dependent regulation of Bcl-2 in viral infec-
tion. Intracellular regulation of cellular redox has been
shown to be an important factor in viral establishment, rep-
lication, and progression (11). A pro-oxidant environment
has been demonstrated during infection with influenza (64),
human immunodeficiency virus (HIV) (65), and hepatitis C
(57). Bcl-2 has been demonstrated to influence cellular redox
and alter viral replication in various settings. During influ-
enza A replication, cellular levels of GSH are decreased,
resulting in a pro-oxidant environment. Cells overexpressing
Bcl-2 exhibited higher levels of GSH and produced less virus
(126). Influenza A infection has also been shown to increase
ROS in an NOX-4-dependent manner (6). Mechanistically,
viral activation in Bcl-2+ cells induced p38MAPK-mediated
phosphorylation of Bcl-2 at Thr56 and Ser87, resulting in
cell death. siRNA-mediated knockdown of BCL2 resulted in
increased influenza A replication and viral ribonucleoprotein
(vRNP) export (125). In asymptomatic HIV-infected pa-
tients, H2O2 production was increased in monocytes with
parallel downregulation in thioredoxin and Bcl-2. These re-
ductions were suggested to be a result of significantly in-
creased oxidative stress (45). These studies highlight the
importance of redox regulation in altering Bcl-2-mediated
cell fate in viral infections. The role of Bcl-2 in viral infec-
tions and its interaction with viral proteins is comprehen-
sively reviewed by Alibek et al. (4) Redox in viral infections
have previously been reviewed elsewhere (101, 123, 168).
A brief overview of Bcl-2 inhibitors: past, present,
and future
As the discovery and development of Bcl-2 inhibitors have
been recently comprehensively reviewed (8, 98), this section
focuses primarily on molecules that have been or are cur-
rently under investigation through clinical trials (Fig. 9).
Oblimersen is an antisense oligonucleotide targeted to the
BCL2mRNA, thus preventing Bcl-2 protein expression (41).
It was the first molecule against Bcl-2 to be investigated
clinically. Oblimersen has been extensively investigated in
clinical trials in a wide variety of solid tumors and blood
cancers, and in combination with a wide variety of cancer
therapeutics, however, its use as a single agent or in combi-
nation have not been approved for any clinical indication
(51). The related molecule SPC2996 has also been investi-
gated in clinical trials, which failed to demonstrate effective
downregulation of Bcl-2 expression (42). Oblimersen was
demonstrated in PC3 cells to increase the oxidation of nuclear
DNA, measured by 8-hydroxy-2¢-deoxyguanosine staining,
FIG. 9. 2D structures of
small molecule Bcl-2 in-
hibitors. (A) ABT-737. (B)
Navitoclax (ABT-263). (C)
Venetoclax (ABT-199). (D)
Obatoclax. (E) Representative
molecule from the patent de-
scribing the production of
S55746-relatedmolecules. (F)
(-)-Gossypol (AT-101).
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suggesting that cell death was due to an ROS-dependent
mechanism (90).
ABT-737, which is generally regarded as the prototypical
small molecule Bcl-2 family protein inhibitor, was first re-
ported in 2005 (134). ABT-737 was discovered through a
SAR by NMR (structure-activity relationship by nuclear
magnetic resonance) approach, through which small organic
‘‘fragment’’ molecules (<200 Da) were assessed for weak/
moderate binding to Bcl-2 via NMR approaches (primarily
saturation transfer difference spectroscopy and heteronuclear
single quantum coherence spectroscopy), and subsequently
‘‘assembled’’ to generate molecules capable of tightly bind-
ing to Bcl-2. ABT-737 targets the hydrophobic peptide-
binding groove of Bcl-family proteins nonselectively. The
lack of oral bioavailability of ABT-737 has limited its clinical
development, instead prompting the development of alter-
natives. Hepatocellular carcinoma (HCC) cells with high
Bcl-2 expression demonstrated resistance to ABT-737 by
suppressing the ROS-JNK pathway. In HCC cells expressing
low levels of Bcl-2, apoptosis was induced after treatment
with ABT-737 through increased ROS levels and activation
of the ROS-JNK pathway (128). This study demonstrates that
high levels of Bcl-2 can determine the effectiveness of ABT-
737 in a ROS-dependent mechanism.
Navitoclax (ABT-263) is an orally bioavailable analog of
ABT-737 that has progressed to Phase II clinical trials. Na-
vitoclax features three modifications relative to ABT-737: (i)
replacement of the nitro group with a triflyl group; (ii) re-
placement of the dimethylamine with a morpholine group;
and (iii) replacement of the 4-chlorobiphenyl group with a
1-(4-chlorophenyl)-4,4-dimethyl-cyclohexene group (137).
These modifications enhance oral bioavailability relative to
ABT-737, while maintaining protein binding and cellular
efficacy. Navitoclax elicits thrombocytopenia as a result of
Bcl-xL inhibition (32, 158, 186), which limits its tolerated
dose and has delayed its clinical development; nonetheless,
trials involving navitoclax or combinations thereof are on-
going, largely against blood cancers.
Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective
inhibitor derived from navitoclax, currently approved for
the treatment of chronic lymphocytic leukemia. Venetoclax
features three modifications relative to navitoclax: (i) re-
placement of the triflyl group with a nitro group (as in ABT-
737); (ii) substitution of the para-aminobenzamide motif
with a 1H-pyrrolo[2,3-b]pyridine-5-yloxy group; (iii) re-
placement of the morpholine and thiophenol arms with a
methyl-tetrahydropyran group. Venetoclax retains the oral
bioavailability of navitoclax, but is over 100-fold more se-
lective for Bcl-2 over Bcl-xL, thus averting thrombocytope-
nia induced by navitoclax (167). Current clinical trials
involving venetoclax are largely focused on broadening
its application to include a wider variety of blood cancers,
and involve both therapeutic combinations and venetoclax
monotherapy (98).
Obatoclax (GX15-070) is a nonselective Bcl-2 family
protein inhibitor, initially identified for its ability to inhibit
Mcl-1 (127). Obatoclax features a comparatively simple
scaffold compared to ABT-737 and related molecules;
combined with its nonselectivity, this suggests that obatoclax
may only interact with part of the binding groove present
in Bcl-2 family proteins. Obatoclax has been evaluated for
childhood cancers (both blood cancers and solid tumors),
blood cancers in adults, and lung cancers in adults. Phase I
studies indicated that the drug was well tolerated in patients
with blood cancers (162), solid tumors (76), and exhibited
modest single-agent activity (130). Obatoclax has been dem-
onstrated to induce cell death in oral squamous cell carci-
noma cells through a mitochondrial-dependent oxidative
stress-induced mechanism (171). However, Phase II studies
have generally failed to demonstrate its clinical useful-
ness (59, 136, 163). Its further development was discontinued
in 2013.
S55746 (BCL-201, Servier-1) is an inhibitor developed by
Servier selective for Bcl-2, built on the previously reported
low-affinity, but highly Bcl-2-selective, phenylpyrazole
molecule series (149). Preliminary results from a clinical
trial of S55746 in patients with relapsed or refractory non-
Hodgkin lymphoma suggest that S55746 monotherapy is
safe, tolerable, and efficacious (92). Servier has previously
reported S44563, a dual Bcl-2/Bcl-xL inhibitor, an analog of
ABT-737 with conformational restriction on the phenylpi-
perazine region (124). Given this molecule’s high similar-
ity to ABT-737, it may also exhibit similarly poor oral
bioavailability, which may have prompted the identifica-
tion of alternative scaffolds and the ultimate development of
S55746.
(-)-Gossypol (AT-101), a terpenoid phenol derived from
the cotton plant, has been shown to act as a weak inhibitor of
Bcl-2 and Bcl-xL (133). In addition to acting as a BH3 mi-
metic, AT-101 also appears to impair DNA repair mediated
by APE1, a redox-active enzyme that is a known binding
partner for Bcl-2 (152, 155). Unlike ABT-737 and related
molecules, which directly prevent peptide binding to Bcl-2,
(-)-gossypol induces a conformational change in Bcl-2 from
an antiapoptotic to a proapoptotic state (96). (-)-Gossypol
was evaluated in combination with androgen deprivation
therapy for the treatment of castration-sensitive metastatic
prostate cancer in a Phase II clinical trial (169); the results
suggested this combination was not worth further develop-
ment. (-)-Gossypol has also been evaluated for the treatment
of progressive or recurrent glioblastoma multiforme; the
majority of patients (62.5%) exhibited disease progression in
the trial (72). (-)-Gossypol has been demonstrated to poten-
tiate cell death induced by temozolomide (180); a Phase I
clinical trial investigating this combination in the treatment
of glioblastoma multiforme has been completed, but results
are not currently available (23).
APG-1252 is a dual selective Bcl-2/Bcl-xL inhibitor cur-
rently under development by Ascentage Pharma Group.
Limited details of this molecule have been made publicly
available, however, as of this writing, recruitment is currently
underway for a clinical trial of APG-1252 in patients with
small-cell lung cancer and other solid tumors (70).
Perspective
It has been more than 30 years since the discovery of Bcl-2
and its association with drug resistance and aggressive he-
matopoietic malignancies. Over the years, the structural and
functional biology of this remarkable protein has been un-
raveled. These pursuits have resulted in the discovery of a
number of related proteins with opposing biological activities
and grouped under a broader family, the Bcl-2 family. It is
now well established that the balance between the pro- and
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antiapoptotic members of the family is critical in cell fate
decisions, which is a function of physical interactions be-
tween proteins from within and outside of the family. While
the canonical antiapoptotic activity of Bcl-2 is associated
with its ability to prevent MOMP by sequestering Bax and
Bak from oligomerizing at the mitochondria, recent evidence
also points to a redox-dependent regulation of cell fate by
Bcl-2, which appears to involve its post-translational modi-
fication. Furthermore, the altered gene expression and mu-
tational landscape in a host of human cancer, not limited to
hematopoietic malignancies, underscore the importance of
Bcl-2 as an important ‘‘pro-oncogenic’’ protein.
Based on its interacting domains, there has been a continu-
ous focus on developing small molecule inhibitors to overcome
chemotherapy resistance induced on Bcl-2 overexpression.
Bcl-2 expression has been used as a biomarker for patient re-
sponse to chemotherapy. Could we now extend this to patient
profiles of Bcl-2 expression in terms of ROS high and ROS
low, and would this have a stronger predictive power?
There is a large body of evidence that directly links Bcl-2
and cellular redox. Earlier observations suggested an anti-
oxidant role for Bcl-2, however, more recent work indicates
a remarkable dichotomy when it comes to Bcl-2 and its ef-
fects on cellular redox metabolism. These divergent effects
appear to be a function of cellular redox status itself. As such,
the effect might differ under states of normoxia, hypoxia,
and oxidative stress. To complicate matters further, the
same ROS can have seemingly opposite effects on the anti-
apoptotic activity of Bcl-2. H2O2 in one context can cause
degradation through oxidation of cysteines and promote cell
death, and on the other hand can cause increased stability and
promote cell survival. Similarly, the effect of an increase in
NO and its reaction product with O2
.-, OONO-, could be
associated with carbonylation or S-NO modification. Inter-
estingly, an altered redox milieu impacts post-translational
state of Bcl-2, such as its phosphorylation, which could have
different functional consequences depending on whether the
phosphorylation is multisite (inhibits its activity) or monosite
as with serine 70 (stabilizes its activity). Based on these
outcomes, it is imperative to clearly delineate the mecha-
nisms behind the opposing effects of an altered redox state on
Bcl-2 biology, particularly from the standpoint of its role in
promoting chemotherapy resistance in cancer. This is even
more important as many clinically approved drugs induce
increases in intracellular ROS, which could fuel the process
of carcinogenesis and its progression by promoting Bcl-2
stability.
A number of promising small molecules are being devel-
oped and are undergoing clinical evaluation, however, se-
lectivity remains a major issue. The early generation of Bcl-2
inhibitors, based on BH3 domain interaction, did not
show the level of stringency in terms of targeting the specific
antiapoptotic protein within the family. More recent ap-
proaches, such as in the case of venetoclax, appear to have
addressed this issue. One possible scenario still needs atten-
tion: the reciprocal upregulation of another antiapoptotic
member on specific inhibition of one. For example, is it
possible that specific inhibition of Bcl-2 might activate
the compensatory upregulation of Mcl-1 or Bcl-xL? Future
strategies could also leverage on the noncanonical function of
Bcl-2 in terms of regulating cellular redox status. In this re-
spect, one might envision the potential application of mo-
dalities that favorably tailor the cellular redox milieu for
death execution as well as overcome the inhibitory effect on
putative tumor suppressors, such as the phosphatase PP2A.
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Wnt signaling pathways are of significant interest in develop-
ment and oncogenesis. The first step in these pathways typically
involves the binding of a Wnt protein to the cysteine-rich
domain (CRD) of a Frizzled receptor.Wnt-Frizzled interactions
can be antagonized by secreted Frizzled-related proteins
(SFRPs),which also contain aFrizzled-likeCRD.The largenum-
ber of Wnts, Frizzleds, and SFRPs, as well as the hydrophobic
nature of Wnt, poses challenges to laboratory-based investiga-
tions of interactions involving Wnt. Here, utilizing structural
knowledge of a representativeWnt-FrizzledCRD interaction, as
well as experimentally determined binding affinities for a selec-
tion ofWnt-Frizzled CRD interactions, we generated homology
models of Wnt-Frizzled CRD interactions and developed a
quantitative structure-activity relationship for predicting their
binding affinities. The derivedmodel incorporates a small selec-
tion of terms derived from scoring functions used in protein-
protein docking, as well as an energetic term considering the
contributionmadeby the lipid ofWnt to theWnt-Frizzled bind-
ing affinity. Validationwith an external test set suggests that the
model can accurately predict binding affinity for 75% of cases
and that the error associated with the predictions is comparable
with the experimental error. The model was applied to predict
the binding affinities of the full range ofmouse andhumanWnt-
Frizzled and Wnt-SFRP interactions, indicating trends in Wnt
binding affinity for Frizzled and SFRP CRDs. The comprehen-
sive predictions made in this study provide the basis for labora-
tory-based studies of previously unexplored Wnt-Frizzled and
Wnt-SFRP interactions, which, in turn, may reveal furtherWnt
signaling pathways.
The Wnt signaling pathway is an evolutionarily conserved
pathway found in vertebrates and insects (1). It functions to
regulate body axis formation, cell fate, cell proliferation, and
morphogenesis in embryonic development (2), whereas aber-
rant Wnt signaling is a hallmark of many cancers (3). Wnt sig-
naling pathways can be divided into three separate branches: a
canonical or !-catenin-dependent pathway and two non-ca-
nonical or !-catenin-independent pathways, known as the pla-
nar cell polarity (PCP)4 andWnt/Ca2! pathways (4, 5) (see Fig.
1). Wnt signaling is generally initiated by the binding of Wnt
ligands to a Frizzled (Fzd) receptor (6). In the canonical Wnt
signaling pathway (Fig. 1a), low-density lipoprotein-related
protein 5/6 (LRP5/6) acts as a co-receptor for Wnt binding (7).
Signal transduction by the threemajorWnt signaling pathways
is regulated by the interaction of Fzd with the cytoplasmic pro-
tein Dishevelled (Dvl) (8). In the canonical pathway, !-catenin-
dependent signaling is mediated through the cytoplasmic
“destruction complex” composed of Axin, protein phosphatase
2A, adenomatous polyposis coli protein, glycogen synthase
kinase 3 (GSK3), and casein kinase 1" (CK1") (9). In the pres-
ence ofWnt stimulation, Fzd is activated, permitting Dvl bind-
ing and resulting in the stabilization of the destruction complex
and the accumulation of non-phosphorylated !-catenin,
which then translocates to the nucleus and binds to T cell fac-
tor/lymphoid enhancer-binding factor transcription factors on
the promoter of target genes (4). In the absence of Wnt stimu-
lation, the destruction complex is destabilized, allowing for
thephosphorylationof!-cateninbyCK1"andGSK3(10);phos-
phorylated !-catenin is then proteolytically degraded (11). The
Wnt/Ca2! pathway (Fig. 1b) is activated through Wnt ligands
binding to Fzd receptors, resulting in an increase in intracellu-
lar calcium (12). Calcium ions are able to activate both cal-
modulin-dependent protein kinase II (13) and protein kinase C
(PKC) (14), which subsequently activate transcription factors
NF#B and cAMP-response element-binding protein. The cyto-
solic phosphatase calcineurin (Cn) is also activated by calcium
ions. Cn-dependent dephosphorylation and activation of
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nuclear factor of activated T cells lead to the transcription of
genes in cardiomyocytes, neuronal cells, and skeletal muscle
(15). Signal transduction via the PCP pathway (Fig. 1c) is initi-
ated through Wnt binding to Fzd and co-receptors ROR and
Ryk. Fzd activation leads to Dvl-mediated activation of Rac and
Rho. JNK and Rho-associated protein kinase (ROCK) are acti-
vated by Rac and Rho, respectively, which mediates actin poly-
merization and activates transcription factors AP-1 and JUN
(16).
Wnts comprise a group of 19 proteins that are subject to
numerous post-translational modifications, including the for-
mation of a large number of characteristic disulfide bonds, gly-
cosylation in the endoplasmic reticulum (17), and palmitoyla-
tion by Porcupine, which aids in their secretion and facilitates
their interaction with Frizzled (18). Structurally, as determined
by the co-crystallization of Xenopus Wnt8 (XWnt8) with the
mouse Fzd8 CRD, Wnts are composed of two domains: an
N-terminal domain and a C-terminal domain (19). The N-ter-
minal domain contains 10 cysteine residues forming five disul-
fide bridges in a cluster of "-helices, whereas the C-terminal
domain contains six disulfide bridges and a two-stranded
!-sheet (19). Frizzled receptors are a group of 10 membrane-
bound receptors comprising themajority of Class F G protein–
coupled receptors (GPCRs). Frizzleds, like other GPCRs, con-
sist of seven hydrophobic transmembrane helices but feature
an extracellular cysteine-rich domain (CRD) in their N termi-
nus (20). The CRD is characterized by a conserved pattern of 10
cysteines and can bind Wnt and Norrin ligands (21, 22). The
five mammalian secreted Frizzled-related proteins (SFRPs) are
secreted glycoproteins composed of an N-terminal CRD and a
C-terminal netrin-like domain (23). These proteins function to
antagonize the Wnt signaling pathway (24) through binding of
either the CRD (25) or the netrin-like domain to Wnt ligands
(26), thus interfering with Wnt binding to Fzd and preventing
!-catenin-mediated gene transcription. The SFRPs have been
studied in great detail for their potential roles as tumor suppres-
sors and their implications in carcinogenesis (23).
Because of the large number of possibleWnt-Fzd CRD inter-
actions (which, considering CRDs from both Fzds and SFRPs,
totals 285 interactions per species), it is challenging to investi-
gate these experimentally. A recent study utilized biolayer
interferometry (BLI) to investigate a small set of mouse Wnt-
Fzd CRD interactions in a combinatorial manner (27). Numer-
ous other interactions have been identified via co-immunopre-
cipitation (coIP) or proposed based on co-expression of
particular Wnts with particular Fzds (6). Although coIP and
co-expression are valuable methods for suggesting the exist-
ence of specific protein-protein interactions, they are unable to
provide an indication of the likely strength of an interaction.
Computational studies provide the opportunity to complete
the knowledge of interactions betweenWnts andFzdCRDs and
may reveal previously unexplored high-affinity interactions.
In this study, we have generated homology models of Wnt
complexes with both Fzd and SFRPCRDs and predict the likely
binding affinity associated with these interactions. For a series
of Wnt-Fzd CRD interactions for which dissociation constants
have been reported (27), we then evaluated the interaction
energy for the protein-protein and lipid-protein components of
the interactions; this was achieved through scoring the interac-
tions against the full set of functions contained in CCharPPI
(28) (for the protein-protein component) and scoring using
Prime MM-GB/SA (for the lipid-protein component). Strike
was then used to develop and evaluate binding affinity predic-
tion models using scores obtained from CCharPPI and Prime
MM-GB/SA as descriptors for the model building. A model
with high predictive performance was identified and subse-
quently applied to predict the binding affinities of all Wnt-Fzd
and Wnt-SFRP CRD interactions in both mouse and human
cases.
Figure 1. Wnt signaling pathways. A, canonical Wnt signaling. Wnt binding to Fzd CRD initiates the destabilization of the cytoplasmic destruction complex
(adenomatouspolyposis coli protein (APC), Axin, GSK3, CK1, andDvl). This allows cytosolic!-catenin (!-cat) accumulation and subsequent translocation to the
nucleus where it binds to T cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factors to transcribeWnt target genes. SFRPs antagonize this
cascade, and!-catenin is polyubiquitinated by!-transducin repeats-containing protein (!-TrCP) and degraded by proteolysis. B, theWnt/Ca2! pathway.Wnt
binding to Fzd CRD or Ryk co-receptor activates Dvl, which stimulates calcium release. Downstream effectors PKC, calmodulin-dependent protein kinase II
(CaMKII), and Cn activate transcription factors cAMP-response element-binding protein (CREB), NF-#B, and nuclear factor of activated T cells (NFAT). C, the PCP
pathway. Wnt stimulation is effected initially through Fzd-Dvl interaction and co-receptors ROR/Ryk and passed through multiple effectors (Rac, phospho-
lipase C (PLC), Disheveled-associated activator of morphogenesis (DAAM)) downstream to ROCK and JNK. ROCK regulates the actin cytoskeleton, and JNK
activates AP1 and JUN transcription factors to regulate cell polarity and migration.
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Results
Preparation of homologymodels ofWnt-Fzd CRD complexes
We prepared homology models of all mouse and human
Wnts and all mouse and human Fzd and SFRP CRDs; details of
UniProt accession numbers, sequence ranges, and sequence
alignments used to build the models are provided in supple-
mental Table S1 and Figs. S2 and S3. The vast majority of pro-
teins modeled did not feature large insertions or deletions rel-
ative to either XWnt8 or mFzd8 CRD with the exceptions of
mouse and human Wnt6, Wnt10a, and Wnt10b; these Wnts
feature insertions relative to XWnt8 larger than that able to be
built by Prime (greater than 20 residues). To build these struc-
tures, we utilized an alternative procedure incorporating the
I-TASSER server (described in detail under “Experimental pro-
cedures”), which is capable of building much longer insertions
than Prime through its use of an iterative template fragment
assembly approach to model building (29).
Following assembly of the complexes and refinement using a
procedure automated using KNIME (supplemental Fig. S4), the
MolProbity score of all models was calculated. TheMolProbity
score provides a single value metric of structural quality, sum-
marizing the number of atomic clashes, percentage of backbone
conformations in regions outside the Ramachandran favored
regions, and the percentage of bad side-chain rotamers (30).
The TM-score and the root-mean-squared deviation (RMSD)
of the C" atoms of the models with respect to the XWnt8-
mFzd8 CRD complex structure (Protein Data Bank code 4F0A)
(19), which was the template for all models, were also calcu-
lated. These measures assess differences in the coordinates of
two structures (31). The mean value for the MolProbity scores
for the mouse and human models was slightly greater than the
MolProbity score obtained for the XWnt8-mFzd8 CRD com-
plex structure (Table 1) but nonetheless comparable, indicating
the generally high quality of the models. The mean values for
themodelTM-scoreswith respect to the template crystal struc-
ture were generally high, and themean values for themodel C"
RMSD values very low, further indicating the generally high
quality of the models and their limited divergence from the
template crystal structure. Selected complexes are shown in
Fig. 2. Quality metrics are summarized in Table 1, and full
details are provided in supplemental Tables S5–S10.
Development and validation of aWnt-Fzd CRD binding
affinity predictionmodel
We used a set of mouse Wnt-Fzd CRD binding affinities
determined by BLI (27) to develop and validate our binding
affinity prediction model. The model building and evaluation
procedure is summarized in Fig. 3 and herein described.
Within the BLI data, we designated a training set, used to
optimize the model, and a test set, used to demonstrate the
performance of themodel for data againstwhich it hadnot been
trained.Our training set was designated as complexes that were
not part of our test set; our test set consisted of complexes
involving interactions with either mFzd1 or mWnt4. The defi-
nition of the test set in this manner provided a simple means of
selecting a test set covering a wide range of affinities. For all of
these complexes, we then rescored, with separate procedures,
the protein-protein portion and the lipid-protein portion of the
interaction. The protein-protein portion was rescored against
the majority of functions available within CCharPPI (28)
(listed in supplemental Table S11), a server compiling a wide
range of scoring functions suitable for use in protein-protein
docking. The lipid-protein portion was rescored used Prime
MM-GB/SA, which provides a rapid means for evaluating
ligand-receptor binding energies with improved accuracy com-
pared with typical docking scoring functions. The Prime MM-
GB/SA calculation is also decomposed into its components
(Coulomb/electrostatic, covalent binding, van der Waals, lipo-
philic, polar solvation/desolvation, hydrogen bonding, and$-$
components; components used in this study listed in supple-
mental Table S11). The two strategies function complementa-
rily to one another; the functions in CCharPPI are only capable
of considering interactions between standard protein amino
Table 1
Summary of model quality metrics
XWnt8-mFzd8
CRD complex
Mouse
modelsa
Human
modelsa
MolProbity score 1.72 2.13" 0.46 2.08" 0.42
TM-scoreb 1.00 0.91" 0.04 0.91" 0.05
C" RMSD (Å)b 0.00 1.39" 0.39 1.39" 0.45
aMean values"2 S.D. shown; data for individual complexes shown in supplemen-
tal Tables S5–S10.
b TM-score and C" RMSD values calculated with respect to the XWnt8-mFzd8
CRD complex (Protein Data Bank code 4F0A). By definition, the TM-score for
an optimally overlaid structure compared with itself is 1; the RMSD for an opti-
mally overlaid structure compared with itself is 0.
Figure2.Homologymodelsof selectedWnt-FzdCRDcomplexesoverlaid
to the repaired XWnt8-mFzd8 CRD crystal structure (Protein Data Bank
code 4F0A). Gray, repaired Protein Data Bank code 4F0A; pink, mWnt5-
mFzd1 CRD complex; yellow, mWnt10a-mFzd6 complex; green, hWnt3a-hS-
FRP4 CRD complex; cyan, hWnt2b-hFzd9 CRD complex. Lipid is shown in all
structure as stickswith transparent spheres.
Wnt-Fzd CRD binding affinity prediction
11220 J. Biol. Chem. (2017) 292(27) 11218–11229
 at CURTIN UNIV OF TECHNOLOGY (CAUL) on July 10, 2017
http://www.jbc.org/
Downloaded from 
acids, whereas Prime MM-GB/SA is capable of studying inter-
actions between small organic molecules with proteins. With
this in mind, the Wnt lipid was removed from the CCharPPI
calculations, and theWnt protein was removed from the Prime
MM-GB/SA calculations (that is, only the interaction between
theWnt lipid and the FzdCRDwas assessed by PrimeMM-GB/
SA). Multiple linear regression models combining one Prime
MM-GB/SA component with one or more CCharPPI compo-
nents (all herein referred to as descriptors) were then generated,
thus allowing the development of a single model considering
both the protein-lipid and the protein-protein portions of the
interaction.
As it was computationally accessible to consider all possible
three-descriptor models incorporating one Prime MM-GB/SA
term and two CCharPPI-derived terms, we initially explored
these. The performance of all models was evaluated using two
principal metrics: 1) the root-mean-squared error (RMSE)
between the predicted values and the average experimental val-
ues (RMSEtrain and RMSEtest); lower values indicate a better fit
between the predictions and experimental values; and 2) the
percentage of complexes for which the predicted value
occurred within the experimental range reported (InExptrain
and InExptest); higher values indicate a better fit between the
predictions and experimental values.
High-performing three-descriptor models of Wnt-Fzd CRD
binding typically incorporated the van der Waals term of the
Prime MM-GB/SA calculation (supplemental Table S12). The
lipophilic term of the Prime MM-GB/SA calculation also
appears frequently in high-performing models. This is unsur-
prising considering the physicochemical properties of palmito-
leic acid, whichwould suggest that the binding energywill likely
be associated with van der Waals/non-polar interactions. The
best performing three-descriptor models generally displayed
RMSEs for both the training and test sets in the range of 0.3–0.4
kcal/mol, which is well outside the error range of the experi-
ments of #0.2–0.3 kcal/mol (27); this indicates that three-de-
scriptor models are insufficiently predictive.
Twomodels containing four descriptors were identified that
were capable of high-prediction performance (Table 2). Both of
these displayed RMSEs for the training and test sets less than
0.3 kcal/mol. Both included the van der Waals term of the
Prime MM-GB/SA calculation, the PyRosetta hydrogen bond-
ing potential (HBOND2) (32), and either the RW or RWplus
statistical potentials (AP_calRW and AP_calRWp) (33). The
fourth term inModel 1 is the antibody-antigen energy function
of FireDock (FIREDOCK_AB) (34), whereas inModel 2, it is the
total RosettaDock weighted energy (ROSETTADOCK). As the
performance of Model 1 appeared slightly improved over
Model 2, this model was selected for further study. Addition-
ally,Model 1 was preferred overModel 2 for featuring a smaller
constant term, suggesting that it may be able to predict affini-
ties over a wider range than Model 2. The RMSE values for
Model 1 suggest that the error associated with its use will be
slightly larger than, but nonetheless similar to, the error range
achieved by experiment.
The maximum difference between any prediction made by
the model, either in the training set or the test set, is #0.6
kcal/mol, which corresponds to a difference in Kd of approxi-
mately an order of magnitude (Fig. 4 and Table 3). Because
there appears to be no particular Wnts or Fzds for which poor
Figure 3. Overview of themodel building process. RMSE and InExp cutoffs used to select models at the relevant stages of model building are described in
the Experimental Procedures.
Table 2
Best performing four-descriptor models predictingWnt-Fzd CRD binding energy
Number Model RMSEtrain RMSEtest InExptrain InExptest
kcal/mol kcal/mol % %
1 $G% 0.0038165& AP_calRW' 0.22506&MMGBSA dG Bind vdW'
0.24626&HBOND2' 0.049875& FIREDOCK_AB' 3.3475
0.23 0.27 80 75
2 $G% 0.0021829& AP_calRWp' 0.22111&MMGBSA dG Bind vdW'
0.20861&HBOND2' 0.08699& ROSETTADOCK' 7.7974
0.30 0.23 73 75
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predictions aremade, failure tomake accurate predictionsmost
likely occurs randomly and is not associated with a particular
Wnt or Fzd structure; this is perhaps expected given the overall
high structural quality of the models used. The binding affini-
ties of the vast majority of cases in the training and test sets are
predictedwithin 0.25 kcal/mol of themean experimental values
reported, which is within the experimental error range.
Further elaboration of the selected four-descriptor models
into five-descriptor models was performed but did not result in
models providing significant improvements in predictions
(data not shown); similar RMSEs and a similar number of pre-
dictions occurring within the experimental ranges in both the
training and test sets were obtained for the best four- and five-
descriptor models. Thus, four-descriptor models were deemed
sufficient for use in predicting binding affinities.
Prediction of binding affinities ofWnt-CRD interactions
In applyingModel 1 to predictWnt-CRDbinding affinities in
themouse proteins, numerous trends are apparent (Fig. 5A and
supplemental Table S13). Fzd3, Fzd5, SFRP3, and SFRP4 gen-
erally display high-affinity, nonspecific binding ofWnts, as evi-
denced bymore than half of the interactions predicted to afford
strong binding affinities (i.e. (10 nM). Fzd8 also displays non-
specific binding of Wnts; however, the majority of interactions
are predicted to be of lower affinity than those with Fzd3, Fzd5,
SFRP3, and SFRP4. Fzd1, Fzd4, Fzd7, andFzd9 generally display
moderate affinity for a wide variety of Wnts. Fzd1, Fzd7, and
Fzd9 display high affinity for limited Wnts, indicating more
selective binding compared with Fzd3, Fzd5, Fzd8, SFRP3, and
SFRP4, whereas Fzd4 displays high affinity for several Wnts,
indicating less selective binding. Fzd1 displays high affinity for
Wnt6, Fzd7 displays high affinity forWnt10a, and Fzd9 displays
high affinity for both Wnt7a and Wnt16. Fzd2, Fzd6, Fzd10,
SFRP1, SFRP2, and SFRP5 all displaymoderate- to high-affinity
binding to less than half of the Wnts. However, this does not
strictly translate to high selectivity; Fzd6 and Fzd10 bind with
moderate affinity to several Wnts. Fzd2 displays high affinity
for Wnt3a, Wnt7b, andWnt10a. SFRP1, SFRP2, and SFRP5 all
display high selectivity for specificWnt ligands but retainmod-
erate affinity for the majority of remaining Wnts. SFRP1
appears highly selective for Wnt7a, whereas SFRP2 is selective
for Wnt2b and Wnt3a. SFRP5 displays moderate affinity for
Wnt2b, Wnt5b, and Wnt6.
The human data generally display trends similar to the
mouse data (Fig. 5B and supplemental Table S14). Fzd3, Fzd5,
SFRP3, and SFRP4 still display generally high-affinity, nonspe-
cific binding ofWnts; however, there are some specific points of
difference. The interactions of human Fzd3 with Wnt8a and
Wnt9a are predicted to bemuch higher affinity than in the case
of the mouse, although the hFzd9-hWnt9a interaction is still
predicted to be of only moderate affinity. Conversely, the inter-
Figure 4. Comparison of binding energy predictions by Model 1 in the
training set (A) and test set (B). Points indicated by open squares are those
where the predicted binding energy falls outside themodel RMSE (0.23 kcal/
mol for the training set; 0.27 kcal/mol for the test set).
Table 3
Comparison of predictions by Model 1 with experimental data for the training and test sets
Interaction !GExpa !GPreda ! GExp' $GPred!a,b
Experimental
Kdc
Predicted
Kdc
Experimental range
(predicted range)d Set
mWnt3a-mFzd2 '10.64 '11.16 0.52 15.7 6.5 !!! (!!!!) Training
mWnt3a-mFzd4 '11.27 '11.21 0.06 5.4 6.0 !!!! (!!!!) Training
mWnt3a-mFzd5 '11.60 '11.65 0.05 3.1 2.9 !!!! (!!!!) Training
mWnt3a-mFzd7 '11.28 '10.85 0.43 5.3 11.0 !!!! (!!!) Training
mWnt3a-mFzd8 '12.03 '11.86 0.17 1.5 2.0 !!!! (!!!!) Training
mWnt5-mFzd2 '10.38 '10.33 0.05 24.4 26.5 !!! (!!!) Training
mWnt5-mFzd4 '10.38 '10.26 0.12 24.4 29.9 !!! (!!!) Training
mWnt5-mFzd5 '11.31 '11.19 0.12 5.1 6.2 !!!! (!!!!) Training
mWnt5-mFzd7 '10.05 '9.98 0.07 42.6 47.9 !! (!!) Training
mWnt5-mFzd8 '11.45 '11.43 0.02 4.0 4.1 !!!! (!!!!) Training
mWnt5b-mFzd2 '9.60 '9.47 0.13 91.0 113.4 !! (!) Training
mWnt5b-mFzd4 '9.95 '10.29 0.34 50.4 28.4 !! (!!!) Training
mWnt5b-mFzd5 '10.44 '10.35 0.09 22.0 25.7 !!! (!!!) Training
mWnt5b-mFzd7 '9.65 '9.89 0.24 83.7 55.8 !! (!!) Training
mWnt5b-mFzd8 '11.04 '11.19 0.15 8.0 6.2 !!!! (!!!!) Training
mWnt3a-mFzd1 '10.66 '10.61 0.05 15.2 16.5 !!!! (!!!!) Test
mWnt4-mFzd2 '9.53 '9.53 0.00 102.5 102.5 ! (!) Test
mWnt4-mFzd4 '10.04 '9.72 0.32 43.3 74.3 !! (!!) Test
mWnt4-mFzd5 '10.68 '11.25 0.57 14.7 5.6 !!! (!!!!) Test
mWnt4-mFzd7 '9.58 '9.83 0.25 94.2 61.7 ! (!) Test
mWnt4-mFzd8 '10.95 '10.70 0.25 9.3 14.2 !!!! (!!!) Test
mWnt5-mFzd1 '10.33 '10.31 0.02 26.5 27.4 !!! (!!!) Test
mWnt5b-mFzd1 '9.60 '9.85 0.25 91.0 59.7 ! (!) Test
a $Gexp calculated from experimental Kd values as $G% RT ln Kd where R is the gas constant (1.987& 10'3 kcal K'1 mol'1) and T is the temperature at standard condi-
tions (298 K). Predicted $G ($Gpred) calculated according to Model 1. $G values expressed as kcal/mol.
b Absolute value of difference between experimental and predicted $G values.
c Kd values were obtained from Dijksterhuis et al. (27) and represent the average values reported. All Kd values expressed in nM.
d Guide to affinity range classifications:(10 nM,!!!!; 10–40 nM,!!!; 40–100 nM,!!; 100–400 nM,!;)400 nM,'. Cases in which the experimental and predicted
Kd values occur in different ranges are underlined. Range in which value of experimental Kd occurs shown outside parentheses; range in which predicted Kd value occurs
shown inside parentheses.
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action of human Fzd3 with Wnt5b is predicted to be of much
lower affinity than the equivalent mouse interaction. The affin-
ity of the mouse Wnt2 for SFRP3 and SFRP4 is predicted to be
lower than the equivalent interactions in humans; however,
Wnt9a is predicted to have increased affinity for these proteins
in mouse compared with human. Significant differences in the
predicted affinities of human Fzd4 for Wnt1, Wnt5a, and
Wnt11 compared with the mouse interactions are observed; all
of these interactions are predicted to be very low in binding
affinity in humans, whereas inmice these are all predicted to be
very high affinity. Large differences in the predicted affinities
occur when comparing the interactions of mouse and human
Fzd6, Fzd10, SFRP1, SFRP2, and SFRP5 (Fig. 5C); however,
these interactions are generally predicted to be of low to mod-
erate affinity and may not be indicative of different roles for
Wnt interactions with these proteins in the two species.
Analysis of residues of functional importance toWnt-Fzd CRD
interactions
To propose residues of functional importance to Wnt-Fzd
interactions, all 570 Wnt-Fzd CRD models were subject to
MM-GB/SA analysis with per-residue decomposition using
AMBER14 (35). This calculation allows the identification of
specific residues making large contributions to the binding
energy, which, in turn, can be used to suggest the most signifi-
cant intermolecular contacts in the interaction. High-affinity
complexes will generally have more residues making large con-
tributions to the binding energy compared with low-affinity
complexes; thus, high-affinity complexes will have greater
influence on the designation of sequence positions of general
importance to Wnt-Fzd CRD interactions.
Analysis of Fzd CRD-binding regions of Wnt indicates two
major regions utilized by Wnt in binding Fzd CRDs (Fig. 6A).
These correspond to the thumb and index finger regions of
Wnt, which are already well known as Fzd CRD-binding
regions (19, 36). Interestingly, Wnt residues beyond these two
regions are rarely implicated in Fzd CRD binding (supplemen-
tal Fig. S15), and the majority of Wnt residues in these regions
frequently implicated in Fzd CRD binding are highly (often
entirely) conserved in human and mouse Wnts.
In contrast to the Fzd CRD-binding regions of Wnt, which
appear highly conserved and occupy relatively small sections of
the Wnt sequence, the Wnt-binding regions of Fzd CRDs are
distributed across several segments of the CRDs and often
incorporate poorly conserved residues. Four sequences in the
Fzd CRDs can be defined (Fig. 6A), two of which interact with
theWnt thumb region and two of which interact with theWnt
index finger region, with several additional residues of impor-
tance identified in specific cases (supplemental Fig. S16).
Highly conserved Fzd CRD residues frequently implicated in
Wnt binding are generally associated with lipid binding: the
FXP motif, which frequently occurs within a helix forming one
side of the lipid-binding site of the Fzd CRD, and the phenyla-
lanine of an FXWmotif in the latter part of the sequence both
interact directly with theWnt lipid (Fig. 6B). Hydrophobic res-
idues adjacent to the final cysteine in the Fzd CRD are fre-
quently implicated in binding the Wnt index finger, as are
hydrophobic residues adjacent to the fourth cysteine of the Fzd
CRD. However, the involvement of particular Fzd CRD resi-
dues in binding is often highly influenced by sequence varia-
tion, even for positions frequently implicated in Wnt binding.
The greatest deviations in the utilization of Wnt-binding resi-
dues with respect to the set of Fzd CRDs occur in Fzd3, Fzd6,
SFRP3, and SFRP4. The region corresponding to the FXPmotif
in SFRP4 occurs as YEE; the tyrosine and glutamate residues in
this sequence are never implicated as strong contributors to
Figure 5. Binding affinity predictions by Model 1 for Wnt-Fzd interac-
tions. A, mouse interactions. B, human interactions. C, binding affinity differ-
ences ($Kd) between equivalent Wnt-Fzd interactions of mouse and human
calculatedas$Kd%mouseKd'humanKd. Positive$Kd is indicativeof a lower
affinity interaction inmouse comparedwith human; negative$Kd indicates a
higher affinity interaction in mouse compared with human.
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binding any Wnt. In SFRP3, the phenylalanine of the motif is
retained, but the proline is replaced by glycine; the phenylala-
nine is strongly implicated in binding to all Wnts, whereas this
is never the case for glycine. The glutamates of a motif fre-
quently occurring as EAGLE are often implicated in Fzd CRD
binding toWnt. In Fzd3 and Fzd6, the residue corresponding to
the first glutamate is never strongly implicated in binding to any
Wnt; this is replaced by a threonine in Fzd3 and an isoleucine in
Fzd6. Substitution of this residue with aspartate (as occurs in
several Fzds and SFRPs) or glutamine (as occurs in SFRP3 and
SFRP4) does not appear to greatly influence the frequency
with which this residue is involved in Wnt binding. Similarly,
replacement of the second glutamate in the motif with alanine,
as occurs in Fzd3, SFRP3, and SFRP4, eliminates the impor-
tance of this position to Wnt binding, whereas retaining it as a
glutamate (as in Fzd6 and other Fzds and SFRPs), aspartate, or
even glutamine does not seem to affect the frequency of its
importance to binding.
Discussion
In this study, we have developed a model for predicting the
binding affinity of Wnt-Fzd interactions. Although the model
was developed against a relatively small set of data from a single
study, there is nonetheless excellent agreement between affin-
ities predicted in the current study and those experimentally
determined in other studies that were not included in model
building and testing here. The binding affinity ofWnt3a for the
mouse SFRP3was determined by surface plasmon resonance to
be 7.9 nM (37); our model predicts this interaction to be at 0.28
nM, suggesting strong binding affinity. Binding affinities of
Wnt3a, Wnt7a, Fzd10, and SFRP4 measured using ELISA (38)
confirm our model’s prediction that the Fzd5-Wnt3a interac-
tion was stronger than that of Fzd10-Wnt7a and Wnt7a-
SFRP4. However, direct comparisons of Kd values predicted by
our model and those determined by ELISA are challenging as
our model has been optimized against BLI data, where a direct
interaction ismeasured,whereas ELISA is a coupled assay; thus,
Kd values obtained fromBLI are likely to indicate higher affinity
than those obtained from ELISA.
As experimentally determined binding affinities of Wnt-Fzd
CRD interactions are largely limited to those included in our
training and test sets, it is also pertinent to investigate whether
interactions demonstrated experimentally through coIP were
predicted by our model to have strong binding affinities.
mFzd4-mWnt2b (39), hFzd4-hWnt2 (40), mFzd4-mWnt7b
(41), mFzd6-Wnt4 (42), and hWnt3a-hSFRP4 (43), which were
shown by coIP to interact, are predicted by our model to bind
with an affinity in the intermediate or tighter range ((40 nM).
However, the interaction of SFRP1withWnt5a, which has been
demonstrated by coIP (44), is suggested by ourmodel to bind in
the low micromolar range. Although this would be within the
range detectable by coIP and is indeed a typical range for other
interactions of biological relevance, particularly protein-carbo-
hydrate interactions (45), binding affinities of functionally rel-
evant Wnt-Fzd CRD interactions generally appear to occur in
the low-to-mid nanomolar range, as evidenced in the data upon
which we have based our prediction model. Therefore, it is
likely that the affinity of the SFRP1-Wnt5a interaction is dras-
tically underestimated by the model.
Despite the failure of the model in selected cases to achieve
accurate predictions, the model nonetheless performs remark-
ably well at predicting binding affinities and likely interactors,
particularly when considering that the Wnt-Fzd CRD interac-
tion is rather complex due to involvement of both protein-pro-
tein and protein-lipid interactions at different sites. This would
further suggest its usefulness in predicting the effect of Wnt/
Fzdmutations to residues involved in either of the binding sites.
The predictive success of the model is likely attributable to two
main factors. The first is the use of a test set of cases separated
from the training set to validate the model, which is not always
performed in developing quantitative structure-activity rela-
tionships; evenmore remarkably, the use of an external data set
for model validation appears to be a matter of some debate in
the quantitative structure-activity relationship literature (46).
Figure 6. Residues making significant contributions to the binding
energy in the majority of Wnt-Fzd CRD complexes. A, logo analyses of
Wnts (first row) and Fzd CRDs (second two rows) highlighting the major
regions involved in interactions. Fzd sequences interacting with a specific
region of Wnt are shown below the sequence of Wnt corresponding to
that region. Green, aromatic residues (Trp, Phe, His, and Tyr); gray, aliphatic
residues (Val, Leu, Ile, Met, and Ala); blue, basic residues (Arg and Lys); red,
acidic residues (Asp andGlu); yellow, cysteine; light blue, palmitoleoylserine (A
only); black, all other residues (Gly, Pro, Ser, Thr, Gln, and Asn). Logos are
presented as frequency plots. Intensity of purple shading indicates the num-
ber of complexes in which the residue at that position is a significant contrib-
utor to the complex binding energy. B and C, cross-eyed stereoviews of the
“front” (B) and “rear” (C) of the XWnt8-mFzd8 crystal structure complex (Pro-
tein Data Bank code 4F0A) with major interacting regions highlighted. Resi-
dues corresponding to positions frequently involved in interactions across
the full set of Wnt-Fzd CRD complexes are shown as sticks. Regions are col-
ored according to the caption color in panel A. The front view displays the
regions of themiddle row of panel A; the rear view displays the regions of the
bottom row of panel A.
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The second is the incorporation of a term in the model specif-
ically considering the contribution to bindingmade by the lipid.
The direct involvement of Wnt lipidation in facilitating the
Wnt-Fzd interaction is likely unusual among protein-protein
interactions; lipidation typically appears to influence the solu-
bility and localization of proteins, rather than directly facilitate
protein-protein interactions (47). However, other post-transla-
tionalmodificationofproteins, suchasglycosylation,phosphor-
ylation, and methylation, are very common and are often
involved in facilitating protein folding and mediating protein-
protein interactions (48–50). Because post-translational mod-
ifications such as these are generally not accommodated
in protein-protein docking and scoring, the strategy demon-
strated here is one that could be adapted to facilitate their inclu-
sion in protein-protein docking and scoring.
This study has revealed trends with regard to the selectivity
and promiscuity of Wnt ligands for Fzd CRDs. The study par-
ticularly highlights the promiscuous nature of SFRP4, a Wnt
antagonist of interest to our group (51–56). SFRP3 is predicted
to display similarly low selectivity for Wnt ligands, whereas
SFRP1, SFRP2, and SFRP5 are predicted to displaymuch higher
selectivity. The various levels of selectivity are likely to be due to
the evolutionary development of tissue expression patterns of
Wnt ligands and Fzd receptors, where SFRPs can partially limit
aberrant Wnt signaling for controlled tissue development (57).
This study has focused on the interactions of Wnt proteins
with the Frizzled-type cysteine-rich domains of the Fzd recep-
tors and the secreted Frizzled-related proteins.However, a vari-
ety of other proteins also contain Frizzled-typeCRDs, albeit less
closely sequence-related to those of the Fzds and SFRPs. These
include Smoothened, atrial natriuretic peptide-converting
enzyme (CORIN), the tyrosine protein kinase transmembrane
receptors ROR1 and ROR2, the skeletal muscle receptor tyro-
sine protein kinase (MuSK, for which a structure of the Fzd
CRD has been experimentally solved (58)), the collagen XVIII
"-1 chain, carboxypeptidase Z, and the membrane Frizzled-
related protein. With the exception of the RORs (59–62), it is
unknown whether any Wnt binds to these proteins and, if so,
whether such an interaction is functionally relevant in the con-
text of Wnt signaling. The approaches utilized in the current
study could be applied to investigate the binding ofWnts to the
Frizzled-type CRDs of these proteins, which in turn could stim-
ulate further research into alternativeWnt signaling pathways.
It is important to note that a high-affinity interaction
between a given Wnt and a given CRD does not necessarily
translate into a signal transduction event. Wnt signaling
involves several additional proteins both extracellularly and
intracellularly. For example, in canonical Wnt signaling, Wnt
binds to a Fzd CRD as well as the co-receptor LRP5/6 (63); on
the intracellular side, this likely causes a conformational change
in Fzd, resulting in movement of the Fzd intracellular loop 3
and C-terminal helix, which in turn permits Dvl binding and
subsequent signal transduction (64, 65). Thus, the biological
relevance of given Wnt-Fzd CRD interactions will be influ-
enced by the co-expression/co-localization of these other
proteins. Recent structural data on LRP6 (66–68) and the
Smoothened receptor, a Class F GPCR related to Fzd receptors
(69–72), as well as the availability of Dvl domain structures
(73–76) and knowledge of key residues in the Fzd-Dvl interac-
tion (64, 77, 78) provide the opportunity to investigate more
completely the structural basis of canonical Wnt signaling.
Additionally, the structures of several intracellular components
in non-canonical Wnt signaling pathways are known or adopt
structurally characterized folds, suggesting the potential for
structural investigations. The models generated in this study
provide a solid basis by which to pursue further structural stud-
ies of Wnt signaling and, perhaps of greater importance, given
the combinatorial nature of potential Wnt-Fzd interactions,
suggest specific interacting partners on which to focus experi-
mental and computational efforts.
Experimental procedures
Template preparation
The template structure for all models was the complex of the
XWnt8 with the mouse Fzd8 CRD (Protein Data Bank code
4F0A) (19). This structurewas initially processed by the Protein
PreparationWizard, withmissing side chains and loops filled in
by Prime. Although the identity of the lipid modification to
XWnt8 in this structure could not be conclusively determined
(19), we have presumed thismodification to be palmitoleic acid,
as indicated either by direct experimental evidence or compar-
ison with similar sequences for which this modification has
been demonstrated (18, 79–83). The lipid in the structure was
manuallymodified usingMaestro to be a palmitoleic acidmod-
ification, which involved the creation of a double bond between
carbons 9 and 10 and the addition of carbons 15 and 16 to the
lipid, which were missing from the structure. The lipid was
subject to a Monte Carlo multiple minimum conformational
search using Macromodel, with the region comprising carbons
9–16, as well as the hydrogen atoms attached to these carbons,
defined as a freelymoving substructure, residueswithin 6.0Åof
this defined as a frozen shell, and a torsional constraint to
ensure cis double bond geometry about carbons 9 and 10. Auto-
matic setup of the substructure was used to define rotatable
bonds to be searched; however, all torsion check parameters
were removed. Extended torsion sampling was used. A maxi-
mum of 10,000 steps was used for the search with a maximum
of 2000 steps per rotatable bond. The lowest energy structure
obtained from the search provided a template structure for the
lipid that was used in all models.
Homologymodeling
Sequences of Wnts, Frizzled, and SFRP CRDs from both
mouse and human were obtained from the UniProt database
(84) (accession numbers are provided in supplemental Table
S1). Homology models were prepared using Prime 4.1 (85)
(sequence ranges and alignments used are provided in supple-
mental Figs. S2 and S3). All models were prepared using knowl-
edge-based building; however, because of the presence of large
insertions in the human and mouse Wnt6, Wnt10a, and
Wnt10b sequences relative toXWnt8, an alternative strategy to
building these structures was performed (see below). Disulfide
bonds c13–c17 and c16–c24 in Wnt (see Ref. 36 for descrip-
tion of cysteine numbering inWnts) typically could not be cre-
ated during themodel building process due to being adjacent to
insertions/gaps in the sequence alignment; these bonds were
Wnt-Fzd CRD binding affinity prediction
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manually inserted, and the residues involved were energy-min-
imized. The lipid structure generated during template prepara-
tion was not included duringWntmodel building butmanually
attached following model building.
To build the structures of the human and mouse Wnt6,
Wnt10a, and Wnt10b, an initial model of the complete mouse
Wnt10a was generated using the I-TASSER server (86). Struc-
tures of the remaining Wnts were then built using knowledge-
based building in Prime against both the mouseWnt10amodel
generated by I-TASSER (to provide the structure of the inser-
tion) and the XWnt8 structure (to provide a template for mod-
eling the remainder of the structure).
Complex generation and refinement
All combinations ofWnt-CRD complexes were generated by
merging the structures of each of the models built in the previ-
ous step. The generated complexes were subject to refinement
using Prime 4.1. The refinement process was facilitated
through the use of a KNIME workflow (supplemental Fig. S4).
In each complex, non-template residues and residueswithin 6.0
Å of the binding interface were subject to Prime Minimization
and Prime Side-Chain Prediction, followed by a second Prime
Minimization. The Wnt lipidation was excluded from the first
minimization to allow CRD residues to relax around it but
included in the second minimization. For complexes involving
mouse and human Wnt6, Wnt10a, and Wnt10b, the large
insertions modeled by I-TASSER were also subject to the
refinement procedure. The quality of the refined models was
assessed using the MolProbity score as calculated by the Mol-
Probity module within PHENIX (87). The quality of the refined
models was also assessed by calculating the RMSD of the C"
atoms and the TM-score with respect to the XWnt8-mFzd8
CRD complex. These measurements were both calculated
usingMM-align (88), with the option to enforce interface align-
ment by the default cutoff enabled.
Development and validation of the binding affinity prediction
model
Complexes ofmouseWnt3a,Wnt4,Wnt5a, andWnt5b with
mouse Fzd1, Fzd2, Fzd4, Fzd5, Fzd7, and Fzd8 were rescored
using all of the scoring functions contained in the CCharPPI
server (28). As the scoring functions are generally only capable
of considering interactions between protein residues, the lipid
modification to Wnt was removed prior to rescoring. To con-
sider contributions to the binding affinity made by the lipid,
PrimeMM-GB/SA calculations on the interaction between the
lipid and the CRDs were performed. For these calculations, the
protein component of Wnt was removed.
The scores for each complex by each scoring function in
CCharPPI as well as the values of the terms provided by the
Prime MM-GB/SA calculations were loaded into Maestro. A
property containing the dissociation constants determined by
BLI for selected mouse Wnt-Fzd CRD pairs (27) was manually
created and used to define the activity property. Complexes
involving interactions with eitherWnt4 or Fzd1 comprised the
test set, whereas all other complexes comprised the training set;
the training and test sets are summarized under “Results”
(Table 3). Both the training and test sets cover a diverse range of
Wnts, Fzds, and binding affinities for Wnt-Fzd interactions.
Strike was used to generate affinity prediction models. Mul-
tiple linear regressionwas used to buildmodels. Functions from
CCharPPI and properties from Prime MM-GB/SA provided
the descriptors used in model building; the full list of functions
and properties considered inmodel building is provided in sup-
plemental Table S5. The success of the models in predicting
binding affinities for complexes in both the training and test
sets was evaluated using RMSE and the percentage of com-
plexes for which the predicted value occurredwithin the exper-
imental range (RMSEtrain, RMSEtest, InExptrain, and InExptest).
All possible three-descriptor models incorporating one term
from Prime MM-GB/SA and the remaining two terms from
CCharPPI were investigated. Models with RMSEtrain less than
0.5 kcal/mol and InExptrain greater than 50% were selected for
testing. Models performing at least as well for the test set as for
the training set (i.e. RMSEtest % 0.5 kcal/mol and InExptest &
50%) were selected for further elaboration into four-descriptor
models, which were generated by adding an additional term
from CCharPPI to the best performing three-descriptor mod-
els. Four-descriptor models giving RMSEtrain and RMSEtest less
than 0.3 kcal/mol and InExptrain and InExptest greater than 75%
were selected as high-performing models. Elaboration of the
four-descriptor models into five-descriptor models was also
pursued by adding another term from CCharPPI.
As a final check of model quality, we also checked whether
the approximate range of binding affinity predicted by the best
models is in that expected. Dijksterhuis et al. (27) used a sim-
plified scheme whereinWnt-Fzd binding affinities were classi-
fied as strong ((10 nM; !!!!), intermediate (10–40 nM;
!!!), weak (40–100 nM; !!), very weak ()100 nM; !), and
non-binding (').Wehave utilized this schemewith somemod-
ification; we have considered predictions of 100–400 nM to
constitute the very weak (!) category and predictions greater
than 400 nM to be effectively non-binding ('); the 400 nM limit
was chosen in relation to the intermediate/weak affinity range
defined.
Analysis of functional residues inWnt-Fzd interactions
All 570 Wnt-Fzd CRD models were subject to MM-GB/SA
analysis using AMBER14 (35). Wnt-Fzd complexes were
parameterized using the ff14SB force field (89). Parameter gen-
eration for O-palmitoleoylserine was facilitated by Antecham-
ber (90), adapting procedures described in both the AMBER14
reference manual and AMBER tutorials. MMPBSA.py facili-
tated MM-GB/SA calculations (91). The modified generalized
Born model of Onufriev et al. (igb% 5) (92) with a salt concen-
tration of 0.1 M was used to calculate the polar desolvation
energy. The non-polar desolvation energy was calculated using
surface areas derived from the linear combinations of pairwise
overlaps (LCPO) method (93) multiplied by surface tension
(the default of 0.0072 kcal/(mol Å2) was used). Energies calcu-
lated by MM-GB/SA were decomposed on a per-residue basis
with 1–4 terms added to the internal potential terms (ide-
comp% 1) (94). Residues contributing greater than"2.0 kcal/
mol to the total MM-GB/SA binding energy were selected as
being of functional importance to binding. Logo analysis of
Wnt-Fzd CRD binding affinity prediction
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regions within theWnt and Fzd sequences frequently found to
contain residues of functional importance to Wnt-Fzd binding
was performed using theWebLogo server (95). Sequence logos
were generated as frequency plots.
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Wnt signaling in triple-negative breast cancer
SÖ-G Pohl1,2,3, N Brook1,2,3, M Agostino1,2,3,4, F Arfuso1,2,3, AP Kumar2,3,5,6,7 and A Dharmarajan1,2,3
Wnt signaling regulates a variety of cellular processes, including cell fate, differentiation, proliferation and stem cell pluripotency.
Aberrant Wnt signaling is a hallmark of many cancers. An aggressive subtype of breast cancer, known as triple-negative breast
cancer (TNBC), demonstrates dysregulation in canonical and non-canonical Wnt signaling. In this review, we summarize regulators
of canonical and non-canonical Wnt signaling, as well as Wnt signaling dysfunction that mediates the progression of TNBC. We
review the complex molecular nature of TNBC and the emerging therapies that are currently under investigation for the treatment
of this disease.
Oncogenesis (2017) 6, e310; doi:10.1038/oncsis.2017.14; published online 3 April 2017
INTRODUCTION
Breast cancer represents one of the most significant disease burdens
of any cancer worldwide. Today, women have a one in eight chance
of developing breast cancer over their lifetime, a risk that is
significantly increased if they have inherited harmful mutations in
BRCA1 or BRCA2.1 However, breast cancer is a complex, hetero-
geneous disease characterized by a great multitude of aberrations at
the genomic and molecular level, which can manifest in dysregulated
signaling pathways. A hallmark of many cancers is aberrant regulation
of the Wnt signaling pathway, and breast cancer is no exception.2
Triple-negative breast cancer (TNBC), an aggressive subtype of
breast cancer with a poor prognosis,3 is characterized by tumors
that do not express estrogen receptors (ERs) or progesterone
receptors (PRs), nor display an overexpression of human
epidermal growth factor receptor 2 (HER2).4 Therapies targeted
against HER2-positive breast cancers, such as trastuzumab
(Herceptin),5 and those targeted against ER-positive breast
cancers, such as tamoxifen,6 have no therapeutic benefit to
individuals with the TNBC subtype. Surgical intervention and
chemotherapy have been the major treatment avenues for TNBC;
however, recently developed small molecules and
immunotherapeutics7 are showing promise. In this review, we
will summarize the involvement of dysregulated Wnt signaling in
the progression of TNBC and TNBC stem cells, as well as the
emerging therapies that are currently under investigation.
THE WNT SIGNALING PATHWAY
The Wnt/β-catenin pathway (canonical pathway)
There are currently two models of canonical Wnt/β-catenin
signaling. In the classical model, the destruction complex remains
intact in the absence of Wnt stimulation (Figure 1a). Casein kinase 1
(CK1) primes β-catenin for destruction by phosphorylating Ser45,
which then allows activated Glycogen synthase kinase 3 (GSK3) to
phosphorylate β-catenin at Ser33, Ser37 and Thr41.8 The phos-
phorylated residues of β-catenin interact with the β-propeller
domain of the E3 ubiquitin ligase β-TrCP, which then ubiquitinates
β-catenin, thus targeting it for proteosomal degradation.9
Wnt/β-catenin signaling is initiated by Wnt ligands binding to a
Frizzled receptor (FZD), as well as the co-receptors low-density
lipoproteins 5/6 (LRP5/6). This results in activation of FZD,
permitting binding of Dishevelled (Dvl)10 and phosphorylation of
one or more cytoplasmic motifs of LRP5/6. A single phosphorylated
motif is sufficient to activate Wnt signaling.11 Phosphorylated
LRP5/6 can then interact with Axin. This interaction destabilizes the
β-catenin destruction complex, which requires Axin as a scaffold
and contains Dvl, the serine–threonine kinases casein kinase 1α/β
(CK1), glycogen synthase kinase 3α/β (GSK3) and adenomatous
polyposis coli (APC).12 Destabilizing the destruction complex
prevents phosphorylation of β-catenin, which then accumulates in
the cytosol before translocating to the nucleus. Once there, it binds
to Transcription factor/lymphoid enhancer-binding factor (TCF/LEF)
transcription factors and displaces transcriptional repressor Groucho
to initiate the transcription of Wnt target genes (Figure 1b).13 In the
new model,14–16 the destruction complex is stabilized by Axin in
both the presence and absence (Figure 1c) of Wnt activation, and
β-catenin is degraded through phosphorylation-mediated
recognition by β-TrCP in the intact complex. This allows newly
synthesized β-catenin to accumulate in the cytosol before nuclear
translocation (Figure 1d). This was demonstrated through
co-immunoprecipitation, whereby β-catenin phosphorylated at
Ser33/Ser37/Thr41 was shown to interact with the destruction
complex upon Wnt activation, which also disrupted the interaction
of β-TrCP with the Axin1-β–catenin complex.15 It has also been
proposed that GSK3 inhibition, and thus β-catenin translocation
after Wnt activation, is mediated through the sequestration of GSK3
inside multivesicular endosomes.17 This further demonstrates the
complexity of Wnt signaling.
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Planar cell polarity pathway
The planar cell polarity pathway (Figure 1e) is a non-canonical,
β-catenin-independent pathway that regulates cellular organization
and polarity, partly through cytoskeletal organization.18 Wnt ligands,
such as Wnt5a, bind to FZD receptors and co-receptors, including
ROR,19 Ryk20 and PTK.21 Dvl interacts with Rac122 and Dvl-associated
activator of morphogenesis 1 (DAAM1). Rac1 activates c-Jun
N-terminal kinase, leading to actin polymerization,22 while DAAM1
activates Rho, which in turn activates Rho-associated kinase (ROCK)
to regulate cellular cytoskeletal arrangements.23
Figure 1. Classical and new Wnt/β-catenin pathway canonical and non-canonical pathways. (a) Overview of the ‘classical’ model of
Wnt/β-catenin signaling in OFF state with no ligand bound to FZD receptor. (b) Overview of the ‘classical’ model of Wnt/β-catenin signaling
pathway in ON state where Wnt ligand is bound to FZD receptor. (c) Overview of ‘new’ model of Wnt/β-catenin signaling in OFF state with no
ligand bound to FZD receptor. (d) Overview of the ‘new’ model of Wnt/β-catenin signaling in ON state with Wnt ligand bound to FZD receptor.
(e) Overview of Wnt planar cell polarity (PCP) pathway in ON state. Wnt binds multiple receptors including FZD and co-receptors ROR and Ryk.
This activates Rho and Rac, which activate ROCK and c-Jun N-terminal kinase (JNK), respectively, leading to actin polymerization and
regulates cytoskeletal arrangements. (f) Overview of Wnt/Ca2+ pathway in ON state. Wnt is able to bind FZD, Ryk to initiate signal
transduction, which is effected through Dvl and G proteins (α, β, γ). Gene transcription is induced through proteins PKC, CaMKII and
Cn (Calcineurin)-activating transcription factors.
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The Wnt/Ca2+ pathway
The Wnt/Ca2+ pathway (Figure 1f) is activated through Wnt
binding to FZD, which interacts with G proteins and Dvl.24 These
interactions can activate cGMP-specific phosphodiesterase or
phospholipase C, resulting in a release of intracellular calcium.
This results in the activation of downstream signaling proteins
PKC, calcineurin and CaMKII.25 CaMKII activates nuclear factor of
activated T-cells, which can regulate cell adhesion and
migration.26 Wnt5a induces activation of CaMKII-dependent
Wnt/Ca2+ signaling. CaMKII phosphorylates transforming growth
factor β-activated kinase, which activates Nemo-like kinase.27 This
cascade antagonizes canonical Wnt/β-catenin signaling by Nemo-
like kinase phosphorylation of TCF4 and prevents the β-catenin–
TCF4 complex from binding to DNA.28
Wnt ligands
To date, 19 members of the Wnt family have been identified in
mammals, all ranging between 350 and 400 amino acids in length
and characterized by a conserved fold containing a conserved
motif of 24 cysteine residues (Figure 2a).29 Wnt ligands are
modified by lipidation, specifically, the addition of a palmitoleyl
group to a conserved serine by the membrane-bound
Figure 2. Molecular structures of the key Wnt signaling proteins and interactions. (a) X-ray crystal structure of the Xenopus Wnt8 complex with
the mouse FZD8 cysteine-rich domain (PDB 4F0A). The key structural regions of the Wnt fold are highlighted, as are the major Wnt-interacting
regions of the CRD. (b) X-ray crystal structure of the Smoothened receptor (PDB 5L7D), a Class F G protein-coupled receptor, related to FZD.
The key structural regions of Smo are highlighted, as well as helix 8, which is of relevance for Dishevelled binding by FZD. (c) Schematic
representation of the location of the DIX, PDZ and DEP domains within Dvl. (d) X-ray crystal structure of the DIX homodimer (PDB 4WIP).
(e) X-ray crystal structure of the PDZ domain bound to a peptide (red; PDB 3CBX). The peptide-binding site is shown in yellow. (f) X-ray crystal
structure of a DEP homodimer (PDB 5LNP), highlighting residues known to affect Wnt signaling (shown in red). (g) Model of the LRP6
ectodomain generated by molecular dynamics flexible fitting of the crystal structures of the P1E1–P2E2 domains (PDB 3S94) and P3E3–P4E4
domains (PDB 4A0P), and a homology model of the LDL-R type A domains (generated in Prime, based on the crystal structure of the LDL
receptor ectodomain (PDB 1N7D)) to the electron microscopy structure (EMDatabank accession 1964). Gaps in the crystal structures and
between the various components modeled using Prime. (h) X-ray crystal structure complex of the cysteine-rich domain 2 of Dickkopf with
Kremen and the LRP6 P3E4–P4E4 domains (PDB 5FWW).
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O-acyltransferase Porcupine.30 Wnt lipidation is crucial for secre-
tion from the endoplasmic reticulum31 and essential for Wnt
function. Wnt lipidation was initially suggested to occur at Cys77
of Wnt3a (cysteine 3 of the Wnt fold);32 however, lipidation at this
cysteine has been conclusively disproven by crystallographic,33
mutational31 and imaging studies.30
FZD receptors
FZD receptors are a group of 10 membrane proteins featuring
an extracellular cysteine-rich domain (CRD) and a seven-
transmembrane domain.34 Along with the Smoothened receptor
(Smo), the FZDs comprise the family of Class F G protein-coupled
receptors. The crystal structure of XWnt8 in complex with the
mouse FZD8 CRD33 revealed an unusual interaction involving the
direct binding of the Wnt lipid to a binding site on one side of
the CRD (the ‘thumb’ region), as well as the binding of the region
from cysteines 19 to 22 of XWnt8 to the other side of the CRD
(the ‘index finger’ region; Figure 2a).35 Although no complete
structures are available for any FZD, several structures of Smo
are known,36–38 most recently including both the CRD and
seven-transmembrane regions (Figure 2b),39 which are suggestive
of the likely structure of FZD.
Disheveled
Three Dvl homologs are known (Dvl1/2/3), sharing high overall
sequence similarity.40 Dvl consists of three structurally defined
domains: the DIX, PDZ and DEP domains. These three domains are
separated by large insertions of unknown structure (Figure 2c);
however, some functional significance has been ascribed to
conserved sequences within the unstructured regions.41
Dvl polymerizes via the head-to-tail interaction of its DIX
domain (Figure 2d). The DIX domain also mediates interaction
with Axin.42 Mutations (V67A, K68A, Y27D) in the polymerization
interface of the DIX domain strongly suppress Wnt signaling.43 The
PDZ domain of Dvl (Figure 2e) interacts with a conserved motif in
the FZD C-terminal (KTxxxW).24 The PDZ–FZD interaction is
relatively weak, and is likely supplanted by interactions of the
DEP domain with FZD. Greater insight in the role of the DEP
domain in Wnt signaling was recently revealed, with this domain
shown to bind as a monomer to FZD, then undergo subsequent
domain swapping to assemble Wnt signalosomes. Furthermore,
upon Wnt stimulation, DEP domain swapping initiates
DIX-dependent Dvl and Axin polymerization, leading to the
inhibition of GSK3 and Wnt signal transduction. Mutants (E499G,
D460K, G436P, K438M, D449I and D452I) in the DEP domain
strongly diminish Wnt signaling upon Wnt stimulation
(Figure 2f).44,45 Dvl has also been shown to promote ubiquitina-
tion-mediated FZD degradation by RNF43.46 This finding suggests
a dual agonist/antagonist role for Dvl in Wnt signaling.
Low-density lipoprotein receptor 5/6
The extracellular domain of LRPs consists of four β-propeller
repeats interspersed with epidermal growth factor repeats,
followed by three LRP type A repeats (Figure 2g).10 The majority
of Wnts bind to the first β-propeller/epidermal growth factor
repeat (P1E1–P2E2), although Wnt3 and Wnt 3a preferentially
bind to the second repeat (P3E3–P3E4).47 Wnt3 and Wnt3a
binding to LRPs is competitively inhibited by Dickkopf binding to
LRP (Figure 2h).48–50 The intracellular action of LRP5/6 is less
clearly understood, although it is known that Wnt activation
initiates phosphorylation of the intracellular PPPSPxP motifs of
LRP5/6 by GSK3 and CK1, allowing the recruitment of Axin.51
Importantly, it has also been shown that without the FZD–Dvl
interaction, Wnt is unable to induce phosphorylation of
LRP6, reinforcing the complex interplay of proteins involved in
Wnt signaling.24,51
ROR family receptor tyrosine kinases
The ROR family of receptor tyrosine kinases consists of two
evolutionarily conserved members, ROR1 and ROR2.52 The ROR
ectodomains feature a FZD-type CRD most closely related to that
of the skeletal muscle receptor tyrosine-protein kinase.53 ROR2 is
involved in Wnt5a-mediated signaling; Wnt5a binding to ROR2
initiates ROR2 homodimerization, stimulating autophosphoryla-
tion at Tyr646.54 It has been demonstrated that Wnt5a and Wnt3a
bind to ROR2; however, only Wnt5a is able to initiate the
activation of the ROR2 signaling cascade.55 Recently, high
expression of ROR1 has been demonstrated in TNBC cell lines,
where it interacts with CK1ε to promote tumor survival and
growth after stimulation with Wnt5a to activate phosphoinositide
3-kinase (PI3K)/AKT signaling.56
DEAD-box helicases
DEAD-box helicases (DDXs), named for a conserved amino-acid
sequence in their ATP-binding domain (Asp-Glu-Ala-Asp), belong
to a highly conserved family of ATP-dependent DNA/RNA
helicases.57 They consist of a highly conserved helicase core
with two domains, displaying high similarity to the recA bacterial
DNA recombination protein (Figure 3).58 These multifunctional
proteins have roles in translation initiation, pre- and post-
translational modifications, DNA repair, microRNA (miR) proces-
sing, ribosome biogenesis and RNA decay.59–61 Furthermore,
DDXs have been recently implicated in breast tumorigenesis
and activation of cancer stem cell (CSC) stemness through
various pathways, including Wnt.62,63 DDXs can be regulated by
β-catenin/TCF-driven transcription and have also been shown to
regulate upstream Wnt signaling. The role of DDXs is discussed in
further detail later in the section titled ‘DDXs, Wnt and TNBC’.
BREAST CANCER SUBTYPES
Breast cancer is a diverse and complex disease, broadly
characterized by four molecularly distinct subtypes, including
luminal A, luminal B, HER2-overexpressed and triple-negative
breast cancer (TNBC).64 The luminal A subtype is characterized as
ER/PR-positive and HER2-negative, expressing Bcl-2, cytokeratin
8/18 and low Ki67.65 Luminal B subtypes are more aggressive ER+
breast tumors, characterized as HER2− with high Ki67, or HER2+,
PR− and ER+,66 with cyclin B1 overexpression.67 The HER2 subtype
is characterized by amplification of the ERBB2/HER2 gene.68
TNBC, including basal-like and claudin-low subtypes, accounts
for 10–20% of breast cancers and is characterized by a lack of PR,
ER and HER2 overexpression.69 TNBC patients present with higher
Figure 3. X-ray crystal structure of the ATP-binding and C-terminal
helicase domains of the DEAD-box helicase DDX3 (PDB 5E7M).
AMP-PNP, a non-hydrolyzable ATP analog, is shown in spheres in the
ATP-binding site.
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incidence of distant disease recurrence within 3 years of diagnosis,
with a high frequency of visceral metastases.70 The prognosis for
patients diagnosed with TNBC is poor, with patients who respond
poorly to adjuvant treatment exhibiting worse outcomes.4
TNBC subtypes
TNBC has been categorized into a number of distinct molecular
subtypes; however, there remains much intertumoral mutational
and transcriptional heterogeneity within these subtypes. The
molecular heterogeneity of TNBC confounds the clinical approach
to TNBC treatment. TNBCs are characterized by high clonal
frequencies of single gene mutations in the key tumorigenesis
driver genes, including TP53, PIK3CA and PTEN, indicating that
clonal evolution of these mutated genes is an early event in TNBC
development.71 However, mutation frequencies within these
genes are not uniform among TNBC cases.71,72
Lehmann et al.73 determined gene expression signatures in
587 TNBC cases from 21 breast cancer data sets and identified
six molecularly distinct TNBC subtypes. These include basal-like 1,
basal-like 2, immunomodulatory, mesenchymal (M), mesenchymal
stem-like (MSL), and luminal androgen receptor (LAR). These
subtypes, various gene ontology pathways and associated Wnt
genes are described in Table 1. Recent RNA profiling performed by
Burstein et al.92 showed overlap of LAR and MES subtypes based
on Lehmann’s gene expression profiling, but was unable to
reproduce all observations.92 The findings of both of these studies
indicate the presence of at least four molecularly distinct and
stable TNBC subtypes, defined as LAR, mesenchymal (MES), basal-
like immune-suppressed (BLIS) and basal-like immune-activated
(BLIA).92 Furthermore, these studies suggest molecular targets for
the development of therapeutics specific to the treatment
of TNBC.
LAR subtype
The LAR subtype accounts for ∼ 10% of TNBCs, whereby tumor
cells exhibit positive staining for androgen receptors (ARs) and are
driven by AR signaling.69,73 The LAR subtype of TNBC displays
genomic amplification of CCND1, a gene regulated by the
Wnt/β-catenin pathway.92 There is some discordance within the
literature in regards to the prognostic utility of AR status, with
studies indicating no significant effect on survival rates associated
with AR expression,93 although AR+ TNBC individuals have been
shown to have a positive clinical response to the nonsteroidal
antiandrogen, bilcautamide.94,95 In a study designed to test the
benefit of tamoxifen on ER− and TNBC patients, it was found that
expression of AR+ versus AR− individuals predicted a decreased
recurrence rate and treatment benefit with AR+ patients;96
this is a result of tamoxifen exhibiting agonist activity on
AR-expressing cells.97
MES subtype
The MES subtype, encompassing Lehmann’s M, MSL and
claudin-low subtypes, is characterized by the overexpression of
genes associated with cellular motility, proliferation and growth
signaling pathways.73,92 MES subtypes have high expression of
platelet-derived growth factor, insulin-like growth factor 1 and
c-kit.92 MES tumors express mesenchymal stem cell markers,
including the breast stem cell marker ALDH1A1, and are enriched
in genes associated with epithelial–mesenchymal transition (EMT)
and other stem-like properties.73,98 Within Lehmann’s M and MSL
subtypes, there are a number of enriched genes associated with
EMT that are also modulated by Wnt signaling, including MMP2,
TWIST, SNAI2 and TCF4.77 A gene set involved in Wnt/β-catenin
signaling in the M and MSL subtypes, including CTNNB1
(β-catenin), DKK2, DKK3, SFRP4, TCF4, TCF7L2 and FZD4, was also
found to be enriched.73 MES tumors are associated with a poorer
distant metastasis-free survival at 5 years compared to other
subtypes, likely associated with increased expression of cellular
motility genes leading to increased metastasis.73
BLIS subtype
BLIS is characterized as an immune-suppressed TNBC subtype
with downregulated immune signaling pathways and reduced
expression of immune function genes.92,99 BLIS tumors exhibit
enhanced expression of mitotic and cell cycle pathway genes,
with overexpression of proliferative genes, including CENPF, BUB1
and PRC1,99 Sry-related HMG box (SOX) transcription factors, and
the immune-regulatory molecule V-domain-containing T-cell
activation inhibitor.92 SOX transcription factors share a closely
related consensus binding sequence to TCF/LEF transcription
factors100 and are known modulators of Wnt/β-catenin
signaling.101 Survival analysis shows that patients with the BLIS
subtype TNBC experience lower rates of recurrence-free survival
compared to other TNBC subtypes.99
BLIA subtype
The BLIA subtype is characterized by upregulation of immune
activating pathways, with overexpression of STAT transcription
factors and cytotoxic T-lymphocyte-associated protein 4.92
Furthermore, the BLIA subtype demonstrates amplification of
CDK1, which was recently found to phosphorylate the Wnt
regulator TAZ.92,102 BLIA tumors have increased levels of
lymphocytic infiltration and are thus associated with improved
disease-free survival rates and patient outcomes compared to
other TNBC subtypes, although still associated with a relatively
high risk of recurrence (~20%).92,103
Table 1. Summary of the six molecular subtypes of TNBC characterized by Lehmann et al.73
TNBC subtype Gene ontology pathway (GOP) Genes found in GOPs with Wnt association
Luminal androgen receptor (LAR) Steroid pathway FKBP574
Androgen metabolism SPDEF75
Fatty-acid synthesis FASN76
Mesenchymal (M)/mesenchymal stem-like
(MSL)
EMT MMP2,77 SNAI2,77 TCF4,77 TWIST1,77 ZEB178
Wnt/β-catenin signaling CTNNB1,73 DKK2/3,73 TCF4,73 TCF7L2,73 CCND2,73 FZD4,73 CAV1,73 CAV273
Basal 1 (BL1)/Basal 2 (BL2) DNA damage CHEK1,79 FANCA,80 FANCG,80 MSH2,81 RAD2182
Proliferation/cell cycle AURKB,83 PLK1,84 CENPA,84 BUB1,84 CCNA2,85 PRC1,86 MYC,87 NRAS88
Immunomodulatory (IM) JAK/STAT cytokine pathway CCR2,89 CCR590
IL7 pathway IL791
Abbreviations: EMT, epithelial–mesenchymal transition; IL, interleukin; TNBC, triple-negative breast cancer. Various gene ontology pathways were found to be
enriched in the LAR, MSL, BL1, BL2 and IM subtypes. Analysis of the genes enriched in these pathways identified genes associated with Wnt signaling.
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Wnt dysregulation in TNBC and TNBC stem cells
Aberrant Wnt signaling is a characteristic of TNBC, with
both canonical and non-canonical pathways implicated in
TNBC tumorigenesis104,105 and metastasis.106 Enrichment of
Wnt/β-catenin signaling is evident in TNBC and is associated with
poor clinical outcomes within this subtype.107,108 TNBC patients
displaying dysregulated Wnt/β-catenin signaling are more likely to
develop lung and brain secondary metastases.106 Studies have
shown that nuclear accumulation of β-catenin promotes cell
migration, colony formation, stem-like features and chemoresis-
tance of TNBC cells in vitro and TNBC tumorigenesis in mouse
cancer models, thus suggesting that canonical Wnt signaling is
a major driving force of TNBC tumorigenesis.104 Although the
Wnt/β-catenin pathway is associated with the clinicopathological
features of TNBC, this is not due to CTNBB1 mutations.108 Studies
have also implicated dysregulation of non-canonical Wnt signaling
pathways in the highly metastatic behavior of TNBC cells and
CSCs, specifically through aberrant c-Jun N-terminal kinase
activation.109
CSCs, or cancer stem-like cells, are a small subset of cells within
the heterogeneous tumor bulk that are thought to be responsible
for tumor initiation.110 These cells also have intrinsic mechanisms
for chemoresistance, such as upregulation of drug transporters,
including the breast cancer resistance protein (also known as
ABCG2).111 By evading the standard chemotherapeutic treatments,
it is thought that the CSCs are also responsible for the relapse
experienced in many cancers, especially TNBCs.112 Studies have
also shown that these cells are a main contributor to metastasis,
and are able to initiate solid tumor formation when xenotrans-
planted at low cell densities.113 TNBC stem cells are isolated from
tumors as CD44+ (homing cell adhesion molecule), CD24− (heat
stable antigen), CD49f+ cells.114 CSCs also differ metabolically to
other cancer cells. They are more reliant on mitochondrial
respiration, which is supported by their higher mitochondrial
reactive oxygen species, enhanced oxygen consumption and
higher mitochondrial mass, allowing for features such as
resistance to DNA damage.115
Wnt signaling is essential for normal breast stem cell function
and mammary gland development during embryogenesis,
postnatal development and pregnancy,116 with adult mammary
glands containing Wnt-responsive stem cell populations.117
Studies have shown that aberrant Wnt signaling in breast cancer
stem cells (BCSCs) is a key event in breast tumorigenesis.118
Wnt/β-catenin signaling has been linked to TNBC tumorigenesis
by regulating the key tumor-associated characteristics, including
migration, stemness, proliferation and chemoresistance in
TNBC cells and CSCs.104 A recent study has also demonstrated
that Wnt/β-catenin signaling activity is higher in breast CSCs than
the bulk tumor population, based on β-catenin, TCF4 and LEF1
expression in Aldefluor-positive cells versus Aldefluor-negative
cells.119 Treatment with Wnt3a increased the number of ALDH+
breast CSCs, and knockdown of Wnt1 reduced the tumor-forming
efficiency of breast CSCs in vitro.119
Furthermore, studies have shown that Wnt-derived breast tumors
are maintained by clones capable of re-activating Wnt overexpres-
sion post-Wnt inhibition, indicating that aberrant Wnt activation is a
key driver of breast cancer recurrence and progression.120 A recent
review highlighted the potential importance of Wnt/β-catenin
signaling, along with other developmental signaling pathways,
including Cripto-1 and Notch/CSL, in the regulation of TNBC stem
cells and therapy resistance in TNBC.121 An overview of Wnt signaling
dysregulation is given in Figure 4.
FZDs in TNBC
FZD6. FZD6 exhibits increased gene copy number variations and
overexpression in breast cancers. This is more frequent in TNBC
than ER+ tumors. A study by Corda et al.122 determined that FZD6
was involved in the regulation of cell motility, invasion and three-
dimensional (3D) growth, although it did not regulate proliferation
in TNBC. This was confirmed by a significant reduction in distant
metastases detected in various organs in vivo after the injection of
MDA-MB-231 cells depleted of FZD6. Short hairpin RNA directed at
FZD6 in vitro was found to reduce cell invasion through
a reduction in active Rho and the subsequent reduction
in fibronectin fibres. This indicated that FZD6 regulates cell
motility and invasion through non-canonical Wnt signaling. This
study also suggests that FZD6 overexpression in TNBC has a high
prognostic value in determining the risk of metastasis.122
FZD7. Microarray analysis determined that FZD7 expression is
upregulated in TNBC tissue and cell lines, and promotes
tumorigenesis via canonical Wnt signaling pathways.123 Short
hairpin RNA-mediated silencing of FZD7 reduced invasiveness and
colony formation in TNBC cell lines.123 A recent study found that
ΔNp63, an isoform of Transformation-related protein 63 (p63),
enhanced FZD7 expression and increased Wnt signaling in TNBC
tumor tissue and cell lines.124
Aberrant FZD7 expression is implicated in TNBC stem
cell-mediated tumorigenesis. A study recently found that knock-
down of ΔNp63 in TNBC cell lines decreased FZD7 expression and
tumorsphere formation, indicating that ΔNp63/FZD7 upregulation
induced TNBC stem cells and promoted tumor formation in
TNBC.124 The findings of this study highlight the potential clinical
importance of ΔNp63/FZD7-Wnt signaling in TNBC stem cells as
a key driver of tumorigenesis and progression of TNBC.124,125
FZD8. Gene expression studies have recently linked FZD8-driven
Wnt signaling to chemoresistance in TNBC cell lines and TNBC
stem cells. Treatment with cisplatin and tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) in TNBC cell lines
Figure 4. Overview of Wnt signaling regulators contributing to TNBC
progression and their targeted therapies. Canonical and
non-canonical Wnt pathways are activated through Fzd, LRP and
ROR receptors. Blue arrows indicate suppression/inhibition of Wnt
regulators and pathways (with a net result of downregulation of Wnt
target gene transcription, indicated by yellow cross); red arrows
indicate activation of Wnt regulators and pathways.
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resulted in increased FZD8 expression in residual tumors of
xenograft models.126 Furthermore, FZD8 silencing led to increased
Wnt pathway-driven TNBC cell apoptosis in vitro and in vivo.126
The study showed that treatment with TRAIL/cisplatin increased
expression of LEF-1 and TCF-7 in residual TNBC stem cells, thus
implicating upregulation of Wnt signaling components in the
development of chemoresistance.126 An inverse correlation
between FZD8 and miR-100 was shown, where decreased
miR-100 expression was linked to increased FZD8 expression
and Wnt signaling, resulting in increased loco-regional breast
cancer metastasis.126,127 The role of miRs in Wnt signaling and
TNBC is discussed in further detail below. c-Myc overexpression
has been linked to FZD8 overexpression in TNBC cell lines,
associating c-Myc-driven transcription to chemoresistance and
TNBC CSC survival.128
LRP5/6 in TNBC
LRP5/6 are essential for normal mammary development by
regulating breast stem cell activity and are linked to basal-
derived breast tumorigenesis.129–131 Studies in transgenic mice
indicated that LRP5 knockdown led to resistance to Wnt1-induced
tumor formation.130
Gene expression analyses found that LRP6 is overexpressed in
human TNBC.123,131 In vivo studies have shown that LRP6 silencing
inhibited tumor growth in TNBC cell line-derived xenograft
models.132 LRP6 and Wnt target gene SOX9 have been shown
to influence regulation of one another in TNBC cell lines.
LRP6 overexpression led to SOX9 upregulation, while knockdown
of SOX9 reduced LRP6 transcription and decreased cell invasion
and proliferation.133
LRP6 overexpression led to the upregulation of Wnt signaling
and was associated with increased stemness in TNBC cells.134
CD138 (Syndecan-1) is an EMT marker associated with both
development and breast tumorigenesis,135 and has been shown to
modulate TNBC stem cell properties by targeting Wnt signaling.134
Ibrahim et al.134 showed that CD138 modulates Wnt signaling in
TNBC stem cells through LRP6, whereby CD138 silencing resulted
in downregulated LRP6 expression and Wnt signaling.134
RORs in TNBC
Primary breast cancer DNA microarray data set analysis has shown
that ROR1 is expressed on breast cancer cells and absent in
normal breast cells, with high ROR1 expression associated with
poorer survival.136 Furthermore, the study showed that ROR1
silencing in TNBC cell lines increased apoptosis and reduced cell
growth. High ROR1 expression in breast cancer cells is associated
with high expression of EMT gene profiles and high incidences of
disease recurrence and progression.137 ROR1 knockdown in TNBC
cell lines resulted in reduced EMT-associated protein expression,
reduced cell migration and invasion in vitro, and inhibited
metastasis in xenograft models.137 ROR2 expression is present in
both TNBC and non-TNBC, with ROR2+ TNBC patients exhibiting
poorer survival outcomes compared to other subtypes.138 ROR2
knockdown in TNBC cell lines inhibited Wnt signaling and reduced
TCF/LEF transcription.138 These findings indicate the potential
prognostic and therapeutic significance of high ROR1/2 expression
in TNBC.
DDXs, WNT and TNBC
DDX3. DDX3 is a regulator of Wnt/β-catenin signaling, where it
interacts with and increases the kinase activity of casein kinase 1ε
and is required for the phosphorylation of Dvl2.139 It is known to
have an oncogenic role in breast cancer, where non-tumorigenic
MCF10A cell lines overexpressing DDX3 showed increased EMT,
motility and invasiveness.140 The same study demonstrated that
DDX3 expression was positively correlated with a more aggressive
phenotype, and was highly expressed in TNBC cell lines. DDX3
overexpression resulted in E-cadherin downregulation and
subsequent nuclear β-catenin translocation.140 Similarly, DDX3
inhibition by NZ51, a ring-expanded nucleoside analog that is
predicted to bind to the ATP-binding site of DDX3, led to
decreased proliferation, motility and invasiveness in TNBC cell
lines and reduced tumor load and metastatic burden in preclinical
in vivo models.141
DDX5 (p68). DDX5 acts as a co-activator of Wnt/β-catenin signaling
through regulation of TCF4 expression. In turn, β-catenin/TCF4
regulates DDX5 expression, forming a positive feedback loop
associated with increased EMT marker expression in TNBC cells.142
DDX5 is thought to regulate p53-mediated repair of DNA damage,
and DDX5 overexpression contributes to tumorigenesis and
progression in breast cancers.143 DDX5 is highly expressed in
basal-like breast cancers compared to luminal-like, and correlates
with high EGFR and Ki67 expression in TNBC tissue.144 Furthermore,
the study found that DDX5 regulates the expression of miR-21 and
miR-182 in basal breast cancers, and is associated with malignant
disease.
THE ROLES OF MIRS IN WNT SIGNALING AND TNBC
miRs are endogenous, short, non-coding RNA molecules that
regulate cancer-related genes at the post-transcriptional level.145
miRs are differentially expressed in BCSCs and cancer cells,
indicating that breast cancer-specific miRs are important in
maintaining stemness and promoting tumorigenesis in BCSCs.146
Twenty-seven miRs differentially expressed in locally advanced
TNBC have been previously identified, with many of these predicted
to be involved in regulation of Wnt signaling pathway genes.147,148
miR-374a overexpression led to suppression of Wnt pathway
inhibiting components (PTEN and WIF1) and ultimately increased
Wnt-mediated EMT and metastasis in multiple TNBC cell lines.149
miR-340 is downregulated in TNBC cell lines and has been
linked with TNBC tumorigenesis regulation in multiple studies.150
Induction of miR-340 resulted in downregulation of Wnt pathway
target genes (CTNNB1, MYC and ROCK1), decreased proliferation
and increased apoptosis in a metastatic TNBC cell line. The study
showed that miR-340 overexpression reduced cell motility and
invasiveness, indicating that miR-340 has a fundamental role in
regulating breast metastases.151 Another study recently found that
induction of miR-340 in TNBC cell lines led to reduced expression
of SOX2, an oncogene associated with the canonical Wnt signaling
pathway.152
A study by Isobe et al.153 found that miR-142 upregulation is
associated with BCSCs and activates canonical Wnt signaling by
promoting APC breakdown in TNBC cell lines. The study found
that miR-142 expression activated canonical Wnt signaling,
leading to increased miR-150 expression, thereby contributing to
breast tissue hyperproliferation, BCSC proliferation and reducing
apoptosis in TNBC cell lines.153
A recent study has shown that miR-218-5p expression was
significantly increased in TNBC, as well as bone metastases, from
breast cancer patients.154 Anti-miR-218-5p led to a reduction in
cell proliferation in vitro and decreased tumor growth, active
osteoclasts and osteolytic lesions in vivo, while the opposite was
seen with transfection of miR-218-5p. The miR was also shown to
directly modulate Wnt/β-catenin signaling by binding to secreted
FZD-related protein 1 and SOST. Anti-miR-218-5p suppressed
Wnt signaling, which downregulated Parathyroid hormone-related
protein expression, reducing breast cancer-induced osteolytic
disease.154
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CURRENT AND EMERGING THERAPIES FOR TNBC AND TNBC
STEM CELLS
Systemic cytotoxic chemotherapy is clinically indicated in early
TNBC and is associated with a greater treatment benefit than
hormone receptor-positive tumors.155 Numerous early-phase
clinical trials are currently underway, investigating various
targeted molecules and combination therapies for the treatment
of TNBC. In this section, we review current and emerging small
molecule therapeutics for the treatment of TNBC (Figure 4);
immunotherapeutics are reviewed elsewhere.7
Chemotherapy
Anthracycline/taxane-based regimens are currently the standard
of care in the treatment of adjuvant and neoadjuvant TNBC.
However, a recent in vitro study has shown that treatment with
docetaxel or doxorubicin had transient and negligible impact on
cell growth in two TNBC cell lines, respectively. Furthermore, the
study found that docetaxel and doxorubicin treatment resulted in
deregulation of genes associated with stemness in TNBC cells.156
Molecular analysis found that doxorubicin treatment deregulated
stem cell signaling pathways associated with cell growth, renewal
and differentiation, with altered gene expression demonstrated in
components of the Wnt signaling pathway, including FZD2, FZD4,
FZD5, FZD6, FZD7, FZD9, Axin1, Wnt11, Wnt10a and Wnt5a. As
such, the study concluded that docetaxel and doxorubicin induce
stemness in differentiated TNBC cells, which likely accounts for
acquired chemoresistance seen in refractory TNBC tumors.156
Platinum agents
Platinum-based chemotherapeutics are a class of DNA-damaging
agents, including cisplatin, carboplatin and oxaliplatin; these have
established efficacy in breast cancer treatment.157 In vitro studies
have indicated that combining TRAIL and cisplatin significantly
increased BCSC death compared to other standard of care
treatments in TNBC cell lines.158 The study showed that treatment
with TRAIL and cisplatin inhibited Wnt1-mediated signaling
and expression of cyclin D1, as well as the phosphorylation of
β-catenin. Combination treatment with cisplatin and TRAIL also
enhanced apoptosis, and inhibited proliferation and tumorsphere
formation.158
Wnt signaling inhibitors
Treatment with the small molecule β-catenin/TCF inhibitor
CWP232228 inhibited β-catenin-mediated transcription, leading
to inhibition of stem cell proliferation and reduction in tumor bulk
in TNBC cell lines and TNBC patient-derived xenograft models,
respectively.159 PRI-724, a CREB-binding protein inhibitor, and
LGK-974, a Porcupine inhibitor, are two small molecules currently
undergoing clinical development. Both molecules are currently
under investigation for single agent use in ongoing phase I clinical
trials in TNBC patients,160 with interim results yet to be released.
Recent in vitro studies have shown that LGK-974 in combination
with the PI3K/AKT/mTOR inhibitor BKM120 worked synergistically
to decrease cell viability and enhance antitumor efficacy in TNBC
cell lines.161
PARP inhibitors
Poly (ADP-ribose) polymerase (PARP) is an enzyme involved in
DNA repair mechanisms necessary for maintaining BRCA-mutated
cell viability.162,163 Included in the PARP enzyme family are
tankyrase (TNKS)-1 and TNKS2. TNKS1 and TNKS2 are regulators of
Wnt signaling through their interaction with Axin.164,165 TNBCs
share phenotypic characteristics with BRCA-mutated cancers, thus
providing support for the use of PARP inhibitors.166 The small
molecule TNKS1/2 inhibitor XAV939 showed effectiveness in the
destabilization of Axin and reduction of Wnt activity, although
data suggest that a combination approach may be more
beneficial.165 Clinical trials evaluating the oral PARP inhibitor
olaparib in BRCA1/2-positive metastatic breast cancer are currently
underway, with interim results showing efficacy.167 Veliparib is
another PARP inhibitor currently being evaluated in combination
with paclitaxel and carboplatin for metastatic TNBC.168 Data from
Phase I clinical trials of veliparib show acceptable safety, tolerance
and good antineoplastic activity.168
Histone deacetylase inhibitors
Histone deacetylase (HDAC) inhibitors are emerging as promising
anti-TNBC agents because of their multifunctional capacity to
regulate gene expression, cell growth and survival, as well as their
ability to restore cellular aberrations due to epigenetic effects.169
Entinostat is an HDAC inhibitor recently shown to have anti-CSC
effects in TNBC stem cells. An in vivo study found that entinostat
treatment reduced TNBC stem cell populations, tumorsphere
formation and miR-181a expression in TNBC cell lines.170
Furthermore, the study found that entinostat treatment in TNBC
patient-derived xenografts reduced tumor growth and inhibited
the development of lung metastases.170 Further in vivo studies
have shown that triple therapy, combining entinostat, all-trans
retinoic acid and doxorubicin, induced apoptosis of TNBC stem
cells in culture and induced differentiation of TNBC CSCs both
in vitro and in vivo.171 Panobinostat (LBH589) decreased cell
survival and cell cycle progression at the G2/M stage in TNBC cell
lines and in vivo. It also increased acetylation of the histones
H3 (Lys3) and H4 (Lys8).169 Treatment with panobinostat
upregulated cadherin-1 (CDH1) and reversed the M phenotype;
CDH1 has been identified as a Wnt-signaling component in
invasive breast carcinoma.172 An in vivo study found that
salinomycin, a compound that selectively inhibits CSCs,173 in
combination with panobinostat, significantly inhibited the growth
of TNBC stem cells in TNBC patient-derived xenografts. The study
found that salinomycin and panobinostat worked synergistically
to inhibit cell cycle progression, enhance apoptosis and regulate
EMT in TNBC stem cells.173
CONCLUSIONS
The dysregulation of Wnt signaling is synonymous with cancer.
TNBC is an aggressive, highly proliferative phenotype, which is
characteristic of overactive signaling pathways. The accelerated
development of sequencing technologies has allowed us to
characterize the highly heterogeneous molecular landscape of
TNBC with unprecedented detail. These technologies have
allowed the discovery of new potential therapeutic targets, as
well as to suggest where existing drugs may be of therapeutic
value, for instance, in the use of tamoxifen on AR-positive TNBC
patients. Like TNBC, Wnt signaling is highly complex and not yet
fully characterized. The discovery of novel regulators in TNBC, such
as DDXs, adds to the complexity, but also presents exciting new
opportunities for the development of potential therapeutic
targets. Structural knowledge of Wnt pathway proteins and
interactions has expanded in recent years, providing opportunities
for rational/structure-based drug design of novel cancer
therapeutics.
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a b s t r a c t
Malignant mesothelioma (MM) is an aggressive cancer, characterized by rapid progression, along with
late metastasis and poor patient prognosis. It is resistant to many forms of standard anti-cancer treat-
ment. In this study, we determined the effect of secreted frizzled-related protein 4 (sFRP4), a Wnt
pathway inhibitor, on cancer cell proliferation and metabolism using the JU77 mesothelioma cell line.
Treatment with sFRP4 (250 pg/ml) resulted in a significant reduction of cell proliferation. The addi-
tion of the Wnt activator Wnt3a (250 pg/ml) or sFRP4 had no significant effect on ATP production and
glucose utilisation in JU77 cells at both the 24 and 48 h time points examined. We also examined their
effect on Akt and Glycogen synthase kinase-3 beta (GSK3β) phosphorylation, which are both important
components of Wnt signalling and glucose metabolism. We found that protein phosphorylation of Akt
and GSK3β varied over the 24 h and 48 h time points, with constitutive phosphorylation of Akt at serine
473 (pAkt) decreasing to its most significant level when treated with Wnt3aþsFRP4 at the 24 h time
point. A significant reduction in the level of Cytochrome c oxidase was observed at the 48 h time point,
when sFRP4 and Wnt3a were added in combination.
We conclude that sFRP4 may function, in part, to reduce/alter cancer cell metabolism, which may lead
to sensitisation of cancer cells to chemotherapeutics, or even cell death.
& 2016 Elsevier Inc. All rights reserved.
1. Introduction
Malignant mesothelioma (MM) is a particularly aggressive
cancer that is characterised by rapid progression, late metastases,
and poor prognosis [1]. Although this tumour is relatively un-
common, the incidence continues to rise in Australia as a con-
sequence of high past asbestos use and the long latency period
between exposure to asbestos and subsequent tumour develop-
ment. MM is highly resistant to conventional forms of anti-cancer
therapy, and both radiotherapy and chemotherapy have a limited
effect [1]. There is an urgent need for more effective therapies for
this cancer based upon identification of molecular targets through
improved biological understanding of the disease. The Wnt sig-
nalling pathways play a key role in development and homo-
eostasis. There is convincing evidence in a number of different
cancers that chronic activation of Wnt signalling is important in
tumorigenesis, and this has fuelled interest in targeting this
pathway [2–5]. Aberrations of Wnt signalling have been described
in mesothelioma [6], and there is a need to identify the extent to
which this pathway drives cell growth and survival in MM. The
investigation of biological and immunological therapies for MM in
preclinical models has been a major interest. In human and mouse
MM cells, we have investigated regulators of the Wnt signalling
pathway [7]. In particular, we have shown differential expression
of secreted frizzled-related protein 4 (sFRP4) [6], which is a Wnt
antagonist, and of longstanding interest to our group for its role in
apoptotic signalling in morphogenesis, developmental biology,
and neoplasia [8–11].
Cancer cells “rewire” metabolism to maintain continued pro-
liferation. Changes in cellular metabolism occur down-stream of
oncogene/tumour suppressors [12]. It has been demonstrated that
tumour cells consume large amounts of glucose to yield ATP [13].
It is well established that deregulated pathways in cancer also
impact on metabolism. The difference in metabolic properties of
cancer cells and normal cells suggests that targeting metabolic
dependence could be a selective approach to treat cancer patients.
In 1956, Warburg observed that the rate of glycolysis was
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abnormally high in cancer cells. This ‘Warburg effect’ indicates
that cancer cells prefer glycolytic breakdown of glucose for energy,
rather than mitochondrial oxidative phosphorylation [14]. Al-
though the molecular mechanisms that define the Warburg effect
are not yet fully understood, the increased glycolysis observed in
cancer cells is well accepted to be important for the support of
malignant phenotypes [15,16].
In this study, we are the first to report the effects of the Wnt-
pathway inhibitor, sFRP4, on mesothelioma cancer cell metabolism
via assessment of ATP production, glucose utilisation, and bioe-
nergetics, together with downstream signalling molecules such as
total and phosphorylated glycogen synthase kinase-3 beta
(GSK3β), Protein kinase B (also known as Akt), and cytochrome C
oxidase (COX IV).
2. Materials and methods
2.1. Cell culture and treatment
The malignant mesothelioma cell line JU77, originally derived
from pleural effusions of different patients presenting with ma-
lignant pleural mesothelioma, was used in this study [17]. The cells
were cultured in RPMI1640 (Hyclone) with 10% FBS (Bovogen),
penicillin (100IU/ml), and streptomycin (100 μg/ml) (Life Tech-
nologies). JU77 cells were seeded in 6-well plates (Corning) at a
density of 30,000/cm2, and treated with recombinant Wnt3a
(250 pg/ml) and sFRP4 (250 pg/ml) (R&D Systems) for 24 and 48 h.
2.2. Morphology
Phase contrast images were obtained following the different
treatments using an Olympus bright field microscope.
2.3. MTT assay
Cell proliferation in response to various treatments was quan-
titated using the MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide)) assay. Cells were seeded into 96-well
plates at a density of 10,000–20,000 cells/well, depending on the
experiment. Following 24 h incubation, treatments were added
and cells incubated for a further 24–48 h (depending on experi-
ments). The MTT assay was performed as previously described
[18], and absorbance was read at 595 nm with a microplate reader
(Enspire, Perkin Elmer). For each treatment, the mean absorbance
for the assay replicates (3 wells) was calculated. The data are ex-
pressed as mean7standard deviation for at least 3 independent
experiments, and plotted using Prism for Windows v 6.07
(Graphpad Software, CA, USA).
2.4. Viability assay
Trypan blue is a stain used to selectively stain dead cells blue.
To minimise operator bias, trypsinised cells were stained with
trypan blue, and live and dead cells enumerated using Invitrogen
Countess™ Automated Cell Counter chambers [19].
2.5. Measurement of cellular ATP and cellular glycolytic activity
Relative cellular ATP content was measured by the luciferase-
based Cell Titer-Glo Luminescent Cell Viability kit (Promega), with
modifications from the manufacturer's protocol. Briefly, cells were
plated in 96-well plates at 5000 cells per well to allow for at-
tachment overnight. At the desired harvest time, an equal volume
of the single-one-step reagent provided by the kit was added to
each well and rocked for 15 min at room temperature. Cellular ATP
content was measured and quantified using an ATP standard curve
and a luminescent plate reader (Enspire, Perkin Elmer).
Glycolytic activity was determined by measuring glucose con-
sumption. Cells were seeded in 96-well cell culture microplates at
5000 cells per well per 100 ml according to their growth rate, and
allowed to attach overnight. Fresh medium was replaced the next
morning along with treatment conditions and incubated for 24 or
48 h prior to the assay. Cell culture medium with no cells present
was used to calculate the initial level of glucose in the medium
(11.1 mM). The glucose consumed from the cell culture medium
was measured using the Amplex Red Glucose kit (Invitrogen,
Molecular Probes). The samples were diluted 150 fold and the
assay was performed according to the manufacturer's instructions.
The fluorescence emission was measured at 590 nm following
excitation at 550 nm using a Perkin Elmer microplate reader. The
values were calculated according to the standard curve, and then
subtracted from the base line to obtain values of glucose con-
sumption from the growth culture medium by the cells [20]. Data
were then presented as a percentage of the initial glucose
concentration.
2.6. Seahorse XFe96 measurements and analysis
The Seahorse Bioscience XFe96 Flux analyser and the Mito Stress
Test kit (Seahorse Biosciences) were used according to manufac-
turer's instructions. In brief, cells were seeded into 96 well plates at
a density of 5,000 cells/well and allowed to adhere overnight (cell
density was previously optimised for oxygen consumption rates
(OCR) and proton production rates (PPR)). Prior to Seahorse analy-
sis, the culture medium was changed to serum-free DMEM (pH 7.4)
containing 1 mM sodium pyruvate, 2.5 mM Glucose, and without
sodium bicarbonate, and plates were then incubated for 60 min at
37 °C in a non-CO2 incubator. Following instrument calibration, the
Mito Stress Test was performed using the following injection
strategy: DMEM (2.5 mM glucose) with or without Wnt3a, sFRP4,
or Wnt3a and sFRP4 in combination, oligomycin (2 mM), carbonyl
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 0.4 mM), and
finally, rotenone/antimycin A in combination (1 mM). OCR and PPR
were determined using three 3.5 min assay cycles of mix, and
measurement undertaken following each injection. Normalisation
of data was performed by determining the cell density using the
neutral red uptake assay after the stress test, and measurements
were compared to ensure there were no significant changes in re-
lative cell numbers among treatment groups. The concentrations of
all inhibitors used were optimised to ensure the lowest con-
centration was used to produce the maximum effect.
Basal respiration was calculated by subtracting the minimum
OCR following addition of rotenone/antimycin A (non-mitochon-
drial respiration) from the last OCR measurement recorded prior
to the addition of oligomycin. Proton leak was calculated by sub-
tracting the minimum OCR following the addition of rotenone/
antimycin A (non-mitochondrial respiration) from the minimum
OCR measurement recorded after addition of oligomycin. OCR re-
lated to ATP production (turnover) was calculated by subtracting
the proton leak from the basal respiration. Coupling efficiency
percentage was calculated by dividing the ATP turnover-depen-
dent OCR by the basal respiration and multiplying by 100. Max
respiration was determined by subtracting the non-mitochondrial
respiration from the maximum OCR following the addition of
FCCP. The spare respiratory capacity was calculated by subtracting
the basal OCR from the maximum OCR after FCCP addition. The
glycolytic response of JU77 cells was measured by first correcting
the extracellular acidification rate (ECAR) experimental values to
PPR by including the buffer capacity of the medium, which was
determined by monitoring the pH change of DMEM following
5 additions of a known quantity of protons from 0.1 M
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hydrochloric acid. Basal PPR was indicative of glycolytic response,
while glycolytic reserve capacity was determined by subtracting
the basal PPR from the maximum PPR following the addition of
oligomycin. Each treatment was measured in quadruplicate wells
and repeated on 3 independent occasions (n¼3).
2.7. Western blotting
Whole cell lysates were extracted at 24 and 48 h times points
by scraping cells into radio immunoprecipitation assay (RIPA)
buffer (Sigma Aldrich) with 200 mM phenylmethylsulphonyl-
fluoride (PMSF) and proteinase/phosphatase inhibitor cocktail
(100X) (Cell Signalling Technologies). Whole cell lysates were
quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific). The lysates were loaded into a 10% SDS-PAGE gel after
being boiled for 5 min at 95 °C. After electrophoresis, the proteins
were transferred onto a nitrocellulose membrane using the iBlot
Dry Blotting System (Life Technologies). The membranes were
blocked with 5% low-fat skim milk powder in phosphate buffered
saline with 0.1% Tween-20 (Sigma Aldrich) (PBST) for an hour at
room temperature. Antibodies for total GSK3-β, pser9GSK3-β, total
Akt, and Cytochrome c oxidase subunit IV (all Cell Signalling
Technologies) were probed at a dilution of 1:1000 using SNAP i.d s
2.0 (Merck Millipore) for 10 minutes at room temperature, washed
with PBST, and incubated in a 1:2000 dilution of HRP-linked anti-
rabbit secondary antibody for a further 10 minutes at room tem-
perature. pser473Akt antibody (1:1000 dilution) (Cell Signalling
Technologies) was probed overnight at 4 °C, washed with PBST,
and then the HRP-linked anti-rabbit secondary antibody (1:2000)
(Cell Signalling Technologies) was added for 1 h at room tem-
perature. All blots were developed using Amersham ECL Prime
Western Blotting Detection Reagent (GE Life Sciences).
Fig. 1. The Effect of Wnt3a and sFRP4 on cell morphology and viability in JU77 cells. Panel (a) Treatment with sFRP4 had significant morphological effects upon the cultures.
Many cells showed a characteristic loss of attachment and a rounded up appearance (Fig. 1a, iii, Nikon inverted microscope-10 magnification). i- Control, ii- Wnt3a
(250 pg), iii- sFRP4 (250 pg), iv- Wnt3aþsFRP4 (250 pg). Calculation of viable cell numbers/mL demonstrates the significant reduction in cell viability following the addition
of sFRP4 (Fig. 1b).
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2.8. Statistical analysis
Statistical comparison between two groups was performed
using an unpaired t-test with Instat (Graphpad Software). The
difference was determined to be statistically significant if po0.05.
3. Results
3.1. Wnt signalling molecules modulate mesothelioma cell
proliferation
We found that sFRP4 suppressed cell proliferation/viability in
JU77 cells at 24 h and 48 h (Figs. 1b and 2). We next determined
the effect of the canonical Wnt ligand, Wnt3a, and Wnt3aþsFRP4,
on proliferation. Though Wnt3a was able to increase proliferation,
it was not statistically significant compared to control. sFRP4 could
reduce the Wnt3a-induced proliferation. These results indicate
that Wnt signalling molecules can modulate cellular proliferation
in mesothelioma cells.
3.2. ATP and glucose utilisation
The addition of Wnt3a (250 pg), sFRP4 (250 pg), or
Wnt3aþsFRP4 (250 pg) for 24 and 48 h did not significantly
modulate cellular ATP levels or glucose utilisation in JU77 cells
(Fig. 2a and b, respectively). ATP levels were slightly decreased
following 48 h in comparison with 24 h (panel a). However, ATP
levels associated with Wnt3a, sFRP4, or Wnt3aþsFRP4 were not
significantly different from the control at 24 and 48 h. As expected,
JU77 cells consumed approximately 20% of the glucose present in
the medium over 24 h, and a further 20% over an additional 24 h
period (48 h in total), and this was independent of the presence of
Wnt3a, sFRP4, or Wnt3aþsFRP4 (panel b).
3.3. Acute effect on cellular bioenergetics
Since Wnt3a (250 pg), sFRP4 (250 pg), or Wnt3aþsFRP4
(250 pg) did not significantly alter ATP and glucose utilisation over
24 and 48 h, we investigated the impact of acute exposure of these
factors on JU77 cellular bioenergetics using the Seahorse 96e Flux
Analyser. Similar to the ATP data above, neither Wnt3a, sFRP4, nor
Wnt3aþsFRP acutely modulated ATP turnover, proton leak, nor
the coupling efficiency in JU77 cells (Fig. 3a). Furthermore, the
basal OCR (respiration) was not significantly altered by acute ad-
dition of Wnt3a, sFRP4, or Wnt3aþsFRP4 (Fig. 3b). In addition, no
significant change in JU77 max respiration or spare respiratory
capacity was observed, indicating that Wnt3a, sFRP4, and
Wnt3aþsFRP4 did not impact on oxidative bioenergetics at the
chosen concentrations (Fig. 3b). JU77 cells displayed a high level of
PPR, suggesting high glycolytic activity indicative of tumour cells.
Furthermore, the treatments used did not modulate basal PPR or
the reserve glycolytic capacity of these cells (Fig. 3c) (Fig. 4).
3.4. Effect on signalling protein phosphorylation and expression
Protein phosphorylation of Akt and GSK3β varied over the 24 h
and 48 h time points, with constitutive phosphorylation of Akt at
serine 473 (pAkt) decreasing to its most significant level when
treated with Wnt3aþsFRP4 at the 24 h time point (Fig. 5d). Al-
though there was a reduction in pAkt at 24 h with the addition of
sFRP4 alone, this was not shown to be significant. After 48 h, pAkt
was seen to increase with every treatment group relative to the
48 h control (Fig. 5d). Conversely, the most significant reduction in
the phosphorylation of GSK3β at serine 9 (pGSK3β) by treatment
with sFRP4 occurred at the 48 h time point (Fig. 5b). Interestingly,
the reduction of total GSK3β due to the addition of Wnt3a alone
and when combined with sFRP4 was significant at the 24 h time
period (Fig. 5a), while total Akt was also significantly decreased
with Wnt3a treatment at the same time point (Fig. 5c). The only
significant reduction in the level of Cytochrome c oxidase (COXIV)
was at the 48 h time point, when sFRP4 and Wnt3a were added in
combination (Fig. 5e).
4. Discussion
Studies of sFRPs in mesothelioma have mainly investigated
Fig. 2. The effect of sFRP4 on cell proliferation. MTT data demonstrate a significant
reduction of cell proliferation following treatment with sFRP4 at 24 h but not at
48 h.
Fig. 3. The Effect of Wnt3a and sFRP4 on ATP and glucose utilisation in JU77 cells.
(a) ATP levels in treated cells did not alter significantly among treatment groups,
and was only slightly decreased between 24 and 48 h. After 24 h the level of ATP
ranged between 19 and 20 nM, while after 48 h it ranged between 16 and 18 nM.
(b) Glucose utilisation was also not significantly altered between treatment groups
at both time-points. After 24 h JU77 cells utilised approximately 20% of glucose
from the initial medium, which doubled to 40% after 48 h, indicating that JU77 cells
consumed 20% of glucose per 24 h period.
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their role in apoptosis and cancer, and their ability to chemo-
sensitise tumour cells [5]. sFRPs are structurally related to the
frizzled receptors [4]. Previously it has been reported that ex-
pression of sFRP 1, 3, 4, and 5 were apparently down-regulated in
mesothelioma tissue samples and two mesothelioma cell lines [2],
and that sFRP4 may suppress growth and induce apoptosis in β-
catenin null mesothelioma cells [5]. We have shown that both
sFRP4 and Wnt3a may modulate mesothelioma cell growth in
more biologically relevant models, since most mesotheliomas ex-
press β-catenin [6].
Previous studies have shown that targeting factors that reg-
ulate drug-induced apoptosis, cell cycle arrest, or inhibit angio-
genesis [9] can influence chemosensitivity [10]. Our previous work
was the first to demonstrate that sFRP4 not only plays a key role in
the chemo-response of ovarian tumour cells but also, when up-
regulated in chemoresistant cells, can enable these cells to re-
spond better to Cisplatin treatment [10]. Similar findings have
been demonstrated in glioblastoma [21] and other tumours such
as breast, prostate, head and neck, and mesothelioma [22]. An-
other advantage of sFRP4 is that this molecule can suppress tu-
morigenic growth either in the presence or absence of the cano-
nical Wnt/β-catenin signalling pathway, as demonstrated in me-
sothelioma cell lines [2,5]. In the present study, we examined the
role of sFRP4 role in malignant mesothelioma cell metabolism. The
metabolic activities that allow a cell to resist death in a stressful
environment are very important for cancer cell survival [23]. In
order to continue proliferating, cancer cells have to maintain en-
ergy levels when nutrients and oxygen become limited, which can
occur due to the disordered vasculature and hypoxic conditions
associated with tumours [24].
One of the primary metabolic changes associated with pro-
liferating tumour cells is induction of aerobic glycolysis. Glucose is
a critical nutrient for cell division, and in proliferating cancer cells,
the majority of the pyruvate generated from glucose (490%) is
converted to lactate by lactate dehydrogenase, where it is readily
secreted into the extracellular environment rather than oxidised to
completion [25,26]. Interestingly, we found that while sFRP4,
Wnt3a, and Wnt3aþsFRP4 combination treatment altered cell
morphology and/or cell proliferation (Figs. 1 and 2), but it did not
alter ATP production, intracellular ATP levels, or glucose con-
sumption significantly (Fig. 2a and b). It is possible that MM cells
have an inherent capacity to proliferate independent of ATP pro-
duction or glucose consumption. This could be one reason for their
highly chemoresistant nature. Attempts have been made to ma-
nipulate metabolic reprogramming by treating highly chemore-
sistant cells with compounds that inhibit glycolysis [27]. However,
it may be possible that the cells are able to use other nutrient
sources for energy that does not affect its ability to utilise glucose.
In fact, it could well be that glucose utilisation is at its maximum
and cannot be increased any further in the controls cells. Since the
treatment groups did not significantly alter the ATP and glucose
utilisation over the time points examined, we investigated the
effect of acute exposure of these factors on JU77 cellular bioe-
nergetics. Interestingly, similar to the ATP data, the treatment
groups did not alter ATP turnover, proton leak, the coupling effi-
ciency, basal OCR, max respiration, or spare respiration capacity in
JU77 cells (Fig. 3a–c). However, JU77 cells displayed a high level of
PPR, suggesting high glycolytic activity indicative of tumour cells.
It is surprising that we did not observe any significant changes in
metabolic parameters from chronic or acute exposure of sFRP4 at
the chosen concentrations. Expression of this factor has been re-
ported to be modulated in metabolic disease, such as type 2 dia-
betes mellitus (T2DM). It has been demonstrated that sFRP4 was
elevated in the serum of T2DM patients, where it impacted on islet
Ca2þ handling, which is central to insulin release [28,29]. How-
ever, the role of sFRPs in metabolism is unclear, as other isoforms,
such as sFRP1, have been shown to be initially over-expressed
during initial weight gain, but subsequently decreased following
progression to obesity, which is a major-risk factor for T2DM [30].
Nonetheless, these reports point to a regulatory function in me-
tabolism, and in fact the pro-apoptotic mechanism of action of
sFRP4 is believed to involve higher cellular reactive oxygen species
generation, which may possibly stem from enhanced electron
transport chain activity. However, the lack of metabolic changes
observed in the current study may be due to either cell type- or
concentration-dependent effects.
In addition, we observed biphasic modulation of GSK3β phos-
phorylation by sFRP4 (Fig. 4a–c.). This interesting finding indicates
that sFRP4 may be suppressing tumour growth and tumour cell
proliferation by not only inhibiting Wnt/β-catenin pathways but
also altering GSK3β phosphorylation. The mechanism by which
sFRP4 alters GSK3β activity needs to elucidated. Though there was
no change in oxygen consumption between treatments or the two
time points examined, the COXIV protein level showed a sig-
nificant reduction at 48 h following combination treatment, sug-
gesting cytochrome c oxidase might be the rate-limiting step of
overall respiration in tumour cells and could also serve as the
regulatory site for oxidative phosphorylation [31–33]. However, no
bioenergetic alterations were observed during the metabolic flux
assay, and the COXIV protein expression largely confirm this.
Fig. 4. The acute effect of Wnt3a and sFRP4 on cellular bioenergetics in JU77 cells.
JU77 cell bioenergetics was determined using the Seahorse XFe96 and Mito Stress
Test kit. (a) No significant change in ATP turnover, proton leak, or coupling effi-
ciency was detected 20 mins after acute addition of Wnt3a, sFRP4, or
Wnt3aþsFRP4. (b) Neither factor altered the basal or max respiration of JU77 cells,
in addition to the spare respiratory capacity. (c) Interestingly, JU77 cells displayed a
high level of PPR, but acute addition of the agents did not modulate basal PPR or
the reserve glycolytic capacity.
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Our cell proliferation data using both cell viability and MTT
assays indicate that sFRP4 can induce cell death on its own and
can also reduce Wnt3a-induced proliferation. The probable me-
chanism by which sFRP4 causes cell death is by abrogating Akt
survival signalling. Interestingly, inactivation of GSK3β through
phosphorylation may result in nuclear accumulation of β-catenin
and thereby provides a link, at least in one direction, to the clas-
sical Wnt/β-catenin pathway. Our data presented here support this
view. Being a member of the sFRP family, it is probable that sFRP4
abrogates a Wnt-regulated signal transduction pathway. Since
cells treated with sFRP4 showed reduced levels of both Akt kinase
activity and reduced GSK3β, we conclude that the observed cor-
relation between sFRP4 expression and increased rate of apoptosis
is because of an inactivation of an Akt-dependent survival path-
way. Furthermore, caspase-3 activation induced by inhibition of
mitochondrial complex I has been shown to be facilitated by
GSK3β [34]. Since both Akt as well as Wnt signalling inhibit GSK3β
activity, one might speculate that sFRP4-induced inhibition of the
Wnt pathway reactivates GSK3β and thereby promotes cell death
at the 24 h time point but not at 48 h. It is interesting that the
Wnt3aþsFRP4 combination treatment increased total and pAkt,
suggesting that sFRP4 was not able to counteract the effect of
Wnt3a at the 24 h time point whereas it could at 48 h.
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Mesenchymal  stem  cells  (MSCs)  are  multipotent  precursor  cells  originating  from several  adult  connective
tissues.  MSCs  possess  the  ability  to  self-renew  and  differentiate  into  several  lineages,  and are  recognized
by  the  expression  of  unique  cell  surface  markers.  Several  lines  of  evidence  suggest  that  various  signal
transduction  pathways  and  their  interplay  regulate  MSC  differentiation.  To  that  end,  a critical  player  in
regulating  MSC  differentiation  is  a group  of  proteins  encoded  by  the  Wnt  gene  family,  which  was pre-
viously  known  for  influencing  various  stages  of  embryonic  development  and  cell  fate  determination.  As
MSCs  have  gained  significant  clinical  attention  for  their  potential  applications  in  regenerative  medicine,  it
is  imperative  to  unravel  the  mechanisms  by  which  molecular  regulators  control  differentiation  of  MSCs
for  designing  cell-based  therapeutics.  It is  rather  coincidental  that  the  functional  outcome(s)  of Wnt-
induced  signals  share  similarities  with  cellular  redox-mediated  networks  from  the  standpoint  of MSC
biology.  Furthermore,  there  is evidence  for  a crosstalk  between  Wnt  and  redox  signalling,  which  begs  the
question  whether  Wnt-mediated  differentiation  signals  involve  the  intermediary  role  of  reactive  oxygen
species.  In  this  review,  we  summarize  the  impact  of Wnt  signalling  on  multi-lineage  differentiation  of
MSCs,  and  attempt  to unravel  the  intricate  interplay  between  Wnt  and  redox  signals.
©  2015  Elsevier  Ltd.  All  rights  reserved.
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1. Introduction
1.1. Clinical significance of mesenchymal stem cells and their
differentiation
There has been a recent surge in interest in the clinical use
of mesenchymal stem cells (MSCs) in regenerative medicine, tis-
sue repair, and other cell-based therapies (Pittenger et al., 1999).
MSCs have been isolated from various sources such as bone mar-
row (Bianco et al., 2001), adipose tissue (Zuk et al., 2001), umbilical
cord tissue (Weiss and Troyer, 2006), periodontal ligament (Seo
et al., 2004), synovial membrane (Harvanova, 2011), menstrual
fluid (Patel et al., 2008), and dental pulp (Agha-Hosseini et al., 2010).
Although bone marrow was the earliest identified source of MSCs
(Friedenstein et al., 1970), the utility of marrow-derived MSCs was
limited due to several factors such as invasive surgery and subse-
quent patient discomfort. Hence, sources of MSCs other than the
bone marrow, such as described above, have been aggressively
explored in recent years.
MSCs are capable of extensive self-renewal in an undifferenti-
ated state, but upon appropriate and specific stimuli are capable
of multi-potent differentiation towards various cell lineages.
Although the preference is for differentiation to mesenchymal lin-
eages, there is strong experimental evidence for differentiation to
all three germ layers – mesoderm, ectoderm, and endoderm (Seo
et al., 2004; Choi et al., 2010; Safford et al., 2002; Kuroda et al., 2010;
Zuk et al., 2002). As such, a better understanding of the process
of MSC  differentiation at the molecular level is essential if MSCs
are to achieve the potential for their application in regenerative
medicine. This demands an understanding of the signal transduc-
tion pathways regulating MSC  differentiation, amongst which Wnt
signalling is one of the key players. Hence, in this review, we  high-
light how the Wnt  signalling network impacts MSCs and influences
their fate. Our primary focus will be the interaction between the
canonical Wnt  signalling pathway and MSC  differentiation. Further,
we will describe the effect of reactive oxygen species (ROS) on MSC
differentiation and the crosstalk between ROS and Wnt  to influence
MSC  differentiation.
1.2. Wnt  signalling
Wnt  signalling is evolutionarily conserved from nematodes to
mammals, regulating various stages of embryonic development
as well as tissue homeostasis in adulthood (Cadigan and Nusse,
1997; Wodarz and Nusse, 1998). Wnt  signalling affects major
cellular events such as proliferation, survival, apoptosis, angiogen-
esis and cell polarity. It is also involved in regulating self-renewal
and differentiation of stem cells in adult tissues, and regulating
the regenerative processes in response to disease, trauma, and
ageing. The Wnt  molecules are secreted glycoproteins composed
of 350–400 amino acid residues, of which 23–24 are highly con-
served cysteine residues (molecular weight: 39–46 kDa) (Cadigan
and Nusse, 1997). The difference in mode of signalling subsequent
to the generation of the Wnt  signal classifies the Wnt  signalling
network into two  main branches, depending on the intracellular
response it triggers. One is the canonical pathway mediated by -
catenin, while another is the non-canonical signalling pathway that
involves protein kinase C (PKC) and c-jun N-terminal kinases (JNK).
1.2.1. Canonical Wnt  signalling
The canonical Wnt  signalling pathway is -catenin mediated.
Here, the Wnt  ligand forms a ternary complex with a Frizzled (Fz)
receptor and low-density lipoprotein receptor-related protein 5/6
(LRP5/6) co-receptor to activate the intracellular Dishevelled (Dvl)
protein. Dvl in turn phosphorylates and inhibits glycogen synthase
kinase-3 (GSK-3) of the destruction complex. The destruction
complex is composed of the proteins, axin, adenomatous polyposis
coli (APC), casein kinase 1 (CK1), and GSK-3,  and is responsible
for the phosphorylation and subsequent degradation of -catenin
in the absence of Wnt  signalling. In the presence of a Wnt  stim-
ulus the complex remains inactive, leading to accumulation of
the unphosphorylated -catenin in the cytoplasm and consequent
translocation to the nucleus. In the nucleus, -catenin replaces the
co-repressors and binds to the transcriptional factor complex com-
posed of T cell factor/lymphoid-enhancing factor (TCF/LEF), thereby
triggering the transcription of the Wnt  target genes.
1.2.2. Non-canonical Wnt  signalling
Non-canonical Wnt  signalling is independent of -catenin and
involves several distinct pathways. One of the non-canonical path-
ways impacts on cell migration by regulating the activation of
calcium/calmodulin-dependent protein kinase II (CaMKII) and pro-
tein kinase C (PKC), thereby resulting in the release of intracellular
calcium (Huelsken and Behrens, 2002; Komiya and Habas, 2008).
This association with cellular Ca2+ mobilization has led to the
description ‘Wnt/Ca2+ signalling pathway’. A second, non-canonical
pathway controlling cell polarity and cytoskeletal organization is
referred to as the Wnt/planar cell polarity (PCP) signalling path-
way. It acts by activating Rho-GTPases and Jun N-terminal kinases
(JNKs) (Huelsken and Behrens, 2002; Komiya and Habas, 2008). The
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molecular events occurring in these non-canonical pathways are
generally less well defined than the canonical pathway.
1.2.3. Regulators of the Wnt  signalling pathway
Among the various molecules that modulate the Wnt  signalling
pathway (Nusse, 2005) are extracellular Wnt  antagonists such
as secreted Frizzled-related proteins (sFRPs), Dickkopfs (Dkks),
and Wnt  inhibitory factor 1 (WIF1) (Kawano and Kypta, 2003;
Gonsalves et al., 2011). Briefly, sFRPs are the first identified secreted
antagonists of the canonical and non-canonical Wnt  signalling
pathways and, in humans, they are five in number (sFRP1-5)
(Gonsalves et al., 2011; Wolf et al., 1997; Huang et al., 2009; Jones
and Jomary, 2002; Boudin et al., 2013). Among them, the major
Wnt  antagonist sFRP4 was first isolated by our group by the use of
a rat cDNA library (Wolf et al., 1997). By inactivating Wnt, sFRPs
prevent the accumulation of active unphosphorylated -catenin in
the cytoplasm, thereby suppressing the activity of Wnt  target genes
(Kawano and Kypta, 2003; Muley et al., 2010).
The Fz receptors possess an extracellular cysteine-rich domain
(CRD) composed of 120 amino acids (Wodarz and Nusse, 1998),
which shares structural homology to the CRD in the N-terminal
region of sFRPs (Rattner et al., 1997); sFRPs lack the transmembrane
domain present in Fz receptors. sFRP anatgonizes Wnt  signalling by
interfering with the Wnt–Fz interaction through direct binding to
the Wnt  or to the Fz receptor, thereby forming a non-functional
complex. While the latter mechanism (sFRP–Fz binding) is facil-
itated by the CRD of the sFRPs (Bafico et al., 1999), the former
mechanism (sFRP–Wnt binding) can occur either via the CRD (Lin
et al., 1997) or the domains in the C-terminal region of sFRPs (Uren
et al., 2000). In addition, the biphasic regulatory potential of sFRPs
has been elucidated by evidence of Wnt  binding to the CRD in the
N-terminal region of sFRPs and inhibiting -catenin accumulation;
while Wnt  binding to the domain in the C-terminal region of sFRP
allows the CRD at the N-terminus to interact with Fz, hence facili-
tating Wnt  signalling (Uren et al., 2000).
Other Wnt  anatagonists such as the Dickkopf (Dkk) family
includes four members (Dkk 1–4), which inhibit only the canonical
Wnt  signalling by binding to the LRP5/6 co-receptor (Kawano and
Kypta, 2003). In addition to these naturally occurring extracellular
Wnt  antagonists, there are pharmacologically derived antagonists
such as XAV939 (Jones and Jomary, 2002) and iCRT3 (Boudin et al.,
2013). In this review we focus on how these different Wnt  regu-
lators play a role in Wnt  signal transduction and influence the cell
fate determination of MSCs.
2. Role of Wnt  signalling pathways in differentiation of
mesenchymal stem cells
2.1. Role of Wnt  signalling in adipogenic differentiation
Evidence from the last decade indicates an important role
for Wnt  signalling in adipogenic differentiation from precursor
cells. (Christodoulides et al., 2009). An inhibitory effect on adi-
pogenesis by Wnt-activating molecules such as Wnt  10b, GSK-3
inhibitors such as lithium chloride (LiCl) (Ross et al., 2000), and
CHIR 99021 (Bennett et al., 2002) has been demonstrated using 3T3
pre-adipocytes. Wnt4 and Wnt5a, both non-canonical Wnt  ligands,
have been shown to possess a promoting effect on 3T3 cell adipo-
genesis through the PKC-CamKII pathway. Additionally, the authors
refer to antagonism of the canonical Wnt  signalling pathway by
Wnt5a (Nishizuka et al., 2008).
In MSCs, the inhibitory effect on adipogenesis has been
demonstrated using the GSK-3 inhibitor (Wnt activator) –
6-bromo-indirubin-3′-oxime (BIO) (Zaragosi et al., 2008). Wnt
activation (by silencing the Wnt  antagonists sFRP4 and Dkk1)
was performed in adipose MSCs, which resulted in significant
down-regulation of adipogenic differentiation with regard to lipid
accumulation as well as adipogenic markers (Park et al., 2008). It
has also been reported that a short 48 h treatment with sFRP1 and
sFRP4 upregulated adiponectin secretion in human MSCs (Ehrlund
et al., 2013).
Additionally, during adipogenic differentiation of MSCs, the lev-
els of the Wnt  antagonists sFRP4 and Dkk1 were seen to be higher
than in the undifferentiated state (Park et al., 2008). Our laboratory
has demonstrated that addition of exogenous sFRP4 promoted adi-
pogenic differentiation of MSCs (Visweswaran et al., 2015). This
in vitro evidence indicates the presence and significance of the
suppressed state of Wnt  signalling during adipogenesis. The impor-
tance of Wnt  antagonist levels has been tested out by a few clinical
studies. In one of them, sFRP4 levels were seen to be directly propor-
tional to impaired glucose and triglyceride metabolism (Hoffmann
et al., 2014), and in another study sFRP4 was proposed as a
biomarker for predicting type II diabetes mellitus (Mahdi et al.,
2012). Overall, the activation of the Wnt  signalling pathway inhibits
adipogenic differentiation in MSCs, while the presence of Wnt
antagonists promotes a contrary effect on adipogenesis, which
could be considered when developing new strategies to manage
obesity and diabetes.
2.2. Wnt  signalling regulates osteogenic differentiation
Growing evidence suggests a regulatory role for Wnt  signalling
in bone development and homeostasis. In MSCs, the in vitro
potential of Wnt  signalling on osteogenic differentiation has been
controversial, with both stimulatory and inhibitory effects being
reported. It has been shown that the canonical Wnt  signalling path-
way activates differentiation of MSCs into osteoblasts (Liu et al.,
2009). The disruption of Wnt  signalling by a functional mutation
or targeted destruction of LRP5 in mice has been shown to pro-
mote osteoporosis and a low bone mass phenotype (Gong et al.,
2001; Kato et al., 2002), while its over-expression leads to a high
bone mass syndrome (Boyden et al., 2002). In another study, the
supportive role of Wnt  proteins towards osteogenesis was shown
by preventing apoptosis of osteoblast progenitors and differenti-
ated osteoblasts in the osteoblast cell line OB-6 and pre-osteoblast
cell line MC3T3-E1 (Almeida et al., 2005). The Wnt  ligand Wnt10b
was shown to prevent bone loss occurring due to oestrogen defi-
ciency and ageing in mice (Bennett et al., 2005). It was reported
that Wnt  signalling favoured osteogenesis at the expense of adi-
pogenesis (Kang et al., 2007; Cawthorn et al., 2012). It was  also
demonstrated that suppression of PPAR and C/EBP, and the
simultaneous enhancement of the expression of osteoblastogenic
transcription factors such as RunX2, Dlx5, and Osterix occurred in
mouse mesenchymal cells (Bennett et al., 2005; Kang et al., 2007).
With regard to the effect of Wnt  antagonism on osteogenesis, it
has been reported to be mostly inhibitory. In mice over-expressing
the Wnt  antagonist sFRP4 in osteoblasts, there was  a reduction
observed in bone formation, leading to a low bone mass (Nakanishi
et al., 2008). This inhibitory effect of Wnt  antagonists on osteo-
genesis was also demonstrated by an in vitro study where sFRP4
inhibited osteogenic differentiation in MSCs from periodontal tis-
sue (Yamada et al., 2013). Among other Wnt  antagonists, sFRP1
over-expression was found to also inhibit in vivo bone formation
(Yao et al., 2010) and increase the rate of osteoblast and osteo-
cyte cell death (Nakanishi et al., 2008). The lack of sFRP1 reduced
apoptosis and accelerated osteoblast proliferation and differenti-
ation in human osteoblasts and MSCs (Bodine et al., 2005), and
also enhanced trabecular bone formation and improved fracture
healing (Bodine et al., 2005; Gaur et al., 2009; Trevant et al., 2008),
indicating the inhibitory effect of Wnt  antagonists on osteogenesis.
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Many other signalling pathways, such as the Hippo signalling
pathway, interact with Wnt. Hippo signalling involves Yes-
associated protein 1 (YAP1), which upregulates Dkk1 and, in turn,
suppresses canonical Wnt  signalling to inhibit the osteogenic
potential of MSCs (Seo et al., 2013). The stimulatory effect of Wnt
has been shown in human MSCs (Gregory et al., 2005) and also in
mouse MSCs (Gaur et al., 2005), where an increased expression of
the osteogenic transcription factor RunX2 was observed (Gaur et al.,
2005). Overall, these studies indicate that canonical Wnt  activation
promotes osteogenesis, while Wnt  antagonists inhibit osteogenesis
from MSCs.
Other studies have reported an inhibition of osteogenesis by the
canonical Wnt  pathway in human bone marrow MSCs (Boland et al.,
2004; de Boer et al., 2004; Baksh et al., 2007). One group reported
that sFRP3 promoted osteoblast differentiation (Chung et al., 2004).
A recent study explained this phenomenon in further detail by
showing that sFRP3 antagonizes the non-canonical Wnt  pathway
through Wnt5a binding, which in turn blocks Wnt5a’s inhibitory
effect on the canonical Wnt  pathway, and hence promotes osteo-
genesis (Yamada et al., 2013). This mechanistic approach adds
further evidence to the role of canonical Wnt  signalling in pro-
moting osteogenic differentiation. All these studies indicate the
extensive crosstalk contributed by the Wnt  signalling network dur-
ing osteogenic differentiation, which should be considered when
devising possible new therapeutic interventions for bone-related
diseases. Moreover, the available evidence reinforces the recipro-
cal relationship that exists between bone and fat development in
response to an activated canonical Wnt  pathway.
2.3. Role of Wnt  signalling in chondrogenic differentiation
Wnt  signalling is one among the main regulators of chondroge-
nesis. The promoting role of Wnt  signalling in chondrogenesis has
been demonstrated by a study showing that sFRP1-deficient mice
demonstrated enhanced chondrocyte maturation in both in vivo
and in vitro conditions (Gaur et al., 2006). A functional role for
Wnt5a, a non-canonical Wnt  ligand, in the chondrogenesis of MSCs
derived from the chicken wing bud has also been demonstrated
(Jin et al., 2006). The level of Wnt5a was up-regulated after treat-
ment with transforming growth factor  (TGF), which promoted
chondrogenesis. This was further supported by the upregulated
pre-cartilage condensation and chondrogenesis in in vitro micro-
mass cultures in MSCs transfected with Wnt5a (Jin et al., 2006). The
mode of action underlying this could be the blunting of canonical
Wnt  signalling by the non-canonical Wnt  ligand Wnt5a, and hence
promoting chondrogenesis. An increased expression of Wnt3a was
associated with the chondrogenic differentiation of high density
C3H10T1/2 murine mesenchymal cells (Fischer et al., 2002a), and
the overexpression of Wnt3a was also demonstrated to promote
this process in the same cell line (Fischer et al., 2002b).
On the other hand, it has been reported that continuous treat-
ment with Wnt1 protein for 21 days reduced the expression of
chondrogenic-specific markers, while treatment with the Wnt
antagonist Dkk1 increased the expression of chondrogenic markers
such as collagen II, Sox9, and aggrecan in human adipose-derived
MSCs (Luo et al., 2013). These results are corroborated by studies
demonstrating that both sFRP1 and Dkk1 enhanced glycosamino-
glycan synthesis, Sox9, and type II collagen expression in early
chondrogenesis of human MSCs (Im and Quan, 2010), and these
Wnt  antagonists also exhibited a chondrogenesis-promoting effect
in long-term pellet cultures (Im et al., 2011).
2.4. Role of Wnt  signalling in cardiogenic differentiation
Previous studies in chick and frog embryos demonstrated
that Wnt  antagonism induced cardiac development while an
activated canonical signalling pathway inhibited the differentia-
tion (Schneider and Mercola, 2001; Marvin et al., 2001). Later,
it was  found that stimulation of canonical Wnt  signalling (by
use of LiCl) increased the bioavailability of -catenin, and hence
improved myogenic differentiation in MSCs derived from aged car-
diac patients (Brunt et al., 2012). The non-canonical Wnt  ligand,
Wnt11, promoted cardiomyocyte differentiation in MSCs trans-
duced with Wnt11 by upregulating GATA-4. The authors postulated
that the mechanism involved Wnt11-mediated activation of the
non-canonical PKC or JNK pathway (He et al., 2011). Contrastingly,
MSCs overexpressing sFRP2 have been shown to have reduced apo-
ptosis rates and improved engraftment and cardiac function in mice
(Alfaro et al., 2010). Exogenous addition of sFRP2 inhibited type
I procollagen maturation, which is important in scar formation
post-myocardial infarction (He et al., 2010), and therapeutic con-
centrations of sFRP2 significantly reduced fibrosis and improved
cardiac function in rats (He et al., 2010). However, in another study,
a reduced infarct size was  observed in sFRP2 null mice, thus the
authors referred to the known biphasic effect of sFRP2 to explain
their findings (Kobayashi et al., 2009). Overall, an activated Wnt
signalling pathway contributes to enhanced cardiogenic differen-
tiation in MSCs and this phenomenon should be considered when
devising MSC-based therapies for myocardial infarction.
2.5. Wnt  signalling inhibits hepatogenic differentiation
The Wnt  pathway has been demonstrated to work synergis-
tically with the MAP/ERK signalling pathway to support hepatic
progenitor cell proliferation (Jin et al., 2011). A study on hepatic
progenitor cells of the mouse embryo demonstrated that inhibition
of Wnt  signalling (accomplished using the Wnt  antagonist sFRP3)
prevented the differentiation of progenitor cells into the hepatic
lineage (Bi et al., 2009).
Hepatic differentiation in the mouse has been shown to be
tightly regulated, with the distinct expression of Wnt  antagonists
such as sFRPs and Dkks in embryonic liver tissues (Bi et al., 2009).
In humans, hepatic differentiation is differentially regulated by the
Wnt  signalling pathway, depending on the stem cell source. Wnt
signalling was shown to be down-regulated during the hepatic
differentiation of adipose tissue-derived MSCs (ADSCs), while it
was activated in human embryonic stem cells (hESCs) (Heo et al.,
2013). The distinct response seen in hESCs was  also observed
when Wnt3a pre-treatment facilitated the differentiation of hESCs
towards hepatic endoderm (Fletcher et al., 2008).
Similar to the effect seen on ADSCs (Heo et al., 2013), during
hepatic differentiation of umbilical cord tissue-derived MSCs, there
was a downregulation of canonical Wnt  signalling. Hence, suppres-
sion of Wnt  signalling in turn promoted hepatic differentiation
(Yoshida et al., 2007). It has also been demonstrated that appli-
cation of Frizzled 8 siRNA on MSCs, in which Wnt  signalling was
reduced, resulting in enhanced hepatic differentiation in human
bone marrow-derived MSCs (Ishii et al., 2008). Overall, these stud-
ies indicate that enhanced hepatic differentiation is observed in
human MSCs following down-regulation of Wnt  signalling.
2.6. Wnt  signalling promotes myogenic differentiation
The effect of different Wnt  molecules on myogenic differenti-
ation has been well documented in embryonic development. In
MSCs, the Wnt  molecules – Wnt1, Wnt3, Wnt7a, Wnt7b, Wnt4,
and Wnt11 had a promoting effect on gene expression of at least
one myogenic marker. Among these Wnt  proteins, Wnt11 was the
most potent activating factor demonstrating gene expression of
all myogenic factors-Myf5, MyoD, myogenin, and myogenin reg-
ulating factor (Mrf4) (Belema Bedada et al., 2005). The promoting
effect of Wnt3a in myogenic differentiation has also been reported
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in rat bone marrow MSCs (Shang et al., 2007). The GSK-3 inhibi-
tion by LiCl and consequent Wnt  activation resulted in an increased
bioavailability of -catenin and enhanced the myogenic differen-
tiation potential in aged MSCs (Brunt et al., 2012). Another study
demonstrated that hypoxia-preconditioned MSCs possessed better
engraftment potential into ischaemic tissue, and improved skele-
tal and vascular muscle regeneration when compared to normal
MSCs. They found that this enhanced effect was brought about by a
Wnt4-dependent pathway, and that hypoxia-preconditioned MSCs
had an increased number of Wnt4 transcripts in the ischaemic area
compared to the normal MSCs (Leroux et al., 2010). Altogether,
it suggests that activated Wnt  signalling enhances the myogenic
differentiation potential of MSCs.
2.7. Wnt  signalling positively influences neurogenic
differentiation
It has been demonstrated that Wnt3a protein promotes the
differentiation of neural stem cells into neuronal lineages while
inhibiting their self-renewal (Muroyama et al., 2004). In corti-
cal mouse neural precursor cells, Wnt7a also enhanced neuronal
differentiation (Hirabayashi et al., 2004). Further, in MSCs, the acti-
vating role of canonical Wnt  signalling has been determined using
specific neuronal markers such as neuron-specific enolase and
nestin. These markers were up-regulated when Wnt  signalling was
activated using Wnt3a and down-regulated when Wnt  signalling
was blocked by siRNA for -catenin (Yu et al., 2013). It was also
found that Wnt7a enhanced neuronal differentiation in human
MSCs via both canonical and non-canonical signalling pathways
(Tsai et al., 2014). Further, the Wnt  antagonists Dkk1 and sFRP4
reversed Wnt7a’s promoting effect (Tsai et al., 2014). Re-activation
of the Wnt  signalling pathway reversed the age-related decline in
neurogenic differentiation in MSCs derived from dental pulp (Feng
et al., 2013). Further investigation into the mechanism of Wnt-
induced up-regulation of neurogenic differentiation in MSCs has
revealed the role of T-cell leukaemia 3 (Tlx3) in interacting with the
TCF3/4 of the canonical Wnt  signalling pathway. In this study, it was
shown that Wnt1 upregulates Tlx3, and a forced expression of Tlx3
improved neurogenic differentiation (Kondo et al., 2011). Wnt5a
promoted neurogenic differentiation in human ADSCs, binding to
Fz3 and Fz5, and signalling through the Wnt5a-JNK pathway (Jang
et al., 2015). In summary, activation of Wnt  signalling plays a key
role in promoting the differentiation of MSCs towards a neuronal
fate.
The overall impact exerted by the activation of the Wnt
signalling pathway on the differentiation of human MSCs has been
schematically represented in Fig. 1.
3. Link between Wnt/-catenin signalling and reactive
oxygen species
Recent findings have demonstrated that there is a close associ-
ation between reactive oxygen species (ROS) and activation of the
Wnt/-catenin pathway. -Catenin is translocated to the nucleus
after the inhibition of the protein complex comprised of Axin, APC,
GSK-3, and CK1 (Korswagen, 2006). This inhibition is assisted
by Dishevelled (Dvl), a protein present in the cytoplasm, which
inhibits GSK-3-mediated phosphorylation of -catenin, allow-
ing its translocation (Li et al., 1999). Dvl and a thioredoxin-like
protein, nucleoredoxin (NRX), have been shown to directly inter-
act and inhibit Wnt/-catenin signalling and this association is
attenuated by hydrogen peroxide (H2O2), suggesting that Wnt/-
catenin signalling may  be modulated by oxidative stress (Funato
et al., 2006). Wnt  signalling is carefully balanced by the competition
between NRX and a Kelch-like 12 (KLHL12) protein, both associated
with the PDZ-domain of Dvl. In the absence of a Wnt  ligand, the
binding of NRX to Dvl promotes the inactive state of Dvl, thereby
preventing aberrant activation of the pathway until a sufficient Wnt
stimulus occurs. Upon Wnt  binding, Dvl frees itself from NRX, acti-
vates downstream signalling, and is then ubiquitylated by KLHL12,
thus preventing persistent activation of the Wnt  signalling path-
way (Funato et al., 2010). Recently it was  also demonstrated that
inhibition of Ca2+-mediated ROS production from the mitochon-
dria attenuated the Dvl/NRX association, which led to a decrease in
Wnt/-catenin activation and inhibited the ability of neuronal cells
to differentiate in vitro (Rharass et al., 2014). Although a full under-
standing of ROS activation of the Wnt/-catenin pathway has yet
to be elucidated, it is known that Wnt  antagonists also play a role in
the modulation of ROS. It has been shown that sFRP4 can increase
superoxide and H2O2 levels while decreasing catalase activity in
endothelial cells, and thus inhibiting angiogenesis (Muley et al.,
2010). Further research into the mechanisms of ROS activation of
the Wnt/-catenin pathway has the potential to provide possible
treatment options for many Wnt-associated diseases.
3.1. The source and generation of reactive oxygen species
There are many potential sources of ROS within the cell; the pri-
mary source of ROS is from the mitochondria where free-radical
superoxide anion (O2−) is generated via the electron transport
chain, primarily from complex I (Kushnareva et al., 2002) and
III by single electron reduction of molecular oxygen (Chen et al.,
2003). Superoxide (O2−) is converted to H2O2 (which has a much
longer half-life) through ROS scavengers such as superoxide dismu-
tase (SOD) in the cytosol (SOD1/CuZn-SOD), mitochondrial matrix
(SOD2/MnSOD), and in extracellular compartments (SOD3) (Zelko
et al., 2002).
Another important source of ROS is from the nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase complexes,
which together are known as NOX enzymes (Holmstrom and
Finkel, 2014). Oxygen is converted to superoxide through pyri-
dine nucleotide-mediated reduction by NOX enzymes at specific
membrane-associated sites (Atashi et al., 2015), thus generating
superoxide for release into phagolysosomes (in phagocytic immune
cells) and either cytosolic or extracellular release. The superoxide
anion can also react with nitric oxide (NO) to form peroxynitrite
(ONOO−) (Pacher et al., 2007), which has been shown to induce
apoptosis through caspase activation (Zhuang and Simon, 2000).
Hydrogen peroxide is classed as a reactive oxidizing chemical
that can be converted to water and oxygen in the peroxisome
and cytosol through enzymatic action by catalase. Furthermore,
it is reduced to H2O through the enzymatic action of antioxi-
dant glutathione peroxidases (GPx), which catalyze the reaction
2GSH + H2O2 → GSSG + 2H2O and by peroxiredoxins (Prxs) in the
cytosol, Prxs (reduced) + H2O2 → Prx (oxidized) + 2H2O (Gough and
Cotter, 2011).
Other intracellular sources of ROS include the endoplasmic
reticulum as well as other enzyme systems such as xanthine
oxidase, lipoxygenase, cyclooxygenase, cytochrome P450, and
monooxygenase (Holmstrom and Finkel, 2014). ROS, together with
the peroxisomes and mitochondria, serve many functions including
cellular proliferation (Gauron et al., 2013), migration (Hurd et al.,
2012), differentiation (Atashi et al., 2015), survival (Trachootham
et al., 2008; Pervaiz and Clement, 2007; Clement et al., 2003) – and
cell signalling (Thannickal and Fanburg, 2000). ROS  play a crucial
role in cellular homeostasis and a variety of processes within all
cell types. Interestingly, the study of ROS within MSCs has gathered
pace recently due to its complex nature, the involvement of a vari-
ety of cell signalling pathways, including Wnt, a myriad of protein
interactions, and its involvement in mesenchymal differentiation.
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Fig. 1. Schematic illustration of the effect of Wnt  signalling on the various MSC  differentiation pathways.
3.2. Mesenchymal stem cells and reactive oxygen species
MSCs exhibit relatively low levels of ROS, possibly due to their
increased levels of glutathione, SOD1/SOD2, catalase, and GPx
(Valle-Prieto and Conget, 2010). It has also been shown that vary-
ing levels of ROS control different signalling pathways within MSCs,
which are responsible for many cellular functions and cellular dif-
ferentiation. These pathways include Wnt, Forkhead box (FOXO),
Hedgehog (Riss et al., 2006), Nel-like protein 1 (NELL-1), insulin-
like growth factor (IGF), and bone morphogenetic protein (BMP).
Various, highly defined levels of ROS activate these aforemen-
tioned signalling pathways to regulate MSC  differentiation into
chondrocytes (Kim et al., 2010), adipocytes (Kanda et al., 2011),
and osteocytes (Takada et al., 2009). Although the role of redox
regulation in MSCs has yet to be fully elucidated, other stem cells
such as haematopoietic stem cells and progenitor cells have been
described in terms of stem cell development, function, and sur-
vival in this regard (Pervaiz et al., 2009). In this review we have
aimed to comprehensively summarize the redox regulation of MSC
differentiation.
4. Reactive oxygen species-mediated differentiation of
mesenchymal stem cells
4.1. Adipogenic differentiation
MSCs differentiate to an adipogenic lineage through the acti-
vation of several transcription factors including CCAAT/enhancer
binding protein (C/EBP), which induces C/EBP  and PPAR (Rosen
et al., 2000). It has now been shown that adipogenic differenti-
ation may  be mediated by NADPH oxidase 4 (Nox4) via the cAMP
response element-binding protein (CREB) (Kanda et al., 2011). It has
been shown that CREB over-expression in pre-adipocytes promotes
the expression of C/EBP  and RXR (Reusch et al., 2000); while
concurrently, it has been demonstrated that antioxidants such as
N-acetylcysteine (NAC) or apocyanin will suppress CREB (Kanda
et al., 2011). There is further evidence for ROS-mediated adipogenic
differentiation in MSCs by Prx1 over-expression inhibiting lipid
accumulation, as well as antioxidant (NAC) inhibition of C/EBP
and PPAR (Kanda et al., 2011). Superoxide generating complex III
has also been implicated in the transcriptional activation of PPAR
(Tormos, 2011), while H2O2 increases adipogenesis (Schroder et al.,
2009) and diminishes the expression of adipo-cytokines (Atashi
et al., 2015). This evidence suggests that increasing intracellular
levels of ROS are involved in signalling cascades responsible for the
differentiation of MSCs into adipocytes.
4.2. Osteogenic differentiation
There have been numerous signalling pathways implicated
in osteogenic differentiation in MSCs including Wnt, FOXO, and
Hedgehog; all of which have been shown to be suppressed by high
levels of ROS (Atashi et al., 2015). The Wnt  signalling pathway is
a positive regulator of osteogenesis through the translocation of
-catenin into the nucleus, where it binds TCF/LEF, allowing the
activation of Wnt  target genes such as Axin2 as well as increas-
ing the expression of Run2x, Dlx5, and Osterix, which are critical
osteogenic transcription factors (Kim et al., 2013). Wnt  signalling
has been shown to decrease the expression of C/EBP and PPAR,
and thus favours osteogenesis rather than adipogenesis (Ross et al.,
2000); although high levels of ROS, specifically H2O2 (which has
been shown to inhibit Wnt/-catenin signalling), would then pro-
mote a more favourable adipogenic environment (Shin et al., 2004).
The FOXO signalling pathway is also mediated by ROS, where
high levels induce phosphorylation and drive its translocation into
the nucleus where it is activated. FOXO has been shown to suppress
osteogenic differentiation (Iyer et al., 2013) while concurrently pro-
moting adipocyte differentiation (Nakae et al., 2003). Increased
levels of H2O2 stimulate FOXO transcription, although it also pro-
motes the association of FOXO with -catenin, which leads to an
inhibition of Wnt  target genes essential for osteogenic differen-
tiation (Almeida et al., 2007). Overall, higher levels of oxidative
stress antagonize the Wnt/-catenin pathway, leading to attenua-
tion of osteogenesis while stimulating FOXO-mediated adipogenic
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Fig. 2. Schematic demonstrating the effect of ROS (depicted here as H2O2) in block-
ing  Wnt/-catenin signalling and promoting differentiation of MSCs into adipocytes
and osteoblasts.
differentiation. It is noteworthy that a shift to adipogenic lineage
in MSCs has been reported in patients with osteoporosis. This has
been linked to the increased expression of the histone H3 methy-
lating protein Enhancer of Zeste Homology 2 (EZH2) which silences
the Wnt  genes, and hence pharmacological inhibition of EZH2 with
3-deazaneplanocin A (DZNep) reverted the cells to osteogenic lin-
eage (Jing et al., 2015). These data argue in favour of targeting EZH2
as a potential strategy against osteoporosis. Alternatively, the use
of anti-oxidants, such as N-acetyl cysteine (NAC), or SOD mimet-
ics might also serve to tailor the redox environment for osteogenic
differentiation.
The interaction between ROS (in the form of H2O2) and the Wnt
signalling pathway, and the resultant effect on MSC  differentiation
into adipocytes and osteoblasts is demonstrated in Fig. 2.
4.3. Chondrogenic differentiation
Recent studies have demonstrated that ROS is required for chon-
drogenic differentiation, primarily through NADPH oxidase 2 and 4
(Nox2 and Nox4) (Kim et al., 2010). This was demonstrated by inhi-
bition of chondrogenic differentiation gene markers Sox9, Col2a1,
and Col10a1 by the introduction of the ROS scavenger NAC; and
so, provide proof that ROS is necessary for chondrogenic differ-
entiation (Kim et al., 2010). Although less is known in regards to
chondrogenic differentiation mediated by ROS in MSCs, this is an
attractive area of study and may  have wider implications in the
field of regenerative medicine.
5. Conclusions
In this review we have exemplified the differential impact that
Wnt  signalling exerts on MSC  differentiation pathways. Summa-
rizing the broad spectrum of the influence of Wnt  signalling on
MSC  differentiation, we have shown that the outcomes of activated
Wnt  are inhibition of adipogenic and hepatogenic differentiation.
On the other hand, a different outcome of activated Wnt  signalling
favours neurogenic and myogenic differentiation. Wnt  signalling
exerts mixed effects on osteogenic, chondrogenic, and cardiogenic
differentiation, where it can either promote or inhibit the process;
and this could be dependent on many factors such as cell type and
interaction with other signal transduction pathways, etc. The exact
mechanism underlying the molecular regulation of differentiation
processes remains to be unravelled.
The role of ROS in MSC  differentiation has also yet to be com-
pletely elucidated, although research has shown that the level of
H2O2 tends to favour differentiation into adipocytes, chondrocytes,
or osteocytes. ROS-mediated differentiation into the other possible
MSC  lineages such as neuronal cells, hepatocytes, and myocytes has
yet to be investigated in detail. MSC  differentiation occurs through
the interplay of different pathways including the FOXO and Wnt/-
catenin signalling pathways. It has been demonstrated that these
pathways can regulate ROS levels, and concomitantly ROS levels
can influence the activity of these pathways. ROS signalling has
been implicated in osteogenic differentiation, where high levels
of H2O2 inhibit Wnt/-catenin signalling and favour osteogene-
sis, and low levels of H2O2 activate Wnt/-catenin signalling to
promote adipogenesis. Further studies into the mechanisms of
ROS-mediated differentiation are important for a complete under-
standing of MSC  differentiation.
MSCs have gained a lot of clinical interest, considering their
potential for various tissue engineering and reconstructive surgery
applications, due to their extensive self-renewal and multipotent
differentiation capabilities. Hence the mechanism underlying these
differentiation processes, tightly regulated by signal transduction
networks such as the Wnt  signalling pathway and ROS, needs to
be further examined. A profound knowledge about these processes
will in turn aid in the development of novel strategies in regener-
ative medicine. Recent evidence points to a critical role of tissue
hypoxia on the proliferation and differentiation of multipotent
MSCs (Holzwarth et al., 2010; Valorani et al., 2012). To that end,
manipulation of the cellular redox milieu could have potential ther-
apeutic implications, whereby the use of anti-oxidants could serve
to switch MSCs from adipogenic to osteogenic differentiation; how-
ever, if the desired outcome is to obtain adipogenic differentiation,
one could be tempted to employ agonists of the nuclear PPAR
receptor. Furthermore, hypoxia was shown to enhance MSC via-
bility and proliferation as well as differentiation into adipocytes
and osteocytes (Valorani et al., 2012), which could have potential
implications in regenerative medicine.
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Abstract Secreted frizzled-related protein 4 (SFRP4) is a
glycoprotein that acts as an antagonist ofWnt ligands, causing
inhibition of the canonical Wnt signalling pathway. First
noticed due to high expression levels during times of in-
creased apoptosis, SFRP4 has been implicated in cell prolif-
eration and differentiation and plays an important role in
carcinogenesis. Many tumours such as endometrial, cervical,
ovarian, prostate, bladder, colorectal, mesothelioma, pancre-
atic, renal, and oesophageal tumours are characterised by
aberrant promoter hypermethylation, which causes variations
in the expression level of SFRP4 when compared to normal
cells. Combined experimental data appear to confirm the
suggested role of SFRP4 as a local initiator of apoptosis;
however, increased SFRP4 expression may not always corre-
late with an increase in apoptosis, possibly due to the complex
interactions between different signalling pathways. SFRP4
can be explored for its use in novel therapeutic modalities as
well as being a potential diagnostic biomarker.
Keywords SFRP4 . Apoptosis . Cancer . Wnt signalling
Introduction
Secreted frizzled-related proteins (SFRP1–5) are a family of
glycoproteins that act as antagonists of the Wnt ligands [1].
Included in this family is secreted frizzled-related protein 4
(SFRP4). This inhibits the canonical Wnt signalling pathway,
which normally acts to increase cell proliferation and decrease
apoptosis [2]. TheWnt signalling cascade is normally initiated
by the binding of the Wnt ligands to the frizzled receptor
family [3], which are G-coupled protein receptors located on
the cell membrane [4], and binding to the low-density lipo-
protein receptor-related proteins (LRP) 5 and 6.
Two classes of Wnt antagonists exist. The first class binds
the Wnt ligands and frizzled receptors directly [5], while the
second class binds to LRP5/6 [6]. The first class includes
SFRPs and Wnt inhibitory factor 1, which is able to inhibit
all Wnt signalling pathways. The second class includes
Dickkopf and only inhibits the canonical pathway [5].
Various other Wnt antagonists have been recognised, which
includeWise/SOST, Cerberus, insulin-like growth factor bind-
ing protein 4, adenomatosis polyposis coli down-regulated 1,
Shisa, and Tiki1 [7]. Wnt activators such as N-spondin and
norrin have also been identified, which are unrelated families
of growth factors known to promote Wnt activity [7].
The SFRP4 gene is located on the short arm of chromo-
some 7 (7p14.1) and is comprised of six coding exons, span-
ning 10.99 kb [8]. SFRP4 also demonstrates the least struc-
tural homology when compared to other members of the
SFRP family [9]. This is due in part to the existence of a
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Secreted frizzled-related protein 4 and its implications
in cancer and apoptosis
region of six conserved cysteine residues that is linked by a
disulphide bridge [9]. With a molecular weight of 39.9 kDa
[8] and a length of 346 amino acids, SFRP4 is the largest
member of the SFRP family [8].
Structurally, SFRPs comprise a C-terminal domain and an
N-terminus domain, each operating independently of the other
[7]. The N-terminus is comprised of a 120 amino acid long
cysteine-rich domain (CRD)made up of a conserved region of
ten cysteine residues [8]. It also contains a 20–30 amino acid
signal peptide [8]. Studies have shown the CRD is vital in the
inhibition of angiogenesis [2]. Within the C-terminal domain
is the netrin-like domain (NLD), which precedes a conserved
region of six cysteine residues. Recent studies have demon-
strated that the NLD can induce apoptosis [2]. The CRD and
the NLD have both been shown to increase intracellular
calcium levels, leading to the activation of the Wnt/Ca2+
signalling pathway [2].
Wnt signalling pathways
Wnt signalling pathways have been implicated in cell fate
specification, cell proliferation, body axis patterning, cell migra-
tion, embryonic development, and carcinogenesis [10]. Wnt
signalling pathways can be grouped into the canonical (Wnt/
β-catenin dependent) [11] pathway and the non-canonical (β-
catenin independent) pathway, which comprises the Wnt/Ca2+-
mediated pathway and the planar cell polarity pathway [12].
Canonical Wnt pathway (Wnt/β-catenin dependent)
The canonical Wnt signalling pathway has two states: an
inactive ‘off’ due to Wnt inhibition by antagonists such as
SFRPs, and an active ‘on’ state where Wnt signalling is initi-
ated byWnt ligands binding to the frizzled receptors (Fzd) and
co-receptor LRP5/6 [8]. This pathway isβ-catenin dependent.
The inactive off state (Fig. 1) is characterised by β-catenin
being bound by theβ-catenin destruction complex (BDC) [13],
which is made up of glycogen synthase kinase-3-β (GSK3β),
Axin, and adenomatosis polyposis coli (APC) [8]. β-Catenin is
phosphorylated by GSK3β, which is then ubiquitylated by β-
transducin repeating protein that marks it for proteasome-
mediated degradation [8, 13]. Concurrently, Groucho binds to
the T cell factor (TCF)/lymphoid enhancing-binding factor
(LEF) family, which inhibits transcription in the nucleus [14].
The active on state (Fig. 2) occurs in the presence of β-catenin
due to the disruption of the BDC, inhibiting the phosphoryla-
tion of β-catenin. This causes an accumulation of β-catenin in
the cytoplasm, which then translocates to the nucleus [15].
Inside the nucleus, it binds to transcription factors of the T
family such as LEF1, TCF1, and TCF2/3 [16]. This activates
the transcription of targeted genes involved in cell proliferation
such as c-myc, cyclinD1, c-jun, and Axin2 [8].
Non-canonical Wnt pathways
Planar cell polarity pathway
This pathway operates independently of β-catenin [17] and is
believed to be mediated through the frizzled receptor, which
also acts independently of LRP5/6 receptors. The Dishevelled
protein is a cytoplasmic protein that acts directly downstream
of the frizzled receptors and, when activated, stimulates the
activation of both GTPases Rho and Rac [18]. The cellular
cytoskeleton is then modified [15] due to the activation of
Rho-associated kinase [18] and myosin [19]. Rac stimulates c-
Jun N-terminal kinase, leading to downstream effects that
have not been completely elucidated [15].
Wnt/Ca2+ pathway
TheWnt/Ca2+ pathway is stimulated by the release of calcium
from the endoplasmic reticulum due to the activation of phos-
pholipase Cβ (PLC) [20]. PLC activates protein kinase C [19]
Fig. 1 The inactive Wnt signalling cascade. In the absence of Wnt
signalling, due to antagonism by SFRP4, β-catenin is phosphorylated
by the Axin/APC/GSK3 β complex, leading to degradation by
ubiquitination and leading to the inactive state. APC adenomatosis
polyposis coli, Dkk Dickkopf, Dvl Dishevelled, Fzd frizzled, GSK3β
glycogen synthase kinase-3-β, LRP low-density lipoprotein receptor-
related proteins, P phosphorylated, TCF T cell factor
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and calcium/calmodulin-dependent kinase II (CamK11) [21],
which are calcium-sensitive proteins. CamK11 has been
shown to activate the transcription factor NEAT in Xenopus
embryos [22], indicating a role for Camk11 in the Wnt/Ca2+
pathway [19].
Aberrant Wnt signalling has been implicated in
tumourigenesis, as the downstream targets are involved in cell
survival, differentiation, and proliferation; therefore, inhibi-
tion of this pathway may be a potential target for cancer
therapy. One such way to inhibit the Wnt canonical and non-
canonical pathways is through Wnt antagonists, such as
SFRPs and more specifically SFRP4.
Research involving SFRP4 and its implications in cancer is
beginning to gain momentum due to promising results.
SFRP4 is said to be a modulator of cell proliferation and
implicated as a tumour suppressor [23], and therefore, recent
research has focussed on a correlation between epigenetic
modification and gene expression to determine the role of
SFRP4 in cancer, which will now be discussed.
SFRP4 and its implications in cancer
Endometrium
SFRP4 is normally expressed in endometrial tissue, although
expression levels are higher in the stromal cells during the
proliferative phase of the menstrual cycle [24]. It has also been
implicated in endometrial cell growth, as it has been found to
be expressed at much higher levels in the stromal cells of
endometrial carcinomas compared to that of the secretory and
menstrual endometrium [25].
Promoter hypermethylation [26] and downregulation of
SFRP4 have been independently shown in stromal endome-
trium sarcomas [27]. The expression of SFRP4 has been
shown to be decreased when compared to normal epithelium
in both low-grade endometrial sarcoma and the more aggres-
sive, undifferentiated endometrial sarcoma [27]. This was
verified by qRT-PCR and in situ hybridization [27]. The
expression levels of β-catenin were shown to be inversely
related to those of SFRP4, indicating that SFRP4 is a putative
modulator of the Wnt signalling pathway, important in endo-
metrial cell proliferation, and may also be implicated as a
tumour suppressor [27].
Carmon et al. have shown that Wnt7a activates the canon-
ical Wnt signalling pathway by binding to frizzled receptor 5
(Fzd5) and the non-canonical planar cell polarity pathway by
binding to frizzled receptor 10 [26]. Activation of the canon-
ical pathway has been shown to increase the level of cellular
proliferation in the endometrium [26]. SFRP4 expression
levels were also demonstrated to be decreased in endometrial
carcinomas, while stable overexpression of SFRP4 and treat-
ment with recombinant SFRP4 protein could inhibit the
growth of endometrial cancer cells in vitro [26].
Furthermore, this study demonstrated that SFRP4 regulates
the Wnt7a signalling pathway, which plays an important role
in endometrial cell growth.
Cervix
There have been numerous studies on the methylation status
of SFRP4 in various cervical cancer cell lines, with the results
varying in response to the type of tumour. In two studies of
cervical adenocarcinoma (AdCA) samples, promoter methyl-
ation was found to occur with an intermediate frequency, with
one study giving a range of 33–50% [28] and the other stating
it was 65.2 % [29]. Both of these studies demonstrated a
significantly higher methylation frequency in AdCA than in
normal cervical tissue [28, 29]. In squamous cell carcinomas
(SCC), the promoter was hypermethylated in 67.9 % of sam-
ples, while in high-grade squamous intraepithelial lesions
(HSIL), it occurred in 36.7 % of samples and only in 4.4 %
of low-grade squamous intraepithelial lesions (LSIL) [30].
Both SCC and HSIL showed significantly higher promoter
Fig. 2 The activeWnt signalling state. Wnt ligands bind to Fzd receptors
and co-receptors LRP5/6. This activates intercellular Dvl, which inhibits
GSK3 β. This results in nuclear translocation of β-catenin, activation of
the TCF family of transcription factors, and induction of gene
translocation. APC adenomatosis polyposis coli, BIO 6-bromo indirubin
3′-oxime,DkkDickkopf,DvlDishevelled, Fzd frizzled,GSK3β glycogen
synthase kinase-3-β, LiCl lithium chloride, LRP low-density lipoprotein
receptor-related proteins, TCF T cell factor
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hypermethylation than that of normal cells [30]. This shows
that SFRP4 promoter hypermethylation is associated with
cervical carcinogenesis, indicating its use in molecular screen-
ing of cervical neoplasias [30]. SFRP4 is absent in cervical
carcinoma while present in normal epithelia, leading to the
activation of the Wnt canonical pathway and subsequent cell
signalling driving cell proliferation [31].
Ovary
Drake et al. have demonstrated, using immunohistochemistry
on tissue microarrays, that SFRP4 expression has an inverse
correlation with β-catenin expression in 84 % of serous ovar-
ian carcinoma samples [32]. While SFRP4 protein expression
was found to decrease in ovarian tumours, it was revealed in a
2008 study that SFRP4 methylation frequencies did not vary
significantly between patients with ovarian malignancy, bor-
derline malignancy, and benign tumours [33].
Studies have shown that high levels of SFRP4 expression
are present in the tubular epithelium of the ovary, although
there is a marked decrease in these levels associated with
ovarian malignancy at both the RNA and protein levels [34].
Furthermore, the loss of membranous expression of SFRP4
predicted a poorer outcome and prognosis, while the increased
risk of death from this disease was by a factor of 1.8 [34].
These results demonstrated that via inhibition of the Wnt
signalling pathway, SFRP4 acts as a tumour suppressor, lead-
ing towards its use as a therapeutic agent as well as a predictor
for ovarian malignancies [34]. Shortly after publication of
these findings, another research group using in vitro experi-
mental models demonstrated that chemosensitive ovarian can-
cer cell lines expressed significantly higher levels of SFRP4
than chemoresistant ovarian cancer cell lines [35].
Chemoresistant cell lines increased their sensitivity to the
chemotherapy drug cisplatin when cells were transfected with
SFRP4. Furthermore, following silencing of SFRP4 expres-
sion, the chemosensitive cell lines demonstrated an increase in
chemoresistance [35]. These results implicate SFRP4 as a
predictive biomarker of chemosensitivity in ovarian cancer
and suggest a possible therapeutic role for this protein [35].
Prostate
The overexpression of SFRP4 has been functionally associat-
ed with a decreased rate in cellular proliferation and invasive-
ness of the PC-3 prostate cancer cell line [36, 37]. Increased
expression of SFRP4 at the membranous level in malignant
epithelial cells has also been shown to be a good predictor for
a longer biochemical relapse-free period, although this is only
relevant for individuals with localised prostate cancer [36].
Concurrently, the loss of SFRP4 expression has been associ-
ated with prostate cancer progression.
SFRP4 overexpression has also resulted in morphologic
changes in the prostate cancer cell lines, LNCaP and PC-3
[37]. Increased localization of β-catenin and cadherins (E-
cadherin in LNCaP and N-cadherin in PC-3) to the cell mem-
brane has also been shown following overexpression of
SFRP4 [37]. It has also been demonstrated that SFRP4 is an
inhibitor of prostate cell growth and invasion and provides
support for the development of new therapeutic strategies
using SFRP4 to modulate Wnt signalling [37]. This is signif-
icant to both localised androgen-dependent prostate cancer
and metastatic disease [37].
Bladder
Promoter methylation of the SFRP4 gene has been demon-
strated to be higher in bladder tumour samples than that of
samples of adjacent tissues [38]. In one study, bladder tumour
tissue samples and the corresponding urine of the patients
demonstrated that, in 79.2 % of tissue samples and 54.2 %
of urine samples, SFRP4 methylation was evident [38]. The
samples were a combination of invasive or superficial bladder
tumours and showed that bladder urine levels of SFRP4 may
be used as a novel, non-invasive diagnostic biomarker [38].
Furthermore, this study demonstrated the role of hypermethy-
lation of SFRP4 in bladder tumour pathogenesis [38]. Review
articles by Kim et al. [39] and Enokida et al. [40] also give
evidence of higher levels of SFRP4 methylation in bladder
tumour samples.
Colorectal
SFRP4 has been shown to have less frequent promoter hyper-
methylation in colorectal carcinomas when compared to other
members of the SFRP family [41, 42]. However, there is
conflicting evidence for the expression levels of SFRP4 in
colorectal carcinomas. It has been shown to be overexpressed
in colorectal carcinomas when compared to adjacent normal
mucosa in some studies [41, 43] and therefore is a possible
candidate marker for colorectal lesions [43]. In other studies,
SFRP4 expression was either silenced or significantly reduced
in the majority of tumours [44]. Qi et al. demonstrated the
silencing or reduction of SFRP4 expression in 61.1 % of
colorectal carcinomas and 9.1 % of colorectal adenomas
[44]. The reasons for these different observations are unclear.
It is also possible that these results indicate that, in colorectal
cancer, SFRP4 may not act as a tumour suppressor [41].
However, more recently, a single nucleotide polymorphism
(SNP) within the SFRP4 gene (rs1802073), described as
P320T, has been found to have a significant association with
an increased risk of rectal cancer and also in the early stages of
colorectal carcinoma [45]. It is postulated that this SNP may
induce increasedWnt signalling, which can lead to the gradual
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loss of apoptotic processes and, therefore, uncontrolled gene
expression and tumourigenesis [45].
Mesothelioma
Studies have shown that SFRP4 is downregulated [6, 46, 47]
in numerous mesothelioma cell lines, which has been corre-
lated with methylation of the promoter region of SFRP4 [6,
46, 48]. Lee et al. demonstrated that, in 89 % (17 of 19) of
mesothelium tumour tissue samples, SFRP4 methylation had
occurred [46]. Furthermore, He et al. have shown that CpG
hypermethylation of the promoter region in β-catenin-
deficient mesothelioma cell lines correlates with SFRP4 si-
lencing [6]. The same study found that by treating these
hypermethylated cell lines with a demethylating agent, 5-
aza-2′-deoxycytidine, SFRP4 expression was restored [6].
RNA interference and expression studies have demonstrated
that when SFRP4 is silenced, there is promotion of cell growth
and inhibition of apoptosis [6, 46], indicating that silencing of
SFRP4 enhances the canonicalWnt signalling pathway. These
studies suggest a crucial role of SFRP4 in the development of
mesothelial tumour cells.
Pancreas
SFRP4 has been associated with pancreatic carcinogenesis in
a study by Bu et al. in 2008 [49]. Hypermethylation of SFRP4
occurred in 60 % of pancreatic cancer samples, whereas this
only occurred in 10 % of adjacent tissue samples [49].
Furthermore, loss of SFRP4 expression was found to be
55 % in pancreatic cancer samples, compared to 18 % in
adjacent tissue samples obtained from patients during surgery.
The pancreatic cell lines PC-3, PANC-1, and CFPAC-1 and
human tissue sample methylation status were determined by
methylation-specific PCR [49]. The hypermethylation and
loss of expression of SFRP4 in these samples suggest that
SFRP4 may play an important role in pancreatic cancer
pathogenesis.
Kidney
SFRP4 expression has a strong trend towards being an inde-
pendent biomarker in the prediction of renal cell carcinoma
(RCC). In a study of 62 patients with RCC, 53.2 % of the
individuals showed positive methylation status in their tumour
tissue samples, whereas methylation only occurred on the
SFRP4 gene in 14.5 % of normal renal tissue samples [50].
Oesophagus
Hypermethylation of SFRP4 has been implicated as a com-
mon early event in the development of oesophageal adeno-
carcinoma and its precursor, Barrett’s oesophagus [51].
Aberrant methylation of the promoter region of SFRP4 has
been found to lower the protein expression of SFRP4 and
promote these conditions [51]. Zou et al. used immunohisto-
chemistry to show that protein expression levels of SFRP4
were downregu la ted in 90 % of cancers [51] .
Hypermethylation was detected (using methylation-specific
PCR) in 73 % of oesophageal adenocarcinomas and 78 % of
Barrett’s oesophagus, while no methylation was detected in
normal oesophagogastric epithelia [51]. These results demon-
strate the potential use of SFRP4 as a biomarker for Barrett’s
oesophagus.
Glioblastoma multiforme
SFRP4 was examined in relation to its ability to
chemosensitise a glioma cell line, U138MG, and glioma stem
cells (GSCs) to the chemotherapeutic agents cisplatin and
doxorubicin [52]. Cisplatin is an apoptosis-inducing chemo-
therapeutic agent, while doxorubicin is an inhibitor of repli-
cation. U138MG is a grade IV glioblastoma cell line in which
the GSCs are U138 enriched. When SFRP4 was added alone,
and in combination with the chemotherapeutic agents, it was
shown to reduce proliferation and increase cell death through
apoptotic pathways in the GSC-enriched population [52].
Western blotting provided evidence of a decrease in β-
catenin protein expression, further justifying the role of the
Wnt/β-catenin signalling pathway. RT-PCR confirmed an
increase in apoptotic markers Bax and p21, while concurrently
demonstrating a decrease in CycD1, a pro-proliferative mark-
er, and a decrease in the GSC marker CD133 [52].
These results provide strong evidence that SFRP4 is able to
sensitise glioma cells and glioma stem cells to cisplatin and
doxorubicin [52]. Furthermore, this indicates that SFRP4 may
be able to destroy GSCs and become an effective treatment of
glioblastoma multiforme, one of the most aggressive forms of
cancer [52].
Recent research by Schiefer et al. examined four human
glioblastoma cell lines, U87, U138, LN18, and A172, to
determine the methylation status of their SFRP4 promoter
regions and the expression levels of SFRP4 messenger
RNA (mRNA) and protein [53]. Methylation-specific PCR
demonstrated that SFRP4 was hypermethylated in all four
cell lines. All four cell lines were treated with 5-azacytidine
to determine the association of promoter demethylation and
SFRP4 expression before and after drug treatment. SFRP4
mRNA expression levels showed an increase ranging from
1.6- to 3.5-fold after promoter demethylation. Western blot
analysis demonstrated an increase in all cell lines of SFRP4
protein expression after demethylation, with A172 cells
exhibiting a 2.3-fold increase. These results show that
methylation-induced gene silencing of SFRP4 may be a
key feature in human glioblastoma multiforme and validate
its potential use as a therapeutic biomarker.
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Pituitary adenoma
Pituitary adenomas are usually benign although they can
sometimes be aggressive, invading surrounding tissues and
becoming difficult to treat. These aggressive pituitary adeno-
mas also have a higher rate of recurrence, requiring extra
doses of radiotherapy [54]. A recent study by Wu et al. inves-
tigated the levels of SFRP4 mRNA and protein in normal
pituitary tissue and compared it to samples from aggressive
and non-aggressive pituitary adenomas. RT-qPCR demon-
strated that SFRP4 mRNA levels were significantly lower in
aggressive pituitary adenomas when compared to normal
pituitary tissue and even lower when compared to non-
aggressive pituitary adenomas [54]. Western blot analysis of
SFRP4 protein levels demonstrated a significant downregula-
tion in aggressive pituitary adenoma when compared to nor-
mal and non-aggressive pituitary tissue. These results were
further verified by immunohistochemistry, where the percent-
age of SFRP4-positive cells in aggressive pituitary adenomas
was significantly lower than that in both the normal and non-
aggressive samples [54]. Methylation status of the promoter
region was also determined byMassArray, which showed that
the ratio of methylation in aggressive tissues was significantly
higher than that in both the normal and non-aggressive sample
groups [54].
These results indicate that the downregulation of SFRP4 in
pituitary adenomas correlates with methylation of the SFRP4
promoter and that SFRP4 also acts as a tumour suppressor.
Furthermore, SFRP4 expression is inversely correlated to the
aggressiveness of pituitary adenomas. The progressive loss of
SFRP4 observed from normal tissue to aggressive pituitary
adenomas validates its potential use as a biomarker with
prognostic implications [54].
SFRP4 and its role in apoptosis
First described in 1972 by Kerr et al., apoptosis is the process
of controlled elimination of unrequired or damaged cells [55].
This involves the ‘killing’ of the cell and the removal of debris
by phagocytosis and degradation [56]. Apoptosis is activated
by either an intracellular or extracellular signal, which leads to
the initiation of a proteolytic caspase cascade [57].
Mammalian apoptosis can occur through two pathways
termed intrinsic and extrinsic [58]. The intrinsic pathway
relies on caspases that cleave specific proteins in the cyto-
plasm and nucleus, leading to cellular shrinkage, the collapse
of the cellular cytoskeleton, disassembly of the nuclear enve-
lope, and fragmentation of the nuclear DNA, following which
the cell then undergoes rapid phagocytosis [57]. Caspases
exist in the cell as inactive zymogens awaiting activation
[59]. Initiator caspases are activated autocatalytically, which
in turn activate effector caspases that result in the morpholog-
ical features associated with apoptosis [58]. The extrinsic
pathway is activated by Fas and tumour necrosis factor [60],
which recruit procaspase 8 to form a ‘death-inducing signal-
ling complex’ that transduces a signal cascade resulting in
apoptosis [61].
Apoptosis is genetically regulated [62], and disruption in
this regulation mechanism can interfere with tissue homeosta-
sis, resulting in developmental disorders, autoimmune dis-
ease, and cancers [63]. As previously mentioned, SFRP4
was first noticed owing to its unique expression in mammary
gland, ovarian corpus luteum, and ventral prostate, which
were tissues that were all undergoing apoptosis [64].
Subsequently, the role it plays in apoptosis has been investi-
gated more thoroughly, as we will now exemplify.
Mammary gland
In the words of Lacher et al., ‘the obvious question is whether
SFRP4 is causally involved in initiating apoptosis’. They set
out to investigate this by conducting a study in which SFRP4
overexpressing, transgenic mice were created and the effects
of this overexpression during mammary gland involution
were investigated [65]. Lactation insufficiency was observed,
coupled with an abnormally high number of apoptotic cells in
the alveoli from day 19 of pregnancy to day 4 of lactation, and
it was concluded that SFRP4 was involved in reduced levels
of cellular survival at the commencement of involution in the
mammary gland, especially as it interrupts the Akt/PKB sig-
nalling pathway, which is known to block apoptosis [66].
While investigating a novel cancer treatment using
hydroxytyrosol, Granados-Principal et al. equated the inhibi-
tion of proliferation in rat mammary tumours to an increase in
apoptosis that was initiated by an increase in expression levels
of SFRP4 [67].
Ovary
It is known that apoptosis is an integral part of the ovulatory
process, with levels of expression increasing prior to follicular
rupture [68], and studies of ovulation have allowed a greater
understanding of the role of SFRP4. Hsieh et al. demonstrated
the upregulation of SFRP4 in follicular granulosa cells in
response to the administration of human chorionic gonadotro-
pin [69], and Drake et al. conducted an investigation to deter-
mine whether levels of SFRP4 expression in the rat ovary
increased with levels of apoptosis when ovulation was hor-
monally induced [70]. TUNEL staining showed higher num-
bers of apoptotic cells in the ovarian theca, and in situ
hybridisation demonstrated a rise in SFRP4 mRNA when
ovaries from treated rats were compared with those of healthy
controls. These results provided further evidence for a role of
SFRP4 in apoptosis. Saran et al. demonstrated differential
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expression of SFRP4 between chemosensitive and
chemoresistant ovarian cancer cell lines and that higher apo-
ptotic levels in non-cancerous cell lines correlated with higher
levels of SFRP4 expression when compared to cancerous cell
lines [35].
Corpus luteum
Guo et al., who had previously observed apoptosis-associated
upregulation of SFRP4 in both mammary and prostate tissue
[71], carried out a study examining the expression of
apoptosis-associated genes in the corpus luteum of the rat
[72]. SFRP4 was demonstrated to be specifically expressed
in tissues undergoing programmed cell death, and a distinct
spike in expression was reported at the commencement of
luteal regression, a phenomenon driven by high levels of
apoptotic cells. The authors were the first to suggest that
SFRP4 functions as an antagonist of Wnt. A further study
involving hormonally induced ovulation in mice has also
demonstrated that SFRP4 upregulation coincides with an in-
crease in apoptosis in the corpus luteum [69].
Heart
Further evidence of the role of SFRP4 as an initiator of
apoptosis has been demonstrated in a study of atrophied
cardiac tissue [73]. It is suspected that apoptosis of
cardiomyocytes is a contributing factor to the progression of
pressure overload-induced heart failure [74], and when
healthy cardiac tissue was compared with tissue from failing
ventricles, an upregulation in the pro-apoptotic SFRPs 3 and 4
was observed [73].
Mesothelioma
In a study involving β-catenin-deficient mesothelioma cell
lines, He et al. demonstrated a relationship between SFRP4
promoter hypermethylation (and therefore gene silencing) and
β-catenin deficiency [6]. When SFRP4 expression was re-
stored to these cells, apoptosis was induced; the downregula-
tion of Dishevelled and the apoptosis inhibitor survivin were
also observed following SFRP4 re-expression. However, fur-
ther studies have given inconsistent results when comparing
SFRP4 expression levels to cellular β-catenin levels, suggest-
ing that two or more downstream pathways are involved [75].
Numerous other studies have also shown that when upregu-
lation of SFRP4 is induced in cancer cells, the levels of
apoptosis increase and a reduction in tumourigenesis is ob-
served [44, 76–79]. Increased silencing of SFRP4 genes is
also positively correlated with a reduction in apoptosis and
subsequent tumour progression [37, 78, 80].
Skin
Maganga et al. observed an increase in SFRP4 protein levels
in conjunction with an increase in apoptosis and differentia-
tion of keratinocytes. They found that the addition of purified
SFRP4 protein resulted in a decrease in cell proliferation and
an increase in apoptosis [81]. It was also noted, when expos-
ing cells to purified SFRP4, that the onset of apoptosis was
delayed in comparison to apoptosis triggered by the addition
of the protein kinase-inhibiting antibiotic staurosporine. This
suggested that the observed induction of apoptosis was likely
to be a biological response to the protein, as opposed to a
demonstration of its toxicity. It was also demonstrated that a
dose of 500 μg/ml induced greater levels of apoptosis than
250 μg/ml. This study provided strong evidence for the role of
SFRP4 as an apoptosis initiator. However, in 2008, in exper-
iments conducted by Cho et al. that involved the treatment of
osteoblastic cells with SFRP proteins 1–4, SFRP4 was not
observed to affect apoptosis, and only SFRP3 significantly
increased apoptotic levels [82]. The reasons for these seem-
ingly anomalous results remain unclear.
SFRP4 as a therapeutic agent
The Wnt signalling pathway is intimately associated with
cancer development and spread, as well as the survival of
cancer stem cells. Hence, it is not surprising that there have
beenmany attempts to target this pathway in order to eradicate
cancer. Several pharmacological Wnt antagonists have been
used such as non-steroidal anti-inflammatory drugs, antibod-
ies, RNAis, etc. Their role and effectiveness are beyond the
scope of this review, but readers are directed to a comprehen-
sive review of this topic by Takahashi-Yanaga et al. [83].
Our group has shown that recombinant SFRP4 has anti-
angiogenic, anti-proliferative, and pro-apoptotic properties
when used as a treatment modality for the disruption of cancer
growth in a mouse xenograft model of ovarian cancer [23].
Furthermore, wewere also able to demonstrate cancer-specific
effects of SFRP4, which is an endogenously expressed pro-
tein. In addition, we have recently demonstrated that SFRP4 is
able to increase chemosensitisation of glioblastoma and head
and neck cancer stem cells to the clinically used drugs doxo-
rubicin and cisplatin [52, 84].
Another common occurrence in cancers is the hyperme-
thylation of various genes. We recently demonstrated that in
highly aggressive human glioblastomas, the SFRP gene fam-
ily is hypermethylated [53]. This raises the interesting concept
of using pharmacologic modulators to reverse this effect, thus
allowing endogenously expressed SFRP4 to exert its normal
homeostatic role.
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We have recently undertaken further research into the
effects of peptides derived from the CRD and NLD of
SFRP4, in combination with a variety of clinically used che-
motherapeutics, on cancers such as glioma, breast, prostate,
and head and neck, and found they are more efficacious in
targeting the cancer cells than when using the whole protein
(unpublished data). Our preliminary results give us great hope
to establish these peptides as clinically applicable therapy in
the future.
Conclusions
Since the discovery of SFRP4, this protein has garnered much
interest owing to its unique role in apoptosis, as well as a
possible therapeutic potential due to its ability to inhibit an-
giogenesis [2] and chemosensitise some CSCs [52]. The role
of SFRP4 and its utilisation for cancer therapy is a relatively
new area of study, although results have shown that it may
have many uses both therapeutically and as a potential diag-
nostic biomarker. There are, however, some conflicting re-
ports, particularly in the case of cancerous colon epithelial
cells, where increased levels of SFRP4 appear to correlate
with increased levels of proliferation and tumour progression
[41, 43, 44].
Cancer has often been referred to as a wound that will not
heal. Part of the healing process involves the selective removal
of defective cells through apoptosis. Hence, aberrations in
apoptosis are often associated with cancer development and
progression. Combined experimental data confirm the sug-
gested role of SFRP4 as a local initiator of apoptosis [24, 79,
85]. Indeed, our group has demonstrated that SFRP4, when
administered as a therapeutic agent, was able to selectively
induce apoptosis in tumour endothelium [23]. However, in-
creased SFRP4 expression may not always correlate with an
increase in apoptosis [82], which is most likely due to the
complex interactions between different signalling pathways.
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3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the
licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock at
the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
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6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
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any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
6/19/2018 RightsLink Printable License
https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=dbd91965-c353-43d7-a89a-361432799ddc 1/5
American Society for Biochemistry and Molecular Biology LICENSE
 TERMS AND CONDITIONS
Jun 18, 2018
This is a License Agreement between Sebastian OG Pohl ("You") and American Society for
Biochemistry and Molecular Biology ("American Society for Biochemistry and Molecular
Biology") provided by Copyright Clearance Center ("CCC"). The license consists of your
order details, the terms and conditions provided by American Society for Biochemistry and
Molecular Biology, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 4359660114868
License date May 31, 2018
Licensed content publisher American Society for Biochemistry and Molecular Biology
Licensed content title Journal of biological chemistry
Licensed content date Jan 1, 1905
Type of Use Thesis/Dissertation
Requestor type Academic institution
Format Print, Electronic
Portion chapter/article
The requesting
person/organization is:
Sebastian Pohl
Title or numeric reference of
the portion(s)
Entire article
Title of the article or chapter
the portion is from
Structure-based prediction of Wnt binding affinities for Frizzled-type
cysteine-rich domains
Editor of portion(s) George Carman
Author of portion(s) Mark Agostino, Sebastian Öther-Gee Pohl, Arun Dharmarajan
Volume of serial or
monograph.
292
Issue, if republishing an
article from a serial
27
Page range of the portion
Publication date of portion July 2017
Rights for Main product
Duration of use Life of current edition
Creation of copies for the
disabled
no
With minor editing privileges no
For distribution to Worldwide
In the following language(s) Original language of publication
With incidental promotional
use
no
The lifetime unit quantity of
new product
Up to 499
Title Mediation of Triple-Negative Breast Cancer Cell Fate via Cellular
Redox and Wnt Signalling
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Instructor name Arun Dharmarajan
Institution name Curtin University
Expected presentation date Jul 2018
Billing Type Invoice
Billing Address Sebastian OG Pohl
 Kent St
 
Bentley, Australia 
 Attn: Sebastian OG Pohl
Total (may include CCC user
fee)
0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
The following terms are individual to this publisher:
None
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License enables the User to
obtain licenses for republication of one or more copyrighted works as described in detail on
the relevant Order Confirmation (the “Work(s)”). Copyright Clearance Center, Inc. (“CCC”)
grants licenses through the Service on behalf of the rightsholder identified on the Order
Confirmation (the “Rightsholder”). “Republication”, as used herein, generally means the
inclusion of a Work, in whole or in part, in a new work or works, also as described on the
Order Confirmation. “User”, as used herein, means the person or entity making such
republication.
2. The terms set forth in the relevant Order Confirmation, and any terms set by the
Rightsholder with respect to a particular Work, govern the terms of use of Works in
connection with the Service. By using the Service, the person transacting for a republication
license on behalf of the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
Confirmation (and/or any invoice) and payment by User of the full amount set forth on that
document includes only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not
expressly granted are hereby reserved.
3.2 General Payment Terms: You may pay by credit card or through an account with us
payable at the end of the month. If you and we agree that you may establish a standing
account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance
Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable
upon their delivery to you (or upon our notice to you that they are available to you for
downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-
1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise
specifically set forth in the Order Confirmation or in a separate written agreement signed by
CCC, invoices are due and payable on “net 30” terms. While User may exercise the rights
licensed immediately upon issuance of the Order Confirmation, the license is automatically
revoked and is null and void, as if it had never been issued, if complete payment for the
license is not received on a timely basis either from User directly or through a payment
agent, such as a credit card company.
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3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the
licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock at
the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
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PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Nature Publishing Group LICENSE
 TERMS AND CONDITIONS
Jun 18, 2018
This is a License Agreement between Sebastian OG Pohl ("You") and Nature Publishing
Group ("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The
license consists of your order details, the terms and conditions provided by Nature
Publishing Group, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 4359650882224
License date May 31, 2018
Licensed content publisher Nature Publishing Group
Licensed content title Oncogenesis
Licensed content date Jan 1, 2011
Type of Use Thesis/Dissertation
Requestor type Academic institution
Format Print, Electronic
Portion chapter/article
The requesting
person/organization is:
Sebastian Pohl
Title or numeric reference of
the portion(s)
Entire article
Title of the article or chapter
the portion is from
Wnt signaling in triple-negative breast cancer
Editor of portion(s) N/A
Author of portion(s) SÖG Pohl, N Brook, M Agostino, F Arfuso, AP Kumar, A Dharmarajan
Volume of serial or
monograph.
6
Issue, if republishing an
article from a serial
e310
Page range of the portion
Publication date of portion April 2017
Rights for Main product
Duration of use Life of current edition
Creation of copies for the
disabled
no
With minor editing privileges no
For distribution to Worldwide
In the following language(s) Original language of publication
With incidental promotional
use
no
The lifetime unit quantity of
new product
Up to 499
Title Mediation of Triple-Negative Breast Cancer Cell Fate via Cellular
Redox and Wnt Signalling
Instructor name Arun Dharmarajan
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Institution name Curtin University
Expected presentation date Jul 2018
Billing Type Invoice
Billing Address Sebastian OG Pohl
 Kent St
 
Bentley, Australia 
 Attn: Sebastian Pohl
Total (may include CCC user
fee)
0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
The following terms are individual to this publisher:
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this
material for this purpose, and for no other use, subject to the conditions below:
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of this
material. However, you should ensure that the material you are requesting is original to
Nature Publishing Group and does not carry the copyright of another entity (as credited in
the published version). If the credit line on any part of the material you have requested
indicates that it was reprinted or adapted by NPG with permission from another source, then
you should also seek permission from that source to reuse the material.
2. Permission granted free of charge for material in print is also usually granted for any
electronic version of that work, provided that the material is incidental to the work as a
whole and that the electronic version is essentially equivalent to, or substitutes for, the print
version. Where print permission has been granted for a fee, separate permission must be
obtained for any additional, electronic re-use (unless, as in the case of a full paper, this has
already been accounted for during your initial request in the calculation of a print run).
3. Permission granted for a first edition does not apply to second and subsequent editions
and for editions in other languages (except for signatories to the STM Permissions
Guidelines, or where the first edition permission was granted for free).
4. Nature Publishing Group's permission must be acknowledged next to the figure, table or
abstract in print. In electronic form, this acknowledgement must be visible at the same time
as the figure/table/abstract, and must be hyperlinked to the journal's homepage.
5. The credit line should read:Reprinted by permission from Macmillan Publishers Ltd:
[JOURNAL NAME] (reference citation), copyright (year of publication)For AOP papers,
the credit line should read:Reprinted by permission from Macmillan Publishers Ltd:
[JOURNAL NAME], advance online publication, day month year (doi: 10.1038/sj.
[JOURNAL ACRONYM].XXXXX) Note: For republication from the British Journal of
Cancer, the following credit lines apply.Reprinted by permission from Macmillan Publishers
Ltd on behalf of Cancer Research UK: [JOURNAL NAME] (reference citation), copyright
(year of publication) For AOP papers, the credit line should read:Reprinted by permission
from Macmillan Publishers Ltd on behalf of Cancer Research UK: [JOURNAL NAME],
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL
ACRONYM].XXXXX)
6. Adaptations of single figures do not require NPG approval. However, the adaptation
should be credited as follows:Adapted by permission from Macmillan Publishers Ltd:
[JOURNAL NAME] (reference citation), copyright (year of publication)Note: For
adaptation from the British Journal of Cancer, the following credit line applies.Adapted by
permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: [JOURNAL
NAME] (reference citation), copyright (year of publication)
7. Translations of 401 words up to a whole article require NPG approval. Please visit
http://www.macmillanmedicalcommunications.com for more information. Translations of up
to a 400 words do not require NPG approval. The translation should be credited as
follows:Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME]
(reference citation), copyright (year of publication).Note: For translation from the British
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Journal of Cancer, the following credit line applies.Translated by permission from
Macmillan Publishers Ltd on behalf of Cancer Research UK: [JOURNAL NAME]
(reference citation), copyright (year of publication)
We are certain that all parties will benefit from this agreement and wish you the best in the
use of this material. Thank you.
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License enables the User to
obtain licenses for republication of one or more copyrighted works as described in detail on
the relevant Order Confirmation (the “Work(s)”). Copyright Clearance Center, Inc. (“CCC”)
grants licenses through the Service on behalf of the rightsholder identified on the Order
Confirmation (the “Rightsholder”). “Republication”, as used herein, generally means the
inclusion of a Work, in whole or in part, in a new work or works, also as described on the
Order Confirmation. “User”, as used herein, means the person or entity making such
republication.
2. The terms set forth in the relevant Order Confirmation, and any terms set by the
Rightsholder with respect to a particular Work, govern the terms of use of Works in
connection with the Service. By using the Service, the person transacting for a republication
license on behalf of the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
Confirmation (and/or any invoice) and payment by User of the full amount set forth on that
document includes only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not
expressly granted are hereby reserved.
3.2 General Payment Terms: You may pay by credit card or through an account with us
payable at the end of the month. If you and we agree that you may establish a standing
account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance
Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable
upon their delivery to you (or upon our notice to you that they are available to you for
downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-
1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise
specifically set forth in the Order Confirmation or in a separate written agreement signed by
CCC, invoices are due and payable on “net 30” terms. While User may exercise the rights
licensed immediately upon issuance of the Order Confirmation, the license is automatically
revoked and is null and void, as if it had never been issued, if complete payment for the
license is not received on a timely basis either from User directly or through a payment
agent, such as a credit card company.
3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the
licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock at
the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
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for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
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reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Elsevier Science and Technology Journals LICENSE
 TERMS AND CONDITIONS
Jun 18, 2018
This is a License Agreement between Sebastian OG Pohl ("You") and Elsevier Science and
Technology Journals ("Elsevier Science and Technology Journals") provided by Copyright
Clearance Center ("CCC"). The license consists of your order details, the terms and
conditions provided by Elsevier Science and Technology Journals, and the payment terms
and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 4372240854647
License date Jun 18, 2018
Licensed content publisher Elsevier Science and Technology Journals
Licensed content title Experimental cell research
Licensed content date Jan 1, 1950
Type of Use Thesis/Dissertation
Requestor type Academic institution
Format Electronic
Portion chapter/article
Number of pages in
chapter/article
7
The requesting
person/organization is:
Sebastian Pohl
Title or numeric reference of
the portion(s)
All
Title of the article or chapter
the portion is from
Therapeutic approach to target mesothelioma cancer cells using the
Wnt antagonist, secreted frizzled-related protein 4: Metabolic state
of cancer cells
Editor of portion(s) N/A
Author of portion(s) Vanathi Perumal, Sebastian Pohl, Kevin N. Keane, Frank Arfuso,
Philip Newsholme, Simon Fox, Arun Dharmarajan
Volume of serial or
monograph.
341
Issue, if republishing an
article from a serial
2
Page range of the portion 218-224
Publication date of portion February 2016
Rights for Main product
Duration of use Life of current edition
Creation of copies for the
disabled
no
With minor editing privileges no
For distribution to Worldwide
In the following language(s) Original language of publication
With incidental promotional
use
no
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The lifetime unit quantity of
new product
Up to 499
Title Mediation of Triple-Negative Breast Cancer Cell Fate via Cellular
Redox and Wnt Signalling
Instructor name Arun Dharmarajan
Institution name Curtin University
Expected presentation date Jul 2018
Billing Type Invoice
Billing Address Sebastian OG Pohl
 Kent St
 
Bentley, Australia 
 Attn: Sebastian OG Pohl
Total (may include CCC user
fee)
0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
The following terms are individual to this publisher:
None
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License enables the User to
obtain licenses for republication of one or more copyrighted works as described in detail on
the relevant Order Confirmation (the “Work(s)”). Copyright Clearance Center, Inc. (“CCC”)
grants licenses through the Service on behalf of the rightsholder identified on the Order
Confirmation (the “Rightsholder”). “Republication”, as used herein, generally means the
inclusion of a Work, in whole or in part, in a new work or works, also as described on the
Order Confirmation. “User”, as used herein, means the person or entity making such
republication.
2. The terms set forth in the relevant Order Confirmation, and any terms set by the
Rightsholder with respect to a particular Work, govern the terms of use of Works in
connection with the Service. By using the Service, the person transacting for a republication
license on behalf of the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
Confirmation (and/or any invoice) and payment by User of the full amount set forth on that
document includes only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not
expressly granted are hereby reserved.
3.2 General Payment Terms: You may pay by credit card or through an account with us
payable at the end of the month. If you and we agree that you may establish a standing
account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance
Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable
upon their delivery to you (or upon our notice to you that they are available to you for
downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-
1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise
specifically set forth in the Order Confirmation or in a separate written agreement signed by
CCC, invoices are due and payable on “net 30” terms. While User may exercise the rights
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licensed immediately upon issuance of the Order Confirmation, the license is automatically
revoked and is null and void, as if it had never been issued, if complete payment for the
license is not received on a timely basis either from User directly or through a payment
agent, such as a credit card company.
3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the
licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock at
the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
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CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Elsevier Science and Technology Journals LICENSE
 TERMS AND CONDITIONS
Jun 18, 2018
This is a License Agreement between Sebastian OG Pohl ("You") and Elsevier Science and
Technology Journals ("Elsevier Science and Technology Journals") provided by Copyright
Clearance Center ("CCC"). The license consists of your order details, the terms and
conditions provided by Elsevier Science and Technology Journals, and the payment terms
and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 4372241285385
License date Jun 18, 2018
Licensed content publisher Elsevier Science and Technology Journals
Licensed content title The international journal of biochemistry
Licensed content date Jan 1, 1995
Type of Use Thesis/Dissertation
Requestor type Academic institution
Format Electronic
Portion chapter/article
Number of pages in
chapter/article
9
The requesting
person/organization is:
Sebastian Pohl
Title or numeric reference of
the portion(s)
All
Title of the article or chapter
the portion is from
Multi-lineage differentiation of mesenchymal stem cells – To Wnt, or
not Wnt
Editor of portion(s) N/A
Author of portion(s) Malini Visweswaran, Sebastian Pohl, Frank Arfuso, Philip
Newsholme, Rodney Dilley, Shazib Pervaiz, Arun Dharmarajan
Volume of serial or
monograph.
68
Issue, if republishing an
article from a serial
1
Page range of the portion 139-147
Publication date of portion November 2015
Rights for Main product
Duration of use Life of current edition
Creation of copies for the
disabled
no
With minor editing privileges no
For distribution to Worldwide
In the following language(s) Original language of publication
With incidental promotional
use
no
The lifetime unit quantity of Up to 499
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new product
Title Mediation of Triple-Negative Breast Cancer Cell Fate via Cellular
Redox and Wnt Signalling
Instructor name Arun Dharmarajan
Institution name Curtin University
Expected presentation date Jul 2018
Billing Type Invoice
Billing Address Sebastian OG Pohl
 Kent St
 
Bentley, Australia 
 Attn: Sebastian OG Pohl
Total (may include CCC user
fee)
0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
The following terms are individual to this publisher:
None
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License enables the User to
obtain licenses for republication of one or more copyrighted works as described in detail on
the relevant Order Confirmation (the “Work(s)”). Copyright Clearance Center, Inc. (“CCC”)
grants licenses through the Service on behalf of the rightsholder identified on the Order
Confirmation (the “Rightsholder”). “Republication”, as used herein, generally means the
inclusion of a Work, in whole or in part, in a new work or works, also as described on the
Order Confirmation. “User”, as used herein, means the person or entity making such
republication.
2. The terms set forth in the relevant Order Confirmation, and any terms set by the
Rightsholder with respect to a particular Work, govern the terms of use of Works in
connection with the Service. By using the Service, the person transacting for a republication
license on behalf of the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
Confirmation (and/or any invoice) and payment by User of the full amount set forth on that
document includes only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not
expressly granted are hereby reserved.
3.2 General Payment Terms: You may pay by credit card or through an account with us
payable at the end of the month. If you and we agree that you may establish a standing
account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance
Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable
upon their delivery to you (or upon our notice to you that they are available to you for
downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-
1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise
specifically set forth in the Order Confirmation or in a separate written agreement signed by
CCC, invoices are due and payable on “net 30” terms. While User may exercise the rights
licensed immediately upon issuance of the Order Confirmation, the license is automatically
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revoked and is null and void, as if it had never been issued, if complete payment for the
license is not received on a timely basis either from User directly or through a payment
agent, such as a credit card company.
3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the
licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock at
the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
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OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Licensed content title Tumor biology
Licensed content date Jan 1, 1987
Type of Use Thesis/Dissertation
Requestor type Academic institution
Format Print, Electronic
Portion chapter/article
The requesting
person/organization is:
Sebastian Pohl
Title or numeric reference of
the portion(s)
Entire article
Title of the article or chapter
the portion is from
Secreted frizzled-related protein 4 and its implications in cancer and
apoptosis
Editor of portion(s) N/A
Author of portion(s) Sebastian Pohl, Ross Scott, Frank Arfuso, Vanathi Perumal, Arun
Dharmarajan
Volume of serial or
monograph.
36
Issue, if republishing an
article from a serial
1
Page range of the portion
Publication date of portion January 2015
Rights for Main product
Duration of use Life of current edition
Creation of copies for the
disabled
no
With minor editing privileges no
For distribution to Worldwide
In the following language(s) Original language of publication
With incidental promotional
use
no
The lifetime unit quantity of
new product
Up to 499
Title Mediation of Triple-Negative Breast Cancer Cell Fate via Cellular
Redox and Wnt Signalling
6/19/2018 RightsLink Printable License
https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=b9529804-d5f5-4e58-9ce6-73e0754754c0 2/5
Instructor name Arun Dharmarajan
Institution name Curtin University
Expected presentation date Jul 2018
Billing Type Invoice
Billing Address Sebastian OG Pohl
 Kent St
 
Bentley, Australia 
 Attn: Sebastian OG Pohl
Total (may include CCC user
fee)
0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
The following terms are individual to this publisher:
A maximum of 10% of the content may be licensed for republication.
The user is responsible for identifying and seeking separate licenses for any third party
materials that are identified anywhere in the work. Without a separate license, such third
party materials may not be reused.
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License enables the User to
obtain licenses for republication of one or more copyrighted works as described in detail on
the relevant Order Confirmation (the “Work(s)”). Copyright Clearance Center, Inc. (“CCC”)
grants licenses through the Service on behalf of the rightsholder identified on the Order
Confirmation (the “Rightsholder”). “Republication”, as used herein, generally means the
inclusion of a Work, in whole or in part, in a new work or works, also as described on the
Order Confirmation. “User”, as used herein, means the person or entity making such
republication.
2. The terms set forth in the relevant Order Confirmation, and any terms set by the
Rightsholder with respect to a particular Work, govern the terms of use of Works in
connection with the Service. By using the Service, the person transacting for a republication
license on behalf of the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
Confirmation (and/or any invoice) and payment by User of the full amount set forth on that
document includes only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not
expressly granted are hereby reserved.
3.2 General Payment Terms: You may pay by credit card or through an account with us
payable at the end of the month. If you and we agree that you may establish a standing
account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance
Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable
upon their delivery to you (or upon our notice to you that they are available to you for
downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-
1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise
specifically set forth in the Order Confirmation or in a separate written agreement signed by
CCC, invoices are due and payable on “net 30” terms. While User may exercise the rights
licensed immediately upon issuance of the Order Confirmation, the license is automatically
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revoked and is null and void, as if it had never been issued, if complete payment for the
license is not received on a timely basis either from User directly or through a payment
agent, such as a credit card company.
3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the
licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock at
the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
6/19/2018 RightsLink Printable License
https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=b9529804-d5f5-4e58-9ce6-73e0754754c0 4/5
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
